TW509688B - Piperazine derivatives - Google Patents
Piperazine derivatives Download PDFInfo
- Publication number
- TW509688B TW509688B TW088121878A TW88121878A TW509688B TW 509688 B TW509688 B TW 509688B TW 088121878 A TW088121878 A TW 088121878A TW 88121878 A TW88121878 A TW 88121878A TW 509688 B TW509688 B TW 509688B
- Authority
- TW
- Taiwan
- Prior art keywords
- trifluoromethyl
- nmr
- mass
- apci
- alkyl
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 88
- 150000003839 salts Chemical class 0.000 claims abstract description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 102000003141 Tachykinin Human genes 0.000 claims abstract description 5
- 108060008037 tachykinin Proteins 0.000 claims abstract description 5
- 230000001404 mediated effect Effects 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- -1 pyrrolidinesulfonyl Chemical group 0.000 claims description 540
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 319
- 125000000217 alkyl group Chemical group 0.000 claims description 195
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 178
- 150000001875 compounds Chemical class 0.000 claims description 165
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 80
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 65
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 64
- 125000002757 morpholinyl group Chemical group 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 45
- 125000003545 alkoxy group Chemical group 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 125000004076 pyridyl group Chemical group 0.000 claims description 19
- 125000001475 halogen functional group Chemical group 0.000 claims description 17
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 150000001412 amines Chemical class 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 125000006267 biphenyl group Chemical group 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000006178 methyl benzyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 3
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- JSKYPBXAHHTFRT-ZCFIWIBFSA-N (3r)-3-(methoxymethyl)morpholine Chemical compound COC[C@@H]1COCCN1 JSKYPBXAHHTFRT-ZCFIWIBFSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 199
- 241001465754 Metazoa Species 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 774
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 277
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 231
- 238000011049 filling Methods 0.000 description 194
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 156
- 101150041968 CDC13 gene Proteins 0.000 description 154
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 128
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 124
- 230000002079 cooperative effect Effects 0.000 description 114
- 101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 107
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 102
- 235000019439 ethyl acetate Nutrition 0.000 description 92
- 238000003756 stirring Methods 0.000 description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 81
- 229910001868 water Inorganic materials 0.000 description 74
- 239000000243 solution Substances 0.000 description 73
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 69
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 67
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 60
- 235000002639 sodium chloride Nutrition 0.000 description 59
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 55
- 239000012044 organic layer Substances 0.000 description 55
- 238000010898 silica gel chromatography Methods 0.000 description 54
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 51
- 235000019341 magnesium sulphate Nutrition 0.000 description 51
- 239000003921 oil Substances 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- OHEDMAIVEXQCOZ-UHFFFAOYSA-N piperidine;dihydrochloride Chemical compound Cl.Cl.C1CCNCC1 OHEDMAIVEXQCOZ-UHFFFAOYSA-N 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 38
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 38
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000000843 powder Substances 0.000 description 30
- 239000011734 sodium Substances 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 238000001816 cooling Methods 0.000 description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 239000002585 base Substances 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 239000012267 brine Substances 0.000 description 22
- 239000000284 extract Substances 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 18
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- MDZVMZTXIHCNCQ-UHFFFAOYSA-N piperidine;trihydrochloride Chemical compound Cl.Cl.Cl.C1CCNCC1 MDZVMZTXIHCNCQ-UHFFFAOYSA-N 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000005457 ice water Substances 0.000 description 13
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 206010047700 Vomiting Diseases 0.000 description 10
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000009298 Trigla lyra Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000008485 antagonism Effects 0.000 description 9
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 230000008673 vomiting Effects 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 7
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 7
- 150000007857 hydrazones Chemical class 0.000 description 7
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
- 206010006451 bronchitis Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 6
- 125000004385 trihaloalkyl group Chemical group 0.000 description 6
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 201000009906 Meningitis Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102100024304 Protachykinin-1 Human genes 0.000 description 4
- 101800003906 Substance P Proteins 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000010779 crude oil Substances 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- 229940075559 piperine Drugs 0.000 description 4
- 235000019100 piperine Nutrition 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 3
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229940017219 methyl propionate Drugs 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 238000002161 passivation Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- NKYDGSQKHJIVNM-DDWIOCJRSA-N (2r)-4-(2-chloroethyl)-2-(methoxymethyl)morpholine;hydrochloride Chemical compound Cl.COC[C@H]1CN(CCCl)CCO1 NKYDGSQKHJIVNM-DDWIOCJRSA-N 0.000 description 2
- PJXWCRXOPLGFLX-VIFPVBQESA-N (2s)-2-(benzylamino)propan-1-ol Chemical compound OC[C@H](C)NCC1=CC=CC=C1 PJXWCRXOPLGFLX-VIFPVBQESA-N 0.000 description 2
- ULNDTGZJRKQCQY-UHFFFAOYSA-N (4-fluoro-3-methylphenyl)methanol Chemical compound CC1=CC(CO)=CC=C1F ULNDTGZJRKQCQY-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical compound C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 2
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEYGLTRAXBZNAD-UHFFFAOYSA-N 3,3-dimethylmorpholine Chemical compound CC1(C)COCCN1 HEYGLTRAXBZNAD-UHFFFAOYSA-N 0.000 description 2
- ZQLCWPXBHUALQC-UHFFFAOYSA-N 3-hydroxy-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1O ZQLCWPXBHUALQC-UHFFFAOYSA-N 0.000 description 2
- XIRCMFYUQKUYJZ-UHFFFAOYSA-N 3-methoxy-4-(trifluoromethyl)benzaldehyde Chemical compound COC1=CC(C=O)=CC=C1C(F)(F)F XIRCMFYUQKUYJZ-UHFFFAOYSA-N 0.000 description 2
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 102220582664 Astrocytic phosphoprotein PEA-15_N14R_mutation Human genes 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100286123 Mus musculus Hoxa1 gene Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- YMTHMDBBWRQHMB-KGLIPLIRSA-N [(3r,5s)-1-benzyl-5-(2-hydroxypropan-2-yl)pyrrolidin-3-yl] methanesulfonate Chemical compound CC(C)(O)[C@@H]1C[C@@H](OS(C)(=O)=O)CN1CC1=CC=CC=C1 YMTHMDBBWRQHMB-KGLIPLIRSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- YGHUUVGIRWMJGE-UHFFFAOYSA-N chlorodimethylsilane Chemical group C[SiH](C)Cl YGHUUVGIRWMJGE-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- HBNBMOGARBJBHS-UHFFFAOYSA-N dimethylarsane Chemical compound C[AsH]C HBNBMOGARBJBHS-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 125000005059 halophenyl group Chemical group 0.000 description 2
- KGZLFTWMCMEEJR-UHFFFAOYSA-N heptane;hydrochloride Chemical compound Cl.CCCCCCC KGZLFTWMCMEEJR-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000004312 hexamethylene tetramine Substances 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 125000000879 imine group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 2
- PWHZTYXGTAZIQE-UHFFFAOYSA-N piperidine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.N1CCCCC1 PWHZTYXGTAZIQE-UHFFFAOYSA-N 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MLRCCRQJTJQIIB-LLVKDONJSA-N (2R)-2-(butoxycarbonylamino)-3-(4-hydroxy-3-methoxyphenyl)propanoic acid Chemical compound CCCCOC(=O)N[C@@H](C(O)=O)CC1=CC=C(O)C(OC)=C1 MLRCCRQJTJQIIB-LLVKDONJSA-N 0.000 description 1
- ZPELJYYPPKJKBE-ZCFIWIBFSA-N (2r)-2-(methoxymethyl)morpholine Chemical compound COC[C@H]1CNCCO1 ZPELJYYPPKJKBE-ZCFIWIBFSA-N 0.000 description 1
- BBAXRWHVFQQQEC-WCCKRBBISA-N (2s)-2-(dimethylamino)propanoic acid;hydrochloride Chemical compound Cl.CN(C)[C@@H](C)C(O)=O BBAXRWHVFQQQEC-WCCKRBBISA-N 0.000 description 1
- NBPHWKGEMABLPV-RGMNGODLSA-N (2s)-2-(methoxymethyl)morpholine;hydrochloride Chemical compound Cl.COC[C@@H]1CNCCO1 NBPHWKGEMABLPV-RGMNGODLSA-N 0.000 description 1
- NKYDGSQKHJIVNM-QRPNPIFTSA-N (2s)-4-(2-chloroethyl)-2-(methoxymethyl)morpholine;hydrochloride Chemical compound Cl.COC[C@@H]1CN(CCCl)CCO1 NKYDGSQKHJIVNM-QRPNPIFTSA-N 0.000 description 1
- YUWMPSNUXUOFTM-FVGYRXGTSA-N (2s)-4-(3-chloropropyl)-2-(methoxymethyl)morpholine;hydrochloride Chemical compound Cl.COC[C@@H]1CN(CCCCl)CCO1 YUWMPSNUXUOFTM-FVGYRXGTSA-N 0.000 description 1
- IHYNLJHPLBPWIZ-AWEZNQCLSA-N (2s)-4-benzyl-2-(methoxymethyl)-5,5-dimethylmorpholine Chemical compound CC1(C)CO[C@H](COC)CN1CC1=CC=CC=C1 IHYNLJHPLBPWIZ-AWEZNQCLSA-N 0.000 description 1
- PPTNZOLRDCBYIX-NKWVEPMBSA-N (2s,4r)-4-methoxy-2-(methoxymethyl)pyrrolidine Chemical compound COC[C@@H]1C[C@@H](OC)CN1 PPTNZOLRDCBYIX-NKWVEPMBSA-N 0.000 description 1
- IYHGJTYADQDZTC-JSGCOSHPSA-N (2s,5s)-4-benzyl-2-(methoxymethyl)-5-methylmorpholine Chemical compound C[C@H]1CO[C@H](COC)CN1CC1=CC=CC=C1 IYHGJTYADQDZTC-JSGCOSHPSA-N 0.000 description 1
- OVVZKZDOBGFNMZ-QGZVFWFLSA-N (3r)-1-benzyl-3-[(4-chloro-3-methoxyphenyl)methyl]piperazine Chemical compound C1=C(Cl)C(OC)=CC(C[C@H]2NCCN(CC=3C=CC=CC=3)C2)=C1 OVVZKZDOBGFNMZ-QGZVFWFLSA-N 0.000 description 1
- DVIKQFPAPLAYDZ-GOSISDBHSA-N (3r)-1-benzyl-3-[(4-methoxyphenyl)methyl]piperazine Chemical compound C1=CC(OC)=CC=C1C[C@H]1NCCN(CC=2C=CC=CC=2)C1 DVIKQFPAPLAYDZ-GOSISDBHSA-N 0.000 description 1
- CIRLRQQDDNOLRW-JPKZNVRTSA-N (3r)-1-benzyl-3-[[4-(trifluoromethyl)phenyl]methyl]piperazine;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(F)(F)F)=CC=C1C[C@H]1NCCN(CC=2C=CC=CC=2)C1 CIRLRQQDDNOLRW-JPKZNVRTSA-N 0.000 description 1
- ROHMLTGBCWLCIW-FYZOBXCZSA-N (3r)-3-(methoxymethyl)morpholine;hydrochloride Chemical compound Cl.COC[C@@H]1COCCN1 ROHMLTGBCWLCIW-FYZOBXCZSA-N 0.000 description 1
- BBOKUEBNNJFDMI-OLZOCXBDSA-N (3r,5s)-1-benzyl-5-(2-hydroxypropan-2-yl)pyrrolidin-3-ol Chemical compound CC(C)(O)[C@@H]1C[C@@H](O)CN1CC1=CC=CC=C1 BBOKUEBNNJFDMI-OLZOCXBDSA-N 0.000 description 1
- JSZNWUQCOLGFNL-NWDGAFQWSA-N (3r,5s)-1-benzyl-5-(hydroxymethyl)pyrrolidin-3-ol Chemical compound OC[C@@H]1C[C@@H](O)CN1CC1=CC=CC=C1 JSZNWUQCOLGFNL-NWDGAFQWSA-N 0.000 description 1
- JCZPOYAMKJFOLA-ZXZARUISSA-N (3s,4r)-pyrrolidine-3,4-diol Chemical compound O[C@H]1CNC[C@H]1O JCZPOYAMKJFOLA-ZXZARUISSA-N 0.000 description 1
- XHADJZKQYPPMFA-GEMLJDPKSA-N (3s,4s)-3,4-dimethoxypyrrolidine;hydrochloride Chemical compound Cl.CO[C@H]1CNC[C@@H]1OC XHADJZKQYPPMFA-GEMLJDPKSA-N 0.000 description 1
- FZEDGSMVRLKUOQ-UHFFFAOYSA-N (4-fluoro-3-methoxyphenyl)methanol Chemical compound COC1=CC(CO)=CC=C1F FZEDGSMVRLKUOQ-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- MASDFXZJIDNRTR-UHFFFAOYSA-N 1,3-bis(trimethylsilyl)urea Chemical compound C[Si](C)(C)NC(=O)N[Si](C)(C)C MASDFXZJIDNRTR-UHFFFAOYSA-N 0.000 description 1
- PFOAZHMGCLPKOE-UHFFFAOYSA-N 1-(4-chloro-3-methoxyphenyl)propan-2-amine Chemical compound COC1=CC(CC(C)N)=CC=C1Cl PFOAZHMGCLPKOE-UHFFFAOYSA-N 0.000 description 1
- DZAANUYJOGCNLL-UHFFFAOYSA-N 1-(4-chlorophenyl)propan-2-ylazanium;chloride Chemical compound Cl.CC(N)CC1=CC=C(Cl)C=C1 DZAANUYJOGCNLL-UHFFFAOYSA-N 0.000 description 1
- OINTXXMBRBLMHH-UHFFFAOYSA-N 1-(chloromethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CCl)=CC(C(F)(F)F)=C1 OINTXXMBRBLMHH-UHFFFAOYSA-N 0.000 description 1
- URDIBHMLPGUUMT-UHFFFAOYSA-N 1-benzyl-1-(trifluoromethyl)hydrazine Chemical compound FC(F)(F)N(N)CC1=CC=CC=C1 URDIBHMLPGUUMT-UHFFFAOYSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- MYFZXSOYJVWTBL-UHFFFAOYSA-N 1-methylpyrazole-4-carbaldehyde Chemical compound CN1C=C(C=O)C=N1 MYFZXSOYJVWTBL-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 1
- JIDHEIXSIHNMCG-UHFFFAOYSA-N 2-(benzylamino)-2-methylpropan-1-ol Chemical compound OCC(C)(C)NCC1=CC=CC=C1 JIDHEIXSIHNMCG-UHFFFAOYSA-N 0.000 description 1
- KFDXDCZKRGYUAE-UHFFFAOYSA-N 2-(chloromethyl)-1,3-dioxane Chemical compound ClCC1OCCCO1 KFDXDCZKRGYUAE-UHFFFAOYSA-N 0.000 description 1
- GHHHHCJLOIQEPN-UHFFFAOYSA-N 2-(methoxymethyl)-5-methylmorpholine hydrochloride Chemical compound Cl.COCC1CNC(C)CO1 GHHHHCJLOIQEPN-UHFFFAOYSA-N 0.000 description 1
- MDBHOLVVGYYARV-VIFPVBQESA-N 2-[(2s)-2-(methoxymethyl)-5,5-dimethylmorpholin-4-yl]ethanol Chemical compound COC[C@@H]1CN(CCO)C(C)(C)CO1 MDBHOLVVGYYARV-VIFPVBQESA-N 0.000 description 1
- AYLWBYXATIOJAW-DTWKUNHWSA-N 2-[(2s,4r)-4-methoxy-2-(methoxymethyl)pyrrolidin-1-yl]ethanol Chemical compound COC[C@@H]1C[C@@H](OC)CN1CCO AYLWBYXATIOJAW-DTWKUNHWSA-N 0.000 description 1
- GACMLLBMVJSGNX-MRVPVSSYSA-N 2-[(3r)-3-(methoxymethyl)morpholin-4-yl]ethanol Chemical compound COC[C@@H]1COCCN1CCO GACMLLBMVJSGNX-MRVPVSSYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- QGLVWTFUWVTDEQ-UHFFFAOYSA-N 2-chloro-3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1Cl QGLVWTFUWVTDEQ-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- JKPRALRROOFHFZ-UHFFFAOYSA-N 2-methoxyethoxymethanol Chemical compound COCCOCO JKPRALRROOFHFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- CROOPTGQTSCWCM-UHFFFAOYSA-N 3,4-dimethoxypyrrolidine Chemical compound COC1CNCC1OC CROOPTGQTSCWCM-UHFFFAOYSA-N 0.000 description 1
- HVFQJWGYVXKLTE-UHFFFAOYSA-M 3,5-bis(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HVFQJWGYVXKLTE-UHFFFAOYSA-M 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- KAESCUDIYVPBLX-UHFFFAOYSA-N 3-(2-methoxyethoxymethoxy)-4-methylbenzoic acid Chemical compound CC1=C(C=C(C=C1)C(=O)O)OCOCCOC KAESCUDIYVPBLX-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- JSKYPBXAHHTFRT-UHFFFAOYSA-N 3-(methoxymethyl)morpholine Chemical class COCC1COCCN1 JSKYPBXAHHTFRT-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- WBTHOSZMTIPJLR-UHFFFAOYSA-N 3-amino-5-(trifluoromethyl)benzoic acid Chemical compound NC1=CC(C(O)=O)=CC(C(F)(F)F)=C1 WBTHOSZMTIPJLR-UHFFFAOYSA-N 0.000 description 1
- CWBQFMSCOCJRDV-UHFFFAOYSA-N 3-chlorosulfonyl-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC(S(Cl)(=O)=O)=C1 CWBQFMSCOCJRDV-UHFFFAOYSA-N 0.000 description 1
- HRIHSNPFVGMAKX-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C(F)=C1 HRIHSNPFVGMAKX-UHFFFAOYSA-N 0.000 description 1
- HBMINIVKUUVKEB-UHFFFAOYSA-N 3-methoxy-4-(trifluoromethyl)benzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C(F)(F)F HBMINIVKUUVKEB-UHFFFAOYSA-N 0.000 description 1
- CEAVPXDEPGAVDA-UHFFFAOYSA-N 3-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C CEAVPXDEPGAVDA-UHFFFAOYSA-N 0.000 description 1
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 description 1
- POVQJRBWQYLTBX-UHFFFAOYSA-N 3-pyridin-4-yl-5-(trifluoromethyl)benzoic acid;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC(C(=O)O)=CC(C=2C=CN=CC=2)=C1 POVQJRBWQYLTBX-UHFFFAOYSA-N 0.000 description 1
- JSZZBOWCXZQSMO-UHFFFAOYSA-N 3-pyrrol-1-yl-5-(trifluoromethyl)benzoic acid Chemical compound FC(F)(F)C1=CC(C(=O)O)=CC(N2C=CC=C2)=C1 JSZZBOWCXZQSMO-UHFFFAOYSA-N 0.000 description 1
- GXMQVAXKLCFKCD-UHFFFAOYSA-N 3-pyrrolidin-1-ylsulfonyl-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CC(S(=O)(=O)N2CCCC2)=C1 GXMQVAXKLCFKCD-UHFFFAOYSA-N 0.000 description 1
- RAEAVXRWTCNJOT-UHFFFAOYSA-N 3-sulfamoyl-5-(trifluoromethyl)benzoic acid Chemical compound NS(=O)(=O)C1=CC(C(O)=O)=CC(C(F)(F)F)=C1 RAEAVXRWTCNJOT-UHFFFAOYSA-N 0.000 description 1
- FQXQBFUUVCDIRK-UHFFFAOYSA-N 3-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-N 0.000 description 1
- PWIKPHUWKWOZJR-UHFFFAOYSA-N 4-(2-chloroethyl)-2,2-dimethylmorpholine;hydrochloride Chemical compound Cl.CC1(C)CN(CCCl)CCO1 PWIKPHUWKWOZJR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZZGGOSDHWXCOCA-UHFFFAOYSA-N 4-(bromomethyl)-1-fluoro-2-methylbenzene Chemical compound CC1=CC(CBr)=CC=C1F ZZGGOSDHWXCOCA-UHFFFAOYSA-N 0.000 description 1
- YCMHNQSQSFDIQQ-UHFFFAOYSA-N 4-(chloromethyl)-1-fluoro-2-methoxybenzene Chemical compound COC1=CC(CCl)=CC=C1F YCMHNQSQSFDIQQ-UHFFFAOYSA-N 0.000 description 1
- OMOBDLDRCGEQCY-UHFFFAOYSA-N 4-(chloromethyl)-2-methoxy-1-(trifluoromethyl)benzene Chemical compound COC1=CC(CCl)=CC=C1C(F)(F)F OMOBDLDRCGEQCY-UHFFFAOYSA-N 0.000 description 1
- IZSJEIXMICBILL-UHFFFAOYSA-N 4-(chloromethyl)-2-methoxy-1-methylbenzene Chemical compound COC1=CC(CCl)=CC=C1C IZSJEIXMICBILL-UHFFFAOYSA-N 0.000 description 1
- HBBHHVWYCREAGP-UHFFFAOYSA-N 4-(methoxymethyl)morpholine;hydrochloride Chemical compound Cl.COCN1CCOCC1 HBBHHVWYCREAGP-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- VXKYOKPNAXNAFU-UHFFFAOYSA-N 4-bromo-1-fluoro-2-methylbenzene Chemical compound CC1=CC(Br)=CC=C1F VXKYOKPNAXNAFU-UHFFFAOYSA-N 0.000 description 1
- 150000005764 4-bromopyridine Chemical class 0.000 description 1
- NRFKZFFVTGGEQF-UHFFFAOYSA-N 4-fluoro-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1F NRFKZFFVTGGEQF-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150112516 ALG8 gene Proteins 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- IYHGJTYADQDZTC-UHFFFAOYSA-N CC1COC(COC)CN1CC1=CC=CC=C1 Chemical compound CC1COC(COC)CN1CC1=CC=CC=C1 IYHGJTYADQDZTC-UHFFFAOYSA-N 0.000 description 1
- JHYLUMNBQGQTNL-UHFFFAOYSA-N CCP(CC)CC.[Na+] Chemical compound CCP(CC)CC.[Na+] JHYLUMNBQGQTNL-UHFFFAOYSA-N 0.000 description 1
- AUPXBVDHVRZMIB-UHFFFAOYSA-M C[Mg]I Chemical compound C[Mg]I AUPXBVDHVRZMIB-UHFFFAOYSA-M 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- WGEZMHWHCOUJDQ-SBSPUUFOSA-N Cl.CC1=CC=C(C[C@@H](N)C(O)=O)C=C1 Chemical compound Cl.CC1=CC=C(C[C@@H](N)C(O)=O)C=C1 WGEZMHWHCOUJDQ-SBSPUUFOSA-N 0.000 description 1
- VJPRUJDZDWLRKQ-UHFFFAOYSA-N ClCC.[Na] Chemical compound ClCC.[Na] VJPRUJDZDWLRKQ-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- WLTCKEHCTUYJGI-UHFFFAOYSA-N Diethyl aminomalonate Chemical compound CCOC(=O)C(N)C(=O)OCC WLTCKEHCTUYJGI-UHFFFAOYSA-N 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- XJXZEEJFVDRZRT-UHFFFAOYSA-N N1C=CC2=NC=CC=C21.C2=CC=CC=1C3=CC=CC=C3CC21 Chemical compound N1C=CC2=NC=CC=C21.C2=CC=CC=1C3=CC=CC=C3CC21 XJXZEEJFVDRZRT-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229910052778 Plutonium Inorganic materials 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 206010066963 Procedural vomiting Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010066371 Tendon pain Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 1
- AZMXLICPEDMDGL-UHFFFAOYSA-N [5-(hydroxymethyl)oxolan-2-yl]methanol;4-methylbenzenesulfonic acid Chemical compound OCC1CCC(CO)O1.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 AZMXLICPEDMDGL-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- KHMKXHGLZPQIAD-UHFFFAOYSA-N [I].CN1C=CC=CC1Cl Chemical compound [I].CN1C=CC=CC1Cl KHMKXHGLZPQIAD-UHFFFAOYSA-N 0.000 description 1
- HZQCEWLNLSCGHA-UHFFFAOYSA-N [Na].B(Cl)(Cl)Cl Chemical compound [Na].B(Cl)(Cl)Cl HZQCEWLNLSCGHA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- JCFADYTWTKDWKU-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O.CC(O)=O JCFADYTWTKDWKU-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- RMTNSIBBWXZNDC-UHFFFAOYSA-N argon;hydrochloride Chemical compound Cl.[Ar] RMTNSIBBWXZNDC-UHFFFAOYSA-N 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- FCVCYPORNYEAAV-UHFFFAOYSA-N chloromethane;hydrochloride Chemical compound Cl.ClC FCVCYPORNYEAAV-UHFFFAOYSA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 101150103610 citT gene Proteins 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- SKOFFJJKOGPNRR-UHFFFAOYSA-N dichloromethane;formaldehyde Chemical compound O=C.ClCCl SKOFFJJKOGPNRR-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- ONDPGJBEBGWAKI-UHFFFAOYSA-N diphenylphosphane;propane Chemical compound CCC.C=1C=CC=CC=1PC1=CC=CC=C1 ONDPGJBEBGWAKI-UHFFFAOYSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PXJJSXABGXMUSU-UHFFFAOYSA-N disulfur dichloride Chemical compound ClSSCl PXJJSXABGXMUSU-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- KFVDYJVUUMCPDW-SNVBAGLBSA-N methyl (2r)-2-[(2-chloroacetyl)amino]-3-(4-fluoro-3-methoxyphenyl)propanoate Chemical compound ClCC(=O)N[C@@H](C(=O)OC)CC1=CC=C(F)C(OC)=C1 KFVDYJVUUMCPDW-SNVBAGLBSA-N 0.000 description 1
- YRWOKMPWSATUGI-HNCPQSOCSA-N methyl (2r)-2-amino-3-(3-fluoro-4-methylphenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=C(C)C(F)=C1 YRWOKMPWSATUGI-HNCPQSOCSA-N 0.000 description 1
- HGUZJZSDJWQRSI-SBSPUUFOSA-N methyl (2r)-2-amino-3-[4-(trifluoromethyl)phenyl]propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=C(C(F)(F)F)C=C1 HGUZJZSDJWQRSI-SBSPUUFOSA-N 0.000 description 1
- FHEHCZJLZDLUAW-UHFFFAOYSA-N methyl 2-amino-3-(4-fluorophenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)C(N)CC1=CC=C(F)C=C1 FHEHCZJLZDLUAW-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 229940115425 methylbenzyl acetate Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000479 mixture part Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZONTWBYATMRAHQ-UHFFFAOYSA-N n,n-dimethyl-1h-pyrrolo[3,2-b]pyridin-3-amine Chemical compound C1=CN=C2C(N(C)C)=CNC2=C1 ZONTWBYATMRAHQ-UHFFFAOYSA-N 0.000 description 1
- JGOAZQAXRONCCI-SDNWHVSQSA-N n-[(e)-benzylideneamino]aniline Chemical compound C=1C=CC=CC=1N\N=C\C1=CC=CC=C1 JGOAZQAXRONCCI-SDNWHVSQSA-N 0.000 description 1
- UZJLYRRDVFWSGA-UHFFFAOYSA-N n-benzylacetamide Chemical compound CC(=O)NCC1=CC=CC=C1 UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 150000002907 osmium Chemical class 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 125000005825 oxyethoxy group Chemical group [H]C([H])(O[*:1])C([H])([H])O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- AUYNWRLEXAPZAJ-UHFFFAOYSA-N piperazine;trihydrochloride Chemical compound Cl.Cl.Cl.C1CNCCN1 AUYNWRLEXAPZAJ-UHFFFAOYSA-N 0.000 description 1
- OYEHPCDNVJXUIW-UHFFFAOYSA-N plutonium atom Chemical compound [Pu] OYEHPCDNVJXUIW-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- UWECIPNAXRKCIZ-UHFFFAOYSA-N prop-1-yne;hydrochloride Chemical compound Cl.CC#C UWECIPNAXRKCIZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UQHNUDHAZRHRJK-UHFFFAOYSA-N silane stilbene Chemical group [SiH4].C1(=CC=CC=C1)C=CC1=CC=CC=C1 UQHNUDHAZRHRJK-UHFFFAOYSA-N 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000006250 trifluoro ethyl amino group Chemical group [H]N(*)C([H])([H])C(F)(F)F 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical group C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
509688 A7 B7_ 五、發明說明(1 ) 發明領域 本發明係_於一種哌畊衍生物及其鹽。 (請先閱讀背面之注意事項再填寫本頁) 特言之,係關於一種新類哌阱衍生物及其鹽,其具如 速激肱拮抗作用,尤為物質P拮抗作用,神經素A拮抗 作用,神經素B拮抗作用等藥理活性,其製法,含其之 翳藥組成物,及作為醫藥之用途。 因此,本發明目的之一係提供一種新穎且有用哌阱衍 生物及其鹽,其具如速激肱拮抗作用,尤為物質P拮抗 作用,神經素A拮抗作用,神經素B拮抗作用等藥理活 性。 本發明另一目的係提供一種製備該哌阱衍生物及其鹽 之方法。 本發明又另一目的係提供一種醫藥組成物其含該哌阱 衍生物及其製藥容許鹽為活性成份。 經濟部智慧財產局員工消費合作社印制衣 本發明再另一目的係提供該哌阱衍生物及其製藥容許 鹽為速激肱拮抗劑,尤為物質P拮抗劑,神經素A拮抗 劑,或神經素B拮抗劑,Μ防治人畜速激肽仲介病,如 呼吸条疾病(如氣喘,支氣管炎,鼻炎,咳嗽,咳痰, 等),眼病(如结合膜炎,春季結合膜炎,等);皮虜 病(如接觸性皮虜炎,異位性皮虜炎,鼕臃疹及其它濕 疹皮虜炎,等);發炎病(如風溼性_節炎,骨關節炎 ,等);疼痛(如偏頭痛,顗痛,牙痛,癌症疼痛,背 痛,等);等。 背景技藝 -3- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 五 A7 B7 、發明說明(2 ) 如 WO 97/22597 A1 及 WO 98/57954 A1所逑,已知部份 __衍生物具如速激肽拮抗作用之蕖理活性。 發明揭示 本發明目的化合物可由下式(I ): 〇 Γ2
R
i-i-rTA (I) 經濟部智慧財產局員工消費合作社印製 式中 Y 為 R 1為 素 礴 低 _ 基 R 2為 燒 烷 烷 燒 胺 $ 吡 鐽結或低伸烷基; 芳基可取代Ml〜3儸相同或不同取代基選自含鹵 ,低烷基,低烷氧基,單(或二或三)鹵低烷基, 基,胺基,低烷胺基,二低烷胺基,低烷硫基, 烷磺醜基,環低烷磺鼸基,胺磺酿基,低烷胺磺 基,二低烷胺磺醯基·毗咯啶磺醢基,嗎啉磺醢 ,吡咯磺醢基,吡啶磺醢基,吡咯基及毗啶基; 芳基可取代Ml〜3個相同或不同取代基選自含低 基,單(或二或三)鹵低烷基,單(或二或三)鹵低 磺醢氧基,鹵素,低伸烷二氧基,低烷氧基,低 氧羰基,低烷氧低烷氧低烷氧基,羥基,二苯低 矽烷氧基,三低烷矽烷氧基,羥低烷基,氮基, 基,[單(或二或三)鹵低烷羰基]胺基,低烷胺基 Η-(低烷基)-[單(或二或三)鹵低烷羰基]胺基, 咯啶基及嗎啉基而可取代Μ低烷氧低烷基或低燒 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7 五、發明說明( 或 •,氫(3 基為為 基 烷 低 且 基丙丙丙 \—/ \—/ >基基基 基啶啶啶 啶毗吡吡 t - - -S 3 3 3 基各 烷 ,·, 低基基 1 取 取可 其 基 烷 低 唑烷胺唑唑 _ 低烷毗吡 唑低 其 基 甲 烷烷 0 0 或啶 基咯 烷吡 低 取 取可低其 可 可其氧基 二二 啉取 鸣或 .,嗎 同 4-基 基烷 不 2,胺 烷低 或 1,烷 低氧 同 或低 羥烷 相 基, 或低.,個 烷基 基,基 2 低胺 烷基烷或 唑· 低烷低 1 二素 苯低羰 K ·,; 瞎幽 三M啉代 基基4--M K 代嗎取 基烯炔 2,代 代取烷可 低 氧 烷 低 及 基 氧 烷 低 基 甲 羥 基 羥 含 自 選 ; 基基 代烷 代 取 同 不 或 同 相 2 或 1 K 代 取 可 其 ;基 基烷 甲低 啶啶 _ 哌 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 基 ·, 烷基 低烷 氧Ite 烷1 低 及 基 烷基 > } > 基基基 ®罾啉啉啉 ,嗎嗎嗎 f 甲甲甲 鹵 I 二二二二 一 - -6 6 2 3 S » * » * 2 2 2 3 Γ.....L /ν /V /fv 基 基 啶 哌 基基基 烷烷烷 低低低 順 基 烷 低 基 啉 嗎 甲二 基 烷 低 基 啉 嗎 甲二 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 _B7_ 五、發明說明(4 ) (2 -甲氧甲嗎啉基)低烷基; (3-甲氣甲嗎啉基)低烷基; (請先閱讀背面之注意事項再填寫本頁) (2-甲氧甲基-5-甲嗎啉基)低烷基; (2-甲氧甲基-5,5-二甲嗎啉基)低烷基; (3,5-二甲氧甲嗎啉基)低烷基; (2,2-二甲氧甲嗎_基)低烷基; (2,3-二甲氧甲嗎啉基)低烷基; (2,6-二甲氧甲嗎啉基)低烷基; (2-甲氧甲嗎啉基)低烯基; (3 , 3-二甲嗎啉基)低炔基; (2-甲氧甲嗎啉基)低炔基; (2-甲氧甲基-5-甲嗎啉基)低炔基; β啉低烷基; [1Η-吡咯并[3,2-b]吡喃基]低烷基; [4,5,6,7-四氫_盼并[3,2-c]毗啶基]低烷基; [3,4-二氫-21!-吡啶并[3,2-1)卜1,4-11§阱基]低烷 基; (5,6,7,8-四氫-1,6-暸啶-6-基)低烷基;或 低烷基取代Μ如下式飽和雜環基;
經濟部智慧財產局員工消費合作社印製 (式中 r , s及t各為1〜2整數,且q為0〜2整數) -6- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 _B7_五、發明說明(5 ) 其可取代Ml〜2個低烷基, 當R 4 為3-(3-吡啶基)丙基; 為3-(3-吡啶基)丙烯基; 吡唑甲基其可取代Μ羥低烷基; (2-甲氧甲嗎啉基)低烷基; (3-甲氧甲嗎啉基)低烷基;或 (2-甲氧甲嗎啉基)低炔基;時 R 2 不為二低烷苯基。 霈知目的化合物(I )可因不對稱碳原子及雙鍵而含一 Μ上立體異構物,且所有異構物及其混物皆於本發明範 圍內。 需知目的異構物(I)可因光,酸,鹸等而發生異構化 及再排列,該異構化及再排列所得化合物亦於本發明範 圍内。 霈知化合物(I )之媒合形式(如水合物等)及任何化合 物(I )之結晶形式亦於本發明範圍内。 依本發明,目的化合物(I)或其鹽可由下列製法製得。 製法1 Υ - R2 -------1 I--I * I--I I ---訂----I I I ---- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 Y-R2
-Rc (III) 或其鹽 R1- Ο
(ID 或其在亞胺基之 反應性衍生物 或其鹽 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7 五、發明說明( 製法
Ζχ-R5 (la) 邐原
R Y-R2! S /~K 5 丄-ON N-Xj-R5 db) 或其鹽 經濟部智慧財產局員工消費合作社印製 或其鹽 式中 Υ,ίί1 ,R2 ,R3及R4定義如上 X 1為低伸烷基, Z 1為低伸炔基, R 5為3-Btt啶基,且 W i為雛去基。 起始化合物(I)及(I)中,部份為新穎且可由後逑製 備例所述製法或相似製法而製得。 起始化合物及目的化合物之適鹽為習用無毒性鹽且為 製藥容許鹽,含酸加成鹽如有機酸鹽[如乙酸鹽,三氟 乙酸鹽,順丁烯二酸鹽,反丁烯二酸鹽,酒石酸鹽,甲 磺酸鹽,苯磺酸鹽,甲酸鹽,對甲苯磺酸鹽等],無機 酸鹽[如鹽酸鹽,氫溴酸鹽,氫碘酸鹽,硫酸鹽,硝酸 鹽,磷酸鹽等],或與胺基酸之鹽[如精胺酸,天冬胺酸 ,麩胺酸等],或金鼷鹽如鹼金鼷鹽[如納鹽,鉀鹽等] ,鹼土金靨鹽[如鈣鹽,鎂鹽等]等,銨鹽,有機鹼鹽 [如三甲胺鹽,三乙胺鹽,½啶鹽,皮考林鹽,二環己 胺鹽,Ν,Ν’-二苄伸乙二胺鹽等]等。 -8- (請先閱讀背面之注意事項再填寫本頁) · I I 丨 I ---訂-I 丨 ---II — . 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 五、發明說明(7) 本說明書中所示於本發明範圍內之適例及各種定義之 闥明詳逑如下。 (請先閱讀背面之注意事項再填寫本頁) ”低”一詞若無特別說明係指C p e ,宜為C 4 。 適當”低伸烷基”可含直鏈或分岐Cl_6烷基,宜為Ck 4 ,如亞甲基,伸乙基,三亞甲基,伸丙基,四亞甲基, 甲基亞甲基,甲基三亞甲基,六亞甲基,等,其中宜為 亞甲基,伸乙基,三亞甲基,或甲基亞甲基。 適當”低伸炔基”可含C 2- 8基,如伸乙炔基,伸丙炔 基,伸丁炔基等,其中宜為伸丙炔基或伸丁炔基。 適當”鹵素”及於”單(或二或三)鹵低烷基”,”單(或二 或三)鹵Ci- 4烷基”,等之”鹵素”部份可為氟,氯,溴 及碘。 適當”低烷基”及於”羥低烷基”,”毗唑低烷基”等之適 當”低烷基”部份可為直鏈或分岐烷基,如甲基,乙 基,丙基,異丙基,丁基,異丁基,戊基,己基等,宜 為4烷基,且最宜為甲基,乙基或丙基。 於”(2-甲氧甲嗎啉基)低烯基”中適當”低烯基”部份可 含乙烯基,1-(或2-)丙烯基,1-(或2-) 丁烯基,1-(或 2-或3-或4-)戊烯基,1-(或2-或3-或4-或5-)己烯基, 經濟部智慧財產局員工消費合作社印製 甲基乙烯基,乙基乙烯基,1 -(或2-或3-)甲基-1-(或2-) 丙烯基,1-(或2-或3-)乙基-1-(或2-)丙烯基,1-(或2-或3-或4-)甲基-1-(或2-或3-) 丁烯基等,宜為C 2-4烯 基〇 適當”芳基”可含苯基,萘基等,宜為Ce-i0芳基,最 -9- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(8 ) 宜為苯基或萘基。 適當”低烷氧基"及於”低烷氧低烷嗎啉低烷基”低 烷氧低烷嗎咐羰低烷基”等中適當”低烷氧基”部份可含 甲氧基,乙氧基,丙氧基,異丙氧基,丁氧基,異丁氧 基,第三丁氧基,戊氧基,第三戊氧基,己氧基等,宜 為(:1- 4烷氧基且最宜為甲氧基。 適當”雛去基”可含低烷氧基(如甲氧基,乙氧基,丙 氧基,異丙氧基,丁氧基,異丁氧基,第三丁氧基,戊 氧基等),芳氧基(如苯氧基,萦氧基等),酸殘基等。 適當”酸殘基”可含鹵素(如氯,溴,碘等),磺酿氧基 (如甲磺醯氧基,苯磺釀氧基,三亞甲苯磺醯氧基,甲 苯磺釀氧基等),等。 目的化合物(I)之較佳實施例如下: Y 為低伸烷基(宜為C ^4伸烷基,最宜為亞甲基); R 1 為苯基其可含1〜2個相同或不同取代基選自如鹵素 (宜為氟或氯),低烷基(宜為Ci— 4烷基,最宜為甲 基),低烷氧基(宜為C14烷氧基且最宜為甲氧基) ,單(或二或三)鹵低烷基(宜為三鹵低烷基,最宜為 三氟甲基),硝基,胺基,低烷胺基(宜為C ^4烷胺 基,最宜為甲胺基),二低烷胺基(宜為二Ci-4烷胺 基,最宜為二甲胺基),低烷硫基(宜為Ci-4烷硫基 ,最宜為甲硫基),低烷磺酿基(宜為Ci- 4烷磺釀基 ,最宜為甲磺釀基),環低烷磺醯基(宜為環Cp 4烷 磺釀基,最宜為環戊磺釀基),胺磺釀基,低烷胺磺 -10- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) Γ - _1 _ ^ ^ 1 1- mammmm mmmmmmm 1 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(9 ) _基(宜為Ci-4烷胺磺醮基,最宜為甲胺磺醢基), 二低烷胺磺醯基(宜為二CP4烷胺磺醢基,最宜為 二甲胺磺酿基),吡咯啶磺釀基(宜為吡咯啶磺藤基) ,嗎啉磺醯基(宜為嗎琳磺釀基),毗咯磺醜基(宜為 1-吡咯磺醯基),吡啶磺醯基(宜為啶磺釀基), 吡咯基(宜為1-毗咯基)及吡啶基(宜為4-吡啶基); R 2 為苯基其可含1〜2個相同或不間取代基選自如低烷 基(宜為Ci-4烷基,最宜為甲基或異丙基),單(或 二或三)鹵低烷基(宜為單(或二或三)鹵Ci- 4烷基, 最宜為三氟甲基),單(或二或三)鹵低烷磺釀氧基 (宜為單(或二或三)鹵Ci—4烷磺醯氧基,最宜為三 氟甲磺醯氧基),齒素(宜為氟或氯低伸烷二氧基 (宜為Ci_4伸烷二氧基,最宜為亞甲二氧基或伸乙 氧基),低烷氧基(宜為Ci_4烷氧基且最宜為甲氧基) ,低烷氧羰基(宜為Ci-4烷氧羰基,最宜為甲氧羰 基),低烷氧低烷氧低烷氧基(宜為Ci- 4烷氧Ci一 4 烷氧基,最宜為(2-甲氧乙氧基)甲氧基),羥基,二 苯低烷矽烷氧基(宜為二苯C^4烷矽烷氧基,最宜 為二苯第三丁基矽烷氧基),三低烷矽烷氧基(宜為 三Ci- 4烷矽烷氧基,最宜為二甲基(第三丁基)矽烷 氧基),羥低烷基(宜為羥C 14烷基,最宜為羥甲基 或1-羥基-1-甲基乙基),氰基,胺基,[單(或二或 三)鹵低烷羰基]胺基(宜為[單(或二或三)4烷 羰基]胺基,最宜為(三氟甲羰基)胺基,低烷胺基 -11- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------1 I------------訂-------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(Μ ) (宜為(:卜4烷胺基,甲胺基),低烷基-[單(或二 或三)鹵低烷羰基]胺基(宜為N-(Ci —4烷基)-[單 (或二或三)鹵Ci-4烷羰基]胺基,最宜為N-甲基-[(三氟甲羰基)胺基)],吡咯啶基及嗎啉基而可取代 Μ低烷氧低烷基(宜為Ci- 4烷氧Ci- 4烷基,最宜為 甲氧甲基)或低烷基(宜為Ci-4烷基,最宜為甲基); R 3 為氫;且 R 4 為(3-吡啶基)甲基; (3-Ufct唯基)乙基(宜為2-(3-他_基)乙基); 3-(3 -_唆基)丙基; 3-(3-吡啶基)丙烯基(宜為2-(3-吡啶基)-2-丙烯基; 3-(3-吡啶基)丙炔基(宜為2-(3-吡啶基)-2-丙炔基; 晴唑低烷基(宜為瞎唑Ci_ 4烷基,最宜為4-睹唑甲 基);1,2,4-_二唑低烷基(宜為1,2,4-_二唑(;1一4 烷基,最宜為2,4-晴二唑-3-基甲基)或1,2,4-鸣二 唑低烷基(宜為1,2,4-鸣二唑Ci-4烷基,最宜為1, 2,4二唑-5-基甲基),其各可取代Μ鹵素(宜為溴) ,胺基,低烷胺基(宜為C 烷胺基,最宜為甲胺 基)或二低烷胺基(宜為二Ci- 4烷胺基,最宜為二甲 胺基); 吡唑甲基(宜為(4-吡唑基)甲基或(5-毗唑基)甲基, 其可取代Μ三苯低烷基(宜為三苯C^4烷基,最宜 為三苯甲基)或羥低烷基(宜為羥Cf 4烷基,最宜為 2-羥乙基); 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂-------- (請先閱讀背面之注意事項再填寫本頁) 509688 ΚΙ Β7_ 五、發明說明(11 ) 吡唑低烷基(宜為吡唑Ci-4烷基,最宜為(4-吡唑基) 甲基,(5-吡唑基)甲基,或3-(4-毗唑基)丙基,其 可取代Μ低烷基(宜為烷基,最宜為甲基),低 烷氧低烷嗎啉低烷基(宜為Ci-4烷氧Ci-4烷嗎琳 Ci-4烷基,最宜為2 -(2-甲氧甲嗎啉基)乙基)或低 烷氧低烷嗎啉羰低烷基(宜為C^4烷氧Ci-4烷嗎啉 Ci-4烷基,最宜為(2-甲氧甲嗎啉基)羰甲基); 吡咯啶低烷基(宜為吡咯啶4烷基,最宜為2-吡 咯啶乙基),其可取代Ml或2個相同或不同取代基 選自含羥基,羥低烷基(宜為羥C 14烷基,最宜為 羥甲基),低烷氧基(宜為Ci-4烷氧基,最宜為甲氧 基)及低烷氧低烷基(宜為(:^4烷氧Ci_4烷基,最 宜為甲氧甲基); 哌啶甲基(宜為(4-哌啶基)甲基; 哌啶低焼基(宜為哌啶Ci-4烷基,最宜為2-_啶乙 基),其可取代Ml或2個相同或不同取代基選自含 鹵素(宜為氟),低烷基(宜為Ci-4烷基,最宜為甲 基),及低烷氧低燒基(宜為Ci-4烷氧Ci- 4烷基, 最宜為甲氧甲基); 經濟部智慧財產局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) [2,6-二[羥低烷基]哌啶基]低烷基(宜為[2,6-二[羥 Ci 一 4焼基]哌唆基]Ci-4燒基,最宜為2-[2,6-二[ 羥甲烷基]哌啶基]乙基); (2,6-二甲嗎啉基)低烷基(宜為(2,6-二甲嗎啉基)
Ci—4烷基,最宜為2 -(2,6-二甲嗎啉基)乙基); -13- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 12 五、發明說明() (2,2-二甲嗎啉基)低烷基(宜為(2,2-二甲嗎啉基)
Ci—4烷基,最宜為2-(2,2-二甲嗎啉基)乙基); (3,3-二甲嗎啉基)低烷基(宜為(3, 3-二甲嗎啉基) C i—4烷基,最宜為2-(3,3-二甲嗎啉基)乙基); (顒-3,5-二甲嗎咐基)低烷基(宜為(順-3·5-二甲嗎 啉基)Ci-4烷基,最宜為2-(順-3,5-二甲嗎啉基)乙 基); ((3$,55)-3,5-二甲嗎啉基)低烷基(宜為((35,55)- 3.5- 二甲嗎啉基)(:1-4烷基,最宜為2-((35,55)- 3.5- 二甲嗎咐基)乙基); (2-甲氧甲嗎啉基)低烷基(宜為(2-甲氧甲嗎啉基) C^4烷基,最宜為3-(2-甲氧甲嗎啉基)丙基或2-(2-甲氧甲嗎啉基)乙基; (3-甲氧甲嗎啉基)低烷基(宜為(3-甲氧甲嗎啉基)
Ca_-4烷基,最宜為2-(3-甲氧甲嗎啉基)乙基); (2-甲氧甲基-5-甲嗎啉基)低烷基(宜為(2-甲氧甲基 -5-甲嗎啉基)C!-4烷基,最宜為2-(2-甲氧甲基-5-甲嗎啉基)乙基); (2-甲氧甲基-5,5-二甲嗎啉基)低烷基(宜為(2-甲氧 甲基-5,5-二甲嗎啉基)Ci-4烷基,最宜為2-(2-甲 氧甲基-5,5-二甲嗎啉基)乙基); (3,5-二甲氧甲嗎啉基)低烷基(宜為(3,5-二甲氧甲 嗎啉基)(^-4烷基,最宜為2-(3,5-二甲氧甲嗎啉基) 乙基); -14- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -· n n· n n n n 一 口 f I n I a— n 1^1 1 經濟部智慧財產局員工消費合作社印制衣 509688 A7 B7_ 1 ^ 五、發明說明() (2,2-二甲氧甲嗎啉基)低烷基(宜為(2,2-二甲氧甲 嗎啉基)Ci-4烷基,最宜為2-(2,2-二甲氧甲嗎啉基) 乙基); (2,3-二甲氧甲嗎啉基)低烷基(宜為(2,3-二甲氧甲 嗎啉基)(^-4烷基,最宜為2-(2,3-二甲氧甲嗎啉基) 乙基); (2,6-二甲氧甲嗎啉基)低烷基(宜為(2,6-二甲氧甲 嗎啉基)(^-4烷基,最宜為2-(2,6-二甲氧甲嗎啉基) 乙基); (2-甲氧甲嗎啉基)低烯基(宜為(2-甲氧甲嗎啉基) C2_4烯基,最宜為4-(2-甲氧甲嗎淋基)-2-丁_基); (3,3-二甲嗎啉基)低炔基(宜為(3,3-二甲嗎啉基) C2-4炔基,最宜為4 -(3 ,3 -二甲嗎啭基)-2 -丁炔基); (2-甲氧甲嗎啉基)低炔基(宜為(2-甲氧甲嗎啉基) C2-4炔基,最宜為4-(2-甲氧甲嗎啉基)-2-丁炔基); (2-甲氧甲基-5-甲嗎啉基)低炔基(宜為(2-甲氧甲基 -5-甲嗎啉基)C2-4炔基,最宜為4-(2-甲氧甲基-5-甲嗎啉基)-2-丁炔基); 晴啉低烷基(宜為啉基C ±一4烷基,最宜為(6-»奎啉 基)甲基); [1H-吡咯并[3,2-b]吡啶基]低烷基(宜為[1H-吡咯并 [3,2-b]吡啶基]Ci-4烷基,最宜為[1H-吡咯并[3, 2-b]瞅_ -3-基]甲基); [4,5,6,7-四氫睹盼并[3,2-c]吡啶基]低烷基(宜為 -15- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) T . -1 1 _1 ammmmmm tammm J > I 1 emmmmm Mmmmm emmmmm tmmmm emmmm I ·"0 509688 A7 _B7_ 14 五、發明說明() [4,5,6,7-四氫瞎吩并[3,21]吡啶基](:1-4烷基, 最宜為2-[4,5,6,7-四氫瞎吩并[3,2-c]吡啶基]乙基); [3,4-二氫-2卜%啶并[3,2-1>]-1,4-锷阱基]低烷基 (宜為[3,4-二氫-2H-吡啶并[3,2-b]-l,4-B§ 阱基]
Ci—4 焼基,最宜為 2-[3,4 -二氫-2H-Bfcfc 唆并[3,2-b] -1,4-吗畊-4-基]乙基); (5,6,7,8-四氬-1,6-_啶-6-基)低烷基(宜為5,6,7, 8-四氫-1,6-嵘啶-6-基)Ci —4烷基,最宜為2-(5,6, 7,8-四氫-1,6-_啶-6-基)乙基);或 低烷基(宜為Ci—4烷基,最宜為乙基),其可取代Μ 如下式飽和雜環基; (請先閱讀背面之注意事項再填寫本頁) ,(cH2rjy^
(式中 經濟部智慧財產局員工消費合作社印製 r , s及t為1〜2整數,且q為0〜2整數) (宜為915,43)-2-鸣-5-吖雙環并[2.2.1]-庚烷-2-基) 其可取代Ml〜2個低烷基(宜為Ci 4烷基,最宜為 甲基)。 目的化合物(I )之更佳實施例如下: Y 為低伸烷基(宜為Ci-4伸烷基,最宜為亞甲基); R 1 為苯基其可含1〜2個相同或不同取代基選自如鹵素 ,低烷基,低烷氧基,單(或二或三)鹵低烷基,硝 -16- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1 5 五、發明說明() 基,胺基,低烷胺基,二低烷胺基,低烷硫基,低 烷磺醯基,環低烷磺釀基,胺磺釀基,低烷胺磺醯 基,二低烷胺磺釀基,吡咯啶磺醯基,嗎啉磺醯基 ,吡咯磺醯基,吡唆磺醢基,吡咯基及吡啶基; [宜為二鹵苯基, 雙(三鹵低烷基)苯基, (三鹵低烷基)鹵苯基· (三鹵低烷基)低烷基)苯基, (三鹵低烷基)低烷氧基)苯基, (三鹵低烷基)硝苯基, (三鹵低烷基)低烷胺苯基, (三鹵低烷基)二低烷胺苯基, (三鹵低烷基)低烷硫苯基, (三鹵低烷基)低烷磺釀苯基, (三鹵低烷基)環低烷磺釀苯基, (三鹵低烷基)胺磺醯苯基, (三鹵低烷基)低烷胺硝釀苯基, (三鹵低烷基)二低烷胺磺醯苯基, (三鹵低烷基)吡咯啶磺醮苯基, (三鹵低烷基)嗎啉磺釀苯基, (三鹵低烷基)吡啶磺釀苯基, (三鹵低烷基)吡咯苯基或, (三鹵低烷基)毗啶苯基, 最宜為3,5-二氯笨基,3,5-雙(三氟甲基)苯基,3- -17- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------訂·-------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 五、發明說明(16 ) (請先閱讀背面之注意事項再填寫本頁) 氟-5-三氟甲苯基,3-氯-5-三氟甲苯基,3-甲基-5 -三氟甲苯基,3-甲氧基-5-三氟甲苯基,3-硝基-5 -三氟甲苯基,3-甲胺基-5-三氟甲苯基,3-二甲胺基 -5-三氟甲苯基,3-甲硫基-5-三氟甲苯基,3-甲磺 醯基-5-三氟甲苯基,3-環戊磺釀基-5-三氟甲苯基 ,3-胺磺醴基-5-三氟甲苯基,3-甲胺磺醢基-5-三 氟甲苯基,3-二甲胺磺醢基-5-三氟甲苯基 3-吡咯 啶磺醃基-5-三氟甲苯基,3-嗎啉磺醯基-5-三氟甲 苯基,3 -(4 -啦_基)磺醢基-5 -三氟甲苯基,3-(1-Bit咯基)磺醯基-5-三氟甲苯基或3-(4 -_嚏基)-5 -三 氟甲苯基; R 2 為苯基其可含1〜2個相同或不同取代基選自如低烷 基,單(或二或三)鹵低烷基,單(或二或三)鹵低烷 磺醯氧基,鹵素,低伸烷二氧基,低烷氧基,低烷 氧羰基,低烷氧低烷氧低烷氧基,羥基,二苯低烷 矽烷氧基,三低烷矽烷氧基,羥低烷基,氰基,胺 基,[單(或二或三)鹵低烷羰基]胺基,低烷胺基, 經濟部智慧財產局員工消費合作社印製 N-低烷基-[單(或二或三)鹵低烷羰基]胺基,吡咯啶 基及嗎啉基其可取代Μ低烷氧低烷基或低烷基[宜為 (低伸烷二氧基)苯基,低烷氧苯基,,鹵苯基,二 鹵苯基,(三鹵低烷基)苯基,(三鹵低烷基)(低烷基) 苯基,(鹵低烷基)苯基,(鹵低烷氧基)苯基,(_羥 基)苯基,(鹵二苯低烷矽烷氧基)苯基,(三鹵低烷 基)羥苯基,(羥低烷基)羥苯基,(氰基)羥苯基, -18- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 17 五、發明說明() (二鹵低烷基)羥苯基,(低烷基)胺苯基,(低烷基) (低烷胺基)苯基,,(低烷基)[單(或二或三)鹵低烷 磺醯氧基]苯基,(低烷基)[[單(或二或三)鹵低烷羰 基]胺基]苯基,(低烷基)[N-低烷基-[單(或二或三) 鹵低烷羰基]胺基]苯基,(低烷基)(二苯低烷矽烷氧 基)苯基,(低烷基)(低烷氧低烷氧低烷氧基)苯基, (低烷基)(三低烷矽烷氧基)苯基,(低烷氧羰基)(三 低烷矽烷氧基)苯基,(羥低烷基)(三低烷矽烷氧基) 苯基,(低烷基)羥苯基,(低烷基)吡咯啶苯基,(低 烷基)嗎啉苯基,(低烷基)(低烷氧低烷嗎啉基)苯基 ,或(低烷基)(低烷基)(嗎_基)苯基,最宜為1,4 -苯并二嘮-6-基,4-甲氧苯基,4-氟苯基,4-氯苯基, 3,4-二氟苯基,4-(三氟甲基)苯基,3-甲氧基-4-三 氟甲苯基,4-氟-3-甲苯基.4-氟-4-甲氧苯基,3-氟-4-甲苯基,4-氟-3-羥苯基,4-氯-3-甲苯基,4-氯-3-(二甲基(第三丁基)矽烷氧基)苯基,4-氯-3-羥甲苯基,3-羥基-4-三氟甲苯基,3-羥基-4-(羥甲 基)苯基,3-羥基-4-甲苯基,3-羥基-4-(1-羥基-1-甲基乙基)苯基,4-氰基-3-羥苯基,3-羥基-4-(二 氟甲基)苯基,3-羥基-4-異丙苯基,3-胺基-3-甲苯 基,4-甲基-3-甲胺苯基,4-甲基-3 -(三氟甲磺酿氧 基)笨基,4-甲基甲基-(三氟甲羰基)胺基]苯 基,3-二苯基-第三丁矽烷氧基-4-甲苯基,4-甲基-3-[(2-甲氧乙氧基)甲氧基]笨基,3-二甲基(第三丁 -19- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
509688 A7 B7___ 五、發明說明(18 ) 基)矽烷氧基-4-甲氧羰苯基,3-二甲基(第三丁基) (請先閱讀背面之注意事項再填寫本頁) 矽烷氧基-4-(1-羥基-1-甲基乙基)苯基,4-甲基-3-Btfe咯啶苯基,或4-甲基-3-嗎啉苯基)]; R 3 為氫;且 R4 為(2,6-二甲嗎啉基)低烷基(宜為(2,6-二甲嗎啉基) Ct- 4烷基,最宜為2-(2,6-二甲嗎啉基)乙基); (2,2-二甲嗎咐基)低烷基(宜為(2,2-二甲嗎啉基) Ci-4烷基,最宜為2-(2,2-二甲嗎啉基)乙基); (3,3-二甲嗎啉基)低烷基(宜為(3,3-二甲嗎啉基)
Ci一 4烷基,最宜為2-(3,3-二甲嗎啉基)乙基); (順-3,5-二甲嗎啉基)低烷基(宜為(順-3,5-二甲嗎 啉基)Ci —4烷基,最宜為2-(順-3,5-二甲嗎啉基)乙 基); ((35,55)-3,5-二甲嗎啉基)低烷基(宜為((3$,55)- 3.5- 二甲嗎啉基)(:1-4烷基,最宜為2-((35,55)- 3.5- 二甲嗎啉基)乙基); (2-甲氧甲嗎啉基)低烷基(宜為(2-甲氧甲嗎啉基) Ci-4烷基,最宜為3-(2-甲氧甲嗎啉基)丙基或2-(2-甲氧甲嗎啉基)乙基; 經濟部智慧財產局員工消費合作社印製 (3-甲氧甲嗎_基)低烷基(宜為(3-甲氧甲嗎啉基) CP4烷基,最宜為2-(3-甲氧甲嗎啉基)乙基); (2-甲氧甲基-5-甲嗎啉基)低烷基(宜為(2-甲氧甲基 -5-甲嗎啉基)Ck 4烷基,最宜為2-(2-甲氧甲基-5-甲嗎啉基)乙基); 一20- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_
1 Q 五、發明說明() (2-甲氧甲基-5,5-二甲嗎啉基)低烷基(宜為(2-甲氧 甲基-5,5-二甲嗎啉基)(:1-4烷基,最宜為2-(2-甲 氧甲基-5,5-二甲嗎啉基)乙基); (3,5-二甲氧甲嗎咐基)低烷基(宜為(3,5-二甲氧甲 嗎啉基)Ch4烷基,最宜為2-(3,5-二甲氧甲嗎啉基) 乙基); (2,2-二甲氧甲嗎啉基)低烷基(宜為(2,2-二甲氧甲 嗎啉基)(^-4烷基,最宜為2-(2,2-二甲氧甲嗎啉基) 乙基); (2,3-二甲氧甲嗎啉基)低烷基(宜為(2,3-二甲氧甲 嗎啉基)Ci-4烷基,最宜為2-(2,3-二甲氧甲嗎啉基) 乙基); (2,6-二甲氧甲嗎啉基)低烷基(宜為(2,6-二甲氧甲 嗎咐基Ui-4烷基,最宜為2-(2,6-二甲氧甲嗎啉基) 乙基); (2-甲氧甲嗎啉基)低烯基(宜為(2-甲氧甲嗎啉基) C2-4烯基,最宜為4-(2-甲氧甲嗎啉基)-2-丁烯基); (3,3-二甲嗎啉基)低炔基(宜為(3,3-二甲嗎啉基) C2-4炔基,最宜為4-(3,3-二甲嗎啉基)-2-丁炔基); (2-甲氧甲嗎啉基)低炔基(宜為(2-甲氧甲嗎啉基) C2-4炔基,最宜為4-(2-甲氧甲嗎啉基)-2-丁炔基); (2-甲氧甲基-5-甲嗎啉基)低炔基(宜為(2-甲氧甲基 -5-甲嗎啉基)C2-4炔基,最宜為4-(2-甲氧甲基-5-甲嗎啉基)-2-丁炔基)。 -21- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) --------訂·--- 509688 經濟部智慧財產局員工消費合作社印製 A7 B7_ ___ 20 五、發明說明() 製法1及2詳逑製備本發明目的化合 製法1 目的化合物(I )或其鹽可令化合物(I )或其在55胺® 之反應衍生物或其鹽,與化合物(I)或其11胃_胃 化合物(I)在亞胺基之適當反應衍生物含S hiffRil 型亞胺或其由化合物(I )與如醛或_之羰基化合物反應 所形成亞胺型互變異構物,·由化合物(I)與如雙(三甲 矽烷基)乙醢胺,單(三甲矽烷基)乙醢胺,雙(三甲矽烷 基)脲等之矽烷基化合物反應所形成矽烷基衍生物;及 由化合物U )與三氯亞磷或光氣等反應所形成衍生物。 反應於習用溶劑如水,酵[如甲酵,乙醇等],丙酮, 二嗒烷,乙腈,氯仿,二氯甲烷,二氯乙烷,四氫呋喃 ,乙酸乙_, Ν,Η-二甲基甲醯胺,毗啶或任何對反應無 不良影響之有機溶劑下進行。此習用溶劑可與水混用。 反應亦可於存在無機鹼或有機鹸下進行,如鹼金鼷碳 碳鹽(如碳酸鉀等),鹸金麗重碳酸鹽,三低烷胺,吡啶 ,Ν-低烷嗎啉,Η,Ν-二低烷乙胺(如Ν,Ν-二異丙基乙胺 等,Ν,Ν-二低烷苄胺等。 反應溫度無嚴定且一般於冷郤至加熱下進行。 製法2 目的化合物(I b)或其鹽可令化合物(I a)或其鹽進行 邋原反應而製得。 此反應可依下文例8或相似方法進行。 目的化合物(I )及其製藥容許鹽具如速激肽拮抗作用 -22- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) - 訂--------·% 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 21 五、發明說明() ,神經素A拮抗作用,或神經素B拮抗作用之藥理活性 ,因而可用Μ防治速激肽仲介病,尤為物質P伸介病, 例如呼吸系病病[如氣喘,支氣管炎(慢性支氣管炎,急 性支氣管炎及擴散性全支氣管炎等),鼻炎,咳嗽,咳 痰,等]; 眼病如結合膜炎,春季結合膜炎,等; 皮虜病如接觸性皮虜炎,異位性皮嫌炎,蓐麻疹及其 它濕疹皮霜炎,等;發炎病如風溼性黼節炎,骨闥節炎 ,等; 疼痛(如偏頭痛,頭痛,牙痛,癌症疼痛,背痛,神 經痛等);等。 此外,預期本發明目的化合物(I)及其製藥容許鹽可 用Κ防治眼病如青光眼,葡萄膜炎等; 腸胃病如潰瘍,潰楊性結腸炎,剌激性腸病,食物過 敏等; 發炎病如腎炎,等; 循環病如高血壓,狹心症,心衰竭,栓塞,Raynaud 氐症等; 額癇;痙攣麻痺;頻尿;膀胱炎;勝胱壓迫症;小便 失禁;帕金森症;癡呆;與AIDS相關連之癡呆;阿玆海 默氏症;唐氐症;H u n t i n g t ο η氏舞蹈症;輕癌症;與免 疫增進或壓抑相關連之異常;由幽門氏稈菌或其它螺旋 尿酶陽性而葛蘭陰性之细菌所引起之異常;躧傷;血管 生成或由血管生成所引起之疾疾;等。 -23- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂------ (請先閱讀背面之注意事項再填寫本頁) 509688 Α7 Β7 2 2 五、發明說明() (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印制衣 另預期本發明目的化合物(I >及其製藥容許鹽可用Μ 防治慢性破壞性肺病,尤為慢性肺氣腫;虹膜炎5增生 性視網膜玻璃;乾癬;發炎性腸病;尤為Crohn^症,· 肝炎;凍傷,灼傷,帶狀泡疹或糖尿性醫病之表面疼痛 ;血胞過高所引起之腱痛;手術後神經瘤;尤為乳房切 除術;陰道前庭炎;血液滲析所引起之痛5扁平苔癖; 喉炎;支氣管炎,塵埃沈著病;百日咳,肺結核;囊纖 維化;嘔吐(如噁心,乾喔,嘔吐•急性嚯吐,延緩嘔 吐,自發嘔吐,手術後噁心及嘔吐(PONV),由如痛症化 療藥物引發之急性及/或慢性嘔吐等);心理疾病,尤 為憂慮,壓抑,心境惡劣異常及精神分裂;髓鞘脫失症 如多數硬化及肌萎縮性側索硬化;嗎啡釋出異常;水腫 如由熱灼傷所引起之水腫;小细胞癌,尤為小细胞肺癌 (SCLC);過敏性異常如有毒常春藤;纖維化及膠原症如 皮硬化及皮虜瞎伊紅血球過多瓜仁蟲病;反射交感不良 症如肩/手症;上嫌症如酒精上癱;與壓抑相闞連之異 常;風濕病如纖維織炎;激進行為,任意共腋用抗精神 病劑;躁狂,任意共服用抗精神病劑;伴隨經前之徵狀 (PMS)亦稱為晚黃體相症(LLS);身心異常;精神兔疫異 常;有或無過度活力之注意缺乏異常(ADD)等。 此外,本發明目的化合物(I)及其製藥容許鹽為中樞 神經糸滲透劑。 供治療時,本發明目的化合物(I)及其製藥容許鹽可 Μ含一種該化合物為活性成份摻合如適合經口,非經腸 一 2 4 — 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 Ο *2 五、發明說明() 胄,外用(含局部),內服,靜脈,肌肉,吸入,鼻,闞 節內,椎管内,氣管或曝部投予之有機或無機固體或液 體賦形劑等習用製藥容許載體之習用翳藥製劑使用。此 翳藥製劑可為固體,半固體或溶液形式如膠囊,錠劑, 丸,小九,粉,粒劑,栓麵,油膏,乳劑,洗液,吸入 劑,注射用溶液,敷劑,膠,貼布,眼用點滴*溶液, 漿液,氣吸膠,懸浮液,乳化液等。若需要,製劑可含 輔肋物,安定劑,濶濕或乳化劑,鑀衝液及它習用添加 _ 〇 化合物(I)劑量可視病人情況而定,一般平均化合物 (I)單一劑量為0·1毫克,1毫克,10毫克,50奄克, 100毫克,250毫克,500毫克,及1000毫克者足Κ治 療如氣喘等速激肱仲介病。一般每天可投予0·1奄克/ 人〜1000毫克/人。 為_逑目的化合物(I)及其製藥容許鹽之有用性,本 發明部份代表化合物之藥理試驗結果如下所示。 Α.使用h-NKi受器結合分析評估NIU拮抗劑對中樞神系 之轉送效率 [I ]試驗方法 ⑴投予試驗化合物並由腦萃取出化合物 將雄SD鼠由靜脈投予含試驗化合物之溶液(1毫克/公 斤)。5分後將動物K乙醚麻醉,由主動脈灌入Μ 20毫升 食鹽水。快速取出腦,稱重並於4體重冷卻蒸餾水使用 Polytoron(KIHEMATICA)均質化。為萃取試驗化合物,將 -25- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ——------—-----訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 2 4 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) 500微升均質後,100微升甲醇,500微升之0.1N NaOH 及4毫升乙酸乙酿混合並於室溫下搖動10分。於3000rpin 雛心10分Μ收集有機層(2.5毫升),乾燥並溶於二甲亞 硪。 ⑵h-NK i受器結合分析 U)粗製CH0細胞膜之製備 收集表達h-NlU受器之CH0细胞,並於Dounce均質器於 41C及緩衝液(0.25莫耳蔗糖,25毫莫耳TriS-HCl(pH7.4) ,10毫莫耳MgCl2 , 1毫莫耳EDTA, 5微毫克/毫升P- APMSF)中均質化。將均質液雛心(500g, 10分),將製粒 懸浮於相同緩衝液,均質化後雛心。結合二個上清液並 雛心(100000 X g, 1小時)。分雛粗製细胞膜並懸浮於鑀 衝液(25 毫莫耳 Tris-HCl(r>H7.4), 10 毫莫耳 MgCla , 1 毫莫耳EDTA, 5微毫克/製備例p-APMSF),貯於-801C直 到使用。 (b)B Ι-ΒΗ-物質Ρ結合至製備膜 經濟部智慧財產局員工消費合作社印製 將细胞膜(6微奄克/奄升)於存在或無萃取化合物之下 ,於0.25毫升基質(50毫莫耳Tris-HC(pH7.4), 5毫奠耳 MnCl2, 20微毫克/毫升抑糜蛋白酶素,40微毫克/毫升 稈菌ic, 4微毫克/毫升亮Ik素,5微毫克/毫升p-APMSF ,2 00微毫克/毫升BSA)中,於22t:培養WMI-BH-受質P (0·1微毫莫耳)90分。培着終結後,快逮濾經Blue Mat 117 40濾器(使用前預處理K0.U聚乙烯亞胺3小時)。將 濾液清洗K清洗鑀衝液(50毫莫耳THs-HC1(pH7.4), 5 -26 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_
2 R 五、發明說明() 毫莫耳MnCl2 )。使用自動7計數器(Packard RIASTAR 5420A)計算放射活性。所示结果為專一結合,且定義為 由3徼毫奠耳未標定物質P取代者。 [H ]試驗結果 所有下列試驗化合物顯示於1毫克/公斤劑量下, 125 I-BH-物質P結合至h-NK i受器有高於80¾抑制率。 試驗化合物:例4-0) , 4-(2) ,7,和8之目的化合物。 B.狗之嘔吐反應 [I ]試驗方法 將所養成年狗(8-15公斤)各別靜脈投予K含試驗化合 物之溶液。5分後由皮下投予阿朴嗎啡(0.1/0.5毫升/ 公斤)Μ引發嚜吐反應並觀察60分。觀察並記錄各動物乾 嘔及嘔吐時間及次數。試驗間隔至少10天Κ試驗個別動 物。 [I ]試驗結果 所有下列試驗化合物顯示於0.32毫克/公斤劑量下對狗 嘔吐有100¾抑制率。 試驗化合物:例4-⑴之目的化合物。 下列製備例及實施例可用Μ鬭明本發明。 製備例1 將(2-甲氧乙氧基)甲基氯(4·87奄升)於室溫下加至含 3-羥基-4-甲苄酸(2.16克)及Ν,Ν-二異丙基乙胺(9.2毫 升)之1,2-二氯乙烷(40毫升)。回流攪拌24小時。蒸除 溶劑,於稀釋鹽酸及乙酸乙酯中分層。分離有機層並Κ -27- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------訂——— (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(26 ) 食鹽水洗,於硫酸鎂下乾燥,並減壓蒸除。由矽膠柱層析 純化(己烷/乙酸乙酯= 3:1)。收集含目的化合物部份並 減壓蒸除可得3-[(2-甲氧乙氧基)甲氧基]-4-甲苄酸(2-甲氧乙氧基)甲酯(4.82克)之油。 IR (Neat): 1725, 1595 cm"1 NMR (CDC13, δ)Γ~2.29 (3Hf: s), 3.37* (3H, s) , 3.39 (3Hf s), 3.54-3.90 (8H, m), 5.35. (2H, s), 5.60 (2H# s), 7.21 (1H, d, J=8.0Hz), 7.65 (1H, dd, J=1.6 and 8·0Ηζ), 7·74 (1H, d彳 J=1.4Hz) MASS (API-ES): 351 (M+Na)+ 製備例2 將鋁氫化鋰(0.35克)於及氮氣下,於12分内分批加 至含3-[(2_甲氧乙氧基)甲氧基]- 4-甲苄酸(2-甲氧乙氧 基)甲酷(3·5克)之四氫呋喃(20毫升)冰水中。於同溫 下攪拌0.5小時,加入2Ν Na0H(0.5毫升)。攪拌0.5 小時後,濾除不溶物並K四徑呋喃洗。結合濾液及洗液 ,減壓蒸除。溶於乙酸乙酯,加入氧化鎂(IVM3.5克) 。加熱回流攪拌2小時,溏經矽藻土,並K乙酸乙酯洗 不溶物。結合濾液及洗液,減壓蒸除。由矽膠柱層析純 化(己烷/乙酸乙酯=10:1)。收集含目的化合物部份並減 壓蒸除可得3-[(2-甲氧乙氧基)甲氧基]-4-甲苄酸(1.7 克)之油。 IR (Neat): 1687, 1407 cm"1 NMR (CDCI3. δ): 2.31 (3Η, s), 3.38 (3Hf s), 3.55-3.60 (2H# m), 3.82-3.87 (2H, in) , 5.37 (2Hf s) , 7.30 (1H, d, J=7.7Hz), 7.44 (1H, dd, J=1.4 and 7.7Hz)f 7.58 (1H, d, J=1.4Hz)〆 9·92 · (1H: s) . MASS (API-ES) : 279 (M+Na-fMeOH)+, . 247 (M+Na) + 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐)-28- (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 B7______ 2 7 五、發明說明() 製備例3 將含3-[(2-甲氧乙氧基)甲氧基卜4-甲苄酸(1·70克) 及1,4-二乙釀基-2,5-脈啶二_ (1.6克)之Η,Η-二甲基 甲釀胺(17毫升)及第三丁酮(17毫升)攪拌溶液中•於5t! 下加入第三丁氧化鉀(900毫克)。於室溫下攪拌24小時 •倒人水(300奄升)。將水層Μ稀鹽酸調至pH 4-5 ,萃 取Μ乙酸乙_。將萃取液清洗Μ食鹽水,於硫酸鈉下乾 燥並減壓蒸除。由矽膠柱層析純化(甲笨/乙酸乙酯=3:1) 。收集含目的化合物部份並減壓蒸除可得1-乙醯基-3 -[3 -(2-甲氧乙氧基)甲氧基]-4-甲苄基卜亞甲基-2,5-哌 阱二嗣(2·05克)之粉。 IR (KBr): 3208, 1700, 1627, 1598,· 1455, 1375 citT1 NMR (CDC13, δ): 2·26 (3H, 2.夺 5 (3H, s), 3·27 (:川, s), 3.58-3,62 (2Η, m), 3.81-3.86 (2Η, m), 4.49 (2Η, s), 5·32 (2Η, s>, 6·94 (1Η, dd, J=1.5 and 7·8Ηζ), 7·15 {1H, d, J=7.8Hz>, 7·23 (1H, d, J=1.5Hz), 7·27 (lHr s)f 8.34 (1H, br s) MASS (API-ES): 417 (M+MeOH+Na)+ 製備例4 將含1 -乙醮基-3-[3-(2-甲氧乙氧基)甲氧基]-4-甲 苄基]-亞甲基-2,5-哌畊二_(2.0克)之四氫呋喃(20 毫升)於室溫及大氣壓下,於10«Pd-C(50«溼,0.2克) 氫化3小時。濾除觸媒,將濾液減壓濃縮。將殘渣溶於 四氫呋喃(30毫升),加入肼單水合物(1.5毫升)。於室 溫下攪拌1小時,減壓濃縮。碾製Μ異丙酵,濾集固體 一 29- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------訂—------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 2 8 五、發明說明() 可得3-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]_2,5-哌 阱二 _ (1 · 75克)。 (請先閱讀背面之注意事項再填寫本頁) IR (KBr> : 3183, 3060, 1675, 1454 crtT1 NMR (CDC13/ δ): 2.21 (3Η, s), 2.95-4.00 (8H, m), 3.36 (3H, s}/ 4·20-4·27 (1H, m),. 5·19 (1H, d, J=7.0Hz), 5.38 (lHr d, J=7.0Hz), 6.50 (1H, br s), 6.72 (1H, br s), 6.75 (1H, dd, J=1.4 and 7.9Hz), 6.97 (1H, d, J=1.4Hz)f 7.08 (1H, d, J=7.9Hz) MASS (APCI): 323 (M+H)+, 247, 235 製備例5 將鋁氬化鋰(0.62毫克)於5¾及氮氣下,加至含3-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]-亞甲基-2·5-哌畊 二_ (1.7克)之四氫呋喃(17毫升)冰水溶液。攪拌回流 3.5小時。冷卻低於5¾下,加入2Ν NaOH。於同溫下攪 拌0.5小時,濂除不溶物並清洗Μ四氫呋喃。结合濾液 及洗液後減壓蒸除。將殘渣溶於乙酸乙酿,於硫酸納下 乾燥並減壓蒸除可得2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]哌阱(1 ♦ 27克)之油。 經濟部智慧財產局員工消費合作社印製 將苄氧羰氯(0.75克)之二氯甲烷(1毫升),於低於5¾ 及於5分內滴加至含如上所得2-[3-[(2-甲氧乙氧基)甲 氧基]-4-甲苄基]哌阱(1.27克)及三乙胺(2·2毫升)之 二氯甲烷U0毫升)冰水溶液中。於同溫下攪拌0.5小時 ,於低於5C及於10分內滴入含3,5-雙(三氯甲基)-苄醯 氯(0.93毫升)之二氯甲烷(1.0毫升)。於同溫下攪拌〇·5 小時,清洗Κ食鹽水,於硫酸鎂下乾燥並減壓蒸除。 -30- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7
? Q 五、發明說明() 由矽膠柱曆析鈍化(甲苯/乙酸乙酯=5:1)。收集含目的 化合物部份並減壓蒸除可得1-[3,5-雙(三氟甲基)苄醮 基]-4-(苄氧羰基)-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]哌阱(1.61克)之油。 IR(Neat): 2879, 1700, 1645cm NMR (CDC13. δ): 2.19 (3H, s) , 3.35 (3H, s), 2.40-5.40 (17H, ία), 6·40-8·10 (10H, m), 7·82、(1Η, br s) MASS (APCI): 669 (M+H)+ 製備例6 將含l-[3,5-雙(三氟甲基)苄釀基]-4-(苄氧羰基)-2-[3-[(2_甲氧乙氧基)甲氧基]-4-甲苄基]哌阱(1·6克) 之甲醇(20橐升)於室溫及大氣壓下,M10$Pd-C(50!K溼, 0.2克)氫化4小時。濾除觸媒,將濾液減壓濃縮。由 由膠柱層析純化(二氯甲烷/甲醇=40:1)。收集含目的化 合物部份並減壓蒸除可得1-[3,5-雙(三氟甲基)苄釀基] - 2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]哌阱(0·89 克)之油。 IR (Neat): 1732, 1714, 1705, 1647, 1431,cm-1 NMR (CDC13/ δ): 2.20 (3H, s), 2.50~5·20 (16H, m), 3·00 (3H, s}, 6·40-7·40 (5H, m), 7·80 (1H, s) MASS (API-ES): 557 (M+Na)+, 535 (M+H)+ 製備例7 將含(3R)-3-(甲氧甲基)嗎啉鹽酸鹽(4·71克)及三乙 胺(4·11毫升)之甲醇(110毫升),於室溫下加入5.8奠 耳環氧乙烷(22毫升)之甲苯溶液。於室溫下攪拌2天, 減壓蒸除。由矽膠柱層析純化(二氯甲烷/甲酵= 20:1)。 一31- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------· 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 3 0 五、發明說明() 收集含目的化合物部份並減壓蒸除可得2-[(3R)-3-甲氧 甲嗎啉基]乙酵(4·67克)之油。 IR (Neat): 3433, 2860, 1454, 1119, 1055 cnT1 NMR (CDC13, δ): 2·38-3·05 (5H, m)7 3·33 (3H, s>, 3.40-3.80 (8Η, m) MASS (APCI): 176 (M+H)+ 製備例8 仿製備例7之方法可得如下化合物。 (1) 2-[順-2,6-二甲嗎咐基]乙醇 IR (Neat): 3431, 3402, 1456, 1373, 1325, 1146 cm·1 NMR (CDC13, : 1·17 (6Η,山 J=6·3Hz), ‘1·84 (2Η' dd, J=10.2 and 11.4Hz), 2.52 (2Hf t, J=5.5Hz), 2,71-2.78 (2H, m), 3.65 (2H, t, J=.5 · 6Hz.) , 3 · 49-3.76 (2H, m) .MASS (APCI): 160 (M+H)4* (2) 2-[(2S,5S卜2-甲氧甲基-5 -甲氧嗎啉基]乙醇 IR (Neat): 3433, 3400, 1456, 1379, 1327, 1086, 1051 cnT1 NMR (CDC13, δ}·· 1·19 (3H, d, J=6.3Hz), 1·88 (1H, d, J=10.8Hz), 1·96 (1H, t, J-10.5Hz>, 2·54 (2H, t, J=5.5Hz), 2.72-2.83 (2H, m) 3.38 (3H, s) , 3.36-3.45 (2H, m), 3.63 (2H, t, σ=5.2Ηζ), 3.60-3.90 (2H, m) MASS (APCI): 190 (M+H)+ ⑶2-[(2S)- 2-甲氧甲基)嗎咐基]乙酵 -32- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I------------0^ (請先閱讀背面之注音心事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製
509688 A7 B7_ ^ 1 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) IR (Neat) ·· 3435, 1456, 1354, 1302 cm"1 NMR (CDC13, δ): 2.06 (1H, t, J=10.7Hz), 2.27 (1H, td, J=10.7 and 3.3Hz), 2.53-2.58 (2H, m) , 2.68-2,84 (2H, m), 3.38 (3H, s) , 3,38-3.44 (2Hf m) f 3.61-3.75 (4H, m), 3·89-3·98 (1H, MASS (API-ES): 176 (M+H)+, 198 (M+Na)+ 製備例9 於含2-[(3R)-3-甲氧甲嗎啉基]乙醇(505毫克)之甲 苯(2.5毫升)冰水溶液中,於低於5¾及氮氣下滴加入 含磺醵氯(42 9毫克)之甲苯(1.5毫升)。於701C下攪拌 1.5小時。冷卻至室溫,加入乙酸乙酯後減壓蒸除。加 入二異丙醚,於室溫下攪拌15分,濾集沈澱,K二異丙 醚洗並於40¾及減壓下乾煉可得(3R)-4-(2-氯乙基)_3-
(甲氧甲基)嗎啉鹽酸鹽(620毫升)之淡黃色粉。 mp: 162-1630C IR (KBr) : 2945, 1140, 1109, 108.4 cm-1 NMR (DMSO_d6, δ): 3.31 (3H, s), 3·10-4·10 (13H, m) MASS (APCI): 194 (M+H)+ (free) 製備例10 仿製備例9之方法可得如下化合物。 ⑴順-2,6-二甲基-4 -(2-氯乙基)嗎B朵鹽酸鹽 經濟部智慧財產局員工消費合作社印製 IR《KBr): 1513, 1458, 1394, 1336, 1143 cirT1 NMR (DMSCHdg, δ): 1.12 (6H, df J=6,3Hz), 2.60-2.80 (2H, m), 3·44-3·50 (4H, m), 3·95-4·10 (4H, m) MASS (APCI) : 178 (M+H)4* (free) (2) (2S,5S)-4-(2-氯乙基)-2-甲氧甲基-5-甲嗎啉鹽酸鹽 -33- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7__ Q 9 五、發明說明() IR (KBr): 2613, 1456, 1390, 1124, 1082 cirT1 NMR (DMSO-dg, δ): 1.13 (3H, d, J=6.3Hz) , 2.50-3.00 (請先閱讀背面之注意事項再填寫本頁) (3H, m), 3.21 (3H, s), 3.34-3.51' (7H, m) , 4.03-4.10 (4H, m) MASS (APCI): 208 (M+H)+ (free) (3) (2S)-4-(2-氯乙基)-2-(甲氧甲基)嗎啉鹽酸鹽 NMR (DMSO-dg, δ): 3.00 (2Η, m), 3.27 (3Hf s), 3.47 (4H, m), 3.75-4.12 (7H, m), 11-91 (1H, m) MASS (APCI): 194 (M+H)+ (free) 製備例11 將三乙釀氧硼氫化鈉(36.7克)於ου下分批加至含 (2S)-2-胺基-卜丙醇(10.0克)及苄醛(13·53毫升)之二 氯甲烷(140毫升)及乙酸(8·38毫升),於室溫下攪拌過 夜。依次清洗Μ 2Ν Ν0Η吸食鹽水,於硫酸納下乾燥,減 壓蒸除。由矽膠柱層析純化(二氯甲烷/甲酵=30:1)。收 集含目的化合物部份並減壓蒸除可得(2S)-2-苄胺基-1-丙醇(15.96克)。 IR {KBr): 2843, 1496, 1454, 1377, 1340, 1065 cnT1 NMR (CDC13, δ): 1·10 (3H, d,'J=6.4Hz), 2·77-2·93 (1H, 經濟部智慧財產局員工消費合作社印製 m), 3·28 (1Η, dd, J=10.6 and 6·9Ηζ), 3·61 (1Η, dd, J=10.6 and 4.0Hz), 3.75^ 3.87 (2H, ABq, J=13Hz), 7.21-7.34 (5H, m) MASS (API-ES): 166 (M+H)+ 製備例12 將(S)-( + )-甲甘胺酸醚U.25毫升)於室溫下滴加至含 (2S)-2 -苄胺基-1-丙醇(7·6克)之甲酵(7.6毫升)。於 40-50 ¾下攪拌24小時,減歷濃縮。由矽膠柱層析鈍化 -3 4 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7 五、發明說明() (二氯甲烷/甲烷=30:1)。收集含目的化合物部份並減壓 蒸除可得(2S) - 2-[卜苄基U(2S)-2-羥基-3-甲氧丙基] 胺基]-1-丙酵(10·4克)之油。 IR (Neat): 3400, 2929, 1452, 1414, 1373, 1329 cm·1 NMR (CDC13/ δ·) : 0.96 (3H, d, J=6.7Hz), 2.50-2.60 (1H, m), 2·57 (1H, dd, J=13..4 and 6·2Ηζ), 2·67 (1H, dd, J=13.4%and 6.5Hz), 2.95-3,10 (1H, m), 3.21-3.52 (4H, m), 3.30 (3H, s) 3.49 (1H, d, J=13.6Hz)f 3·71-3.75 (1H, m), 3,83 (1H, d, J=13,6Hz), 7.21-7·37 (5H, m) MASS (APCI): 254 (M+H)+ 製備例13 將三苯膦(10.09克)於室溫下加至含(25)-2-[卜苄基-N-[(2S)-2-羥基-3-甲氧丙基]胺基]-1-丙酵(8·86克)之 四氯甲烷(4.06毫升)。於室溫下攪拌2天,減壓濃縮。 碾製Κ二異丙醚(200毫升>3次,倒出水溶性部份後減 壓蒸除。由矽膠柱層析純化(二氯甲烷/甲酵=40:1)。收 集含目的化合物部份並減壓蒸除可得(2S)-1-[N-苄基-Ν-[(lS)-2-氯-1-甲氧乙基]胺基卜3-甲氧基-2-丙酵(4· 90 克)之油。 IR {Neat} : 3463, 1452, 1362 crtfl NMR (CDCl3f δ): 1.43 (3Η, d, J=6.6Hz)f 2.53-2.82 (4H, m>, 3·30-3·39 (2H, m), 3.36 (3H, s), 3·59 (1H,山 J=13.6Hz), 3.83 (1H, d, J=13.6Hz)/ 3.79-3.87 (1H, m), 4.0卜4·09 (1H, m), 7·21-7·.33 (5H, m) MASS (APCI): 272 (M+H)+ -3 5 _ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) 衣 訂---------· 經濟部智慧財產局員工消費合作社印製 509688 A7 B7___ 五、發明說明() 製備例14 將含(2S)-1-[H-苄基-N-[(1S)-2-氯-1-甲氧乙基]胺 基]- 3-甲氧基-2-丙醇(1·90克)之Ν,Ν-二甲基甲醢胺(10 毫升),於Ot下加至含Na0H(0.45克,60»;礦物油)之Η,Η -二甲基甲釀胺(10毫升)冰水溶液中。於同溫下攪拌1 小時,倒至冰水萃取Μ乙酸乙酯。將萃取液清洗Μ食鹽 水,於硫酸鎂下乾燥並減壓蒸除。由矽膠柱層析鈍化 (己烷/乙酸乙酯=10:1)。收集含目的化合物部份並減壓 蒸除可得(2S,5S)-4-苄基-2-甲氧甲基-5-甲嗎啉(0.86 克)之油。 IR (Neat): 2875, 1452, 1362, 1325, 1130, 1082 citT1 NHR (CDC13' δ): 1·15 (3H, d, J=6.3Hz), 1·73-1·93 (2H, m) , 2.68^77 (2E, m)f 3v35 (3Hr s) , 3.49 (2H, s), 3.31-3.49 (2H, m), 3.68-3,81 (2H, m) f 7.25-7.32 (5H, m) MASS (APCI): 236 (M+H) + 製備例15 將含(2S,5S)-4-苄基-2-甲氧甲基-5-甲嗎啉(0·86克) 之澹鹽酸(〇·31毫升)及甲醇(8.6奄升)於將結合有機曆 及大氣壓下,Ml(UPd-C(50i;溼,0.2g)氫化3小時。由 Celite濉除觸媒,將_液減壓澹縮可得(2S,5S卜2-甲氧 甲基-5-甲嗎啉鹽酸鹽(0.71克)之油。 IR (Neat): 3433, 3402, 2939, 1597, 1456, 1392, 1331, 1107 cm"1 NMR (DMSO-d6, δ): 1.12 (3H, d, J=6..3Hz), 2·49-2·75 (2H, m), 3·13-3·19 (2H, m), 3·27《3H,幻,3·38 U'H, d, 3·80-4·00 (2H,,m) MASS (APCI): 146 (M+H)+ (free) 麵36- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ' ~ (請先閱讀背面之注意事項再填寫本頁) - —丨丨丨— —訂丨丨II丨丨! 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 A7 ^------- 五、發明說明(35) 製備例1 6 將Η-乙醣基-3-甲氧基-4-甲基-DL-苯丙胺酸(7·28克) 溶於水(36.5毫升)及1Η HaOH(29毫升)。加入氯化鈷(I) 六水合物(36.5毫升克)及釀酶(Acylase Amano, 365毫 克),於3710下攪拌15.5小時間時以1«“011控制反應液 pH為7.5 。滹除不溶物並M6N鹽酸將濾液pH調為3 ,萃 取Μ乙酸乙酸,水洗,於硫酸鈉下乾燥,並真空蒸除可 得粗製Ν-乙醯基-3-甲氧基-4-甲基-D-苯丙胺酸(3.17克) 。將粗製物進行酿酶反應(氯化鈷(I )六水合物15.2毫 克,醜酶152毫克,3710, ?>Η7·5, 20小時)可得純Ν-乙 _基-3-甲氧基-4-甲基-D-苯丙胺酸(2.70克)之粘油。 ta]g6·8: -36.16° (Ο=0·424, MeOH) IR (Neat} : 3350, 1740, 1725 cirT1 NMR (CDC13/ δ): 1·99 (3H, s) , 2.17 (3H, s), 3.00-3.30 (2Hf m), 3.78 (3H, s), 4,75-4.90 (1H, m) , 6.00-7.10 (3H, ία), 6·36 (2H, br s) MASS (APCI).: 252 (M+H) + 製備例17 將N-乙醣基-3-甲氧基-4-甲基-D-苯丙胺酸(2.55克) 之6N鹽酸(25.5毫升)及甲笨(18毫升)攪拌國流4小時。 冷卻至室溫,分雛水層並將有機層水洗(10奄升)2次。 結合水層及洗液並減壓蒸除。濉集結晶並Μ冰水洗可得 3-甲氧基-4-甲基-D-丙胺酸鹽酸鹽(1.35克)之無色結晶 。將濾液減壓蒸除可得粗製3-甲氧基-4-甲基-D-笨丙胺 酸鹽酸鹽(0.6克)。 -37- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 B7 五、發明說明(36 )
mp·· 207-211eC
[a】g7·2: +2〇·2β (C=0.5, H20) IR (KBr" 1735, 1610, 1508 cnT1 NMR (D2〇, δ): 2.18 (3H, s) , 3.17: (1H, ddf J=7.6 and 14·6Ηζ), 3·32 (1H, dd, J=6,.0 and 14·6Ηζ), 3·85 (3H, s), 4.27 (1H, dd, J=6.0 and 7.0Hz), 6.85 (1H, d, J=7.3Hz), 6.91 (1H, s), 7·21 (1H, d, J=8.0Hz) MASS (APCI): 210 (M+H)+ (free) 製備例18 將磺釀氯(0.7毫升)於室溫及10分內滴加至含3-甲氧 基-4-甲基笨丙胺酸鹽酸鹽(1.75克)之甲酵(8毫升) 。於40-5 0TC攬拌2小時後加入磺醢氯(〇.7毫升)。再 攪拌1小時後減壓蒸除。將結晶碾製K二異丙醚並濾集 可得3-甲氧基-4-甲基-D-苯丙胺酸甲酯鹽酸鹽(1.70克) 之無色結晶。
mp: 196-197°C
[a]g°: -4.60° (C=0.5, MeOH) IR (Nujol): 3400, 1741, 1583, 1465, 1446, 1249 cm·1 NMR (D2〇, δ): 2·19 (3H, 3·2;ί (1H, dd, J=7.4 and 14.5Hz), 3.32 (1H, dd, J=6.0 and 14.5Hz), 3.85 (6H, s), 4·43 (1H, ddf J=6.0 and 7·4Ηζ), 6·82 (1H, dd, J=1.4 and 7.6Hz), 6.87 (1H, d, J^l^Hz), 7.22 (1H, d, J=7.6Hz) MASS (APCI): 224 (M+H)+ (free), 207, 164 製備例19 將碳酸鉀(1.7克)於冰冷下分批加至含3-甲氧基-4- _ 3 8 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ ^ 7 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) 甲基笨丙胺酸甲酯鹽酸鹽(1.60克)之二氯甲烷(7毫 升)及水(9毫升)。於低於5C及於15分内加入氯乙醸氯 (0.6 6毫升)後播拌0.5小時。分雛有機層,清洗Μ食鹽 水,於硫酸鎂下乾燥並減壓蒸除可得(2R)-2-[H-(氯乙 醯基)胺基]-3-(3-甲氧基-4-甲苯基)丙酸甲酯。 IR(Heat): 3305, 1737, 1643, 1583CBT1 製備例20 將苄胺(1·65克)及碳酸鉀(1.28克)於20¾下,依次加 至含(2R) - 2-[Η-(氯乙醯基)胺基]-3-(3-甲氧基-4-甲苯 基)丙酸甲酯(1.85克)之Ν,Ν-二甲基甲醮胺(15毫升)。 於35C下攪拌1.5小時,倒至冰水(20毫升)及二氯甲烷 (20毫升)。从稀鹽酸攪拌調為ΡΗ9 ,分雛有機層,清洗 Κ食鹽水(20毫升),於硫酸鎂下乾燥並減壓蒸除可得 (2R)-2-[Ν-(苄胺乙醯基)胺基]-3-(3-甲氧基-4-甲苯基) 丙酸甲酯之油。將含上逑(2R) - 2-[M-(苄胺乙醸基)胺基] - 3-(3-甲氧基-4-甲苯基)丙酸甲酯及乙酸(0.18毫升)之 異丙醇(10毫升),回流攪拌12小時。 經濟部智慧財產局員工消費合作社印製 冷卻至室溫下,加入異丙醚。濾集沈澱,清洗K異丙 醚可得(3R)-1-苄基-3-(3-甲氧基-4-甲苯基)哌阱-2,5-二_ (1 · 45克)無色結晶。
mp: 205-209°C
[a]g°: +11.12° (C=0-4, DMF) IR (KBr): 3237, 1677, 1656, 1465, 1446, 1442 cirT1 -39- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 五、發明說明(38 ) NMR (DMSO-dg, δ): 2.08 (3Η, s) , 2.76 (1Η, d, (請先閱讀背面之注意事項再填寫本頁) J=17.2Hz), 2.87 (1H, dd, J=4.8 and 13.4Hz), 3.11 (1H, dd, J=4,8 and 13.4Hz), 3.46 (1H, d, J=17.2Hz), 3.69 (3H, s), 4.25 (1H, ql, J=14.6Hz), 4.20-4.30 (1H, m), 4·52 (1H, d, J=14.6Hz), 6·54 (1H, dd, J=1.4 and 7.4Hz), 6.69 (1H, d, J=1.4Hz), 6.87 (1H, d, J=7.4Hz), 7·04-7·11 (2H, m),, 7.24-7·30 (3H, 8.33 (1H, d, J=2.2Hz) MASS (APCI): 339 (M+H)+ 製備例21 將鋁氫化鋰(0.378克)於低於5¾及氮氣下加至含(3R) 經濟部智慧財產局員工消費合作社印製 -1-苄基-3-(3-甲氧基-4-甲苯基)_阱-2,5-二黼(1.35 克)之四氫呋喃(22奄升)。攪拌回流3小時。冷卻低於 BC,加入2H氫氧化納。攪拌30分,濾除不溶物並清洗 Μ四氬呋喃。結合濾液及洗液,減壓蒸除可得(3R) -1-苄基-3-(3-甲氧基-4-甲苯基)哌畊之油。於5分内及低 於5¾下,將含3,5-雙(三氟甲基)苄釀氧(0.80毫升)之 二氯甲烷(1毫升)滴加至含上述所得(3R)-1-苄基-3-(3 -甲氧基-4-甲笨基)哌阱及三乙胺(0.84毫升)之二氯甲 烷(10毫升)冰水溶液中。於間溫下搜拌30分,清洗K食 鹽水,於硫酸鎂下乾燥並減壓蒸除。由矽膠柱層析純化 (己烷/乙酸乙酯= 4:1)。收集含目的化合物部份並減壓 蒸除可得(2R)-4-苄基- l-[3,5-雙(三氟甲基)苄醜基]_ 2-(3-甲氧基-4-甲苄基)哌阱(1.92克)之油。 一 40- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 _ 3 9 五、發明說明() IR (Neat): <2950, 2850, 1640, 1590, 1515 cm"1 NMR (CDC13# δ): 2.16 (3Hf s) f 2.00-5.20 (14H, m)f 6.25-6.32 (1H, m), 6·70~6.90 (2H, m) , 7.20-7.44 (7H, m), 7.80 (1H, br s) MASS (APCI): 551 (M+H)+, 573 (M+Na)+ 製備例22 將三溴化硼之二氯甲烷(1莫耳溶液,3.7毫升)於20 分內滴加至含(2R )-4-苄基-1-[3,5-雙(三氟甲基)苄醯 基]-2-(3-甲氧基-4-甲苄基)毈阱(0.68克)之二氯甲烷 (5毫升)冰水溶液中。於同溫下攪拌2小時,於室溫下 攪拌12小時,倒至飽和碳酸氬納溶液。分雛有機層•於 硫酸鎂下乾燥並減壓蒸除。由矽膠柱層析鈍化(己烷/乙 酸乙酯=4:1)。收集含目的化合物部份並減壓蒸除可得 (2R) - 4-苄基-1-[3,5-雙(三氟甲基)苄釀基]-2-(3-甲氧 基-4-甲苄基)哌畊(0.56克)之紅色泡沫。 IR(Neat): 1630, 1430cm**1 NMR (CDC13, δ}: 2·00-5·20 (14H, m), 5·61 (1H, br s), 6.20-6.25 (1H, m), 6.60-7.70 (2H, m), 7.20-7.60 (7H, m), 7.80-7.85 (1H, m) MASS (API-ES}: 519 (M - H2〇+H>' 537 559 (M+Na) 製備例23 將NaH(60!K礦物油,18毫克)於低於5t!及氮氣下,分 批加至含(2R)-4-苄基- l-[3,5-雙(三氟甲基)苄醢基]_ 2-(3-羥基-4-甲苄基)哌胼(〇·2克)之Ν·Ν-二甲基甲釀 胺(2毫升)冰水溶液中。攢拌5分後,加入(2 -甲氧乙 氧基)甲氯(0.06 4毫升)。於室溫下携拌2.5小時,加入 -41- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 _B7_ 40 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) 水。萃取Μ乙酸乙酿。將萃取液於硫酸鎂下乾燥並減壓 蒸除。由矽膠柱曆析純化(己烷/乙酸乙酯=7: 3)。收集 含目的化合物部份並減壓蒸除可得(2R)-4-苄基-1-[3, 5-雙(三氟甲基)苄釀基]- 2-[3-[(2-甲氧乙氧基)甲氧基] -4-甲苄基]哌阱(0·21克)之油。 IR (Neat): 2950, 1645, 1435 cm·1 NMR (CDC13, δ): 2.19 (3Η, s), 3.34 (3Η, s), 2.00-5.20 (17Hf m), 6.60-7.40 (10H, m) , 7.70-7.80 (1H, m) MASS (API-ES): 625 (M+H)+, 647 (M+Na)+ 製備例24 將(2R)-4-苄基- l-[3,5-雙(三氟甲基)苄釀基]-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]哌阱(0·38克)之甲 醇(6毫升)於室溫及大氣壓下,K 20¾羥鈀-碳(0· 06克) 氫化8小時。由Cel ite濾除觸媒,將濾液減壓濃縮。由 矽膠柱曆析純化(二氯甲烷/甲醇=30:1)。收集含目的化 合物部份並減壓蒸除可得(2R)-l-[3,5-雙(三氟甲基)苄 醯基]-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]哌畊 (0 · 3 2克)之油。 IR《KBr): 3000-2700, 1629, 1513, 14,44 cm·1 經濟部智慧財產局員工消費合作社印製 NMR (CDCI3, δ): 2.20 (3Η, s) , 2.50-5.30 (16Η, m), 3·36 (3Η, s), 6.40-7.50 (5Η, m), 7··80 (1Η, s) MASS (API-ES): 535 (Μ+Η)+,-557 (M+Na)+ 例1 將含1-[3,5-雙(三氟甲基)苄隨基]-2-[3-[(2-甲氧乙 氧基)甲氧基]-4-甲苄基]哌阱(440毫克)之Ν,Ν-二甲基 甲醵胺(2·2毫升),於室溫下加入(3R)-4-(2-氯乙基)- 一 42- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 41 五、發明說明() (請先閲讀背面之注意事項再填寫本頁) 3-(甲氧甲基)嗎啉鹽酸鹽(289毫克),碳酸鉀(434奄 克)及碘化鉀(149毫克)。於73ti下攪拌2小時。冷郤 至於室溫,倒至冰水並Μ飽和碳酸氫納溶液鹸化。萃取 Κ乙酸乙_。將萃取液清洗Μ食鹽水,於硫酸鈉下乾燥 並減壓蒸除。由矽膠柱層析鈍化(二氯甲烷/甲酵=40:1) 。收集含目的化合物部份並減壓蒸除可得1-[3,5-雙(三 氟甲基)苄釀基]-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲 苄基]_4-[2-[(3R)-3-甲氧甲基-嗎啉基]乙基]哌阱(450 毫克)之淡黃色油。 IR (Neat): 2879, 1639, 1437, 1281, 1136, 1009 cnT1 NMR (CDC13, δ): 2·20 (3H, s), 1.95-5.40 (34H, m), 6·40-8·10 (6H, m) MASS (APCI): 692 (M+H)+ 例2 仿例1之方法可得如下化合物。 (1) 1-[3,5-雙(三氟甲基)苄醜基]-4-[2-(順-2,6-二甲嗎 啉基)乙基]-2-[3-[(2-甲氧乙氧基)-甲氧基]-4-甲苄 基]哌畊 經濟部智慧財產局員工消費合作社印製 IR (Neat): 1680, 1643, 1508, 1435 ατΓ1 NMR (CDCl3/.5): 1.17 (6H, d, J=6,3Hz)f 1.78 (2H, t, J=10.8Hz)/ 2.20 (3Hf br s),,2.20-5.30 (23H, m), 3.36 (3H/ s) f 6.42-8.02 (6Hf. m) MASS (APCI): 676 (M+H)+ (2) 1-[3,5-雙(三氟甲基)苄醢基]-2-[3-[(2-甲氧乙氧基) -甲氧基]-4-甲节基]-4 - [2-[(2S,5S)-2-甲氧甲基-5 -甲嗎啉基]乙基]哌畊 一43 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印制衣 509688 A7 B7_ 42 五、發明說明() -、1 . * ,; # * . IR (Neat): 2933, 2881, 1643, 1439, 1281, 1086, 1012 cm-1 NMR (CDC13, δ): 1.18 (3H, d, J=6.2Hz), 1·78-1·96 (2H, m), 2.20 (3H, br s), 2.20-5.30 (25H, m), 3,37 (3H, s), 3.36 (3H, s), 6.66-7.80 (6h, m) MASS (API-ES): 706.3 (M+H)+, 728.3 (M+Na)+ 例3 將1- [3,5-雙(三氟甲基)苄醯基]_2 - [3 -[(2-甲氧乙氧 基)-甲氧基]-4-甲苄基]-4-[2-[(3R) - 3-(甲氧甲基)嗎 啉基]乙基]瞰阱(430毫克)於室溫下溶於甲酵(1〇毫升) ,加入甲磺酸(0.215毫升)。於同溫下攪拌18小時,減 壓濃縮至1/3體積,倒入冰水。M 15!KNa〇H鐮化並萃取 Μ乙酸乙酿。將萃取液清洗Μ食鹽水*於硫酸納下乾煉 並減壓蒸除。由矽膠柱層析純化(二氯甲烷/甲醇=3〇:1> 。收集含目的化合物部份並減壓蒸除,處理Μ4Η鹽酸/ 乙酸乙酿可得1-[3,5-雙(三氟甲基)苄醢基]-2-[3-羥基 -4-甲苄基]-4-[2 - [(3R)-(甲氧甲基)-嗎啉基]乙基]哌 阱二鹽酸鹽(280毫克)之無色粉。 mp: 167-172^ [α]^8: -8.50β (0=0.20, MeOH) IR (KBr>: 3400, 1645, 1429, 1282, 1184, 1138 cnT1 NMR (DMSO-dg, δ): 2,08 (3H, s), 2.60-5.10 (25Hf m), 6.18-7.10 (3H, m), 7:36-8.22 (3H, m), 9·25 (1H, br) MASS (APCI): 604 (M+H)+ (free) 例4 仿例3之方法可得如下化合物。 -44- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------* 訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明()
⑴1-[3,5-雙(三氟甲基)苄釀基]-4-[2-(順-2,6-二甲嗎 啉基)乙基]-2-(3-羥基-4-甲苄基)_畊二鹽酸鹽 mp: 188-200°C
[a]g9: +0.7。。 (C=0.25, MeOH) IR (KBr): 3402, 1643, 1516, 1429 cm"1 NMR (DMSO~d6/ δ): 1.15 (6H, d, J=6.0Hz), 2·08 (3H, br s), 2.00 -5.10 (19H, in), 6·19·8·21 (6H, m) MASS (APCI): 588 (Μ+Η)+ (free) (2) 1-[3,5-雙(三氟甲基)苄醯基]-2-(3-羥基-4-甲苄基) - 4-[2-[(2S,5S)-2-甲氧甲基-5-甲嗎啉基]乙基]哌阱 二鹽酸鹽
mp: 214-218eC
[a】g9: +0·80β (Ο0·25, Me〇H) IR (KBr}: 3433, 3398, 1645, 1516, 1429, 1371, 1281, 1182, 1140 cm·1 ' NMR《DMSOdg, δ) : 1·16 (3H, d, , J=6.0Hz) , 2·08 (3H, br s), 2.50-5.10 (21H, m), ?·27 (3H, s), 6.20-8.20 (6H, m), 9·00-9·20 (1H, m) MASS (APCI): 618 (M+H)+ (free) (3) l-[3,5-雙(三氟甲基)苄醯基]-2-(3-羥基-4_甲苄基) -4-[3-(3-吡喃基)-2-丙炔基]哌阱 NMR (CDC13, δ): 0.60-5.30 (14Η, m)f 5.77 (1H, br s), 6.20-8.90 (10H, m) MASS (APCI): 562 (M+H)+ , 例5 仿例1之方法再仿例3之方法可得如下化合物。 (1) (2R)-1-[3,5-雙(三氟甲基)苄醜基]-4-[2-[(2S)-2- ~ 4 5 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 丨丨—丨丨丨丨丨丨丨· —丨丨丨—訂—-----II— (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 44 五、發明說明() (甲氧甲基)嗎啉基]乙基]-2-(3-羥基-4-甲苄基)哌阱 二鹽酸鹽
mp: 207-210°C
[a]g6·2: -6·40。 (C=0.4, MepH) IR (KBr): 3300, 3000, 2700, 1644, 1428 citT1 NMR (DMSO-dg, δ): 2·18 (3Hf s) , 2.20-5,20 (22H, m), 6·10-8·20 (6H, m), 9.00-9,.40 (1H, br s), 11.00-12.00 (2H, m) MASS (APGI) : 604 (M+H)+ (free)’ (2)1-[3,5-雙(三氟甲基)苄釀基]-4-[2-[(25)-2-(甲氧 甲基)嗎咐基]乙基]-2-(3 -經基-4-甲节基)哌哄二鹽 酸鹽 IR (KBr): 1645, 1516, 1458, 1425, 1369 cm*1 NMR (DMS0-d6/ δ): 2.08 (3H, br s), 3.28 (3H, br s), 2.40-5.10 (22H, m), β·19-8.22 (6H, m) MASS (APCI): 604 (M+H)+ (free) 例6 將l-[3,5-雙(三氟甲基)苄醯基]-2-[3-[(2-甲氧乙氧 基)甲氧基]-4-甲苄基]哌阱(0.4克),1-氯-3-(3-8¾啶 基卜2-丙炔鹽酸鹽(0.17克),碳酸鉀(0.52克)及少量碘 化鉀之Η,Ν-二甲基甲醯胺(7毫升)於801C下攪拌4小時 。冷卻後,蒸除溶劑,加入乙酸乙酯及碳酸氧鈉溶液。 分離有機層,於硫酸鎂下乾燥,並減壓蒸除。由矽膠柱 層析純化(乙酸乙酯)。收集含目的化合物部份並減壓蒸 除可得1- [3,5-雙(三氟甲基)苄醯基]-2-[3-[(2-甲氧乙 氧基)甲氧基]-4-甲苄基]-4-[3-(3-吡啶基)-2-丙炔基] -46- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ---------訂—--- A7 B7 i、發明說明(45 ) 哌阱(0·44克)之油。 NMR (CDC13/ δ): 0.60-5.60 (23Η, m)f 6.30-8.90 (10H, m) MASS (APCI): 650 (M+H)+ 例7 將1- [3,5-雙(三氟甲基)苄醯基]-2 -(3-羥基-4-甲苄 基]-4-[3-(3-吡啶基)-2-丙炔基]哌阱(0.11克)之甲酵 (10毫升)處理K4H鹽酸/乙酸乙酯(1毫升)後減壓蒸除 。碾製Μ二氯甲烷及乙酸乙酯,濉集所得粉可得1-[3, 5 -雙(三氟甲基)苄醯基]-2-(3-羥基-4-甲苄基]-4-[3-(3 啶基)_2·丙炔基]哌畊二鹽酸鹽(〇·〇7克)·
mp: 180-190°C IR (KBr): 1693, 1676, 1645, 1549, 1531, 1516, 1460, 1456, 1427, 1392, 1367, 1317, 1281, 1217, 1188, 1066 cm·1 NMR (DMSO-d6, δ): 1.60-5,20 (14H,'m), 6.10-9.00 (10H, m) MASS (APCI): 562 (M+H)+ (free) 例8 將含l-[3,5-雙(三氟甲基醯基]_2-(3-羥基-4-甲 苄基]-4-[3-(3-吡啶基)-2-丙炔基]哌胼(160毫克)之 甲醇(10毫升)及四氫呋喃(10毫升),於室溫下以10!*Pd -C (20毫克)氫化1.5小時。濉除觸媒,將濾液減壓濃縮 。由矽膠柱層析純化(乙酸乙酯)。收集含目的化合物部 份並減壓蒸除,處理K4H鹽酸/乙酸乙酯可得雙 (三氟甲基)苄醯基]-2-(3-羥基-4-甲苄基]-4 - [3-(3-吡 啶基)丙基]哌阱二鹽酸鹽(17〇毫克)之無色固體。 -47- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------· 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 _ 五、發明說明(46 )
mp: 60-70°C IR (KBr): 1707, 1693, 1676, 1645, 1628, 1558, 1550, (請先閱讀背面之注意事項再填寫本頁) 1541, 1516, 1466, 1456, 1427,, 1387, 1365, 1329, 1319, 1281, 1182, 1136, 1039 cnT1 NMR 《DMSO-d6, δ): 1·80-5·20 (18H, m), 6·00·9·00 (10H, π〇 MASS (APCI): 566 (M+H)+ (free) 製備例25 將含3-甲氧基對甲苯酸(45.32克)之四氫呋喃(280毫 升),於冰浴冷卻及氮氣下加至含棚氫化納(9.29克)之 四氫呋喃(45毫升)。攪拌10分後,於3〜15t!下加入三 氟化硼乙醚(41.5毫升)並於室溫下攪拌過夜。加入水 (210毫升)及二異丙醚(6 0毫升)。分離有機層,將水層 萃取K二異丙醚(100毫升)。將结合有機曆依次清洗Μ IN NaOH及食鹽水,於硫酸鈉下乾燥並減壓蒸除可得3- 甲氧基-4-甲苄酵(41.63克)之油。 IR (Neat) : 3330, 1615, 1590,. 1510, 1465, 1418, 1255 cm-1 NMR (CDC13, δ): 1·70 (1H, br s), 2·21 (3Hf s), 3.84 (3Hf s), 4·65 (2H, s), 6·80,7·16 (3H, m 上 製備例26 經濟部智慧財產局員工消費合作社印製 將含3-甲氧基-4-甲苄酵(41.61克),濃鼸酸(125毫 升)及甲苯(83毫升)於90¾下攪拌1小時。冷卻後,加 入冰水(125毫升)及二異丙醚(80毫升),分離有機層, 將水層萃取K二異丙醚(160毫升)。將結合有機層依次 清洗Μ飽和碳酸氫納溶液及食鹽水,於硫酸鈉下乾燥並 減壓蒸除可得3_甲氧基-4 -甲节氯(46 ·35克)之油。 一 48- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_______ 47 五、發明說明() IR (Neat): 1615, 1590, 1510, 1470, 1415, 1255 cm^1 NMR (CDC13, δ): 2·21 (3Hy s) f 3.85 (3H, s), 4.57 (2H, (請先閱讀背面之注意事項再填寫本頁) s), 6·82-7·15 (3H, m) 製備例27 將3 -甲氧基-4-甲苄氯(46.35克)及乙釀胺丙二酸乙酯 (71.16克)依序加至含乙氯化鈉(24.34克)之乙酵(230毫 升)。攒拌回流2小時,加入冰水(690毫升)及从6N鹽 酸調至PH7 。濾集沈澱,Μ乙酵(3:1, 100奪升)洗,
乾燥可得粗製2-乙釀胺基-2-(3-甲氧基-4-甲苄基)丙二 酸二乙_ (85.03克)。將含此粗製物(80.66克)之庚烷 (400毫升)於501C下攪拌1小時,冷卻至室溫。濾集沉 澱,Μ庚烷洗,乾燥可得純物(74.57克)之無色結晶。 nip: 123-125,C IR 《KBr}: 3251, 1747, 1643, 1518, 1267, 1213, 1190, 1051 cnfl NMR (CDC13, δ): 1.30 (6H, t, J=7.1Hz), 2,03 (3Hf s), 2.16 (3H, s), 3.61 (2H, s), 3·76 (3H, s), 4.28 (4H, q, J=7.1Hz), 6·44-7·06 (4H, m) 製備例28 經濟部智慧財產局員工消費合作社印製 將含2-乙_胺基-2-(3-甲氧基-4-甲苄基)丙二酸二乙 酯(10克),K0HU.88克)之水(25毫升)及乙酵(25毫升) 攪拌回流1小時。再加入K0H(1,88克)之水(1〇毫升)並 攪拌回流2小時。冷卻至室溫後減壓濃縮。加入水(50 毫升)及乙酸乙_(50毫升)。分離有機層及M6N鹽酸調 至pHI.5。萃取Μ乙酸乙酯,清洗K食鹽水•於硫酸納 -49- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7___ 48 五、發明說明() 下乾燥並減壓蒸除可得N-乙醯基-3-甲氧基-4-甲基-DL -苯丙胺酸(7·58克)之粘油。 (請先閱讀背面之注意事項再填寫本頁) IR (Neat): 3350, 1740, 1725 cm’l NMR (CDC13, δ): 1·99 (3H, s), 2·17 (3H, s), 3·00-3·30 (2Hf m), 3.78 (3Hf s) f 4.75-4.90 (1H, m) , 6.00-7.10 (3H, m), 6·37 (2H, br s) 製備例29 依製備例2 7之方法可得如下化合物。 (1) 2-乙_胺基-2-(4-氯-3-甲氧苄基)丙二酸二乙酯
mp: 122-123°C IR (KBr): 3247, 2977, 17 49, 1643, ,1523, 1309, 1205 cirT1 NMR (CDC13/i6): 1.30 (6H, t, J=7.1Hz)f 2.03 (3H, s), 3.64 (2H, s), 3·83 (3H, s), 4··16-4·35 (4H, m), 6·53 (1H, dd, J=2.0 and 8.0Hz)f 6,56 (1H, d, J=2.0Hz), 6.56 (1H, s), 7.23 (1H, d, J=8.0Hz) MASS (APCI): 372 330, 282
⑵2-乙醯胺基-2-( 4-氟-3-甲氧苄基)丙二酸二乙酯 mp: 128-131eC IR (KBr): 2981, 1747, 1641, 1520, 1269, 1211 cnT1 NMR (CDC13, δ): 1.30 (6H, t, J=7.1Hz), 2.04 (3Hf s)f 3.62 (2H, s) f 3.82^ (3H, s), 4.27 (4Hf q, J=7,lHz)f 6·48-7·09 (4H, m) 經濟部智慧財產局員工消費合作社印制衣 MASS (APCI): 356 (M+H)+ (3) 2-乙醯胺基-2-(3,4-二氯苄基)丙二酸二乙酯 IR 《Nujol): 3259, 1749Λ 1645, 1518, 1317, 1277, 1205, 1051, 1016 cm-1 NMR (DMS0-d6, δ): 1.16 (6H, t, J=7.1Hz), 1.91 (3H, s), 3.42 (2H, s) f 4.15 (4H, qf J=7.1Hz), 6,76-7.45 (3Hf m) f 8.19 (lHf s) , MASS (APCI): 344 (M+H)+, 302 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-50 - 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_
4 Q 五、發明說明() (4) 2-乙醯胺基-2-[3-甲氧基-4-(三氟甲氧)苄基]丙二酸 二乙酯
mp: 119-120eC IR 《KBr>: 3500-3150, 2700-2300, 1637, 1631, 1461, 1348, 1238, 1172 cm,1 NMR (CDC13, δ): 1.31 (6H, t, J=7.2Hz>, 2.04 (3H, s>, 3·70 (2H, s), 3·84 (3H, s), 4·2Η·36 (4H, m), 6.57-6.64 (2H, m), 7.44 (1H, d, J=8.2Hz) MASS (APCI}: 406 316 (5) 2-乙釀胺基-2-(4-氟-3-甲苄基)丙二酸二乙_ IR (Neat): 3250, 1740, 1640, 1510,.1460, 1370, 1270, 1210, 1185 cm-1 NMR (CDC13, δ): 1·30 (6H, t, J=7.1Hz), 2.03 (3H, s), 2.22 (3H, s), 3·58 (2H, s), 4.27 (4H, q, J=7.1Hz), 6.53 (1H, s), 6.70-6.95 (3H, m> MASS (APCI): 340 (M+H)+ 製備例30 依製備例28之方法可得如下化合物。
(1) H-乙醸基-4-氯-3-甲氧基-DL-苯丙胺酸 mp: 177-179°C IR《KBr}: 3351, 3200-2500, 1735, 1629, 1548 cm一1
MASS (APCI): 272 (M+H)+, 230 ⑵H-乙醸基-4-氟-3-甲氧基-DL-苯丙胺酸 mp: 150-152eC IR《KBr): 3340, 2947, 1718, 1603, 1514, 1259, 1215 cirT1 NMR (DMSO-dg, δ): 1.79 (3H, s)., 2.74-3.07 (2H, m) , 3.81 (3H, s), 4.41 (1H, m), 6.77 (1H, m), 7.01-7.14 (2H, m) , 8·17 (1H, d, J=8.1Hz), 12.68 (1H, br) MASS (APCI): 256 (M+H)+ -51- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注音2事項再填寫本頁) --------訂— 經濟部智慧財產局員工消費合作社印製 509688 A7 __B7_
K A 五、發明說明() (3) N-乙釀基-3,4-二氟苯基-DL-丙胺酸 IR (KBr): 3360, 1710, 1615, 1550, 1530 cm"1 NMR (DMSOg, δ): 1.78 (3H, s), 2.50-2.88 (2H, m), 4.35-4.47 (1H, m), 7.07-7.41 (3H, m), 8.19 (1H, d, J=8.2Hz) MASS (APCI): 244 (M+H}+, 202 (4) H-乙醯基-3-甲氧基-4-三氟甲基-DL-苯丙胺酸 mp: 156-160eC ^ IR {KBr): 3326, 3200-2300, 1716, 162,1, 1552, 1459 cnT1 NMR (DMSO-dg, δ): 1.80 (3Hf s), 2,85-3.50 (2Hr m)f 3,87 (3H, s), 4·23-4·54 (1H, m), 6·94 (1H, d, J=8.0Hz), 7.13 (1H, s), 7.52 (1H, d, J=8:0Hz)f 8.23 (1H, d, J=8.1Hz), 12.82 (1H, br s) MASS (APCI): 306 (M+H)+ (free) ⑤N-乙醮基-4 -氟-3 -甲基-DL-苯丙胺酸 IR (Neat): 3350, 1720, 1600, 1540, 1500, 1345 ckT1 NMR (DMSO-dg, δ): 1.78 (3H, s), 2.20 (3H, s), 2·71-3·03 {2H, ir〇, 4·3Η·42 (1H, m), 6·97-8·19 (3H, m), 12·68 (1H, br s) " MASS (APCI): 240 (M+H)+ (6) N-乙醯基-3-氟-4-甲基-DL-苯丙胺酸 IR(Neat): 3300, 1740, 1720, 1600, 1540cm-1 製備例31 依製備例16之方法可得如下化合物。
(1)N -乙醯基-4 -氯-3 -甲氧基-D "苯丙胺酸 mp: 116-117°C
[a]g7: -36.6° (0=0.37, MeOH) IR (KBr): 3500-3150, 2700-2300, 1733, 1623 cm"1 MASS (APCI): 272 (M+H)+, 230 一 52- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----------ΦΜ.--------訂--------- (請先閱讀背面之注意事項再填寫本頁) J^688 A7 〜___B7_ 五、發明說明(51 ) (¾ Η-乙醯基-4-氟-3-甲氧基-D-苯丙胺酸 (請先閱讀背面之注音?事項再填寫本頁) IR (Neat): 3330, 2940, 1728, 1618,^1518, 1275, 1223 cm"*1 NMR《DMSO-d6, δ): 1.79 (3H, s), 2.70-3.10 (2H, m) , 3.81 (3H, s)f 4.40 (1H, m), 6.78 (1H, m), 7.01-7.14 (2Hf m}, 8·18 (1H, d, J=8.1Hz)/12.63 (lH,_br) HASS (APCI): 256 (M+H>+ (3) N-乙醯基- 3,4-二氟-D-丙胺酸 IR(KBr): 3395, 1 720, 1 6 1 5, 1 545 , 1 5 1 5 c ro ⑷N-乙醯基-3-甲氧基-4-三氟甲基-D-苯丙胺酸
mp: 156-16〇!C IR 《KBr}: 3326, 3200-2300, 1716,^1621, 1552, 1459 cnT1 NMR (DMSO-dg, δ): 1.80 (3H, s), ,2.85-3.50 (2H, m) , 3.87 • (3H, s), 4·23-4·54 (1H, m), 6·94 (1H, d, J=8.0Hz}, 7·13 (1H, s), 7·52 (1H, d,,J=8、0Hz), 8·23 (1H, d, J=8.1Hz), 12.82 (1H, br s) MASS (APCI): 306 (M+H)+ (free) s'. ⑸N-乙醯基-4-氟-3-甲基-D-苯丙胺酸 [α]§8: -34.60° (C=0.5, MeOH) IR (Nujol): 3400, 1715, 1605, 1530, 1500, 1450, 1240, 1200, 1120 cm"1 NMR (DMSO-dg, δ): 1.78 (3H, s), 2.20 (3H, s), 2.71-3.03 經濟部智慧財產局員工消費合作社印製 {2H, m), 4.31-4.42 (1H, m), 6·97-8·19 (3H, m), 12.68 {1H, br s) MASS (APCI" 240 (M+H) + (6) N-乙醯基-3,氟-4-甲基-D-苯丙胺酸 [a]g9: -46.10° (C=0.5, MeOH) IR (Nujol): 3300, 1705, 1600, 1560 cm"1 -53- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 __B7_ 五、發明說明(52 ) 製備例32 依製備例17之方法可得如下化合物。 (1) 4-氯-3-甲氧基苯丙胺酸鹽酸鹽
mp: 218-222eC
[a]g7: +3.17° (C=0.52, MeOH) IR (KBr) : 3500-3150, 2700-2300, 17.39, 1589, 1488 cm"1 NMR (D20, δ): 3.19 (1H, dd, J=7·5 and 14·5Ηζ), 3·33 (1H, dd, J-5.7 and 14.5Hz), 3.91 (3H, s) , 4.28 (1H, dd, J=5.7 and 7.5Hz), 6·89 (1H, dd, J=1.8 and 8.1Hz), 7.03 (1H, d, J=1.8Hz), 7·42 (1H, d, J=8.1Hz) MASS (APCI): 230 (M+H)+ ⑵4-氟-3-甲氧基-D-苯丙胺酸鹽酸鹽 mp: 210-220?C (decomp·) IR (KBr>: 1738, 1606, 1520, 1487, 1462, 1417, 1274, 1223, 1209, 1157, 1128,ςπΓ1 NMR (DMSO-dg, δ): 3.13 (2H, m), 3.83 (3H, s), 4.00-4.40 (1H, m), 6.70-6.90 (1H, m), 7,00-7.30 (2H, m) MASS (APCI): 214 (M+H)+ (free)
(3) 3-甲氧基-4-三氟甲基-D-苯丙胺酸鹽酸鹽 mp: 156-160°C IR (KBr): 3326,一3200·2300, 1716, 1621, 1552, 1459 citT1 NMR (〇2〇,δ): 3·19 (1H, dd, rJ=7.5 and,;U.4Hz), 3·33 (1H, dd, J=5.7 and 14·4Ηζ), 3·86 (3H, s), 4.20-4.26 (1H, m),6·97 (1H, d, J=8.0Hz),, 7·07 (1H, s), 7·58 (1H, d/ J=8·0Hz) MASS (APCI): 264 (M+H)+ (free) -54一 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ----------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) Α7
五、發明說明(53 ) (4) 4“氟-3-甲基苯丙胺酸鹽酸鹽 IR {Nujol): 1735, 1485, 1460, 1375, 12i〇 cnT1 MASS (APCI): 198 (M+H)+ (free) ⑥3-氟-4-甲基-D-苯丙胺酸鹽酸鹽 IR(Nujol): 1730, 1 480, 1 555, 1 250, 1220, 1200cm"1 製備例33 依製備例18之方法可得如下化合物。 (1) 4-氯-3-甲氧基苯丙胺酸甲_鹽酸鼸
卿:165-168°C IR (KBr) : 3200-2500, 1745, 1583, . 1494 cirT1 NMR (D20, δ): 3.22 (1H, dd, J=7·5 and 14·5Ηζ), 3.35 (1H, dd, J=6.8 and 14·5Ηζ), 3.85 (3H, s), 3.92 (3H, s), 4.44 (1H, dd, J=6.8 and 7·5Ηζ), 6.89 (1H, dd, J=1.9 and 8.1Hz), 7.02 (1H, d, J=1.9Hz)f 7.44 (1H, df J=8.1Hz) MASS (APCI): 244 (M+H)+
⑵4-氟-3-甲氧基-D-苯丙胺酸甲酿鹽酸鹽 mp: 172-1730C IR (KBr): 1745, 1610, 1581, 1518, 1452, 1398, 1294, 1273, 1242, 1215, 1163, 1120, 1061, 1028 cm*1 NMR (DMS0-d6r δ): 3.13 (2H, df J=6.3Hz)f 3.71 (3Hf s) f 3.83 (3Hr〜s), 4.31…(1Ή, t, J=6·3Hz), 6·70-6·90 (1H, m), 7·00-7·30 (2H, m) MASS (APCI): 228 (M+H)+ (free) (3)甲氧基-4-三氟甲基-D-苯丙胺酸甲酯鹽酸鹽 -55- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
- n ·ϋ n n «I ϋ 一一OJI ϋ I I I
Bf 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 5 4 五、發明說明()
mp: 158-165°C IR (KBr): 3326, 3200-2300, 1739, 1617, 1504, 1328 cnT1 NMR (D20, δ): 3.29 (1H, dd, J=7.5 and 14·4Ηζ), 3.42 (1H, dd, and 14·4Ηζ), 3·85.(3Η, s), 3.90 (3H, s), 4.46-4.55 (1H, m), 7.00 (1H, d, J=8.0Hz), 7.12 (1H, s), 7.65 (1H, d, J=8.0Hz) MASS (APCI): 277 (M+H)+ (free) (4) 4-氟-3-甲基-D-苯丙胺酸甲酯鹽酸鹽 IR (Nujol) : 3200, 17 40, 1490,, 1450, 1240 cm"1 NMR (DMSO-dg, δ): 2.22 (3H,rs)f 3.00-3.17 (2H, m) , 3.68 (3H, s), 4·21-4·28 (1H, m), 7·07鐘7.18 (3H, m>, 8·67 (3H, s> MASS (APCI): 212 (M+H)+ (free) (5) 3-氟-4-甲基-D-苯丙胺酸甲酯鹽酸鹽 IR 《Nujol): 1740, 1580, 1510,,1450 cm·1 NMR (DMSO-dg, δ): 2.21 (3H, s) , 3.13 (2H, d, J=6.0Hz), 3·69 (3H, s>, 4.29 (lH,t, J=6.0Hz), 6·95-7·28 (3H, m), 8.70 (3H, s) MASS (APCI): 212 (M+H)+ Cfree)
(6) 4-氟-D-苯丙胺酸甲酯鹽酸鹽 mp: 197.3-197.8°C IR (KBr): 2989, 2956, 2910, 1745, 1741, 1504, 1490, 1450, 1240, 825 cm"1 NMR (DMSO-dg, δ): 3.10 (1H, dd, J=7·0 and 14.0Hz), 3.18 (1H, and ΙΦτΟΗ,ζ), 3·67 (3H, s), 4·26 (1H, dd, J=6.4 and 7·0Ηζ>, 7·11·7·33 (4H, m), 8.67 (3H, br s) MASS: 198 (M+H)+ (free) -56- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) -------------——訂——— (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明()
⑺4-氯苯丙胺酸甲酯鹽酸鹽 mp: 210-211°C IR 《KBr): 1743, 1707, 1693, 1645, 1547, 1541, 1514, 1495, 1454, 1240, 1186, 1L47, 1126, 1099, 1061, 1024 cm*1 / NMR (DMSO-dg, δ): 3.00-3.30 (2H, m), 3.68 (3H, s), 4.28' (1H, t, J=6,5Hz), 7.28 (2H, -d, J=8.4Hz), 7.40 (2H, d, J= 8 · 4 H z) MASS (APCI): 214 (M+H)+ (free)
(8) 4-三氟甲基-D-苯丙胺酸甲酯鹽酸鹽 mp: 198-199°C IR (KBr): 3199, 2864, 1741 cm·1 NMR (DMS0-d6, δ): 3·10-3·30 (2H, m), 3·69 (3H, s), 4.35 (1H, t, J=6.4Hz) , 7.51 (2H, d, J*8.1Hz) , 7.71 (2\l, df J=8·1Hz) MASS (APCI): 248 (M+H)+ (free) 製備例34 依製備例19之方法可得如下化合物。 (1) (2R)-2-(2-氯乙醯胺基)-3-(4-氟-3-甲氧苯基)丙酸甲酯
mp: 68-69eC IR (KBr): 3303, 2954, 1739, 1654, 1538 cm"1 NMR (CDC13, δ): 3·13 (2H, d, J=6.0Hz), 3·75 (3H, s), 3.88 (3H, s), 4·05 (2H, s), 4.84-4·93 (1H, m), 6.65 (1H, ddr J=1.8 and 8.1Hz)f 6.67 (lHf dr J=1.8Hz)f 7.28 (1H, d, J=8.1Hz) / MASS (APCI): 320 (M+H)+, 288, 260 (2) (2R)-2-(2-氯乙醯胺基)-3_(4-氯-3-甲氧苯基)丙酸甲酿 -57- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------------------ —訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7 _ 5 6 五、發明說明()
lap: 86-87°C IR (KBr): 1726, 1687, 1649, 1614, 1550, 1518, 1454, (請先閱讀背面之注意事項再填寫本頁) 1423, 1419, 1362, 1331, 1213, 1227, 1213, 1186 cnT1 NMR (CDC13, δ): 3·12 (2H, d, J=5.8Hz), 3·75 (3H, s), 3·87 (3H, s), 4·05 (2H, s), 4·87 (1H, dt, J=8.0 and 5·8Ηζ}, 6.40-7.20 (3H, m) MASS (APCI): 304 (M+H)+ (3) (2R)-2-(2-氯乙醢胺基)-3-(3,4-二氯苯基)-丙酸甲_ IR (Neat}: 3305, 1470, 1675, 1660, 1515 cm·1 NMR (DMSO-dg, δ): 2.87-3,11 (2H, m), 3.63 (2H, s), 4.03 (3H, s), 4.48-4.57 (1H, m) , 7.03-7.41 (3H, m), 8.68 (lHf d, J=7,8Hz) MASS (APCI): 292 (M+H)+
⑷(2R)-2 -(2-氯乙隨胺基)-3-[3-甲氧基-4 -(三氟甲基) 苯基)丙酸甲酯 rnp: 108-109eC IR (KBr): 3315, 2965, 1751, 1648, 1536, 1459, 1421 cnT1 NMR (CDC13, δ): 3·10-3·29 (2H, , 3·76 (3H, s), 3.89 (3H, s)f 4.05 (2H, s) f 4.87-4.97 (1H, m) , 6.73-6.77 (2H, m), 7.00-7.05 (1H, m), 7·75 (1H, d, J=8,3Hz) MASS (APCI): 354 (M+H)+ 312 (5) (2R)-2-(2-氯乙釀胺基)-3-( 4-氟-3-甲苯基)丙酸甲_ 經濟部智慧財產局員工消費合作社印製 IR (Nujol" 3300, 1730, 1540, 1500, 1450 cirT1 NMR (DMSO-d6, δ): 2·19 (3H, s), 2·82-3·06 (2H, m), 3·62 (3Η, s), 4.06 (2Η, s), 4.32-4.53 (1H, m), 6.97-7.13 (3H, m), 8·66 (1H, d, J=7.5Hz) MASS (APCI): 288 (M+H)+ -· (6) (2R)-2-(2-氯乙醮胺基)-3-(3-氟-4-甲苯基)丙酸甲酯 -58- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7 ^ 7 五、發明說明() (請先閱讀背面之注音?事項再填寫本頁) IR (Nujol): 3300, 1740, 1660, 154Q, 1450, 1360 cm"1 NMR (DMS0-d6/ δ): 2.19 (3H, s), 2,85-3.10 (2Hf m), 3.63 (3H, s), 4-06 (2H, s), 4.45-4.56 (1H, m) , 6.92-7.22 (3Hf m)/ 8.68 (1H, df J=7.8Hz) MASS (APCI): 288 (M+H)+ ⑺(2R) - 2-(2 -氯乙藤胺基)- 3-(4 -氟苯基)丙酸甲酿 IR (KBr): 3330, 1735, 1646, 1538, 1509, 1448, 1367, 1226, 1151 cnT1 NMR (CDCI3/ δ): 3,09 (1Η, dd, ^=5.8 and 14.0Hz), 3.16 (1H, dd, J=5.8 and 14·0Ηζ), 3·74 (3H, s), 4.03 (2H, s)f 4.85 (1H, ddd, J=5.8, 5.8 and 7.9Hz), 6.95-7.12 (5H, m) MASS: 274 (M+H)+
⑻(2R)-2-(2-氯乙醢胺基)-3-(4-氯苯基)丙酸甲酷 mp: 87-88°C IR (KBr): 1738, 1662, 1537, 14.95, 1491, 1446, 1408, 1363, 1265, 1209, 1119, 1090, 1036, 1016 citT1 NMR (CDC13, δ): 2·90·3·30 (3H, m), 3.75 (3H, s), 4·03 (2Hf s), 4.70-5.00 (1H, m)f 7.05 (2Hf d, J=8.0Hz), 7.28 (2H, d, J=8.0Hz) MASS (APCI): 290 (M+H)+ 經濟部智慧財產局員工消費合作社印製 (9) (2R)-2 -(2-氯乙醢胺基)-3-[4-(三氟甲基)苯基)丙酸 甲_
mp: 83-84eC IR (KBr): 3294, 1741, 1655, 1547 cirT1 NMR (DMSO-dg, δ): 3.12-3.32 (2H, m) , 3.76 (3H, s) f 4.04 (2Hf s), 4·86-4·96 (1H, m)" 7·25 (2H, d, J=8.1Hz), 7.57 (2H, d, J=8.1Hz) MASS (APCI): 324 (M+H)+ -59-* 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 5 8 五、發明說明() 製備例3 5 依製備例20之方法可得如下化合物。 (1) (3R)-1-苄基-3-(4-氯-3-甲氧苄基)乙醯胺基)-靦阱-2 · 5-二麵
mp: 149-150°C
[a]g7: +6.38° (C=0.47, MeOH) IR (KBr) : 3253, 1658, 1461 crtT1 NMR (DMSO-dg, δ): 2.94 (1H, dd, J=4.7 and 13.4Hz), 2.96 (lHf d, J=17.4Hz) , 3.14 (1H,,dd, J=4.5 and 13.4Hz), 3.56 (1H, df J=17.4Hz), 3.76 (3H, s), 4.21 (1H, d, J=14.6Hz), 4.30-4.35 (1H, m), 4.61 (1H, d, J=14,6Hz), 6.66 (1H, dd, J=1.8 and 8.0Hz), 6.91 (lH, d, 7.04-7·11 (2H, rt〇, 7·17 (1H, d, J=8.0Hz), 7.26-7.33 (3H, m)^ 8.38 (1H, br s) MASS (APCI): 359 (M+H)+ ^
(2) (3R)-1-苄基-3-(4-氟-3-甲氧苄基)哌阱-2,5-二_ mp: 177-179°C IR《KBr): 3240, 1658, 1516, 1464 crtT1 NMR (CDC13, δ): 3.00-3.30 (3H, m), 3.61 (1H, d, J=17.7Hz), 3.84 (3H, s)f 4.20-4.60 (3H, m), 6.29 (lHf br s), 6.60-7.50 (8H, m) MASS (APCI): 343 (M+H)+ (3) (3R)-1-苄基-3-(3,4-二氟苄基)哌胼-2,5-二酮 IR (KBr) : 3313, 3255, 1650, 1515, 1465, 1275 cm一1 NMR (DMSO-dg, δ): 2.90-4.Z0 (ΊΕ, m), 6.94-7.32 (8H, m), 8.35 (1H, s) MASS (APCI): 331 (M+H)+ -60- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) -------------------丨訂--------- (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 5 9 五、發明說明() ⑷(3R)-1-苄基-3-[3-甲氧基-4-(三氟甲基)苯基]-哌畊 -2,5 -二 _ IR (KBr): 3315, 1751, 1648, 1536, 1459, 1421 cm"1 NMR (DMSO-dg, δ): 2.89-3.25 (2Η,, m) , 3 · 19 (1Η, d, J=17.5Hz), 3.62 (1H/ d, J=17.5Hz), 3.77 (3Hf s), 4.15 (lHf d, J=14.5Hz), 4.30-4.35 (1H, m), 4.68 (1H, d, J=14.5Hz), 6.80 (1H, d, J=8.0Hz), 7.00-7.41 (7H, m), 8.41 (1H, br s) ' MASS (APCI): 393 (M+H)+, 351 (5) (3R)-1-苄基-3-(4-氟-3-甲苄基)哌_-2,5-二_ [a]g8: -15.60。 (C=0.5, DMF) IR (Nujol): 3250, 3225, 1650, 1430, 1320, 1250 cm-1 NMR (DMSO-dg, δ): 2.13 (3H, s), 2.81-4,65 (7H, m), 6.83-7.34 (8H, m) , 8.33 (111, 5) MASS (APCI): 327 (M+H)4, (6) (31〇-1-苄基-3-(3-氟-3-甲苄基)哌阱-2,5-二酮 [a]§7: -16.90° (C=0.5, DMF) IR (Nujol): 3250, 1680, 1640, 1460, 1320 cm-1 NMR 《DMS〇-d6, δ): 2·17 (3H, s), 2·84-4·69 (7H, 6.80-7.34 (8H, m),.8.35 (1H, s) MASS (APCI): 327 (M+H)+ ⑺(2R)-2-[N-(苄胺乙醯基)胺基]-3-(4-氟苯基)丙酸甲酯 MASS : 345 (M + H” (8) (3R)-1-节基-3-(4-氟节基)-哌哄-2,5-二 _ -61- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) ----- tr--------- 經濟部智慧財產局員工消費合作社印製 509688 A7 __B7_ 五、發明說明(6Q )
mp: 190.1-190.8°C IR《KBr) : 1671Γ 1656, 1509, 1448, 1334/1162 citT1 NMR (CDC13, δ): 3.08 (lHf d, J=4.4 and 14.0Hz), 3.19 (1H, d, J=5.9 and 14·0Ηζ),, 3.05 (1H, d, J=17.7Hz>, 3·56 (1H, d, J=17.7Hz), 4·》3 (1H, m), 4·41 (1H, d, J=14.3Hz), 4·54 (1H, d, J=14.3Hz), 6.38-7.35 (10H, m) MASS: 313 (M+H)+
(9) (3R)-1-苄基-3-(4-氯苄基)-哌阱-2,5-二麵 mp: 181-182°C IR (KBr): 1678, 1649, 1564, 1550, 1516, 1489, 1462, 1433, 1408, 1325, 1273, X178, 1112, 1090, 1063 cm-NMR (CDC13, δ): 2.80-3,30 (3H, m), 3.57 (lHf d, J=17.6Hz), 4.20-4.40 (2H, m)),.4.60 (1H, d, J=14.3Hz), 6.80-7.50 (9H, m) MASS (APCI): 329 (M+H)+
脚(31〇-1-苄基-3-[4-(三氟甲基)苄基]-哌阱-2,5-二晒 mp: 180-181°C IR (KBr): 3257, 1678, 1651 cm*1 NMR (DMS〇-d6, δ): 2·86 (1H, d, J=17.3Hz), 3.00 (1H, dd, J=4.8 and 13.5Hz), 3.25 (1H, d, J=4.5 and 13.5Hz), 3.59 (1H, d, J=17.3Hz), 4'08 (1H, d, J=14.3Hz), 4.30-4.40 (1H, m), 4.73 (1H, d, J=14.3Hz), 7.05-7·32 《7H, m), 7·47 (2H, d, J=8.2Hz> MASS (APCI): 363 (M+H)+ 製備例36 依製備例21之方法可得如下化合物。 -62- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 衣 訂--------I. 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(61 ) «(21〇-4-苄基-1-[3,5-雙(三氟甲基)苄釀基]-2-(4-氯- 3-甲氧苄基)哌阱 IR (Neat): 1643, 1517 cm-1 NMR (CDC13/ δ) : 2.00-5 ;20 (14H, m).r 6.20-8.00 (11H, m) MASS (APCI): 571 (M+H)+ (2) (2R)-1 - [3,5-雙(三氟甲基)苄醯基]-2-(3,4-二氟苄基) -4-苄哌阱 IR (Neat): 1645, 1515, 1435, 1280, 1180, 1140 cm*1 NMR (DMS〇-dg/ δ): 2·06-4·82 (11Η, m) , 6·61-8·19 (11Η, m) MASS (APCI): 543 (M+H)+ , 製備例37 將含(2R )-4-苄基-3-[3,5-雙(三氟甲基)苄醢基]2-(4 -氯-3-甲氧苄基)哌阱(2·23克)及氯甲酸1-氯乙酷(0.61 毫升)之1,2-二氯乙烷(10毫升)回流攪拌15小時。冷卻 後減壓濃縮。溶於甲酵(10毫升)並攪拌回流2小時。冷 卻後,減壓濃縮並濾集粉可得(2R)-l-[3,5-雙(三氟甲 基)苄醯基>2-(4-氯-3-甲氧苄基)哌阱鹽酸鹽(2·00克) 黃色粉。
nip: 70-71°C MASS (APCI): 481 (M+H)+ 製備例3 8 將三溴化硼之二氯甲烷(1莫耳溶液,6.0毫升)於20 分內滴加至含(2R)-l-[3,5-雙(三氟甲基)苄醯基]2-U-氯-3-甲氧苄基)哌阱鹽酸鹽(0·98克)之二氯甲烷(5毫 升)冰水溶液中。於間溫下攪拌2小時,於室溫下攪拌 12小時,再加入三溴化硼之二氯甲烷(1莫耳溶液,4.0 -63- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I------------------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 509688 A7 ___B7__ 五、發明說明(62 ) 奄升),於室溫下攪拌4小時。倒至飽和碳酸氫納溶液 後攢拌1小時。分雛有機層,於硫酸鎂下乾燥並減壓蒸 除。由矽膠柱層析鈍化(二氯甲烷/甲酵=20:1)。收集含 目的化合物部份並減壓蒸除可得(2R)-l-[3,5-雙(三氟 甲基)苄醯基]-2-(4-氯-3-羥苄基)哌畊(0·67克)之泡沫。 IR (Neat): 3400-3000, 1635 cm"1 NMR (DMSO-dg, δ): 2.60-4.80 (10H, m), 6.28-7.20 (3H, m) f 7.41 (1H, s>, 7·75 (1H, s), 8·14 (1H, d, J=8.2Hz), 10.00 (1H, br s) MASS (APCI): 467 (M+H)+ 製備例39 依製備例38之方法可得如下化合物。 (1) (2R)-4-苄基氯-3-羥苄基)哌畊
rap: 65-68°C IR (KBr): 2939, 2813, 1444, 1429,.1294, 1236, 1136f 1047 citfl NMR (DMS〇-dg/ δ): 1.60-4.00 (11H, m), 6.60 (lHf dd, J=1.6 and 8·0Ηζ), 6·78 (1H, d, J=1.6Hz), 7.16-7.40 (6H, m) (2) (2R)-l-[3,5-雙(三氟甲基)苄驢基]-2M4-氟-3-羥苄 經濟部智慧財產局員工消費合作社印製 (請先閱讀背面之注音?事項再填寫本頁) 基)哌阱
mp: 82-86°C IR 《KBr): 3282, 1637, 1282, 1182, 1136 cnT1 NMR (CDC13, δ): 2·20-5·20 (10H, m), 6·10-8·!0 (6H, m) MASS (APCI): 451 (M+H)+ (3) (3R)-1-苄基-3-(3-羥基-4-甲苄基)哌畊 -6 4- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) " ^ 509688 A7 B7_ 五、發明說明(63 ) IR (KBr) : 1649, 1516 crrT1 (請先閱讀背面之注意事項再填寫本頁) NMR (CDC13/ δ): 1.95-2.20 (2Η, m)v 2,20 (3H, s) f 2.57-3·06 (7H, m>, 3.51 (1H,. d, J=13 · 1Hz) , 3 · 52 (1H, d, J=13.1Hz), 6.60 (1H, d, J=7.4Hz), 6·61 (1H, s), 7.03 (1H, d, J=7.4Hz), 7.20-7.35 (5H, m) MASS (APCI): 297 (M+H),+ 製備例40 於含(2R)-2-( 4-氯-3-羥苄基)-4-苄哌阱(3.78克)及 三乙胺(5.71毫升)之二氯甲烷,於冰浴冷卻及氮氣下依 次加入4-二甲胺吡啶(0.29克)及第三丁二甲矽烷氯(5.30 克)。於室溫下攪拌遇夜,加入水(50毫升)並分雛有機 層,清洗Μ食鹽水,於硫酸鈉下乾燥並真空蒸除。由矽 膠柱層析純化(二氯甲烷/甲醇=10:1)可得(2R)-4-苄基-2-[4-氯-3-(第三丁二甲矽烷氧基)苄基]哌阱(4.11克) 之油。 IR (Neat): 1600, 1575, 1485, 1420, 1295, ,1250, 1170, 1140 cm一1 NMR (CDCI3, δ): 0.15 (6Η, s), 0.96 (9H, s) f 1.80 (1H, t, J=10.0Hz), 1,94-2.98 (8H, m), 3.40 (1H, d, J=13.0Hz), 3.48 (1H, d, J=13.0Hz), 6.60-7.34 (8H, m) 經濟部智慧財產局員工消費合作社印製 MASS (APCI): 431 (M+H)+, 397 製備例41 將l-[3-(二甲胺基)丙基]-3-乙基碳化二亞釀胺鹽酸 鹽(1.93克),於室溫下加至含(2R)-4-苄基-2-[4-氯-3 -(第三丁二甲矽烷氧基)苄基]哌阱(2.90克)及3-甲氧基- -65- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 五、發明說明(64 ) 5-(三氟甲基)苄酸(1· 48克),1-羥苯并三唑(1.1 4克)之 二氯甲烷(18毫升)。於室溫下攪拌6小時,倒至水(25 毫升)及二氯甲烷(15毫升)。將水層Μ飽和碳酸氧納溶 液調至f>H9 。分雛有機層,清洗Μ食鹽水,於硫酸鈉下 乾燥,再減壓濃縮。由矽膠柱層析鈍化(矽膠:52克; 己_/乙酸乙酯= 2:1)。收集含目的化合物部份並減壓蒸 除可得(2R)-l-[3-甲氧基-5-(三氟甲基)-苄釀基]-2-[4 -氯- 3-(第三丁二甲矽烷氧基)苄基]-4-苄哌阱之槳液 (3· 3 克)。 IR (Neat): 2937f 1639, 1603/ 1421' 1250, 1173f 1132’ 847 citT1 NMR (CDCl3f δ): 0.13 (6Hf s)f 1.00 (9H, s) , 1.60-5,10 * (11H, m), 3·81 (3H, s) , 6.3-0-8.20 (11H, m) MASS (APCI): 633 (M)+ 製備例42 依製備例37之方法可得如下化合物。 (1) (2R)-1-[3-甲氧基-5-(三氟甲基)苄醯基]-2-U-氯-3-羥苄基)哌阱
mp: 154-157eC IR (KBr): 3265, 2956, 1624, 1427, 1173, 1128 cm一1 經濟部智慧財產局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) NMR (DMSO-dgf δ): 2.20-4.90 (10H, m), 3·82 (3H, s), 6.20-7.30 (6H, m), 10.02 (1H, br) MASS (APCI): 429 (M+H)+ (2) (2R)-l-[3-三氟甲基-5-(甲硫基)苄醯基]-2-(4-氯-3-(第三丁二甲矽烷氧基)苄基]哌阱 -66- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7
β R 五、發明說明() IR (Neat): 1645, 1630, 1420, 1170, 1130 cm—1 NMR (CDC13, δ) : 0·18 (6Η, s) , ‘ 1·02- (9Η, s), 2·48 (3Η, ; * · ,; ·-"* ';···♦-»· s) , 2.60-5.10 (10Η,· m) , 6·28-8·26 (6Η, m) (請先閱讀背面之注意事項再填寫本頁) MASS (APCI): 559 .(M+H) +
(3) (2R)-l-[3,5-雙(三氟甲基)苄醜基]-2-[4-氟-3-甲氧 苄基)哌阱鹽酸鹽 mp: 127-134eC IR (KBr) : 2970, 2947, 1645, 1520, ,1281, 1184, 1136 cnT1 NMR (DMSO-dg, δ): 2.60-5.20 (12H, rc〇 , 6 · 50-8 · 30 (6H, m), 9.60 (2H, br) MASS (APCI): 465 (M+H)+ (free) ④(2R)-2-(4-氟-3-甲氧苄基甲氧基-5-(三氟甲 基)苄醢基]哌阱鹽酸鹽 IR (KBr): 1643, 1606, 1518, 1464, 1423, 1377, 1350, 1321,1242/ 1215, 1173, 1126,1053, 1038 cn\*~ 1 NMR (DMSO-d6, δ): 2.30-5.30 (16H, m), 6·30-7·50 (6H, m) MASS (APCI): 427 (M+H)+ (free) * (5) (21〇-1-[3,5-雙(三氟甲基)苄醢基]-2-(3,4-二氟苄 基)哌畊鹽酸鹽 IR (KBr): 3435, 2940, 2800, 1645, 1,520, 1435, 1365, 1280, 1185, 1135 cnT1 經濟部智慧財產局員工消費合作社印製 NMR (DMSO-dg, δ): 2.50-5.17 (9H, m) , 6,60-8.45 (6H, m), . 9.63 (2H, br s) MASS (APCI): 453 (M+H)4* (free) (6) (2R )-1-[3,5-雙(三氟甲基)苄鼸基]-2-[3-甲氧基-4-(三氟甲基)苄基]喊阱 -67- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7 五、發明說明(66 ) IR (Neat): 2952, 1639, 1623, 1461, 1423, 1124 cnT1 NMR (CDC13, δ): 2.60-5·20 (13H, m), 6·40-8·00 (6H, m) MASS (APCI) : 515 (M+H) + (7) (2R) -1 - [3 -甲氧基-5-(三氟甲基)苄釀基]-2-[3 -甲氧 基-4-(三氟甲基)苄基]哌阱 IR (Neat): 2950, 1637, 1461, 1423, 1317 cnT1 NMR (CDC13, δ): 2·60-5·20 (15圬,,m), 6·60義7·60 (6H, m) MASS (APCI): 477 (M+H)4* (8) (2R)-l-[3,5-雙(三氟甲基)苄醮基]-2 -(4-氟-3-甲苄 基]哌畊 IR《Neat): 3350, 1640, 1500, 1430, 1380, 1350, 1275 cm一1 NMR (DMSO-d6/ δ): 2.00-4.84, (12Η, m), 6.69-8.34 (7Η, m) MASS (APCI) : 449 (M+Ιί)+ (9) (2 R )-1-[3,5-雙(三氟甲基)苄釀基]-2-(3-氟-4-甲苄 基]毈畊 IR (Neat) : 3300, 1625, 1425, 1275, 1120 cnT1 NMR (DMS〇-d6f δ): 2.18 (3Η, s) , 2.40-4.86 (9Η, m) r 6·62_8·20 (6H, m) MASS (APCI): 449 (M+H)+
⑽(210-2-(4-氟苄基)- l-[3-甲氧基-5-(三氟甲基)苄醯 基]哌阱鹽酸鹽 mp: 78.8-80.3°C IR《KBr): 1513, 1423, 1349, 1172,’ 1126, 1054 cm一1 NMR (DMSO»d6, δ): 2·50-5·03 (9H,,m>, 3·82 (3H, s}, 6·94- 7.25 (8H, ία) , 9.56 (1H, br s) MASS (APCI): 397 (M+H)+ (free) (11)(2R) -1-[3,5-雙(三氟甲基)苄醯基]-2-(4-氯苄基] 哌畊鹽酸鹽 -6 8 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------· 經濟部智慧財產局員工消費合作社印製 ^9688 A7
五、發明說明(67 )
mp: 240-260°C IR (Neat): 1658, 1496, 1437, 1387, 1362, 1331, 1282, 1186, 1132, 1101, 1059, 1018 citT1 NMR (CDC13, δ): 2.00-5.30 (9H, m) , 6.70-8.50 (7Hr m) MASS (APCI): 451 (M+H)+ (free) (12) (2R)-2-(4-氯苄基)-l-[3-甲氧基-5-(三氟甲基)节醢 基]哌阱鹽酸鹽 IR (KBr): 1643, 1605, 1489, 1464, 1423, 1371, 1350, 1319, 1271, 1242, 1175, 1128, ;097, 1053 citT1 NMR (DMSO-dg, δ): 2.00-5.40 (13Η, m), 6.20-8.20 (7Hf m) MASS (APCI): 413 (M+H)+ (free) — f (13) (2R)-l-(3,5-雙(三氟甲基)苄醢基卜2-[4_(三氟甲 基)苄基]哌阱 NMR (CDC13/ δ): 2.30-5.30 (9Η, m)f 7·26-7.88 (7Η, m) MASS (APCI): 485 (M+H)+ (14) (21〇-1-[3-甲氧基-5-(三氟甲基)苄醢基]-2-[4-三 氟甲基)苄基]哌阱 IR(Neat): 2951,1632,1608cm'1 NMR (CDC13, δ): 2.70-5.10 (9H, m), 3.80 (3Hf s), 6.72-7.87 (7H, m) MASS (APCI): 447 (M+H>+ (15) (2R) -1-[3-甲氧基-5-(三氟甲基)苄醢基]-2 -(2-黎 甲基)哌畊 [a]g8·8: -46.15° (C=0.26, HeOH)
IR (Neat) : 3740, 1630 ciiTI NMR (CDC13, δ): 2.5-5.4 (9H, hi), 3·55 (3H, s), 6·51 (1H, br s), 6.87 (1H, br s), 7.06 (1H, br s) f 6.8-7.9 (7H, MASS (APCI): 429 (M+H) + -69- 本纸張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐〉 (請先閱讀背面之注音?事項再填寫本頁) 訂---------: 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 五、發明說明() (16) (2R)-2-[(lH-H3|B§-3-基)甲基]-l-[3-甲氧基-5 -(三氟甲基)苄釀基]哌阱 IR (Neat): 3280, 1620, 1459, 1427 citT1 NMR (CDCI3# δ): 2.60-3,00 (l〇Hf m), 3.74 (3Hf s), 6.70-7.40 (8H, m), 8.25-8.52 (lHf m) MASS 《APCI): 418 (M+H)+ (17) (2R)-1 -第三丁氧羰基-2 -(3-羥基-4-甲苄基)-哌阱 IR (KBr): 1674 cm"1 NMR (CDCI3/ δ): 1.37 (9Η, s), 2.20 (3H, s)f 2.72-3.15 (8H, m), 3·90-3·93 (1H, m), 4·16 (1H, br s), 6·62 (1H, s), 6.68 (1H, d, J=7.6Hz)f 7.02 (1H, d, J=7.6Hz) MASS (APCI): 207 (M+H-Boc)+ (18) (2R)-1-第三丁氧羰基-2-(4-氯苄基)-哌阱 [a]g7·2: +23.330 (C=0.39, MeOH) IR (Neat): 3340, 2980, 2870, 283Ό, 1690, 1410, 1370 οιγι"1 NMR (CDC13/ δ): 1.36 (9H, s) , 2.6-3.2 (7H, m), 3·90 (1H, br), 4.18 (1H, br s), 7·15 (2H, d, J=8.4Hz), 7.25 (2H, d, J=8.4Hz) MASS (APCI): 311 (M+H)+ 製備例43 依製備例41之方法可得如下化合物。 (1) (2R)-l-[3-三氟甲基-5-(甲硫基)-苄酿基]-2 - [4-氯-3-(第三丁二甲矽烷氧基)苄基]-4-苄哌阱 IR {Neat): 1645, 1490, 1420, 1300, 1170, 1130 citT1 NMR (CDC13^5): 0.15 (6H, s), 1·00 (9H, s) , 1.95-5.02 (11H, m), 2·48 (3H, s}, 6.20-8.25 (11H, m) MASS (APCI): 649 (M+H)+, 615 -70- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
I I I I I I I ^ * I I I--— II 509688 A7 B7__ 五、發明說明(69 ) ②(2 R)-4-苄基-2-(4-氟-3-甲氧节基)-1 - [3-甲氧基-5 -(三氟甲基)芾釀基]哌畊 (請先閱讀背面之注意事項再填寫本頁) IR (Neat): 1738, 1643, 1628, 1616, 1604, 1516, 1464, 1454, 1417, 1371, 1342, 1273, 1099, 1055 crtT1 NMR 《CDC13, δ): 0·60-5·20 (17Η, m), 6·00-7·50 (11Η, m) MASS (APCI): 517 (M+H)+ (3) (2R)-4-苄基- l-[3-甲氧基_5_(三氟甲基)苄醢基]-2 - [3-甲氧基-4-(三氟甲基)哌阱]哌哄 IR《N6at): 2811, 1643, 1280, 1180, 1137 crtT1 NMR (CDC13# δ): 2.20-5.20 (17H, ία), 6·40-7·50 (11H, m) MASS (APCI): 567 (M+H)+ ⑷(2R)-4-节基-2-(4-氟苄基)-1 - [3 -甲氧基-5 -(三氟甲 基)苄醯基]哌阱 IR (Neat): 1639, 1509, 1460, 1423, 1344, 1128, 1010 cm. NMR (CDC13, δ): 2.07 (1Η, br), 2.73-4.91 (8H, m) f 6.57-7.53 (12H, m) MASS: 487 (M+H)+ (5) (2R )-4-苄基-l-[3,5-雙(三氟甲基)苄釀基]-2 -(4-氯 苄基]哌阱 IR (Neat): 1738, 1676, 1647, 1628, 1618f 1498, 1454, 1417, 1387, 1273, 1084, 1068 cnT1 經濟部智慧財產局員工消費合作社印製 NMR (CDC13/ δ): 0.60-5.20 (11H, m), 6.40-8.70 (12H, m) MASS (APCI" 541 (M+H)+ (6) (2R)-4-苄基-2-(4-氯苄基)-1-[3-甲氧基-5-(三氟甲 基)苄醯基]哌阱 IR (Neat): 1707, 1678, 1643, 163.0, 1618, 1604, 1516, 1496, 1489, 1477, 1454, 1417, 1392, 1375f 1342, 1317 cm-1 NMR (CDC13, δ): 0.60-5.20 (14H, m). f 6.40-8.20 (12H, m) MASS (APCI): 503 (M+H)+ -71- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 509688 A7 B7 7 Λ 五、發明說明() ⑺(2R)-4-苄基- l-[3,5-雙(三氟甲基)苄醢基]-2-[4-(三氟甲基)苄基]哌阱 IR (Neat): 2950, 2800, 1765, 1740, 1640 citT1 NMR (DMSO-dg, δ): 1,70-4.30 (HHf m) f 7.13 (1H, d, J=7.8Hz), 7.20-7.70 (10H, m), 8.13 (1H, d, J=7.8Hz) MASS 《APCI): 575 (M+H)+ ⑻(2R)-4-苄基- l-[3-甲氧基-5 -(三氟甲基)苄醯基]- 2- [4-(三氟甲基)苄基]哌阱 IR (Neat): 2945, 2812, 1643 citi"1 NMR (CDCl3f δ): 2.04-5.10 (11H, m), 3.81 (3Hf s), 6,73- 7·93 (12H, m) MASS (APCI): 537 (M+H)+ ® (2R)-4-苄基-1 -[3-甲氧基-5-(三氟甲基)苄釀基]-2 - (2-萘甲基)哌阱 [a]g8·8: -18.34° (C=0,35, MeOH) IR (Neat): 3740, 1640 cm·1 NMR (CDC13, δ): 1.9-2.4 (2H, m) , 2.6-4·0 (11H, m), 4,4-5.2 (1H, m), 6,4-7.9 (15Hf m) MASS (APCI): 519 (M+H)+ ⑽(2R)-4-苄基-2-[(lH-B3l呤-3-基)甲基]-l-[3-甲氧基 -5-(三氟甲基)苄釀基]哌畊 IR (Neat): 3280, 1620, 1459 crrT1 NMR (CDCI3/ δ): 2·00-5.20 (14Hf m) , 6,60-7.60 (13Η, m), 7.90 (1Η, br s) MASS (APCI): 508 (M+H)+ 製備例44 將含4-氯-3-甲氧苄醛(5克)之甲醇(25毫升)於水冰 中滴加入含硼氫化納(368毫克)之0. 1N氫氧化納溶液 -72- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) - 訂---------. 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 7 1 五、發明說明() (5毫升)·並攪拌1小時。減壓蒸除,加入乙酸乙_及 水。分雛有機層,將水層萃取Μ乙酸乙酯。將結合有機 層窣取液於硫酸鎂下乾燥並真空濃縮可得4-氟-3-甲氧 苄醇(5. 22克)之油。 IR (Neat): 1610, 1516, 1462,, 1417, 1315, 1277, 1149, 1115, 1032 cm"l NMR (CDC13, δ): 1·75 (1Η, br s), 3.90 (3H, s), 4·64 (2Hf s), 6.70-7.20 (3H, m) 製備例45 依製備例26之方法可得如下化合物。 (1) 4-氟-3-甲氧苄氯 IR (Neat): 1608, 1516, 1462, 1417> 1325, 1284, 1271, 1219, 1155, 1119, 1032 cnT1 NMR (CDC13, δ) : 3.91 (3Η, s) , 4.55 (2Η, s), 6.70-7.20 (3Η, m) ②3-甲氧基- 4-(三氟甲基)苄氯 IR (Neat): 1606, 1459, 1272, 1174 cm""1 NMR (CDC13, δ): 3·91 (3H, s), 4·73 (2H, s}, 6·95 (1H, dd, J=0.6 and 8.0Hz), 7.04 (1H, d, J=0.6Hz), Ί .53 (1H, d, J=8.0Hz) 製備例46 依製備例24之方法可得如下化合物。 (2R)-l-[3,5-雙(三氟甲基)苄釀基]-2-(4-氟-3-甲氧苄 基)贿阱 IR (Neat): 1641, 1633, 1626, 1514, 1475, 1462, 1452, 1446, 1435, 1423, 1417, 1385, 1340, 1336, 1273, 1095, 1063, 1045 cm·1 NMR (CDC13/ δ): 0.60-5.40 (12Η, m), 6.20-8.60 (6Η, m) MASS (APCI): 465 (M+H)+ -73- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注咅?事項再填寫本頁) ------- —訂---------· 經濟部智慧財產局員工消費合作社印製 509688 A7 B7____ 7 2 五、發明說明() 製備例47 依製備例17之方法再依製備例18之方法可得如下化合 物0 3,4-二氟苯基-卜丙胺酸甲_鹽酸鹽 IR (KBr) : 3400, 1735, 1610, 1235 cirT1 NMR (DMSO-d6, δ): 3.16 (2Η, d, J=6.6Hz)f 3.70 (3H, s>, 4·33 (1H, t, J=6.6Hz), 7.05τ7.52 (3H, m), 8.65 (3H, s) MASS (APCI): 216 (M+H)+ (free) 製備例48
將28¾:甲氧化納之甲酵(50毫升)加至3-氟-4-(三氟甲 基)苄酸(20·8克)之二甲亞确(200毫升)。於90C下攪 拌3.5小時。冷卻至室溫,倒至冰水(1.5升 >,並Μ稀 鹽酸鹼化。攪拌30分後,漶集沈澱,風乾可得3-甲氧基 -4-(三氟甲基)苄酸(22.95克)無色粉。 mp: 203-204eC IR (KBr): 3500-3150, 2700-2300, 1637, 1606, 1459, 1272, 1174 cirT1 NMR (DMSO-dg, δ): 3.95 (3H, s), 7.61-7.77 (3H, m), 13.45 (1H, s) 製備例49 將鋁氫化鋰(4.53克)於氮氣下分批加至含3-甲氣基-4-(三氟甲基)苄酸(23·3克)之四氫呋喃(400毫升)冰 水溶液中,於室溫下攪拌2小時。冷卻Μ冰,於氮氣下 加入2Ν氫氧化納(2毫升)。濾集沈澱,並清洗Μ四氫呋 喃,結合濾液及洗液,並減壓蒸除可得粗製油。由矽膠 -74- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -------- —訂---------· 經濟部智慧財產局員工消費合作社印製 509688 Α7 Β7 7 1 五、發明說明() 柱層析純化(二氯甲烷/甲醇=40:1),可得3-甲氧基-4-(三氟甲基)苄酸(20克)無色油。 IR (Neat): 3500-3150, 2700~23〇〇, 1637, 1606, 1459, 1272, 1174 cm·1 NMR (CDC13/ δ): 2.01 (1Η, t, J=4.6Hz), 3·88 (3H, s), 4·72 (2H, d, J=4.6Hz), 6.95 (1H, dd/ J=0.4 and 8.0Hz), 7.04 (1H, d, J=0.4Hz) 7.52 (lHf df J=8.0Hz) 製備例50 將5-溴-2-氟甲苯(6克)之乙醚(10毫升)及觸媒量之 碘,於氮氣下加至含鎂(960毫克)之乙醚(1〇毫升)並攪 拌回流30分。冷卻後,加入含鄰甲酸乙_(5.4克)之乙 醚(20毫升)並搅拌過夜。加入硫酸(10!«, 20奄升)後分 離有機曆,清洗Μ食鹽水,於硫酸納下乾燥並蒸除。由 矽膠柱層析純化(己烷/乙酸乙酷=10:1)可得4-氟-3-甲 苄醛之油。 IR (Neat): 1695, 1590, 1495, 1280, 1245, 111〇 NMR (CDCI3/ δ): 2,36 (3Hf s), 7.10-7.84 (3H/ m) f , 9.93 (1H, s) 將所得化合物溶於甲醇及四氫呋喃,加入硼氫化納。 攪拌1小時後,除去溶劑並加入水。Μ10»!硫酸酸化, 萃取K乙酸乙酯,清洗Μ食鹽水,於硫酸鈉下乾燥,並 減壓蒸除可得4-氟-3-甲苄醇(1.33克)之油。 IR (Neat) : 3300, 1500, 1250 citT1 NMR (GDCI3, δ) :- 2.28 (3H, s) , 4.62 (2H, s), 6·93-7·26 (3H, m) 製備例51 將四溴化碳(3·08克)分批加至含4-氟-3-甲苄醇(1.3 -7 5 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) C---- 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(74 ) 克)及三苯膦(2.9克)之二氯甲烷(50毫升)並攪拌1小 依次清洗Μ飽和碳酸氧納溶液及食鹽水,於硫酸鈉 Τ乾燥,真空蒸除。碾製Κ己烷並濾集沈澱。將瀘液減 ®蒸除,由矽膠柱層析鈍化(己烷)可得4-氟-3-甲苄溴 (1·28克)之油。 IR (Neat) : 1500, 1250, 1200 citT1 NMR (CDC13, δ): 2·26 (3H, s), 4·45 (2H, s), 6·91-7·26 (3Η, m) 製備例52 依製備例50之方法可得如下化合物。 3-氟-4-甲苄酵 IR(Neat” 3350, 1580, 1510· 1420, 1250〇班4 製備例53 依製備例51之方法再依製備例27之方法可得如下化合 物。 2-乙釀基胺基-2-(3 -氟-4-甲苄基)丙二酸二乙_ IR (Nujol): 3250, 1740, 1630, 1510, 1360 cm·1 NMR (DMSO-dg, δ): 1.20 (6H,,t, J=7·0Hz), 1·94 (3H, s), 2.19 (3H, -s), 3.40 (2H, · s) , 4 · 10 (4H, q, J=7 · 0Hz), 6.67-7.23 (3H, in), 8.13J1H, s) MASS (APCI) : 340 (M+H) + 製備例54 依製備例21前半段之方法可得如下化合物。 (1) (2R )-4-苄基-2-[4-氯-3-甲氧苄基]哌哄二鹽酸鹽 -76- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------· 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7
五、發明說明(75 ) mp: 225-230°C (decomp.) IR (KBr>: 3398, 1460, 1419, 1246, 1030 cm,1 NMR (DMS〇-d6, δ): 2·80-4·60 (11H, κι), 3·87 (3H, s), 6·86 (1H, d, J=8.1Hz), 7·10 (1H, s>, 7·30-7·60 (6H, m), 9.20-10.80 (3H, br) MASS (APCI): 331 (H+H)+ (free) (2) (3R )-1-苄基-3 -(4-氟-3-甲氧苄基)哌阱 IR (Neat): 1666, 1608, 1516, 1456, 1419, 1321, 1275, 1217, 1151, 1126, 1034 cm*1 NMR (CDC13/ δ): 0.60-3.20 (9Η, m), 3.58 (2H, s), 3.86 (3H, s), 6·50-7·10 (3H, m), 7·10-7·60 (5H, m) MASS (APCI): 315 (M+H)+ (3) (2R>-4-苄基-2-[3-甲氧基-4-(三氟甲基)苄醢基]哌畊 IR (Neat): 2938, 2809, 1614, 1583, 1506, 1459, 1421 cm一1 NMR (CDC13/ δ): 1.84-2.16 (2Hf m), 2.50-3.01 (7H, m) f 3.51(2H,s),3.88(3H,s),$.83-6.85(2H,m>,7.25-7·33 (6H, m), 7·47 (1H, d, J=8,2Hz) MASS (APCI): 365 (M+H)+ (4) (2R)-4-Y基-2-(4 -氟-3-甲节基)哌哄 IR {Neat}: 1500, 1450, 1320, ,1245, 1205, 1120 citT1 NMR (DMSO-d6/ δ): 1.60-3.52 (14Hr m)f 6.95-7.40 (8H, m) MASS (APCI): 299 (M+H)+ (5) (2R)-4-苄基-2 -(3-氟-3-甲苄基)哌阱 IR(Neat): 1575, 1510, 1450, 1320, 1250, 1130, 111 0 c in -1 (6) (2 R )-4-苄基-2-(4-氟苄基)哌畊 -77- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 五、發明說明(76 ) IR (Neat): 2937, 2807, 1508, 1(50, 1326, 1135, 827, 742 cnT1 NMR (CDC13, δ): 1·87 (1H, t, J=10.4Hz), 2·14 (1H, dt, J=3.8 and 11.0Hz), 2.35-2.94, (7H, m), 3.47 (1H, d, J=13,0Hz), 3.53 (1H, d, J=13,0Hz)/ 6.92-7.32 (9H, m) MASS (APCI): 285 (M+H)+ ⑺(3R)-1-苄基-3-(4-氯苄基)哌胼 IR (Neat): 1670, 1491, 1450, 1406,·1360, 1329, 1136, 1093, 1036, 1022 citT1 NMR (CDC13, δ): 1,70-3.80 (11H, m) ,.7.12 (2H, d, J=8.4Hz), 7.20-7.60 (7H, m) MASS (APCI): 301 (M+H)4* (8) (3R)-1-苄基-3-[4-(三氟甲基)苄基]哌阱 IR (Neat): 2939, 2810, 1676, 1618 cm一1 NMR (CDC13, δ): 1·89 (1H, t, J=10.5Hz), 2·09 (1H, dt, J=3.9 and 11.0Hz)f 2.55-3.04 (7Hf m) , 3,49 (1H, d, J=13.0Hz), 3.52 (1H, d, J=13.0Hz), 7.25-7.32 (7Hf it〇, 7.55《2H, d, J=8.1Hz) MASS (APCI): 335 (Μ+Η) + ⑼(3R)-1-苄基-3-[4 -(三氟甲基)苄基]哌肼二鹽酸鹽
rnp: 212-225°C IR (KBr): 3398, 2673, 1458, 1331 cm·1 NMR (DMSO-dg, δ): 3,00-4.50 (HHf m) , 7.43-7.76 (9H, m) MASS (APCI): 335 (M+H)+ (free) 製備例55 依製備例21後半段之方法可得如下化合物。 ⑴(2R)-4-苄基- l-[3,5-雙(三氟甲基)苄釀基]-2 -(4-氟 -3-甲氧苄基)哌畊 一 7 8 _ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂--------!線爲 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 7 7 五、發明說明() IR 《Neat): 1736, 1643, 1616, 1516, 1462, 1454, 1435, 1425, 1377, 1273, llp3, 1065, 1038 cm-1 NMR (CDC13/ δ): 0.60-5.20 (14H, m) r 6,20-8.60 (11H# m) MASS (APCI): 555 (M+H)+ (2) (2R)-4-苄基-l-[3,5-雙(三氟甲基)苄釀基]-2-(3-甲 氧基-4-(三氟甲基)苄基)哌畊 IR (Neat): 1643, 1280, 1180, 1137 cm·1 NMR (CDC13, δ}: 2.20-5.20 (14H, m), 6·40-8·00 (11H, m) MASS (APCI): 605 (M+H)+ (3) (2R)-l-[3,5-雙(三氟甲基)苄醢基]- 2-(4-氟-3-甲苄 基)-4-苄_阱 IR (Neat): 1640, 1500, 1430, 1380, 1350, 1275, 1130 crrT1 NMR (DMSO-d6/ δ): 2.00-4,83 (14H, m) , 6.60-8.21 (11H, m) MASS (APCI): 539 (M+H)+ ⑷(2R) -1-[3,5-雙(三氟甲基)苄醢基]-2 -(3-氟-3-甲苄 基)-4-苄哌阱 IR (Neat}: 1640, 1430, 1280, 1170, 1130 cnT1 NMR (DMSO-dg, δ): 2·00讎4·90 (11H, m), 2·16 (3H, s), 6·53-8·24 (11H, m) MASS (APCI): 539 (M+H>+ 例9 仿例1之方法,使用H,N-二異丙基乙胺取代碳酸鉀為 鹸可得如下化合物。 (1) (2R)-1-[3,5-雙(三氟甲基)苄釀基]-2-(4-氯-3-羥苄 基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]-乙基]蹶阱二 鹽酸鹽 一 79 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明()
mp: 160-169eC
[α]。+10·0β (C=0.52, MeOH) IR (KBr): 3500-3150, 2700-2300, 1644, 1423, 1282 cnT1 NMR (DMSO-dg, δ): 2.60-5.00 (25H, m) , 6.30-7.25 (3H, in), 7.43 (1H, s), 7.79 (1H, s)/8.17-8.22 (1H, m) , 10.13 (1H, br s}, 11·00-12·00 (2H, m) MASS (APCI): 624 (M+H}+ (free) (2) (2!〇-1-[3,5-雙(三氟甲基)苄鼸基]-2-(4-氟-3-甲氧 苄基)-4-[2-[(2S)-2 -(甲氧甲基)嗎啉基]-乙基]哌阱 二鹽酸鹽
mp: 180-190°C
[a】g6·7: +13.90° (C=0.5, MeOH) IR (KBr): 1676, 1645, 1547, 1516, 1464; 1427; 1392, 1387, 1367, 1321, 1282, 1217, 118今,1136, 1034 citT1 NMR (DMSO-dg, δ): 2.00-5.40 (28H, m)f 6,30-8.30 (6Hf m) MASS (APCI): 622 (M+H广(free). (3) (2R)-l-[3,5-雙(三氟甲基)苄釀基]-2-[4-(三氟甲基) 苄基]-4-[2-[(2S)-2-(甲氧甲基)-嗎啉基]乙基]哌阱 二鹽酸鹽
mp: 146-159°C
[a】g6·8: +10.670 (C=0.239, MeOH) IR (KBr): 3435, 2656, 2598, 2467,, 1647, 1429, 1329, 1282, 1180, 1132, 1068 cnT1 NMR《DMSO-d6, δ): 2.66-5.32 (27H,/m), 7·10_8·30 (7H, m) MASS 《APCI): 642 (M+H)+ (free) ⑷(2R)-l-[3,5-雙(三氟甲基)苄醢基]-2 - [3-[(2-甲氧 乙氧基)甲氧基]-4-甲苄基]- 4-[2-(5,6,7,8-四氫-1 ,6-暸啶-6-基)乙基]哌阱 -80- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----I I----- —^11^-------丨訂---------線 (請先閱讀背面之注意事項再填寫本頁) A7 〜_____B7___ 五、發明說明(79 ) IR (Neat): 1670, 1643, 1583, 1508, 1452, 1446, 1435, 1429, 1381, 1358, 1350, 1336, 1277 cirT1 NMR (CDC13, δ): 0·70-5·50 (31H,.m), 6·20-8·60 (9H, m) MASS (APCI): 695 (M+H)+ (5) (2R)-l-[3,5-雙(三氟甲基)苄黼基]-2-[4-氯-3-羥苄 基]-4 - [4-(3,3-二甲嗎啉基)-2-丁炔基]-哌阱二鹽酸鹽
mp: 181-186°C
[oOg7·1: +0.571。(C=0.175,,Me〇H) IR (KBr): 3431, 2586, 1647, 1431, 1281, 1180, 1134 cnT1 NMR (DMS〇-d6, δ): 1.32 (3H, s)., 1.39 (3H, s) , 2.60-5·20 (19Hf m), 6.31-7.29 (3H, m) , 7,54-8.21 (3H, m), 10.10 (1H, br) MASS (APCI): 632 (M)+ (free) (6) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 - [4-氯-3-羥苄
基]-4-[2-(順-2,6-二甲嗎啉基)乙基]哌畊二鹽酸盥 mp: 172-1750C
[a]g8·2: -4.430 (C=0.305, MeOH) IR (KBr}: 3431, 2999, 1647, 1429, 1281, 1182, 1140 cirT1 NMR (DMS〇-d6/ δ): 1.15 (6H, d,. J=6.1Hz), 2.60-5.20 (19H, in), 6·32-7·28 (3H, m), 7·42-8·24 (3H, m), 10.12 (1H, br) MASS (APCI): 608 (M)+ (free)
⑺(2R )-1-[3 ,5-雙(三氟甲基)苄釀基]-2-[4-氯-3-羥苄 基]-4-[2-(4,4-二氟哌啶基)乙基]哌阱二鹽酸鹽 mp: 166-170oC
[ot】g8·0: -4.25。(C=0.365, Me〇H) IR (KBr): 3435, 1647, 1429, 1281, 1182, 1140 cnT1 NMR (DMSO-dg, δ): 2.20-5.20 (21Hf m) , 6.32-7.24 (3Hf m), 7·42-8·18 (3H, m), 10.10 (1H, br) MASS (APCI) : 61t (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐)-81- (請先閱讀背面之注意事項再填寫本頁) P衣 訂---------% 經濟部智慧財產局員工消費合作社印製 J^688 A7
五、發明說明(8〇 ) (8) (2R) -1-[3,5-雙(三氟甲基)苄醯基]-2-[4-氯-3-羥苄 基]-4-[2-(5,6·7,8-四氫-1,6-暸啶-6-基)乙基]哌阱 三鹽酸鹽 inp: 237-243°C (decomp.) [o^g6·1: -19·1。(C=0.285, MeOH) IR (KBr}: 3433, 2561, 1645, ,1427, 1281, 1185, 1136 cnT1 NMR (DMSO-dg/ δ): 2.60-6.10 (191^ m) , 6·30-7·20 (3H, m), 7.40-8.20 (3H, m), 7.76 (IB, dd, J=4.5 and 8.1Hz), 8·14 (1H, d, J=8.1Hz), 8·71 (1H, d, J=4.5Hz), 10.20 UH, br) MASS (APCI): 627 (M)+ (free) (9)2(幻-1-[3-甲氧基-5-(三氟甲基)苄醯基]-2-[4-氯-3-羥苄基] -4-[2-[(25)-2-(甲氧甲基)-嗎啉基]乙基]_阱二鹽 酸鹽
mp: 160-168°C
[a]g8·3: +14.83° (C=0.30, MeOH) IR (KBr): 3431, 2586, 1641, 1606, 1462, 1425, 1174, 1130 cm*1 NMR (DMSO-d6r δ): 2.60-5.20 (25Hr m), 3.82 (3H, s), 6.32-7.31 (6H, m), 10.11 (lHf_br) MASS (APCI): 586 (M)+ (free) ⑽(2R)-l-[3-甲氧基-5 -(三氟甲基)苄醯基]-2 -(4-氯-3-羥苄基)-4-[4-(3,3-二甲嗎啉基)-2-丁炔基]脈阱 二鹽酸鹽 -82- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) --------訂---------線* 經濟部智慧財產局員工消費合作社印製 A7
五、發明說明(81 ) mp: 187-195°c [a]g6·9: +9.19。 (C=0.37, MeOH) IR (KBr): 3423, 1641, 1604, 1462, 1425, 1238, 1173, 1126 cm·1 NMR <DMSO-d6, δ): 1·33 (3H, s), 1.37 (3H, s), 2.80-5.20 (19H, m), 3.85 (3H, s) , 6.30-7.30 (6H, m), 10*10 (lHf br) MASS (APCI): 594 (M)+ (free) (ll)(2R)-l-[3-甲氧基-5 -(三氟甲基)苄醮基]-2-(4-氯 -3-羥苄基)-4-[2-(顒-2,6-二甲嗎琳基)乙基]哌哄二 鹽酸鹽
mp: 177_1820C
[a]g7·3: +9·71。 (C=0.34, MeOH) IR (KBr): 3425, 2613, 1641, 1606, 1462, 1425, 1174, 1132 cm"1 NMR (DMSO-dg, δ): 1.15 (6H, d, J=5.8Hz), 2.60-5.20 (19Hf m), 3.82 (3H, s), 6.31-7.32 (6H, m), 9.90 (1H, br) MASS (APCI): 570 (M)+ (free) (12)(2R)-l-[3-甲氧基-5-(三氟甲基)苄醢基]- 2 -(4-氯 -3-羥苄基)-4-[2-(4,4_二氟哌啶基)-乙基]_畊二鹽 酸鹽 inp: 178-182eC 、 [α]^7·1: +5.48° (C=0.21, MeOH) IR (KBr): 3435, 1641, 1606, 1464,.1425, 1173, 1134 citT: NMR (DMSO-dg, δ): 2.20-5,20 (21H, m), 3.83 (3H, s), 6.32-7.40 (6H, m>, 10.17 (1H, br) MASS (APCI): 576 (M)+ (free) -8 3 ~ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂--------- 經濟部智慧財產局員工消費合作社印製 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 ο ο 五、發明說明() (13) (2R)-l-[3-甲氧基-5-(三氟甲基)苄醢基]- 2-(4-氯 -3-羥苄基)-4-[2-(5,6,7,8-四氫-1 ·6-_ 啶-6-基)乙 基]_畊三鹽酸鹽 mp: 225-240°C (decomp·) [α]§8·3: -8.15° (0=0.27, MeOH) IR (KBr): 3435, 1641, 1626, }464, 1425, 1238, 1173, 1130 cnTl NMR (DMSO-dg, δ): 2·60-5·20 (19Hf m), 3.83 (3H, s), 6·30-7·40 (6H, m), 7.71 (1H, dd, J=4.6 and 7·6Ηζ}, 8·12 (1H, d, J=7.6Hz), 8.71 (1H, d, J=4.6Hz>, 10·20 (1H, br) MASS (APCI): 589 (M)+ (free) (14) (21〇-1-[3,5-雙(三氟甲基)苄醸基]-2-(4_氯-3-甲 氧苄基)-4-[2一[(2S)_2-(甲氧甲基)嗎琳基]乙基]哌 畊二鹽酸鹽 mp: 145-149°C .
[a]g7: +11·0β (C=0.5, MeOH) IR 《KBr): 3500讎3150, 2700纖230Q, 1644, 1423, 1282 cnT1 NMR (DMSO-dg, δ) : 2 · 60-5 · 00 (2pH, it〇 , 6 · 53-7 · 39 (3H, m), 7·45 (1H, s), 7·73 (1H, s), ,8.19 (1H, m) MASS (APCI): 638 (M+H)+ (free) (15) (21〇-1-[3-三氟甲基-5-甲硫苄醸基)-2-(4-氯-3-第三丁二甲矽烷氧苄基)-4-[2-(順-2,6-二甲嗎啉基) 乙基]哌畊 IR (Neat) : 1680, 1630, 1490, 1420, 1130, 1085 cirT1 NMR (CDC13, δ): 0·18 (6H, s), 1·01 (9H, s), 1·15 (6H, d, J=6.3Hz), 1·75 (2Η, t, J=10.6Hz), 2·08-5·10 (20Η, m)f 6.30-8·08 (6Η, m) MASS (API-ES): 700 (M+) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-84- (請先閱讀背面之注意事項再填寫本頁) 訂---------線赢 A7 R7 i、發明說明(83 ) (16) (2f〇-l-(3-三氟甲基-5-甲硫节醯基)-2-(4-氯-3-第三丁二甲矽烷氧苄基)-4-[2 -(5,6,7,8-四氫-1,6 -嘹啶-6-基)乙基]哌阱 IR (Neat): 1635, 1490, 1420, 1295, 1170, 1130, 1105 cm"*1 NMR (CDC13,,5): 0.18 (6H, s),. 1.01 (9H, s), 2.08-5.10 (22H, m), 6·30-8·48 (9H, m) MASS (API-ES): 719 (M+) (17) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-[3 - [(2-甲 氧乙氧基)甲氧基]-4-苄氧基]-4-[ 3-(3-吡啶基)-2-丙炔基]哌畊 IR (Neat): 1643, 1583, 1508, 1466, 1452, 1431, 1377, 1358, 1331, 1277,,1086, 1018 crtT1 NMR (CDC13/ δ): 0.70-5.60 (23H, m), 6.20-8.90 (10H, m) MASS (APCI): 650 (M+H)+ (18) (2R)-1 - [3,5-雙(三氟甲基)节醢基]-2-(4-氟-3-甲 氧苄基)-4-[4-(3,3-二甲嗎啉基)-2-丁炔基]-哌阱二 鹽酸鹽
mp: 125-130°C
[α]§6·8: +11·77β (C=0.31, MeOH) IR (KBr): 3425' 2586, 1647, 1518/ 1281, 1182, 1132 cnT1 NMR (DMSO-d6/ δ): 1.33 (3H, s), 1.40 (3H, s), 2.70-5.20 (22H/ m) , 6.50-7.30 (3H, m), 7.50-8.21 (3H, m) MASS (APCI): 630 (M+H)+ (free) (19) (2!〇-1-[3,5-雙(三氟甲基)苄醸基]-2-(4-氟-3-甲 氧苄基)-4-[2-(順-2,6-二甲嗎啉基)乙基]哌阱二鹽 酸鹽 -85- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -------訂---------線赢 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(84 ) nip: 205.0-208.0°C [α]^6·9: +ΐ4·4° (C=0.25, Me〇H) IR (KBr): 3500-3150, 2700-2300, 1644, 1617, 1517, 1463, 1427, 127 8, 1133 crrT1 ~ NMR (DMSO-dg, δ): 2.60-5.20 (28H,. m) , 6.60-8.40 (6H, m) MASS (APCI): 606 (M+H)+ (free) (20) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(4-氟-3-甲 氧苄基)-4-[2-(4,4-二氟哌啶基)乙基]-哌阱二鹽酸鹽
nip: 240-243°C
[a]g8·3: +2Λ.86。(C=0.315, Me〇H) IR (KBr): 3384, 2941f 2418, 1649, 1518, 1282, 1184, 1138 cnT1 NMR (DMSO-d6/ δ): 2.20-5.20 (24Hf m) , 6·50-7.30 (3H, m) f 7.43-8·20 (3H, m) MASS (APCI): 612 (M+H)+ (free) (21) (21?)-1-[3,5-雙(三氟甲基)苄醯基]-2-(4-氟-3-甲 氧苄基)-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基] 哌阱三鹽酸鹽 mp: 175-185°C _ [a]g7: -10.0° (c=0.16, Me〇H) IR (KBr): 3500-3150, 2700-2300, 1641, 1562, 1459, 1432, 1282 cm-1 NMR (DMSO-dg, δ): 2.60-5.20 (22H, m), 6.60-8.70 (9H, m) MASS (APCI): 625 (M+H)+ (free) (22) (21〇-2-(4-氯-3-甲氧苄基)_4-[2-[(25)-2-(甲氧 甲基)-嗎啉基]乙基]-l-[3-甲氧基-5-(三氟甲基)苄 基]哌阱二鹽酸鹽 -86- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I--------------------訂---------線^^ (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明() [a]g6·7: +29.52° (C=0.31, MeOH) IR (KBr): 1643, 1635, 1618, 1606, 1518, 1462, 1419, 1273, 1169, 1132, 1103, 1041 cm 一1 NMR (DMS〇-d6, δ): 0.70-5.40 (31H, m), 6.30-7.50 (6H, m) MASS (APCI): 584 (M+H)+ (free) (23) (2R )-4-[4-(3, 3-二甲嗎啉基卜2-丁 炔基卜2-(4-氟 -3-甲氧苄基)-1-[3-甲氧基-5-(三氟甲基)苄醯基]哌 畊二鹽酸鹽 [a]§8·0: +26.67° (C=0.24, MeCXH) IR (KBr): 1676, 1645, 1635, 1628, 1616, 1516, 1464, 1423, 1346, 1273, 1171, 112.6, 1101, 1049 crtT1 NMR (DMSO-dg, δ): 1.10-5.30 , 6.40-7.50 (6H, m) MASS (APCI): 592 (M+H)+ (free) (2 4)(21〇-4-[2-(順-2,6-二甲嗎啉基)乙基]_2-(4-氟- 3 -甲氧苄基)-1-[3 -甲氧基-5-(三氟甲基)苄醮基]哌 畊二鹽酸鹽 [a]g6·3: +23.54° (C=0.24, MeOH) IR (KBr): 1645, 1612, 1516, 1464, 1423, 1398, 1352, 1315, 1275, 1213, 1173, 1130, .1092, 1055, 1036 cnT1 NMR (DMSO-dg, δ): 0.80-5.30 (31H, m), 6.30-7.50 (6H, m) MASS (APCI): 568 (M+H)+ (free) (25) (2R)-4-[2-(4,4-二氟哌嗤基)-2 -(4-氟-3 - 甲氧节 基)-1-[3-甲氧基-5-(三氟甲基)苄醮基]-噘阱二鹽酸鹽 [a]g6·4: +24.63° (C=0.27, MeOH) IR (KBr): 2538, 2488, 1641, 1604, 1516, 1464, 1417, 1387, 1346, 1290, 1242, 11717 1134, 1047, 1024 cirT1 NMR (DMSO~d6, δ): 1.70-5.40 (27H,. ra) , 6.30-7.50 (6H, m) MASS (APCI): 574 (M+H)+ (free) _ 8 7 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------1—----—丨丨 _—訂-丨 ^—-----Aw. (請先閱讀背面之注意事項再填寫本頁) )的688 經濟部智慧財產局員工消費合作社印製 A7 B7 1、發明說明(86 ) (26) (2R)-2-(4-氟-3-甲氧苄基)-1-[3-甲氧基-5-(三氟 甲基)苄醯基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基) 乙基]毈畊三鹽酸鹽 [α]§5·8: +5.22。 (C=0.345, Me〇H) IR (KBr): 1643, 1635, 1630, 1516, 1464, 1423, 1350, 1317, 1275, 1173, 1128, 1051, 1038 cm"1 WAR (DMSO-dg, δ): 0.80-5.50 (25H, m), 6.20-8.70 (9H, m) MASS (APCI): 587 (M+H)+ (free) (27) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 -(4-氯-3-羥 苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]乙基]較阱 二鹽酸鹽
mp: 156-168°C
[a]g7·6: +5·14° (C=0.36, Me〇H) IR (KBr) : 3458, 1647, 1518, 1433, .1282, 1184, 1140 cirT1 NMR (DMSO-dg, δ): 2.60-5.20 (25H,· in) , 6.30-7.20 (3H, m), 7.43-8.23 (3H, m), 9.77 (1H, br) MASS (APCI); 608 (M+H)+ (free) (28) (21〇-1-[3,5-雙(三氟甲基)苄釀基]-2-(4-氯-3-羥 芣基)-4-[4 -(3,3-二甲嗎啉基)-2-丁炔基]哌畊二鹽 酸鹽 mp: 180-184°C ' [a]g6·8: +2.20° (C=0.25, MeOH) IR (KBr): 3435, 2931, 2584, 1645, 1435, 1281, 1182, 1136 cnT1 ' NMR (DMS〇-d6, δ): 1.32 (3H, s), 1.39 (3H, s), 2.60-5.20 (19H, m) , 6.30-7.20 (3H, m), 7.50-8.21 (3H, m) , 9.76 (1H, br) MASS (APCI): 616 (M+H)+ (free) -8 8 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----------衣·-------訂------- (請先閲讀背面之注咅?事項再填寫本頁) 509688 A7 B7 五、發明說明(87) (29) (21〇-1_[3,5-雙(三氟甲基)苄醯基]-2-(4-氯-3-羥 苄基)-4-[2-(順-2,6-二甲嗎啉基)乙基]哌阱二鹽酸鹽 (請先閱讀背面之注意事項再填寫本頁)
mp: 170-195°C
[a]g7: +6.77。 (C=0.27, Me〇H) IR (KBr): 3500-3150, 2700-2300, 1644, 1519, 1434, 1371, 1282, 1184 cirv-1 NMR (DMS〇-d6, δ): 0·80-5·20 (25H, m), 6·60-8·20 (7H, m), 11·40-11.80 (2Η, br) MASS (APCI): 592 (M+H)+ (free) (30) (2R>-l-[3,5-雙(三氟甲基)苄醮基]-2-(4-氯-3-羥 苄基)-4-[2-(4,4-二氟哌啶基)-乙基]-哌胼二鹽酸鹽 rnp: 190»200°C · [a]g7: +0.83° (C=0.3, MeOH) -IR (KBr): 3500-3150, 2700-2300, 1646, 1517, 1432, 1373, 1282, 1139 cxrT1 NMR (DMSO-dg, δ): 2.60-5.20 (21H, m), 6.20-8,30 (7H, m) , 9.00-10.40 (2H, br) MASS (APCI): 598 (M+H)+ (free) (31) (2R) -1-[3,5-雙(三氟甲基)苄隨基]-2-(4-氯-3-羥 苄基卜4-[2-(5,6·7·8-四氫-1,6-暸啶-6-基)乙基]哌 阱三鹽酸鹽 經濟部智慧財產局員工消費合作社印製 rap: 240.0-241.0°C ^ [a]g6: 一11.660 (C=0.57, MeOH) IR (KBr): 3500-3150, 2700-2300, 1641, 1517, 1432, 1282, 1137 cm"-*· NMR (DMS〇-d6, δ): 2.60-5.20 (19H, m), 6.20-8.80 (10H, m), 9.00-10.50 (2H, br) MASS (APCI): 611 (M+H)+ (free)
H 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 509688 A7 B7_ 五、發明說明(88 ) (請先閱讀背面之注意事項再填寫本頁) (32) (21〇-1-[3,5-雙(三氟甲基)苄_基]-2-(3,4-二氟 苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]乙基]哌畊 二鹽酸鹽 rap: 196-198°C [a]g7: +8.3。 (C=0.5, MeOH) IR (KBr): 3365, 2590, 2475, 1645, 1520, 1440, 1280 cuT1 NMR (DMSO-dg, δ): 2.73-5.07 (22H, m), 3·27 (3H, s), . 6.88-8.21 (6H, m) MASS (APCI): 610 (M+H)+ (free) (33) (2!〇-1-[3,5-雙(三氟甲基)苄醯基]-2-(3,4-二氟 苄基)-4-[4-(3,3-二甲嗎啉基)-2-丁炔基]哌阱二鹽 酸鹽 [a]g7: +4,2° (C=0.5, MeOH) IR (KBr): 2435, 1645, 1520, 1430, 1280 cm"1 NMR (DMSO-dg, δ): 1.32 (3H, s),,1.38 (3H, s), 2.76-5.17 (19H, m), 6.79-8.26 (6H, m) MASS (APCI): 618 (M+H)+ (free) (34) (21?)-1-[3,5-雙(三氟甲基)苄醸基]-2-(3,4-二氟 苄基)-4-[2-(順-2,6-二甲嗎啉基)乙基]哌畊二鹽酸鹽 經濟部智慧財產局員工消費合作社印製 mp: 223-2280C [a]§7: +5.1° (C=0.5, MeOH) IR (KBr) : 3435, 3390, 2600, 2.4 95, 1650, 1520, 1435, 1280 cm"1 NMR (DMSO-dg, δ): 1.45 (6H, d,. J=6.0Hz), 2.60-5.20 (19H, m) r 6.80-8.28 (6H, m) MASS (APCI): 594 (M+H)+ (free) -90- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 509688 A7 B7 五、發明說明(89) (35) (2R)-1-[3,5-雙(三氟甲基)苄醮基]-2一(3,4 一二氟 苄基)-4-[2_(4,4_二氟醱啶基)一乙基]哌阱二鹽酸鹽 [a]g7: +9,1° (C=0.5, MeOH) — IR (KBr): 2380, 1645, 1520, 1430, 1280 cm"1 NMR (DMS〇-d6v δ): 2.10-5.14 (21H, m) f 6.78-8.26 (6H, m) MASS (APCI): 600 (M+H)+ (free) (36) (2R)-1-[3,5-雙(三氟甲基)苄釀基卜2-(3, 4-二氟 苄基)-4-((1-甲基-1H-毗唑-4-基)甲基)哌阱鹽酸鹽
mp: 230°C
[a]g7: -1.6° (C=0.5, MeOH) IR (KBr) : 2520, 2470, 1645, 1525, 1440, 1365, 1275 era—1 NMR (DMS〇-d6, δ): 2·72-5·12 (11¾ in), 3·86 (3H, s), 6.74-8.31 (8H, m) MASS (APCI): 547 (M+H)+ (free) (37) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-2-(3,4-二氟 苄基)-4-(3-ift啶甲基 >哌阱二鹽酸鹽 inp: 203-208°C [a]g7: +5,3° (C=0.5, MeOH) IR (KBr) : 2560, 1640, 1520, 1430, 1370, 1280 crrT1 NMR (DMSO-d6, δ): 2.80-5.14 (11H, m) , 6.72-9.10 (10H, m) MASS (APCI): 544 (M+H)+ (free) (38) (21〇-1-[3,5-雙(三氟甲基)苄釀基]-2-(3,4-二氟 苄基)-4-[3-(3-吡啶基)丙基]哌阱二鹽酸鹽 mp: 215-220°C [a]g7: +2.6° (C=0.5, MeOH) IR (KBr) : 2650, 1645, 1550, 1520, 1430, 1280 cm一1 NMR (DMSO-dg, δ): 2.13-5.15 (X5H, m), 6.78-8.95 (10H, m) MASS (APCI): 572 (M+H)+ (free) -91- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注咅?事項再填寫本頁) --------訂---------線^^-. 經濟部智慧財產局員工消費合作社印製 509688 經濟部智慧財產局員工消費合作社印製 A7 —___B7__ 五、發明說明(9〇 ) (39) (2R)-1 - [3,5-雙(二氟甲基)节釀基]_2-(3·4-二氟 节基)-4-[2-(5·6,7·8-四氫-1,6-暸唆-6-基)乙基]_ 畊三鹽酸鹽 [α]§7: -2.0° (C=0.5, MeOH) IR (KBr) : 2620, 1645, 1515, 1430、1280 cirT1 NMR (DMSO-d6, δ): 2,59-5.17 (19H, m), 6.76-8.69 (9H, m) MASS (APCI): 613 (M+H)+ (free) (40) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-2_[3一甲氧基_ 4-(二氟甲基)苄基]-4-[2-(順-2,6 -二甲嗎啉基)乙基] 哌畊二鹽酸鹽 mp: 160.0-170.0°C [a]g7: +17·160 (C=0.44, MeOH) IR (KBr): 3500-3150, 2700-2300, J648, 1623, 1587, 1511, 1463, 1280, 1132 crrT1 .NMR (DMS〇-d6, δ) : 2.60-5.20 (28H, πι) , 6 · 40-8 · 20 (6H, m) MASS (APCI): 656 (M+H)+ (free) (41) (2R)-l-[3,5-雙(三氟甲基)苄醮基]-2-[3-甲氧基-4-((三氟甲基)苄基)-4-[2-(5,6·7·8-四氫-1,6-暸啶 -6-基)乙基]哌阱三鹽酸鹽 mp: 195-200oC · [a]g7: +1.76° (C=0.34, MeOH) IR (KBr): 3500-3150, 2700-2300, 1646, 1625, 1511, 1465, 1427, 1369, 1280, 1130 cnT1 NMR (DMS〇-d6, δ): 2 · 60-5 · 20 (22H" in) , 6 · 60-8 · 80 (9H, ra) MASS (APCI) :. 675 (M+H)+ (free) (42) (2R) - l-[3-甲氧基-5-(三氟甲基)苄醢基]-2-[3-甲 氧基-4-(三氟甲基基]-4-[2-[(2S)-2-(甲氧甲基) -嗎啉基]乙基]哌阱二鹽酸鼸 - 92- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
^688 A7 '____B7_ 五、發明說明(91 )
ιηρ: 135 - 140oC
[oc]g7: +20.3。(C=0.15, Me〇H) (請先閱讀背面之注意事項再填寫本頁) IR (KBr): 3500-3150, 2700-2300, 1644, 1623, 1463, 1423, 1321, 1128, 1045 cirT1 NMR (DMSO-dg, δ〉: 2 · 80-5 · 20 (31H, m) , 6 · 60-8 · 20 ( 6H, πι), 10.60-12.20 (2H, br) MASS (APCI): 634 (M+H)+ (free) (43) (21〇-1-[3-甲氧基-5-(三氟甲基)苄醢基]-2-[3-甲 氧基-4 -(三氟甲基)苄基]-4-[2-(順-2,6-二甲嗎啉基) 乙基]哌阱二鹽酸鹽
rap: 125 - 1350C
[α]§7: +35·0ο (C=0.18, MeOH) IR (KBr): 3500-3150, 2700-2300,_ 1644, 1623, 1511, 1463, 1423, 1351, 1274, 112/8 cirT1 -NMR (DMSO-dg, δ) : 2.60-5.20 (31H, m), 6·50-8·20 ( 6H, m〉, 11.20-11.80 (2H, hr) MASS (APCI): 618 (M+H)+ (free) (44) (2R)-l-[3-甲氧基-5-(三氟甲基)苄醢基]-2-[3-甲 氧基-4-(三氟甲基)苄基卜4 - [2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌畊三鹽酸鹽 經濟部智慧財產局員工消費合作社印製
rap: 190—2〇〇〇C
[α]§7: +7.5° (C=0.16, MeOH) IR (KBr): 3500-3150, 2700-2300, 1623, 1614, 1511, 1463, 1321, 1126 crtT1 NMR (DMS〇-d6, δ): 2.80-5.20 (25H, m) , 6.60-8.80 (9H, m) MASS (APCI): 637 (M+H)+ (free) (45) (2R)-l-[3,5-雙(三氟甲基)苄醢基]-2-[3-甲氧基- -93- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(92 ) 4-甲苄基]-4 - [2 - [(2S)- 2-(甲氧甲基)嗎啉基]乙基] 哌阱二鹽酸鹽
mp: 148-160°C
[a]g6·5: -2.25° (C=0.222, MeOH) IR (KBr): 3435, 2661, 2593, 2465, 1645, 1514, 1429, 1363, 1324, 1282, 1184, 1140 cnT1 NMR (DMSO-dg, δ): 2.20 (3H, s) , 2.64-5.28 (25H, in), 6.62-8.28 (6H, m) MASS (APCI): 606 (M+H)+ (free) (46) (2R)-l-[3,5-雙(三氟甲基)苄醮基]- 2-[4-甲氧基-4-甲苄基]-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]乙基] 哌胼二鼸酸鹽
mp: 151-156°C
[a]§7: +2.96° (C=0.355, MeOH) IR (KBr): 3435, 2941, 1647, 1510, 1281, 1184, 1138 cnT1 NMR (DMS〇-d6, δ): 2.10-2.21 (3H, m) , 2·65-5·25 (25H, m), 6.70-8.30 (6H, m) MASS (APCI): 606 (M+H)+ (free) (47) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-2-[3-[(2-甲 氧乙氧基)甲氧基]-4-甲苄基]-4-[4-[(2S)-2-(甲氧 甲基)嗎啉基]-2-丁炔基]哌畊 IR (Neat): 1643, 1583, 1510, 1452, 1446, 1433, 1379, 1277, 1095, 1014 cm"1 NMR (CDC13, δ): 0.60-5.40 (37Η, m), 6.20-8.20 (6Η, m) MASS (ESI): 716.3 (M+H)+ (48) (2R )-1-[3, 5-雙(三氟甲基)苄釀基卜4-[4-(3, 3-二 甲嗎啉基)-2-丁炔基]-2-[4-(三氟甲基)苄基]_畊二 鹽酸鹽 _9 4- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)~ --------------------訂--------- (請先閲讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7_ 五、發明說明(93 )
iup: 110 - 130oC
[a]g4: +9.20° (C=0.25, MeOH) IR (KBr) : 1647 citT1 NMR (DMSO-dgy δ): 1.33-1.41 (6H, m) , 2.80-5.30 (19H, m), 7.20-8.17 (7H, ra) MASS (APCI): 650 (M+H)+ (free) (49) (2R)-l-[3,5-雙(三氟甲基)苄醮基]-4-[2-(順-2, 6-二甲嗎咐基)乙基]-2-[4 -(三氟甲基)苄基]哌阱二 鹽酸鹽
rap: 148 - 1590C
[a]g7: +10.60° (C=0.25, MeOH) IR (KBr) : 3437, 1645, 1516, 1427 cirT1 NMR (DMSO-dg, δ): 1.15 (6H, d, J=6.1Hz), 6.60-5.30 (19H, m), 7.25-8.19 (7H, m) MASS (APCI): 626 (M+H)+ (free) (50) (21〇-1-[3,5-雙(三氟甲基)苄藤基]-4-[2-(4,4-二 氟哌啶基)乙基]-2-[4-(三氟甲基)苄基]哌畊二鹽酸鹽
mp: 209-253°C
[a]g6: +15.600 (C=0.25, MeOH) IR (KBr): 1647 cm一1 NMR (DMSCHd6, δ): 2·60-5·20 (21H,m), 7.21 -8·19 (7H, in) MASS (APCI): 632 (M+H)+ (free) (51) (2R)-l-[3,5-雙(三氟甲基)苄酿基]-4-[(l-甲基-1H-毗唑-4-基)甲基]-2-[4-(三氟甲基)苄基]哌阱二 鹽酸鹽
rap: 200-229°C
[α]^4: +5·07。 (C=0.25, MeOH) IR (KBr) : 1647 era"1 NMR (DMSO-dg, δ): 2.84-5.20 (14H, m), 7.14-7.72 (7H, m), 7.94-7.96 (1H, m), 8.21 (1H, s) MASS (APCI): 579 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-95 - (請先閱讀背面之注意事項再填寫本頁)
509688 A7 B7_ 五、發明說明(94 ) (52) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-4-[(3·吡啶基) -甲基]-2-[ 4-(三氟甲基)苄基]哌阱二鹽酸鹽 (請先閱讀背面之注意事項再填寫本頁)
ιηρ: 198 - 2230C
[α]§7: +6.60。 (C=0.25, MeOH) IR (KBr) : 1645 cxtT1 NMR (DMSO-dg, δ): 2.80-5.20 (11H, m), 7.13-7.91 (7H, m), 8.34 (1H, s), 8.62 (1H, d, J=7.7Hz), 8.87 (1H, d, J=5.2Hz), 9.05 (1H, s) MASS (APCI): 576 (M+H)+ (free) (53) (2R)-l-[3,5-雙(三氟甲基)苄醜基]-4-[3-(3-吡啶 基)-2-丙炔基]-2-[4-(三氟甲基)苄基]哌阱 rap: 142-143°C IR (KBr) : 1643 crcT1 NMR (DMSO-d6, δ): 2.20-5.20 (11H, ra) , 7.19-7.64 (7H, ra), 7.80-7.90 (1H, m), 8.16 (1H, br s) f 8.35-8.58 (1H, m) , 8.66 (1H, br s) MASS (APCI): 600 (M+H)+ (54) (21〇-1-[3,5-雙(三氟甲基)苄醮基]-4-[2-(5,6,7, 8-四氫-1,6-嘹啶-6-基)乙基]-2-[4-(三氟甲基)苄基] 哌阱三鹽酸鹽
rap: 174-180°C 經濟部智慧財產局員工消費合作社印製 [a]g7: 一2·80ο (C=0.25, MeOH) IR (KBr) : 3438, 1645, 1516 citT1 NMR (DMSO-dg., δ): 2.60-5.30 (19H, m) , 7.20-8.67 (10H, m) MASS (APCI): 645 (M+H)+ (free) (55) (2R)-4-[2-[(2S) - 2-(甲氧甲基)嗎啉基]乙基]-1 -[3-甲氧基-5-(三氟甲基)苄醯基]-2-[4-(三氟甲基) 苄基]哌阱三鹽酸鹽 -9 6 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(95 ) mp: 126-155〇C 、 [a]g6: +20.60° (C=0.25, MeOH) IR (KBr) : 3460, 1645, 1464 cirT1 NMR (DMS〇-d6, δ): 2·80-5·30 (25H, m), 3·82 (3H, s), 6.31-7.80 (7H, m) MASS (APCI): 604 (M+H)+ (free) (56) (21〇-4-[4-(3,3-二甲嗎啉基)-2-丁炔基]-1-[3-甲 氧基-5-(三氟甲基)苄醯基]-2-[4-(三氟甲基)苄基] 哌哄二鹽酸鹽
rap: 158 - 1650C
[a]§6: +19.93° (C=0.25, MeOH) IR (KBr) : 3430, 1645, 1516, 1462' 1421 citT1 NMR (DMS〇-d6, δ): 1.33 (3H, s), 1·38 (3H, s), 2.90-5.30 (19H, m), 3.83 (3H, s), 6.30-7.70 (7H, m) MASS (APCI): 612 (M+H)+ (free) (57) (2R)-4-[2-(順-2,6-二甲嗎啉基)乙基]-1-[3-甲氧 基-5-(三氟甲基)苄釀基]-2-[4-(三氟甲基)苄基]哌 阱二鹽酸鹽
mp: 139-151°C
[a]§7: +19.00° (C=〇.25, Me0H) IR (KBr) : 3435, 1645, 1464, 1423.^1 NMR (DMS〇-d6, δ): 1.15 (6H, d, J=6.1Hz) , 2.60-5.30 (19H, m), 3·82 (3H, s), 6.30-7·80 (7H, m) MASS (APCI): 588 (M+H)+ (free) (58) (21〇-4-[2-(4,4-二氟哌啶基)-乙基]-1-[3-甲氧基 -5-(三氟甲基)苄醢基]-2-[4-(三氟甲基)苄基]-哌阱 二鹽酸鹽 一97- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) --------訂---------線羞 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 五、發明說明()
mp: ~230°C
[α]§7: +19.80° (C=0.25, MeOH) IR (KBr) : 1643, 1464, 1421 crtT1 NMR (DMS〇-d6, δ): 2.30-5·30 (21H, m), 3.80 (3H, s), 6.30-7·80 (7H' iti) MASS (APCI): 594 (M+H)+ (free) (59) (2R)-1-[3-甲氧基-5-(三氟甲基)苄釀基]-4-[3-(3 -吡喃基)-2-丙炔基]-2-[4-(三氟甲基)苄基]-哌阱 IR (Neat) : 3585, 1637 αχΓ^ NMR (DMS〇-d6, δ): 2.20-5.20 (11Η, m), 3.82 (3H, s), 6.81-7.70 (9H, rri) , 8.55 (1H, d, J=3.5Hz), 8.66 (1H, s) MASS (APCI): 562 (M+H)+ (60) (2R)-1 - [3 -甲氧基-5-(三氟甲基)苄醯基]-4-[2-(5 ,6,7,8-四氫-1,6-暸啶-6-基)乙基]-2-[4 -(三氟甲基) 苄基]-哌阱三鹽酸鹽
mp: 185-1910C
[α]§7: +4.00° (C=0.25, MeOH) IR (KBr): 1645, 1423 cm"1 NMR (DMS〇-d6, δ): 2.90-5·30 (19H, m), 3·83 (3H, s), 6.30-7.80 (8H, m), 8.11 (1H, d, J=7.7Hz), 8.70 (1H, d, J=4.7Hz) MASS (APCI): 607 (M+H)+ (free) (61) (21〇-1-[3,5-雙(三氟甲基)苄醜基]-2-(4-氯苄基) - 4-[2_[(2S)-2-(甲氧甲基)嗎啉基]乙基]-哌畊二鹽 酸鹽 -98- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂——I-----線屬 509688 A7 B7__ ο 7 五、發明說明()
rap: 90 - 120oC
[a]g7·7: +5.18。 (C=0.28, Me〇H) IR (KBr): 1707, 1693, 1676, 1645, 1547, 1539, 1516, 1498, 1489, 1477, 1464, 1454, 1427, 1392, 1387, 1367, 1281, 1182, 1138, 1101 NMR (DMSO~d6, δ): 2.00-5.40 (25H, m), 6.80-8.40 (7H, m) MASS (APCI): 608 (M+H)+ (free) (62) ( 2R )-1-[3 ·5-雙(三氟甲基)苄醢基]-2-[4-氯苄基) -4-[4-(3,3-二甲嗎啉基)- 2-丁炔基]哌阱二盥酸鹽
mp: 120-150oC
[a]g7·6: -0.69° (C=0.29, MeOH) IR (KBr): 2578, 2515, 1645, 1496, 1489, 1431, 1362, 1319, 1281, 1217, 1182, 1136, 1099, 1066 cnT1 NMR (DMS〇-d6, δ): 1·10-1·50 (6H, m), 2·60-5·30 (19H, m), 6.80-8.40 (7Η, m) MASS (APCI): 616 (M+H)+ (free) (63) (2R )-1-[3,5-雙(三氟甲基)苄釀基]-4-[ 2-(順-2, 6-二甲嗎啉基)乙基]-2-(4-氯苄基)哌胼二鹽酸鹽 mp: 150-175°C (decomp.) [a]g7·4: -2·860 (C=〇.28, Me〇H) IR (KBr) : 1693, 1687, 1645, 1514, 1508, 1498, 1489, 1464, 1454, 1429, 1329, 1281, 1182, 1142, 1099, 1038 cia-l NMR (DMSO-dg, δ): 1.15 (6H, d, J=6.1Hz), 1.80-5.40 (19H, m) , 6.80-8..30 (7H, m) MASS (APCI): 592 (M+H)+ (free) (64) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-2-[4-氯苄基) -4-[2-(4,4-二氟哌啶基)-乙基]哌畊二鹽酸鹽 一 99_ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) tT---------% 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 五、發明說明()
mp: 250-255°C
[a]g8·2: -3·520 (C=0.27, Me〇H〉 IR (KBr): 1707, 1693, 1678, 1647, 1628, 1547, 1539, 1516, 1498, 1464, 1454, 1425, 1367, 1279, 1176, 1140, 1101, 1061, 974 cirT1 NMR (DMSO-d6/ δ): 1.80-5.40 (21H, m), 6.80-8.40 (7H, m) MASS (APCI): 598 (M+H〉+ (free) (65) (2R)-1 - [3,5-雙(三氟甲基)苄醯基]-2-[4-氯苄基) -4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌畊三 鹽酸鹽 mp: 172-203°C (decomp.) [a]g7·4: -16.12° (C=0.245, MeOH) IR (KBr): 1674, 1645, 1630, 1558, 1550, 1539, 1516, . 1498, 1489, 1464, 1427, 1392, 1387, 1367, 1281, 1182, 1136, 1101, 1043 cm"1 NMR (DMSO~d6, δ) : 1 · 10-5 · 60 (19H, m) , 6 · 80-8 · 80 (10H, κι) MASS (APCI): 611 (M+H)+ (free) (66) (2R)-2 - U-氯苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎 咐基]乙基]-1 - [3-甲氧基-5-(三氟甲基)-苄醮基]哌 阱二鹽酸鹽
mp: 70-90°C
[a]§8·2: +13.00° (C=0.227a MeOH) IR (KBr): 1643, 1606, 1514, 1508, 1496, 1423, 1387, 1350, 1315, 1271, 1242, 1174, 1130, 1097, 1051 cirT1 NMR (DMS〇-d6, δ): 2.50-5.40 (28H, κι) , 6 · 30-7 · 60 (7H, m) MASS (APCI): 570 (M+H)+ (free) (67) (2R)-2-(4-氯苄基)-4-[4-(3,3-二嗎咐基)-2-丁炔] -100- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------線爲 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印制衣 509688 A7 B7_
Q Q 五、發明說明() 基]-l-[3-甲氧基- 5-(三氟甲基)-苄醯基]賴阱二鹽酸鹽
mp: 110-140°C
[α]§8*2: +8,96° (C=0.24, MeOH) IR (KBr): 1676, 1645, 1539, 1535, 1516, 1498, 1464, 1423, 1348, 1317, 1271, 1242, 1173, 1126, 1097, 1049 cnfl NMR (DMSO-dg, δ): 1.10-1.60 (6H, m) , 2.60-5.40 (22H, m), 6.40-7.60 (7H, m) MASS (APCI): 578 (M+H)+ (free) (68) (21?)-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎啉基)乙 基]-1_[3-甲氧基-5-(三氟甲基)-苄醯基]哌阱二鹽酸鹽
mp: 90-120oC
[α]§7·9: +10.80° (C=0.25, MeOH) IR (KBr): 1676, 1645, 1606, 1516, 1498, 1464, 1423, 1387, 1381, 1377, 1350, 1317, 1271, 1242, 1209, 1174, 1130, 1095, 1051 cm-1 NMR (DMS〇-d6, δ): 1.15 (6H, d, J=6.1Hz), 2.40-5,40 (22H, m), 6.30-7.60 (7H, m) MASS (APCI): 554 (M+H)+ (free) (69) (2R)-2-(4-氯苄基)-4-[2-(4,4-二氟哌啶基)-乙基] -l-[3-甲氧基-5-(三氟甲基)-苄釀基]哌哄二鹽酸鹽
mp: 220-250°C
[a]J8·3: +13.18° (C=0.425, MeOH) IR (KBr): 1641, 1635, 1604, 1539, 1516, 1498, 1464, 1417, 1344, 1292, 1269, 1242, 1174, 1138, 1097, 1047 curl NMR (DMS〇一d6, δ): 2.00-5.40 (24H, in) , 6.30-7.60 (7H, m) MASS (APCI): 560 (M+H)+ (free) -101- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注音?事項再填寫本頁) 訂---------線屬 經濟部智慧財產局員工消費合作社印製 509688 A7 B7__ 五、發明說明(1〇0) (70) (2R)-2-(4-氯苄基)-1-[3-甲氧基-5-(三氟甲基)苄 黼基]-4-[2-(5·6,7·8-四氫-1,6-暸啶-6-基)乙基]哌 畊三鹽酸鹽
mp: 140-170°C
[α]§8·7: -6.110 (C=〇.36, MeOH) IR (KBr): 1645, 1635, 1630, 1516, 1498, 1464, 1417, 1350, 1315, 1271, 1240, 1207, 1174, 1128, 1097, 1053 cm-*1 NMR (DMSO-d6, δ): 2·40-5·40 (22H, m), 6·30-8·90 (1〇H, m) MASS (APCI): 573 (M+H)+ (free) (71) (2R) -1-[3,5-雙(三氟甲基)苄醯基]-4-[4-(3,3-二 甲嗎啉基)-2-丁炔基]-2-(4-氟苄基)哌阱二鹽酸鹽 mp: 76.5-130.6°C [a]g6·3: +7.53° (C=0.25a MeOH) IR (KBr) : 1644, 1513, 1430, 1282, 1182, 1133 crrT1 NMR (DMSO-dg, δ): 1·32, 1.39 (6H, 2 br s) , 2.50-4.58 (19H, m), 6.99-8.20 (7H, m) MASS : 600 (M+H)+ (free) (72) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-4-[2-(順-2,6-二甲嗎啉基)乙基]-2-(4-氟苄基)_畊二鹽酸鹽
mp: 89.0-110.2°C
[a]g8: +7.800 (C=0.25, Me〇H) IR (KBr) : 1644, 1513, 1282, 1182, 1137 cm一1 NMR (DMSOd6, δ): 1·13 (6H, d, J=6.05Hz), 2.73-4.55 (19H, m), 7.00-8.17 (7H, m) MASS : 576 (M+H)+ (free) (73) (21〇-1-[3,5-雙(三氟甲基)苄醢基]-4-[2-(4,4-二 氟哌啶基)-乙基]-2-(4-氟苄基)哌阱二鹽酸鹽 一 102- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂- - -------線爲 509688 A7 B7 五、發明說明(1<n)
mp: 264.0-270.6°C
[α]§6·6·· +5·07ο (C=0.25, Me〇H) IR (KBr) : 1644, 1513, 1427, 1278, 1187, 1141 cra^1 NMR (DMS〇-d6, δ): 2.30-5.00 (21H, m), 6.99-8.17 (7H, m) MASS : 582 (M+H)+ (free) (74) (2R)-l-[3,5-雙(三氟甲基)苄醢基]-2-(4-氣苄基) -4_[3-(3-吡啶基)-2-丙炔基]哌阱 NMR (CDC13, δ): 2.42-4.96 (11Η, m), 6.95-8.66 (11H, m) MASS: 550 (M+H)+ (75) (2R)-1 - [3,5-雙(三氟甲基 >苄酿基]-2-(4-氟苄基) -4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌畊三 鹽酸鹽 mp: 155.5-170.1°C [a]J8: -81.20° (C=0.50, MeOH) IR (KBr) : 1644, 1513, 1427, 1282, 1184, 1135 crcT1 NMR (DMS〇-d6, δ): 2·60-4·85 (19H, m), 7·03-8·69 (11H, m) MASS : 595 (M+H)+ (free) (76) (2R)-2-(4-氟苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉 基]乙基]甲氧基-5-(三氟甲基)-苄醜基]哌阱 二鹽酸鹽 rap: 109.5-119.2°C ta]g6·8: +24.73° (C=0.46, MeOH) IR (KBr): 1643, 1513, 1463, 1423, 1172, 1130, 1101 ckT1 NMR (DMSO-dg, δ): 2.73-4.10 (24H, m), 3.26 (3HA s), 3.87 (3H, s), 6.45-7.41 (7H, ra) MASS : 554 (M+H)+ (free) 一103- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------線赢 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1 〇 9 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) (77) (2R)-4-[4-(3,3-二甲嗎咐基)-2-丁 炔基]-2 -(4-氟 苄基)-1-[3-甲氧基-5-(三氟甲基)-苄釀基]哌阱二鹽 酸鹽 mp: 137.5-140.7°C [α]§7·0: +15.18° (C=0.48, MeOH) IR (KBr): 1643, 1465, 1423, 1348, 1126 cnT1 NMR (DMSO-dg, δ): 1.32 and 1.37 (6H, s), 1.37 (6H, s x2) f 3.10-5.00 (19H, m), 3.83 (3H, s), 6.99-12.0 (8H, m) , MASS : 562 (M+H)+ (free) (78) (21?)-4-[2-(順-2,6-二甲嗎_基)乙基]-2-(4-氟苄 基)-l-[3-甲氧基-5-(三氟甲基)-苄醯基]-哌畊二鹽 酸鹽
mp: 70.3-85.2°C
[α]§7*2: +19.03° (C=0.49, MeOH) IR (KBr): 1$45, 1513, 1463, 1423, 1174, 1130 crrT1 NMR (DMSO-d6, δ): 1,03 and 1.14 (6H, d, J=6.1Hz), 2.89-5.10 (19H, m), 3.83 (3H, s) , 6.46-7.40 (7H, m) MASS : 538 (M+H)+ (free) (79) (21〇-4-[2-(4,4-二氟哌啶基)-乙基]-2-(4-氟苄 基)-l-[3-甲氧基-5-(三氟甲基)苄醯基]哌阱二鹽酸鹽 經濟部智慧財產局員工消費合作社印製 rnp: 258.4-261.4°C [cx]g7·3: +20.400 (C=0.43, MeOH〉 IR (KBr): 1637, 1604, 1417, 1346, 1240, 1047, 970 cm—1 NMR (DMS〇-d6, δ): 2.73-5.09 (21H, in), 3.82 (3H, s), 6.45-7.38 (7H, ra) MASS : 544 (M+H)+ (free) -104 — 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(1<>3) (80) (2R) - 4-(4-氟苄基)-1-[3-甲氧基-5-(三氟甲基)苄 醜基]-4-[3-(3-吡啶基)-2-丙炔基]毫升 NMR (CDC13, δ): 2.38-5·06 (11H, m), 3·82 (3H, s), 6.41 -8.66 (11H, rri) MASS : 512 (M+H)+ (81) (2R)-2-(4-氟苄基)-l-[3-甲氧基-5-(三氟甲基)苄 醸基]-4-[2-(5,6,7,8~四氫-1,6 -瞭喃-6-基)乙基]_ 阱三鹽酸鹽 mp: 148.7-152.3°C [α]§7β1: -0.737° (C=0.48, MeOH) IR (KBr): 1643, 1635, 1514, 1464, 1421, 1350, 1173, 1128 cm"1 NMR (DMS〇-d6/ δ): 2.65-5.10 (19, m), 3.83 (3H, s), 6.50-8.69 (10H, m) MASS : 557 (M+H)+ (free) (82) (2R)-1 -[3,5-雙(三氟甲基)苄醸基]- 4-[2-(順-2,6-二甲嗎啉基)乙基]-2-(2-萦甲基)哌哄二鹽酸鹽
nip: 168-1.95°C
[a]g6·4: -27.26° (C=0.31, MeOH) IR (KBr) : 3410, 1640 οπΓ1·
NMR (DMSO-dg, δ): 1.16 (6H, d, J=6.0Hz), 2.6-5.3 (19HY m) , 7.0-8.2 (10H, m) MASS (APCI): 608 (M+H)+ (free) (83) (2R)-1 - [3,5-雙(三氟甲基)苄醯基]-4-[2 -(4,4-二 氟哌啶基)乙基]-2-(2-萦甲基)哌阱二鹽酸鹽
mp: >250°C
[α]§7·3: -33.11° (C=0.37, MeOH) IR (KBr) : 3740, 2400, 1650 crcT1 NMR (DMSO-dg, δ): 2.9-5.4 (21H, m), 7.0-8.2 (10H, m) MASS (APCI): 614 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-105- ------I--------------訂-------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(1()4) (84) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 -(2-萦甲基) -4-[2-(5,6,7,8-四氬-1,6-嘹啶-6-基)乙基]哌阱三 鹽酸鹽
mp: 189-194°C
[ajg8·1: -34.93° (C=0.28, MeOH) IR (KBr) : 3400, 1640 crrT1 NMR (DMS〇-d6, δ): 2·9-5·4 (19H, in〉,6.9-8.2 (12H, ra), 8.66 (1H, d, J=4.4Hz) MASS (APCI): 627 (Μ+Η)+ (free) (85) (21〇-4-[2-[(25)-2-(甲氧甲基)嗎_基]乙基]-1-[3-甲氧基-5 -(三氟甲基)-苄藤基]-2 -(2-萘甲基)哌 畊二鹽酸
mp: 134-140oC
[a]g8·5: +0.78° (C=0.35, Me〇H) IR (KBr) : 3750, 1640 era"1 NMR (DMS〇-d6, δ): 2 · 8-5 · 4 (28H, m) , 6 · 3-8 · 0 (10H, in) MASS (APCI): 586 (M+H)+ (free) (86) (21?)-4-[4-(3,3-二甲嗎咐基)-2-丁炔基]-1-[3-甲 氧基-5-(三氟甲基)-苄醯基]-2 -(2-萘甲基)哌阱二鹽酸
mp: 190-1990C
[a]g8·7: -2.16° (C=0.26, MeOH) IR (KBr) : 3750, 3400, 1640 crrT1 NMR (DMSO-dg, δ): 1.32 (3H, s), 1.37 (3H, s), 3·0-5·4 (22H, in), 6.3-8·0 (1H, ra) MASS (APCI): 594 (M+H)+ (free) (87) (2R)-4-[2-(順-2,6-二甲嗎啉基)乙基]-1-[3-甲氧 基-5-(三氟甲基)-苄醯基]-2-(2-養甲基)哌哄二鹽酸 -106- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
I · I n n f 一:OJI ·ϋ ϋ I n n I I 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(1<>5)
mp: 188-1930C
[a]g8·5: -7.70° (C=0.31, MeOH) IR (KBr): 3430, 3400, 1640 cm-1 NMR (DMS〇-d6/ δ): 1.16 (6H, d, J=6.0Hz), 2.6-5.4 (22H, m), 6.3-8.0 (1H, m) MASS (APCI): 570 (M+H)+ (free) (88) (2R)-4-[2-(4,4-二氟哌啶基)-乙基]-l-[3-甲氧基 -5-(三氟甲基)-节釀基]-2-(2-#甲基)哌阱二鹽酸 mp: 243-26〇°C .
[a]g8·7: -10.36° (C=0.28, MeOH) IR (KBr): 3400, 1640 cm"1 NMR (DMS〇-d6, δ): 2.2-5.4 (24H, m), 6.3-8.0 (10H, m) MASS (APCI): 576 (M+H)+ (free) (89) (21〇-1-[3-甲氧基_5-(三氟甲基)苄醢基]-2-(2-萦 甲基)-4-[3-(3-吡啶基)-2-丙炔基]哌畊 [a]§8·7: -5.37。 (C=0.27, MeOH) IR (KBr) : 3740, 1640 cirT1 NMR (DMSO-d6, δ): 2.1-5.2 (14H, m) , 6.5-8.0 (12H, m), , 8.57 (1H, ra) , 8.64 (1H, s) MASS (APCI): 544 (M+H)+ (90) (2R)-l-[3-甲氧基-5-(三氟甲基卜苄醯基]-2-(2-萘甲基)-4-[2-(5·6,7,8-四氫-1,6-暸啶-6-基)乙基] 哌阱三鹽酸鹽
mp: 173-183〇C
[a]g7·9: -20.91° (C=0.26, MeOH) IR (KBr) : 3400, 1640 crrT1 NMR (DMS〇-d6/ δ): 2.8-5.4 (22H, m), 6.4-8.0 (11H, m), 8.03 (1H, d, J=8.5Hz), 8.67 (1H, d, J=4.9Hz) MASS (APCI): 589 (M+H)+ (free) -107- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(1Q6) (91) (2R)-l-[3,5-雙(三氟甲基)]-2-[(1Η-吲 B朵-3-基) 甲基]-4-[2-(5,6,7,8-四氩-1,6-暸啶-6-基)乙基]哌 畊三鹽酸鹽
mp: 190-20〇oC
[α]§7: -25.25° (C=0.2, MeOH) IR (KBr): 3500-3150, 2700-2300, 1646, 1519, 1434, 1371, 1272, 1236 cm"1 NMR (DMS〇-d6/ δ): 2.60-5.20 (25H, m) , 6.60-8.70 (11H, m), 11.17 (1H, s) MASS (APCI): 616 (M+H)+ (free) (92) (2R) - 2-[(lH-H3l 哚-3-基)甲基]-l-[3-甲氧基-5-(三氟甲基)苄醯基]-4-[2-(2R)-2-(甲氧甲基)嗎啉基] 乙基]_畊二鹽酸鹽
mp: 200-210°C
[a]g5·6: +34.4。 (C=0.27, MeOH) IR (KBr): 3400-3000, 2900-2500, 1637, 1607, 1461, 1423 cm"1 NMR (DMS〇-d6, δ): 2.81-5.20 (28H, m), 6.60-9.20 (8H, m), 10.98 (1H, s), 11.60-12.20 (2H, ra) MASS (APCI): 575 (M+H)+ (free) (93) (2R)-2-[(lH-B3l_-3-基)甲基]-l-[3-甲氧基-5-(三氟甲基)苄_基]-4-[4-(3,3-二甲嗎啉基)-2-丁炔 基]哌阱二鹽酸鹽 -10 8- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂---------- (請先閱讀背面之注意事項再填寫本頁) A7 _ B7__ 五、發明說明() 107
ιηρ: 190 - 200oC
[α]各5.6: +23.60 (C=0.25, Me〇H) (請先閱讀背面之注意事項再填寫本頁) IR (KBr): 3400-3000, 2900-2500, 1644, 1608, 1457, 1421 cnT1 NMR (DMSO-dg, δ〉: 1·32-1·37 ( 6H, m〉,3·20-5·20 (22H, m), 6·60-8·00 (8ΗΛ in〉,10.96 (1H, s), 12.00-12.40 (2H, m) MASS (APCI): 583 (M+H)+ (free) (94) (2R)-2-[(1H·吲 B朵-3-基)甲基]-4-[2-(順-2,6-二 甲嗎啉基)乙基]甲氧基-5-(三氟甲基)苄醢基] 哌畊二鹽酸鹽
mp: 188-200oC
[a]§6: +28.40 (Ο0·19, Me〇H) IR (KBr): 3500-3150, 2700-2300, 1637, 1606, 1459, 1272, 1174 crtT1 NMR (DMS〇-d6/ δ): 0.80-5.20 (28H, m), 6.60-8.20 (8H, m), 10.96 (1H, s), 11.40-11.80 (2H, br) MASS (APCI): 559 (M+H)+ (free) (95) (2{〇-4-[2-(4,4-二氟賴啶基卜乙基]-2_[(111-吲11榮 -3-基)甲基]-l-[3-甲氧基-5 -(三氟甲基)-节醯基]-哌阱二鹽酸鹽 經濟部智慧財產局員工消費合作社印製
Kip: 130-140°C
[a]g5·6: +22.9° (C=0.22, MeOH) IR (KBr): 3400-3000, 2900-2500, 1635, 1608, 1461, 1423 cirT1 NMR (DMSO~d6, δ): 2.20-5.20 (24H, m), 6.60-8.80 (8H, m), 10.97 (1H, s), 11.20-12.20 (2H, m) MASS (APCI): 565 (M+H)+ (free) -109 - 紙張尺度適用^國國家標準(CNS)A4規格(210 χ 297公釐) " 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 五、發明說明(1Q8) (96) (2R)-2-[(lH-P3l B朵-3-基)甲基]甲氧基-5-(三氟甲基)苄醯基]- 4-[(1_甲基-1H-吡啶-4-基)甲基] 哌畊鹽酸鹽
rap: 210-220oC
[a]§5·6: +18.58° (C=0.24, MeOH) IR (KBr): 3400-3000, 2900-2500, 1639, 1609Λ 1459, 1419, 1321 cm-1 NMR (DMSO-dg, δ): 2,70-5.20 (17H, ra) , 6.50-8.80 (8H, m) , 7.63 (1H, s) f 7.94 (1H, s) f 10.88-10.93 (1H, m), 11.59 (1H, br s) MASS (APCI): 512 (M+H)+ (free) (97) (2R)-2-[(lH-H3lB荣一3-基)甲基]-l-[3-甲氧基-5-(三氟甲基)苄醯基]-4-(3 -吡啶基)哌胼二鹽酸鹽
mp: 190-200oC
[a]g5·6: +22·0ο (C=0.34, MeOH) IR (KBr): 3400-3000, 2900-2500, 1637, 1606, 1463λ 1421 citT1 1<MR (DMSO-d6/ δ): 2.80-5.50 (14H, m) , 6.50-8.00 (8H, m), 7.74-7.92 (1H, m), 8.67 (1H, d, J=8.0Hz), 8.86 (1H, d, J=4.4Hz), 9.07 (1H, s) f 10.87 (1H, br s), 12.00- 12.40 (2H, m) MASS (APCI): 509 (M+H)+ (free) (98) (2R)-2-[(lH - Β3Ι» 朵-3-基)甲基]-l-[3-甲氧基一5-(三氟甲基)苄釀基]-4 - [3-(3-吡啶基)丙基]_阱二鹽 酸鹽 -110- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------------------^-------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7___
1 〇 Q 五、發明說明()
mp: 135-145°C
[α]§6·3: +21.2° (C=0.29, MeOH) IR (KBr) ·· 3400-3000, 2900-2500, 1635, 1607, 1463, 4 1421 cnT1 i^IMR (DMSO-dg, δ): 2.20-5.20 (18H, m) , 6.60-8.80 (11H, m), 11.80-12.00 (2HA m) MASS (APCI): 537 (M+H)+ (free) (99) (2R)-2-[(lH-吲 B 擊-3-基)甲基]-l-[3-甲氧基-5-(三氟甲基)苄醯基]-4-[2-(5,6,7,8-四氫-1,6-暸啶 - 6-基)乙基]哌阱三鹽酸鹽
mp: 180-190°C .[a]g7: -8.3° (C=0.15, MeOH) IR (KBr): 3500-3150, 1700-2300, 1637, 1631, 1461, 1348, 1238, 1172 cm*"1 NMR (DMS〇-d6, δ): 3·20-5·20 (22H, m), 6.60-8.20· (11H, m), 10.98 (1H, s) MASS (APCI): 578 (M+H)+ (free) (100) 1-[3, 5-雙(三氟甲基)苄醜基]-2-(3-羥基-4-甲基 苄基)-4-[2-(4·4-二氟哌啶基)乙基]-哌畊二鹽酸鹽
ιαρ: 250 - 2550C IR (KBr) : 3400-3000, 2900-2500, 1646, 1427, 1280 cirT1 NMR (DMSO-dg, δ): 2,08 (3Η, s), 2.35-5,20 (21H, m), 6.05-8.20 (7H, m), 8.90-9.50 (2H, m) MASS (APCI): 594 (M+H)+ (free) (101) (2R)-l-[3,5-雙(三氟甲基)苄醮基]-2 - [3 - [(2-甲 氧乙氧基)甲氧基]-4-芣氧基]- 4-[2-[(2R)-2-(甲氧 甲基)嗎_基]乙基]哌畊 -111- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------------------訂---I----- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 _ B7 五、發明說明(n<)) IR (Neat): 1643, 1508, 1435, 1381, 1354, 1331, 1279, 1130,1101, 1012 〇11-1 NMR (CDC13, δ): 1.90-5.60 (37Η, ra) , 6.20-8.20 (6H, m) MASS (APCI): 692 (M+H)+ (102) (211卜卜[3,5-雙(三氟甲基)苄_基]+ [2:(那,53卜3,5--二甲嗎啉基)乙基]- 2-[3-[(2 -甲氧乙氧基)甲氧基]_ 4- 甲基苄基]哌胼 IR (Neat): 1643, 1583, 1508, 1435, 1379, 1356, 1329, 127 9, 1132, 1099, 1012 crrT1 NMR (CDC13, δ): 1.01 (6H, d, J=6.4Hz), 1·90-5·50 (31H, m) , 6.20-8.20 (6H, m) MASS (APCI) .:· 676 (M+H)+ (103) (2R)-1-[3,5-雙(三氟甲基)苄醮基]-4-[k順 5- 二甲嗎啉基)乙基]-2 - [3-[(2-甲氧乙氧基)-甲氧基] -4-甲基苄基]哌阱 IR (Neat): 1643, 1583, 1508, 1452, 1435, 1406, 1379, 1356, 1325, 1277, 1099, 1012 crrT1 NMR (CDCI3/ δ): 0.51-5.70 (37Η, m), 6.10-8.20 (6Η, m) MASS (APCI): 676 (M+H)+ (104) (2R)-l-[3,5-雙(三氟甲基)苄醜基卜2-[3-[(2罐甲 氧乙氧基)甲氧基]-4-甲基苄基]-4-[3-[(2钱)-2-(甲 氧甲基)嗎啉基]丙基]哌阱 IR (Neat): 1643, 1583, 1508, 1437, 1406, 1379, 1354, 1331, 1279, 1097, 1014 crtT1 NMR (CDC13, δ): 1.60-5.40 (39Η, m) , 6.30-7.90 (6Η, ία) MASS (APCI〉: 706.3 (Μ+Η)+, 728.3 (M+Na)+ (105) (21?)-1-[3,5-雙(三氟甲基)苄醢基]-2-[3-[(2-甲 氧乙氧基)甲氧基]-4-节氧基]-4-[(E)-4-[(2S)_2-(甲氧甲基)嗎啉基]-2-丁烯基]哌阱 -112- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------------—-----1--------- (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(111) IR (Neat〉 : 1643, 1510, 1454, 1435, 1406, 1379, 1352, 1331, 1281, 1134, 1101, 1012 cnT1 NMR (CDC13, δ): 0.70-5.40 (37Η, ra) , 6.30-7.90 (8Η, m) MASS (ESI): 718.3 (M+H)+, 740.3 (M+Na)+ (106) (21〇-1-[3,5-雙(三氟甲基)苄醢基]-2-[3-[(2-甲 氧乙氧基)甲氧基]- 4-甲基苄基]-4-[2-[4,5,6,7-四 氫_吩并[3,2-c]吡啶-5-基]乙基]哌阱 IR (Neat): 1678, 1645, 1628, 1618, 1510, 1477, 1462, 1454, 1435, 1427, 1385, 1381, 1275 cm^1 NMR (CDCI3/ δ): 0.70-5.40 (31Η, m)·, 6.20-8.20 (8H, m) MASS (APCI): 700 (M+H)+ (107) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-2-[3-[(2-甲 氧乙氧基)甲氧基]-4-甲基苄基]-4-暗_ -6-基)甲基] 哌畊 .IR (Neat): 1693, 1678, 1645, 1630, 1618, 1547, 1539, 1514, 1464, 1454, 1427, 1392, 1387, 1381, 1277 crrT1 NMR (CDC13a δ): 0.70-5.50 (23Η, m), 6.20-9.00 (12Η, m) MASS (APCI): 676 (M+H)+ (108) (2R)-l-[3,5-雙(三氟甲基)苄醮基]-2-[3-[(2-甲 氧乙氧基)甲氧基]-4-甲基苄基]-4-[(3-溴-1,2,4-11等 二唑-5-基)甲基]哌阱 NMR (CDC13, δ): 2.19 (3Η, s), 2.40-5.40 (15Η, m), 3.38 (3Η, s), 3.78 (2Η, s) , 6.30-8,00 (6H, m) MASS (APCI): 695 (M+H)+, 621, 609 例10 仿例1之方法可得如下化合物。 (1) (2R)-1 - [3,5-雙(三氟甲基)苄醣基]-2 - [4-氟苄基]-4-[(2S)-(甲氧甲基)嗎啉基]-乙基]哌阱二鹽酸鹽 一 113- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------I--— II --------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7_ 五、發明說明(112) mp: 129-1330C * [α]§8·0: +6.96° (0=0.28, MeOH) IR (KBr): 1645, 1516, 1281, 1182, 1138 cnT1 NMR (DMS〇-d6, δ): 2.7 0-5.20 (25H, m), 7·〇〇-8·22 (7H, in) MASS (APCI): 592 (M+H)+ (free) (2) (2R)-1-[3,5-雙(三氟甲基)苄 _ 基]-2-(2-# 甲基)-4-[(2S)-(甲氧甲基)嗎啉基]-乙基]哌畊二鹽酸鹽
rup: 145 - 1480C
[a]g8·9: -16.6° (C=0.49, MeOH) IR (KBr)·· 1645, 1429, 1281, 1182, 1134 cirT1 NMR (DMSO-dg, δ): 2.80-5.40 (25H, m), 7.05-8.20 (l〇H, m) MASS (APCI): 624 (M+H)+ (free) (3) 1-[3,5-雙(三氟甲基)苄_基]-2-[3-[(2-甲氧乙氧基) 甲氧基]-4_甲基苄基]-4-[4-[25,55]-2-甲氧甲基-5-甲嗎啉基]-2-丁炔基]哌阱 IR (KBr): 1643 cm"1 NMR (CDC13, δ): 1.20 (3Η, d, J=6.3Hz) , 2/19 (3H, br s), 1·92-2·12 (2H, ra), 2.60-5.40 (25H, ra), 3·36 (6H, s), 6.67-7·81 (6H, m) MASS (ESI+): 730.3 (M+H)+, 752 (M+Na)+ (4) l-[3,5-雙(三氟甲基)苄醯基]-2-[3-[(2-甲氧乙氧基) 甲氧基]-4-甲基节基]- 4-[2-[(lR,4S)-3,3 -二甲基-2- 吖雙環并[2·2·1]庚烷-5-基]乙基]_哄 IR (Neat): 1643, 1437 cm一1 NMR (CDC13, δ): 1.10-1.12 (3Η, η), 1.31 (3H, s), •1·60 -1.75 (1H, πι〉,1·92 (1H, d, J=10.0Hz), 2·20 -(3H, s), 2.28 (1H, d, J=10,0Hz)2.20-4.60 (19H, m) , 3.36 (3H, s), 4·43 (1H, br s), 5.00-5.40 (2H, m), 6.30- 7.79 (6H, m) MASS (APCI): 688 (M+H)+ , 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-114- —------------·—----^--------- (請先閱讀背面之注意事項再填寫本頁) ⑽8 A7 _BL_ 五、發明說明(113) 例11 將三乙醮氧硼氧化鈉(0.3克)分批加至含(2R)-l-[3, 5〜雙(三氟甲基)-苄醮基]-2-[3-[(2-甲氧乙氧基)甲氧 基]-4-甲基苄基]-哌畊(0.5克)及1-甲基-1H-毗唑-4 - 羧醛(0.12克)之二氯甲烷(10毫升),於室溫下攪拌1小 時。清洗Μ碳酸氫納溶液,於硫酸鎂下乾燥並減壓蒸除 ^由矽膠柱層析純化(乙酸乙酯)。收集含目的化合物部 份並減壓蒸除可得(2R)-l-[3,5-雙(三氟甲基)苄釀基]- 2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲基苄基]-4-[(l-甲 基-1H-吡唑-4-基)甲基]哌畊(0.54克)之油。 IR (Neat): 1641, 1579, 1508, 1435, 1381, 1352( 1329, 1277, 1097, 1088, 1014 era一1 NMR (CDC13, δ): 1.75-5.40 (26Η, m), 6·25~7.95 . (8Η, m) ' MASS (APCI): 629 (Μ+Η) + 例12 仿例11之方法可得如下化合物。 ⑴(2R)-l-[3,5-雙(三氟甲基)苄釀基]-2-[3-Ι:(2«甲氧乙氧 基)甲氧基]-4-甲苄基]-4-(3-吡啶甲基)哌阱 IR (Neat): 1643, 1583, 1508, 1431, 1379, 1356, 1352, 1331, 1279, 1097^cm^1 NMR (CDC13, δ): 0.70-5.60 (23Η, m), 6.20-8.80 (10H, m) MASS (APCI): 626 (M+H)+ (2) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(4-氯-3-羥苄 基)-4-[(1-甲基- 唑-4-基)甲基]哌胼鹽酸鹽 -115- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------線赢 經濟部智慧財產局員工消費合作社印製 509688 A7 __B7_ 五、發明說明(114)
rap: 159 - 1630C
[a]g8: -5.25° (C=2.0, MeOH) (請先閱讀背面之注意事項再填寫本頁) IR (KBr) : 3398, 1647, 1427, 1281, 1178, 1138 cirT1 .NMR (DMSO~d6/ δ): 2.60-5.10 (11H, m), 3.85 (3H, s) f 6.26-7.21 (3H, in), 7.51-8.23 (5H, m), 10·20 (1H, br) MASS (APCI): 561 (M+H)+ (free) ③(2R )-1-[3 ·5-雙(三氟甲基)苄醮基]-2-(4-氯-3-羥苄 基)-4-(3-吡啶甲基)脈阱二鹽酸鹽
mp: 187-192°C
[a]g7·3: -8.11° (C=0,185r MeOH) IR (KBr) : 3435, 1645, 1429, Ιέ81, 1182, 1136 cirT1 NMR (DMS〇-d6> δ): 2.60-6.10 (11H, m) , 6.29-7.20 (3H, m), 7.47-8·24 (4H, ra), 8.61-9.03 (3H, m), 10.13 (1H, br) MASS (APCI): 558 (M+H)+ (free) (4) (2R )-1 -[3,5-雙(三氟甲基)苄釀基]-2-(4-氯-3-羥苄 基)-4-[3-(3-吡啶基)丙基]-哌畊二鹽酸鹽
rap: 65-70°C
[a]g7·9: -7·68。 (C=0.28, MeOH) IR (KBr〉: 1647, 1427, 1279, 1180, 113$ cirT1 NMR (DMS〇-d6, δ): 2·10-5·10 (15H, m), 6·30-7·29 rci), 經濟部智慧財產局員工消費合作社印製 7·48. (1H, s), 7·84 (1HA s), 7·95 — 8·89 d in), 10·20 (1H, br) MASS (APCI): 586 (M+H)+ (free) (5) (2R)-l-[3-甲氧基-5 -(三氟甲基)苄醯基]-2-(4-氯-3-羥苄基)-4-[(1-甲基-1H-毗唑-4-基)甲基]哌畊鹽酸鹽 -116- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 A7 ----- —_B7_ 五、發明說明(115)
mp: 140-150°C
[a]g8·3: +4.17。 (C=0.36, Me〇H) 工R (KBr): 3411, 2600, 1641, 1604, 1462, 1423, 1240, 1173, 1128 cirT1 NMR (DMSO~d6, δ): 2.70-5.10 (11H, m), 3.85 (6H, s), 6·3〇一7·32 (6H, ra), 7·60 (1H, s), 7·95 (1Η, s), 10.18 (1H, br) MASS.(APCI): 523 (M-fH)+ (free) 钧(2R)-l-[3-甲氧基-5-(三氟甲基)苄醢基]-2-(4-氯-3-羥苄基)-4 -(3-吡啶甲基)哌阱二鼸酸鹽
rap: 215-2240C
[α]§8·3: .7.60。 (C=〇.25, Me〇H) IR (KBr) : 3400, 1639, 1606, 1464, 1425, 1173, 1128 crrT1 NMR (DMS〇-d6, δ): 2.60-5.10 (11H, m), 3·84 (3H, s), 6·26-7·33 (6H, m〉, 7·92 (1H, dd, J=4.8 and 7·9Ηζ), 8·65 (1H, d, J=7.9Hz), 8·88 (1H, d, J=4.8Hz), 9·04 (1H, s), 10·13 (1H, br) MASS (APCI): 520 (M+H)+ (free) (?) (2R)-l-[3-甲氧基-5-(三氟甲基)苄釀基]-2-(4-氯-3 -羥苄基)-4-[3-(3-吡啶基)丙基]哌阱二鹽酸鹽 mp: 90-110oC ^ [a]g8·3: +0.27° (C=0.185, Me〇H) IR (KBr): 2952, 2600, 1645, 1606, 1464, 1425, 1238, 1171, 1126 crrT1 NMR (DMS〇一d6, δ) ·· 2.10 — 5·2〇 (15H, m) , 3.83 (3H, s), 6.30-7.33 (6H, m), 7.61 (1H, dd, J=4.2 and 8.0Hz), 8.01 (1H, d, J=8.0Hz), 8.58 (1H, d, J=4.2Hz) , 8.65 (1H, s), 10·20 (1H, br) MASS (APCI): 548 (M)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-117- --------------------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(1 ) (8) (2R)-l-[3,5 -雙(三氟甲基)苄醢基]-2 -(4 -氟-3 -甲氧 苄基)-4 - [(1-甲基-1H-吡唑-4-基)甲基]哌阱鹽酸鹽
mp: 127-135°C
[ajg8·1: +2.75° (C=0-20, MeOH) IR (KBr) : 3400, 1645, 1516, 1282, 1182, 1136 cirT1 NMR (DMS〇-d6, δ): 2.80-5.20 (14H, m), 3·85 (3H, s), 6,40-7.30 (3H, m) , 7.58-8.30 (5H, m) MASS (APCI): 559 (M+H)+ (free) ⑨(2R)-1_[3,5-雙(三氟甲基)苄醯基]-2 -(4-氟-3-甲氧 苄基)-4-(3-吡啶基)哌阱二鹽酸鹽
mp: 143-147°C
[alg8·1: +0.889° (C=0.225, MeOH) IR (KBr) : 3400, 1645, 1516, 1282, 1182, 1134 cirT1 NMR (DMSO-dg, δ): 2.80-5,20 (14H, m), 6.40-7.30 (3H, m), 7.50-8·30 (4H, ra), 8·65 (1H, d, J=8.3Hz), 8·88 (1H, d, J=5.0Hz) , 9.08 (1H, s) MASS (APCI): 556 (M+H)+ (free) ⑽(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 -(4-氟-3-甲氧 苄基)-4-[3-(3-吡啶基)丙基]哌阱二鹽酸鹽
mp: 125-130°C
[a]g7·7: +2·50° (C=0.18, MeOH) IR (KBr): 3400, 1645, 1516, 1281, 1182, 1134 cm—1 NMR (DMSO-dg, δ): 2.00-5.20 (18H, m), ^6.40-7·40 (3H, m), 7.50-8.50 (5H, m) , 8.70-9.00 (2H, m) MASS (APCI): 584 (M+H)+ (free) (11M2R)-2-(4-氟-3-甲氧苄基X - [3 -甲氧基-5-(三氟 甲基)苄醮基]-4-[(1-甲基-ΙΗ-Bft唑-4-基)甲基]哌阱 鹽酸鹽 -118- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------1----------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明() [a]g8: +23.270 (C=0.245, MeOH) IR (KBr): 1741, 1707, 1693, 1678, 1645, 1628, 1616, 1562, 1547, 1516, 1464, 1423, 1344, 1317, 1273, 1242, 1215, 1169, 1126, 1051 crrT1 NMR (DMS〇一 d6, δ): 2 · 00-5 · 20 (20H, rn) , 6 · 30-8 · 00 (8H, m) MASS (APCI): 521 (M+H〉+ (free) (12) (2R)-2-(4-氟-3-甲氧苄基)-l-[3-甲氧基-5-(三氟 甲基)苄釀基]-4-(3-毗啶甲基)哌阱二鹽酸鹽 [a]g8: +24.20° (C=0.345, MeOH) IR (KBr): 1643, 1635, 1616, 1516, 1466, 1423, 1350, 1273, 1171, 1126, 1051 cm"1 NMR (DMSO-d6, δ): 0.80-5.30 (17H, m), 6.00-9.00 (10H, m) MASS (APCI): 518 (M+H)+ (free) (13) (2R)-2-(4-氟-3-甲氧苄基卜1 - [3-甲氧基-5-(三氟 甲基)苄醯基]-4-[3-(3-吡啶基)丙基]-哌阱二鹽酸鹽 [α]^7·1: +25,77° (€=0.26, MeOH) IR (KBr): 1645, 1635, 1628, 1618, 1516, 1464, 1425, 1171, 1128, 1088, 1047 cm-1 NMR (DMSO-dg, δ): 1.60-5.30 (21H, m), 6,00-9.00 (10H, m) MASS (APCI): 546 (M+H)+ (free) (14) (21?)-1-[3,5-雙(三氟甲基>节釀基]-2-(4-氟-3-羥 苄基)-4-[(l-甲基-1H-毗唑-4-基)甲基]哌畊鹽酸鹽
mp: 160-170°C
[α]§7·6: -4.45° (C=0.55, MeOH) IR (KBr): 1693, 1674, 1645, 1630, 1533, 1516, 1477, 1446, 1437, 1429, 1392, 1387, 1365, 1282, 1180, 1138, 1057 crrT1 NMR (DMS〇-d6, δ): 0·80-5·20 (14H, m), 6.00-8·40 (8H, m) MASS (APCI): 545 (M+H)+ (free) -119一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------------丨丨訂----------線# (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 __ B7_ 五、發明說明(118) (15) (21〇-1-[3,5-雙(三氟甲基)苄醢基]-2-(4-氟-3-羥 苄基)-4-(3-吡啶甲基)哌阱二鹽酸鹽
mp: 50-60oC
[a]g7·6: -0.95° (C=0.37, MeOH) IR (KBr)·· 1707, 1693, 1676, 1645, 1628, 1618, 1558, 1547, 1533, 1516, 1477, 1466, 1454, 1429, 1392, 1387, 1367, 1281, 1180, 1136 cm-1 NMR (DMSO~dg, δ): 0.80-5.20 (11H, m), 6.00-9.20 (10H, m) MASS (APCI): 542 (M+H)+ (free) (16) (21〇-1-[3,5-雙(三氟甲基)苄醜基]-2-(4-氟-3-羥 苄基)-4-[3-(3-毗啶基)丙基]哌阱二鹽酸鹽
rap: 80-95°C
[α]§6·5: -3·51。 (C=0.285, Me〇H) IR (KBr): 1647, 1518, 1281, 1180, 1136 cnT1 NMR (DMS〇-dg> δ): 2.00-5.20 (15H, m), β·30-7.20 (3H, m), 7.40-8vil0 (5H, m) , 8.60-8.80 (2H, m) , 9.78 (1H, br) MASS (APCI): 570 (M+H)+ (free) (17) (2R) -1-[3,5-雙(三氟甲基)苄醮基]-2 一(4一氯节基) -4-[(l-甲基-1H-吡唑-4-基)甲基]哌阱鹽酸鹽 mp: 210-245°C (decomp·) [a]g7·6: -8.83° (C=0.283, MeOH) IR (KBr): 1647, 1516, 1508, 1498, 1464, 1454, 1446, 1427, 1362, 1281, 1182, 1138, 1057, 1020 crrT1
It NMR (DMS〇-d6, δ) : 2.00-5.40 (14H, m), 6·80-8·30 (9H, m) MASS (APCI): 545 (M+H)+ (free) (18) (2R)-l-[3,5-雙(三氟甲基)苄醢基]_2一(4_氯节基> -4-( 3-吡啶甲基)哌畊二鹽酸鹽 -120- ---------------------訂---------線 (請先閱讀背面之注意事項再填寫本頁)
509688 A7 B7 五、發明說明(119) mp: 220-228°C (decomp.) [α]§7·7: -5·58° (C=0.26, Me〇H〉 IR (KBr): 1643, 1495, 1489, 1468, 1429, 1363, 1319, 1284, 1279, 1186, 1136, 1053 cirT1 NMR (DMSO-dg, δ): 2.00-5.80 (11H, m), 6.70-9.10 (11H, m) MASS (APCI): 542 (M+H)+ (free) (19) ( 2R)-l-[3,5-雙(三氟甲基)苄醢基卜2-(4-氛苄基) -4-[3-(3-吡啶基)丙基]哌阱二鹽酸鹽
inp: 60-100°C ;[α]§8·3: —5·740 (C=0.27, MeOH) IR (KBr): 1645, 1551, 1514, 1498, 1468, 1429, 1363, 1319, 1281, 1184, 1136, 1103, 1039, 1024 cnT1 NMR (DMSO~d6/ δ): 2.00-5.40 (15H, m), 6.80-9.00 (11H, m) MASS (APCI): 570 (M+H)+ (free) (20) (2R)-2-(4-氯苄基)-1-[3-甲氧基-5-(三氟甲基)苄 醜基]-4 - [(1-甲基-1H-吡唑-4-基)甲基]哌阱鹽酸鹽
ιαρ: 70 - 100oC
[α]§7·8: +1.84。 (C=0.435, Me〇H) IR (KBr): 1693, 1641, 1635, 1628, 1604, 1550, 1547, 1539, 1516, 1498, 1466, 1437, 1414, 1352, 1269, 1169, 1128, 1092, 1051 cm"1 NMR (DMS〇-d6, δ): 2·60-5·20 (17H, m), 6,50-8.10 (9H, m) MASS (APCI): 507 (M+H)+ (free) (21) (2R)-2-(4-氯苄基)l-[3-甲氧基-5-(三氟甲基)苄 醢基]-4-(3-吡啶甲基)哌阱二鹽酸鹽
mp: 60-80oC
[α]§7·8: +10.56° (C=0,27, MeOH) IR (KBr): 1643, 1610, 1496, 1466, 1421, 1373, 1350, 1315, 1271, 1242, 117 4, 1130, 1097, 1049 cirT1 NMR (DMSO-d6/ δ): 2.60-5.20 (14H, m) , 6.40-9.20 (11H, m) MASS (APCI): 504 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-121- (請先閱讀背面之注意事項再填寫本頁) ip衣 訂·--------線赢 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688
五、發明說明() (22) (2R)-2-(4-氯苄基)-1-[3-甲氧基_5一(三氟甲基)苄 醢基]-4-[3-(3-吡啶基)丙基]-哌阱二鹽酸鹽 mp: 60-100¾ [α]§8·3: +4.08。 (C=0.245, Me〇H) IR (KBr): 1643, 1606, 1558, 1550, 1516, 1496, 1466, 1421, 1350, 1317, 1271, 1242, 1173, 1128, 1097, 1051 curl NMR (DMSO-dg, δ): 1.80-5,40 (18H, m), 6.40-9.00 (11H, m) MASS (APCI): 532 (M+H)+ (free) (23) (2R) -1-[3,5-雙(三氟甲基)苄醜基]一 2一(4-氟节基) - 4-[(1-甲基-1H-吡唑-4-基)甲基]-哌畊鹽酸鹽 rap: 143.3-146.4°C [a]g6·6: -5/·60° (C=0.25, MeOH) IR (KBr): 1..647, 1513, 1427, 1282, 1182, 1135 citT1 -NMR (DMSO-dg, δ): 2.80-5.04 (14H, m) , 6,96-8.23 (9H, m) MASS: 529 (M+H)+ (free) (24) (2R)-l-[3,5-雙(三氟甲基)苄醚基]-2-(4-氟节基) -4-(3-吡啶甲基)哌阱二鹽酸鹽 mp: 130.0-137.3°C [a]g6: -13.03° (C=0,33, MeOH) IR (KBr) : 1645, 1427, 1282, 1184, 1133 cirT1 - ti NMR (DMSO-dg, δ): 2.84-5.01 (11H, m), 6.94-9.05 (11H, m) MASS: 526 (M+H)+ (free) (25) (2R)-2-(4-氟苄基)-l-[3-甲氧基-5-(三氟甲基)亨 醯基]-4 - [(1-甲基-1H-咐唑-4-基)甲基]-脈哄鹽酸鹽 mp: 225.6-228.4°C [cc]g7·5·· +8.84。 (C=CK25, MeOH) IR (KBr): 1635, 1413, 1351, 1238, 1158, 1122, 1049 cm-1 NMR (DMS0-d6/ δ): 2,85-5.03 (17H, m), 6.59-8.45 (9H, m) · MASS: 491 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-122- (請先閲讀背面之注意事項再填寫本頁) 訂---------線應 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 10 1 五、發明說明() (26) (2R )-2-(4-氟苄基)-1-[3-甲氧基-5-(三氟甲基)苄 釀基]-4-(3-吡啶甲基)哌畊二鹽酸鹽
mp: 81.4-84.3°C
[α]^7·1: +15.58° (C=0.50, MeOH) 工R (KBr) : 1643, 1606, 1513, 1465, 1423, 1349, 1172, 1128 cm"1 NMR (DMS〇-d6, δ): 2·95-5·00 (14H, m), 6·58-7·32 (7H, m), 7.80-9.03 (4H, m) MASS: 488 (M+H)+ (free) (27) (21〇-1-[3,5-雙(三氟甲基)苄釀基卜4-[(1-甲基-1H-吡唑-4-基)甲基]-2-(2-萘甲基)哌阱鹽酸鹽
mp: >250°C
[a]g5·2·•-19·620 (C=0.26, Me〇H) IR (KBr) : 3400, 1640 cirT1 NMR (DMSO-dg, δ): 2.8-5.3 (11H, m), 3.78 (3H, s), 6,96 (1H, d, J=8.1Hz), 7.4-8.2 (11H, m) MASS (APCI): 561 (M+H)+ (free) (28) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(2-萘甲基) -4 -(3-吡啶甲基)哌阱二鹽酸鹽
mp: 198-208°C
[a]g4*8: -12.81° (C=0.26, MeOH) IR (KBr): 3430, 2590, 1640 cm—1 NMR (DMS〇-d6, δ): 3 · 0-5 · 2 (11H, ra) , 6 · 95 (1H, d, J=7.7Hz), 7.4-8.0 (9H, ru) , 8·17 (1H, m) , 8.54 (1H, d, J=8.0Hz)/ 8.80 (1H, br s) r 9.00 (1H, s) MASS (APCI): 558 (M+H)+ (free) (29) (2R)-1 - [3 -甲氧基-5 -(三氟甲基)苄釀基]-4-[(l-甲基-1H-吡唑-4-基)甲基]-2-(2-綦甲基)哌畊鹽酸鹽 一 123 — 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -丨丨丨丨I I丨訂·丨丨丨丨II丨— 赢 509688 A7 B7 12 2、 五、發明說明( mp : 226-228 t! [a]g7·2: -2.55° (C=0.28, MeOH) IR (KBr) : 3400, 1640 cirT1 、 (請先閱讀背面之注意事項再填寫本頁) NMR (DMSO-dg, δ): 2 · 9-5 · 3 (17H, in) , 6 · 6-8 · 0 (12H, m) MASS (APCI): 523 (M+H)+ (free) (30) (2R)-l-[3-甲氧基-5-(三氟甲基)苄醯基]_2_(2_萘 甲基)-4-(3-吡啶甲基)哌阱二鹽酸鹽
mp: 162-168°C
[a]g7·6·•-1·41。(00.29, Me〇H) IR (KBr) : 3400, 1640 crtT1 NMR (DMSO-dgV δ): 2.8-5.3 (11H, m)A 3·65 and 3·73 (3H, s), 6.5-8.0 (11H, m), 8.51 (1H, d, J=8.7Hz), 8.80 (1H, m), 8.98 (1H, s) MASS (APCI): 520 (M+H)+ (free) (31) (21〇-1-[3,5-雙(三氟甲基)苄醮基卜2-[3_[(2_甲 氧乙氧基)甲氧基]-4-甲节基卜4-[2-Ig基)-乙 基]哌阱 IR (Neat): 1674, 1643, 1581, 1547, 1510, 1429, 1381, 1356, 1350, 1333, 1279, 1132, 1097, 1012 cm-1 NMR (CDC13/ δ): 0,70-5.50 (25Η, m), 6.20-8.80 (10H, m) MASS (APCI): 640 (M+H)+ 經濟部智慧財產局員工消費合作社印製 (32) (2R)-l-[3,5-雙(三氟甲基)节醢基]-4««[2-(3,4-二 氫喃并[3,2-b]-l,4 -吗哄-4-基]乙基]-2_[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]哌阱 IR (Neat): 1678, 1645, 1628, 1618, 1510, 1477, 1462, 1454, 1435, 1427, 1385, 1381, 1275 cm'1 NMR (CDC.I3, δ): 0.70-5.60 (29Η, in), 6.20-8.00 (9Η, m) MASS (APCI): 697 (M+H)+ -124- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 __B7_ 五、發明說明(123) (請先閱讀背面之注意事項再填寫本頁) (33) (28)-1-[3,5-雙(三氟甲基)苄醢基]-2-[3-[(2-甲 氧乙氧基)甲氧基]-4-甲苄基]_4-(1-三苯甲基-1H-咐 唑-4-基)甲基]哌畊 -26.15° (C=0*260/ MeOH) IR (Neat): 1645, 1450, 1280, 1130, 1020 cirT1 NMR (CDCI3, δ): 1.86-5.40 (23H, m), 6.30-7.90 (23H, m) MASS (API-ES): 857 (M+) (34) (2R)-l-[3-甲氧基-5-(三氟甲基)苄醯基]-4-[l-甲 基-ΙΗ-Bfct唑-4-基甲基]-2-[4-(三氟甲基)-苄基]哌畊 鹽酸鹽 mp: 218-223。。 [a]g7: +18·73° (0=0-25, MeOH) IR (KBr): 3437, 3400, 1645 cm 1 NMR (DMSO-dg, δ): 2.80-5.30 (11H, mW 3.80 (3H, s), 3.85 (3H, s), 6.48-7,94 (9H, m) MASS (APCI): 541 (M+H)+ (free) (35) (2R)-l-[3-甲氧基-5 -(三氟甲基)苄醯基]- 4 -(3-吡 啶甲基)-2-[4-(三氟甲基)苄基]哌阱二鹽酸鹽
rap: 101-108°C
[a]g7: +15.60° (C=0.25, MeOH) 經濟部智慧財產局員工消費合作社印製 IR (KBr) : 3431, 1643, 1518 cm-1 NMR (DMS〇-d6, δ): 2.80-5.20 (11H, .m), 3.83 (3H, s), 6.42-7.90 (8H, m), 8.56 (1H, d, J=7.6Hz), 8.84 (1H, d, J=5.2Hz), 9·01 (1H,. s) MASS (APCI): 538 (M+H)+ (free) -125- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 五、發明說明(124) 例13 於含(2R) -1-[3,5-雙(三氟甲基)苄醯基]-2_(3-第三 丁二苯矽烷氧基-4-甲苄基)-4-[2 - [(2S)-2-(甲氧甲基) 嗎啉基]-乙基]哌阱(651·9毫克)之四氫呋喃(6.5毫升) ,於51C下加入氟化四丁銨(1莫耳溶液於四氫呋喃, 0.85毫升)。於室溫下攪拌,蒸除並由矽膠柱層析鈍化 (矽膠:65毫升;二氯甲烷/甲酵=3$97)可得油(381.5毫 克)。將含此油之甲酵(3毫升)加入2.17奠耳氯化氩之 甲酵(1.43毫升),濃縮可得(2R)-l-[3-甲氧基-5-(三氟 甲基)苄醯基]-2-(3-羥基-4-甲苄基)-4-[2-[(2S卜2- (甲氧甲基)嗎啉基]-乙基]哌阱二鹽酸鹽之固體。由丙 _(4.55毫升)及水(13.9微升),先於室溫再於01C下再 結晶,於45υ減壓乾燥可得純物之粉( 393.9毫克)。 mp: 206-224.5°C IR (KBr) : 1635 crtT1 NMR (D2〇, δ)": 2.16 (3H, s) , 2.60-5.30 (22H, m) , 3.40 (3H, s), 6.30-8.10 (6H^m) MASS (APCI): 604 (M+H)+ (free) 例14 仿例1 3之方法可得如下化合物。 ⑴(2R)-2 -(3-羥基-4-甲节基)-4-[2-[(2S)-2-(甲氧甲 基)嗎啉基]-乙基]-l-[3-硝基-5-(三氟甲基)苄醯基] 哌阱二鹽酸鹽 mp: 181-1850C ' [α]§3: +24.00° (C=0.25, MeOH) IR (KBr) : 1641 cirT1 NMR (DMSO-dg, δ): 2.08 (3H, s) , 2,80-5,10 (25H, m), 6.18-8.55 (6H, m) MASS (APCI): 581 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -126- (請先閱讀背面之注意事項再填寫本頁) i 丨 I I--—訂---I I 1 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(125) ⑵(2R)-l-[3-二甲胺基-5-(三氟甲基)苄醯基]-2-(3-羥 基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基卜乙 基]哌畊二鹽酸鹽
mp: 182-186°C
[α]§3: +27.00° (C=0.25, MeOH) IR (KBr): 1643 cm"1 NMR(DMS〇-d6,5〉:2.06(3H,s),2.94(6H,brs),2.70- 5.20 (25H, m), 6.·24:7·00 (6H, m) MASS (APCI): 579 (M+H)+ (free) (3) (2R)-2 -(3-經基-4-甲节基)-4-[2-[(2S)-2-(甲氧甲 基)嗎啉基]-乙基]-l-[3 -甲胺基-5-(三氟甲基)节釀 基]哌阱二鹽酸鹽
mp: 159-170°C
[oc]g2: +23.60。(C=0.125, Me〇H) IR (KBr) : 3433, 3400, 1643 crrT1 NMR (DMSO-dg, δ): 2.06 (3H, s) , -2.68 (3H, br s), 2·80-5.10 (25H, m), 6.10-7.00 (6H, in) MASS (APCI): 565,37 (M+H)+ (free) (4) (2R)-2-(3 -經基-4-甲节基)-4-[2-[(2S)-2-(甲氧甲 基)嗎啉基]-乙基]-l-[3-(咐略-1-基)-5-(三氟甲基) 苄釀基]哌畊二鹽酸鹽
mp: 159-170°C
[a]g4: +1·20ο (C=0.125, Me〇H) IR (KBr): 3433, 3400, 1636, 1494 cnT1 NMR (DMS〇-d6, δ)·· 2·05 (3H, s), 2.80-5·10 (25H, m), 6,10-8.02 (10H, m) MASS (APCI): 601.4 (M+H)+ (free) -127- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------線· 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(126) (5) (2R)-2-(3 -羥基-4一甲 f 基)-4-[2-[(2S)-*2-(甲氧甲 基)嗎啉基]-乙基]-l-[3-甲氧基-5-(三氟甲基)苄酿 基]哌畊二鹽酸鹽
mp: 160-1690C
[α]§4: +6.80。 (C=0.125, MeOH) IR (KBr): 343D, 3400, 1643, 1461 cnT1 NMR (DMSO-d6, δ): 2·〇7 (3H, s), 3·27 (3H, s), 3·93 (3H, br s), 2.40-4·10 (22H, ra), 6.10-7.40 (6H, in) MASS (APGI): 566 (M+H)+ (free) (6) (2R) - 2-(3-經基-4-甲节基)-4-[2-[(25)-2-(甲氧甲 基)嗎啉基]-乙基]-l-[3-甲硫基-5-(三氟甲基)苄醯 基]哌畊二鹽酸鹽
mp: 154-1680C
[a]g4: +5.87° (C=0.125, Me〇H) IR (KBr): 3431, 3400, 1639 cm-1 NMR (DMS〇-d6, δ): 2.09 (3H, s), 3.27 (3H, s), 2.40-5.10 (25H, m), 6.17-7.60 (6H, m) MASS (APCI): 582 (M+H)+ (free) ⑺(2R) - 2-(3-經基-4-甲节基)-4-[2-[(2S) - 2-(甲氧甲 基)嗎啉基]-乙基]-1 -[3-甲磺醯基-5-(三氟甲基)苄 醯基]哌阱二鹽酸鹽 mp: 173.5-178.0°C [a]g5: -19.07° (C=0.125, MeOH) IR (KBr): 3437, 3402, 1645 cm—1 NMR (DMS〇-d6, δ): 2.08 (3H, s) , 3.27 (3H, s) , 3.37 (3H, s), 2.20-5.10 (22H, ra) , 6.21-8.31 (6H, m) MASS (APCI): 614 (M+H)+ (free) -1 2 8 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) * -1 n n In 1 1- 一: 口、I 1 mmmmmmm tmmmm n (請先閱讀背面之注意事項再填寫本頁) 線#_ 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(127) (8) (2R)-l-[3-二甲胺磺醮基-5-(三氟甲基)苄酿基]-2-(3-羥基-4-甲苄基)-4 - [2 - [(2S)-2-(甲氧甲基)嗎啉 基]乙基]哌畊二鹽酸鹽 ιαρ: 153.5 - 160oC [a]g5: -15.60° (C=0.125, MeOH) IR (KBr) : 3400, 1643, 1516 cnT1 NMR (DMSO-dg, δ): 2.07 (3H, s) , 2.66 (6H, s), 2.40-5.20 (25H, m), 6.18-8.01 (6H, m) ' MASS (APCI): 643.36 (M+H)+ (free) (9) (2R)-2-(3-羥基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲 基)嗎啉基]-乙基]-l-[3-甲胺磺醯基-5-(三氟甲基) 苄醯基]哌阱二鹽酸鹽 mp : 120-187¾ [α]§5: -15.07° (C=0.125, MeOH) IR (KBr): 1643 cm—1 NMR (DMS〇-d6, δ): 2.07 (3H, s), 2.60-5.10 (28H, in), 6.17-8.10 (6H, m) MASS (APCI): 629 (M+H)+ (free) ⑽(2R)-2-(3-經基-4-甲节基)-4-[2-[(2S) - 2-(甲氧甲 基)嗎啉基]乙基]-l-[3-(l-吡咯啶磺醢基)-5-(三氟 甲基)苄醢基]哌阱二鹽酸鹽
mp: 125-177°C
[a]g4: -11.10° (C=0.25, MeOH) IR (KBr): 1645 cm一1 NMR (DMSO-dg, δ): 1.60-1.76 (4H, m), 2.07 (3H, s), 2.49-5.20 (29H, m), 6.20-8.02 (6H, m) MASS (APCI): 669 (M+H)+ (free) -129- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(128) (11U2R) - 2-(3-經基-4-甲节基)-4-[2-[(2S)-2-(甲氧 甲基)嗎啉基]乙基]-1-[3-(嗎啉磺醯基)-5-(三氟甲 基)苄醯基卜哌阱二鹽酸鹽
rap: 130~175°C
[α]§5: —8·60。 (C=0.25, Me〇H) 工R (KBr) : 1645 crtT1 NMR (DMS〇-d6, δ): 2.08 (3H, s), 2·60-5·10 (33H, m), 6.20-8·01 (6H, m) MASS (APCI): 685 (M+H)+ (free) (12) (2R)-2-(3-羥基-4-甲苄基)-4-[2-[(2S)-2-(甲氧 甲基)嗎啉基]乙基]-1-[3-(4-吡啶基)-5-(三氟甲基) 苄醯基]哌阱三鹽酸鹽
mp: 169-173°C
[a]g8: -1.60。 (C=0.125, Me〇H) IR (KBr): 1635 cm—1 NMR (DMS〇-d6, δ): 1.91-2.04 (3H, m) , 2.84-5.20 (25H, m), 6.17-8.37 (8H, m), 8·96 (2H, d, J=5.9Hz) MASS (APCI): 613 (M+H)+ (free) (13) (2R)-l-[3-三氟甲基-5-(甲硫基)苄醯基]- 2-(4-氯 -3-羥苄基)-4-[2-(順-2,6-二甲嗎啉基]乙基]哌阱二 鹽酸鹽
nip: 162-178°C
[a]g6·2·· +6.420 (C=0.226, MeOH) IR (KBr): 3400, 2665, 2600, 2488, 1643, 1425, 1331, 1311, 1174, 1130, 1043 citT1 NMR (DMS〇-d6-D2〇, δ): 1·17 (6H, d, J=6.2Hz), 2.40-5.20 、 (21H, m)/ 6.26-7.70 (6H, m) MASS (APCI): 586 (M+H)+ (free), 552 -130- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注意事項再填寫本頁) P衣 訂---------線赢 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 12 9 五、發明說明() (14) (21〇-1-[3-三氟甲基-5-(甲硫基)苄釀基]-2-(4-氯 -3-羥苄基)-4-[2-(4,5,6,7·"四氫-1,6-暸啶-6-基)乙 基]哌阱三鹽酸鹽
rap: 169-178°C
[a]g6·4: -7.99° (C=0.263, MeOH) IR (KBr): 3400, 2679, 2561, 1645, 1425, 1173, 1130, 1053 crtTl NMR (DMS〇-d6-D2〇, δ): 2.40-5.40 (22H, m), 6.20-8.80 (9H, m) MASS (APCI): 605 (M+H)+ (free), 571 (15) (2R)-l-[3-(2,5-二甲吡咯-1-基磺醯基)-5 -(三氟 甲基)苄醯基]-2-(3-羥基-4-甲苄基)-4-[2-[(2S)-2- (甲氧甲基)嗎啉基]乙基]_阱 IR (KBr) : 1637 cnT1 NMR (DMSO~d6, δ): 2.05 (3Η, s), 2.30 (6Η, s) , 1.78-4.80 (25Η, m), 6.05 (2Η, s), 6.00-9.17 (6Η, m) MASS (APCI): 693 (M+H)+ (16) (2R) -1-[3,5-雙(三氟甲基)苄驢基]-2-(3-羥基-4 -甲苄基)-4-[(1-(2-羥乙基)-1Η-_唑-4-基)甲基]哌 畊鹽酸鹽
rap: 140-156°C
[a]g2·3: -15.68° (C=0.204, MeOH) IR (KBr): 3400, 1645, 1427, 1279, 1180, 1134 cm—1 NMR (DMS〇-d6-D2〇,δ): 2.02-5.20 (18H, ra〉, 6.14-8.26 (8H, in) MASS (APCI): 571 (M+H)+ (free) -131- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ----------------------訂--------- (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7__ 1 〇 五、發明說明() 例15 仿例3之方法可得如下化合物。 (1) (2R)-l-[3,5-雙(三氟甲基)苄醯基]- 2-(3-羥基-4-甲 苄基)-4-[(1-甲基-1H-吡唑-4-基)甲基]-哌阱鹽酸鹽
lap: 160 - 180oC
[α]§7·0: -13,28° (C=0.32, MeOH) IR (KBr): 2976, 1643, 1446, 1427, 1381, 1363, 1323, 1281, 1217, 1182, 1142, 1088, 1049 cnT1 NMR (DMSO—d6, δ): 1 · 60-5 · 20 (17H, πι) , 5 · 90-8 · 30 (8H, m) MASS (APCI): 541 (M+H)+ (free) (2) (2R)-1-[ 3,5-雙(三氟甲基)苄醢基]-2 -(3-羥基-4-甲 苄基)-4-(3-吡啶甲基)哌阱二鹽酸鹽
rap: 110 - 130oC
[a]§7·0: -7.75° (C=0.4, MeOH) IR (KBr): 1643, 1558, 1550, 1541, 1516, 1464, 1454, 1427, 1365, 1319, 1281, 1242, 1184, 1138, 1053 crrT 1 NMR (DMSO-d6, δ): 1.70-5.80 (14H, ra) , 6.00-9.50 (1H, m) MASS (APCI): 538 (M+H)+ (free) (3) (2R )-1-[3,5-雙(三氟甲基)苄釀基]-2-(3-羥基-4-甲 苄基卜4-[2-( 5#6#7t8-四氫-1·6-暸啶-6-基)乙基]哌 阱三鹽酸鹽
mp: 255-270°C
[a]^5·1: -22.88° (0=0.295, MeOH) IR (KBr〉 : 1643, 1635, 1562, 1550, 1516, 1462, 1427, 1365, 1327, 1282, 1244, 1184, 1138, 1041, 1003 crcT1 NMR (DMSO-d6, δ): 0.80-5.40 (22H, m), 6.00-8.80 (9H, m) MASS (APCI): 607 (M+H)+ (free) ______-132- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公Ϊ)~ -------———--------訂--------- (請先閱讀背面之注咅?事項再填寫本頁) 509688 A7 B7__ 1飞1 五、發明說明() (4) (2R) -1-[3,5-雙(三氟甲基)节醯基]-2-(3-羥基-4 -甲 苄基)-4-[(Z)-3-(3-吡啶基)-2-丙烯基]-哌阱二鹽酸鹽 (請先閱讀背面之注意事項再填寫本頁)
mp: 85-130°C
[α]§2·9: +2.860 (C=0.28, Me〇H) IR (KBr〉 : 1643, 1550, 1516, 1462, 1427, 1362, 1325, 1282., 1184, 1136, 1045, 1001 crrT1 NMR (DMSO-d6, δ): 0.70-5.20 (1·4Η, m), 6.00-10,00 (12H, m) MASS (APCI): 564 (M+H)+ (free) (5) (2R )-1-[3,5-雙(三氟甲基)苄醢基]-2-(3-羥基-4-甲 苄基)-4-[4-[(2S)-(甲氧甲基)嗎啉基]-2-丁炔基]哌哄 IR (KBr): 1741, 1707, 1693, 1678, 1645, 1562, 1558 1547, 1539, 1516, 1454, 1141, 1109 ctcT1 NMR (DMS〇-d6, δ): 0.70-5,00 (28Η, ία), 6.00-8.20 (6Η, m) MASS (APCI): 628 (M+H)+ ® 1-[3·5-雙(三氟甲基)苄酿基]-2-(3-羥基-4-甲苄基)-4-[4-[(2S,5S)-2-甲氧甲基-5-甲嗎啉基]-2-丁炔基] 哌阱二鹽酸鹽
mp: 110-135°C
[a]g9: +3·40。 (C=0.25, Me〇H> IR (KBr): 1645 cm"1 經濟部智慧財產局員工消費合作社印製 NMR (DMS〇-d6,.5〉: 1·16 (3H, d, J=6.2Hz〉, 2.08 (3H, brs), 3.25 (3H, s), 2.52-5.20 (21H, m), 6.17-8.20 (6H, m) MASS (APCI): 642 (M+H)+ (free) ⑺1-[3·5-雙(三氟甲基)苄釀基]-2 -(3-羥基-4-甲苄基)-4-[2-[(11?,45)-3,3-二甲基-2-»|-5-吖雙環并[2.2.1] 庚烷-5-基]乙基]哌阱二鹽酸鹽 -133 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1^2 五、發明說明()
mp: 173-185°C
[α]§7: +14.20° (C=0.25, MeOH) IR (KBr) : 3400, 2981, 1643 crcT1 NMR (DMS〇-d6/ δ): 1.18 (3H, s) f 1.49 (3H, s), 2.09 (3H, s), 2.20-5.10 (19H, m), 6.20-8.25 (6H, m) MASS (APCI): 600 (M+H)+ (free) ⑻(2R)-1 -[3,5-雙(三氟甲基)苄釀基]-2 -(3-羥基-4-甲 苄基)-4-[2-[(2R) - 2-(甲氧甲基)嗎啉基]乙基]哌畊 二鹽酸鹽
rap: 225-2350C
[a]g6·6: -13.02° (C=0,315, MeOH) IR (KBr): 1645, 1516, 1454, 1425, 1365, 1321, 1281, 1190, 1134, 1001 cnT1 NMR (DMS〇-d6, δ): 2.08 (3H, s), 2.50-5.20 (25H, in), 6.00-8.30 (6H, m) MASS (APCI): 604 (M+H)+ (free) 絲(21〇-1-[3,5-雙(三氟甲基)苄醯基]-4-[2-[(38,55)-3,5-二甲嗎啉基]乙基]-2-(3-羥基-4-甲苄基)哌哄二 鹽酸鹽
nip: 240-250oC
[a]g6·7: +10.24° (C=0.21, MeOH) IR (KBr): 1645, 1516, 1454, 1427, 1387, 1365, 1327, 1281, 1184, 1136, 1041 cnT1 NMR (DMS〇-d6, δ): 1·0〇-1.60 (6H, ra), 2.08 (3H, s), 2.30-5.20 (19H, m), 6.10-8.30 (6H, m) MASS (APCI): 588 (M+H)+ (free) ⑽(2R)-l-[3,5-雙(三氟甲基)苄_基卜4-[2-(順-3,5- 二甲嗎啉基]乙基]-2-(3-羥基-4-甲苄基)哌阱二鹽酸鹽 -134- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ---------訂·------—- 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 13¾ 五、發明說明()
mp: 210-220°C
[a]g5·2: -9·81。 (C=0.26, Me〇H) IR (KBr): 1676, 1643, 1533, 1516/ 1454, 1425, 1387, 1367, 1327, 1281, 1236, 1182, 1134, 1057 cm'1 NMR (DMSO~d6/ δ): 0.80-5.30 (28H, m) , 6,10-8.40 (6H, ra) MASS (APCI): 588 (M+H)+ (free) (11) (2R)-1-[3,5-雙(三氟甲基)苄醢基]-2-(3-羥基-4-甲苄基)-4-[3-[(2S)-2-(甲氧甲基)-嗎啉基]丙基]哌 阱二鹽酸鹽
rap: 150-170°C
[a]g5: -10.50° (C=0.30, MeOH) IR (KBr): 1678, 1655, 1649, 1531, 1514, 1454, 1446, 1429, 1392, 1387, 1365, 1327, 1321, 1282, 1186, 1136 cirri . NMR (DMSO-dg, δ): 1.60-5.30 (30H, m), 5.90-8.50 (6H, m) MASS (APCI): 618 (M+H)+ (free) (12) (2R)-l-[3,5-雙(三氟甲基)苄釀基]-2-(3-羥基-4-甲苄基)-4-[(£)-4-[(25)-2-(甲氧甲基)-嗎啉基]-2-丁烯基]哌阱二鹽酸鹽
mp: 50-70°C
[a]g5: -4.79° (C=0.24, MeOH) IR (KBr): 1772, 1739, 1678, 1514, 1498, 1454, 1429, 1363, 1325, 1282, 1186, 1134 cnT1 NMR (DMSO-dg, δ): 1.80-5.20 (30H, ra) , 5.70-8.40 (6H, m) MASS (APCI): 630 (M+H)+ (free) (13) (21〇-1-[3,5_雙(三氟甲基)苄醢基]-2-(3-羥基-4-甲苄基)-4-[2一(3-吡啶基)乙基]哌阱二鼸酸鹽 一 135- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------------—9^--------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明()
mp: 90-120°C
[α]§6·9: -4.19° (C=0.215, MeOH) IR (KBr): 1643, 1550, 1516, 1466, 1454, 1427, 1365, 1327, 1281, 1184, 1138 cirT1 N14R (DMSO~dg, δ): 0.70-5.20 (16H, m), 6.00-8.90 (10H, m) HASS (APCI): 552 (M+H)+ (free) (14) (2R)-1 - [3, 5-雙(三氟甲基)苄酿基]-2-(3-羥基-4-甲苄基)-4-[2-[4,5,6,7-四氱_吩并[3,21]»比啶-5-基]乙基]哌畊二鹽酸鹽
mp: 245-265°C
[a]g7·9: -2.78° (C=0.27, MeOH) IR (KBr): 1693, 1674, 1645, 1547, 1533, 1516, 1454, 1427, 1365, 1329, 1281, 1182, 1138, 1041 citT1 N14R (DMSO-d6/ δ): 1.60-5.50 (22H, m) , 6.00-8.40 (8H, m) MASS (APCI): 612 (M+H)+ (free) (15) (2R)-l-[3,5-雙(三氟甲基)苄醢基]-4-[2-[3,4-二 氫-2H-吡啶并[3,2-b]-l,4-B| 畊-4-基]乙基]-2-(3-羥基-4-甲苄基)哌畊二鹽酸鹽
mp: 190-200〇C
[a]g6·9: +6.79° (C-0.265, MeOH) IR (KBr): 1641, 1618, 1566, 1454, 1427, 1281, 1184, 1132, 1066, 1032 cm"1 NMR (DMSO-dg, δ) : 0.70-5.60 (20HA ra) , 6.00-8,40 (9H, m) MASS (APCI): 609 (M+H)+ (free) (16) (2R)-l-[3,5-雙(三氟甲基)苄釀基卜2 - [(3-羥基-4-甲苄基)-4-[6-B奎啉基]哌畊二鹽酸鹽 -136 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --— — IJIIIII illll — — ^«— — — — — 1 — —^Aw— (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 13 5 五、發明說明()
mp: 170-200oC
[α]§5·8: -28.54° (C=0.247, MeOH) IR (KBr〉: 1724, 1707, 1645, 1514, 1454, 1427, 1385, 1365, 1311, 1281, 1180, 1136 cnT1 NMR (DMS〇-d6, δ): 0.70-5.10 (15H, m), 6.00-9.40 (12H, m) MASS (APCI): 588 (M+H)+ (free) 例16 仿製備例41之方法可得如下化合物。 ⑴(2R)-1 - [3,5-雙(三氟甲基)苄醯基]-2-(3-第三丁二 苯矽烷氧基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)-嗎啉基]-乙基]哌阱 NMR (CDC13,,6): 1.09 (9H, s), 1.89-4.90 (22H, m), 2.35 (3H, s) f 3.38 (3H, s), 6.10-7.92 (16H, m) MASS (ES〇+): 842.4 (M+H)+ (2) (2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-4-[2-[ (2S)-2-(甲氧甲基)嗎啉基]-乙基]-l-[3 -硝基-5-(三 氟甲基)苄_基]哌阱 IR (Neat): 1641 cm—1 NMR (CDC13, δ): 1·09 (9H, s), 2·37 (3H, s), 1·89-4·80 (22Η, ία) , 3.35 (3Η, s), 6.00-8.40 (16Η, m)
It MASS (ESI+): 819.3 (M+H)+ (3) (2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-1-[3-二 甲胺基-5 -(三氟甲基)苄醢基]-4-[2-[(2S)-2-(甲氧 甲基)嗎啉基]-乙基]哌阱 IR (KBr) : 1641, 1608 cnT1 NMR (CDC13, δ): 1·50 (9H, s), 2.25 (3H,br s), 2·95 (6Η, br s), 3·35 (3Η, s), 1·80-4·80 (22Η, ra), 6·05- 7.80 (16Η, m) MASS (ESI+): 817.4 (M+H)+ 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐)-137 - --------------------訂丨丨 ------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(136) ⑷(2R)-2-(3-第三丁二苯矽烷氧基-4 -甲苄基)-4 - [2-[ (2S)-2-(甲氧甲基)嗎啉基]-乙基]-l-[3-甲胺基-5- (三氟甲基)苄醯基]哌阱 IR (KBr): 1614 cm"1 NMR (DMS〇-d6, δ): 1.03 (9H7 s), 1.70-4.80 (28Η, m), 2.26 (3H, br s), 6.00-7.70 (16H, m) MASS (ESI+): 803.4 (M+H)+, 825.3 (M+Na)+ (5) (2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-4-[2-[ (2S)-2-(甲氧甲基)釅啉基]-乙基]咯基) -5-(三氟甲基)苄醮基]哌阱 IR (KBr) : 1643 cirT1 NMR (DMSO-dg, δ): 1.00-1.04 (9Η, m), 1.70-4.80 (28Η, m), 6.00-8.00 (20Η, m) MASS (ESI+): 839.4 (Μ+Η)+, 861·4 (M+Na)+ (6) (2R)-2-(3-第三丁二苯矽烷氧基-4_甲苄基)- 4-[2-[ (2S)-2-(甲氧甲基)嗎啉基]-乙基]-1-[3-甲氧基-5 -(三氟甲基)苄醵基]哌阱 IR (KBr) : 2939, 1643, 1512, 1462, 1423 cirT1 NMR (DMSO-dg, δ): 1.04 (9Η, s), 2.22 (3Η, s) f 1.71-4.60 (28H, m), 5,99-7.75 (16H, m) MASS (ESI+): 804.4 (M+H)+, 826.3 (M+Na)+ ⑺(2R)-2-(3-第三丁二笨矽烷氧基-4 -甲苄基)-4-[2-[ (2S)-2-(甲氧甲基)嗎啉基]-乙基]-l-[3-甲硫基-5 - (三氟甲基)苄醯基]哌阱 IR (KBr) : 2933, 1641, 1510, 1421 crtT1 NMR (DMSO-dg, δ): 1.04 (9Η, s), 2.29 (3Η, s), 3.18 (3H, s), 1.70-4.70 (25H, m) , 6.00-7.80 (16H, rri) MASS (ESI+): 820.3 (M+H)+, 842.3 (M+Na)+ -138- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ------ill — ΙΙΦ^--------訂---------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 13 7 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) (8) (2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)- 4-[2-[ (2S)-2-(甲氧甲基)嗎啉基]-乙基]甲磺醯基~ 5-(三氟甲基)苄醯基]_阱 IR (KBr): 1643 cm"1 ' NMR (CDCl3〇〇, δ): 1.03 (9Η, br s), 1.72-4.60 (28H, m), 2.28 (3H, br s), 6.02-8.28 (16H, m) MASS (ESI+): 852.3 (M+H)+, 874.3 (M+Na)+ (9) (21{)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-1-[3-二 甲胺磺醸基-5-(三氟甲基)苄釀基]-4-[2-[(2S)-2- (甲氧甲基)嗎啉基]-乙基](三氟甲基) IR (KBr) : 1639 cnT1 NMR (DMSO-dg, δ): 1.04 (9Η, s) , 1.71-4.70 (31Η, m), 2.28 (3Η, br s) , 6.04-8.00 (16H, m) MASS (ESI+): 881.4 (M+H)+, 904.3 (M+Na)+ ⑽(2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-4-[2-[ (2S) - 2-(甲氧甲基)嗎啉基]-乙基]-l-[3-甲胺磺藤基 -5-(三氟甲基)苄醯基]哌阱 IR (KBr): 1643 cm"1 NMR (DMSO-dg, δ): 1,04-1.05 (9Η, m), 1.70-4.60 (28Η, m), 2.28 (3Η, br s), 6.03-8.07 (16H, m) MASS (ESI+): 867.3 (M+H)+ ' ' (ll)(2R)-2 -(3-第三丁二苯矽烷氧基-4-甲苄基)-4-[2- 經濟部智慧財產局員工消費合作社印製 [(2S)-2-(甲氧甲基)嗎咐基]-乙基]-1-[3 -(吡咯啶磺 醯基-5-(三氟甲基)苄醯基]哌畊 IR (KBr): 1643 cm"1 NMR (CDC13, δ): 1.09 (9H, s), 1.75-1·82 (4H, in), 2.35 (3Η, s), 2·05-4·80 (29Η, ία), 6·00-8·~65 (16Η, m) MASS (ESI+): 907 (M+H)+ -139 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 13 8 五、發明說明f ) (12) (2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]-乙基]-1 - [3 -(嗎啉磺醯 基-5-(三氟甲基)苄醯基]哌阱 IR (KBr) : 1645 cirT1 NMR (CDC13, δ): 1.09 (9Η, s), 2.35 (3H, s), 2.46-4.80 (33H, m), 6.00-8·56 (16H, m) MASS (ESI+〉 : 923.4 (M+H)+ (13) (2R)-2-(3 -第三丁二苯矽烷氧基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]-乙基卜1-C3-U-毗啶基) -5-(三氟甲基)苄醯基]哌阱 IR (KBr) : 1645 crrT1 - NMR (CDCI3/ δ): 0.99-1.02 (9Η, m) , 1,80-4.80 (28H, κι), 6.00-8.16 (18H, ra) , 8.70 (2h/ d, J=5.6Hz) MASS (ESI+): 851.4 (M+H)+, 873.3 (M+Na)+ (14) (2R)-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎咐基)乙 基]硝基-5-(三氟甲基)苄醢基]哌阱二鹽酸鹽 mp: 133.3-136.2°C [a]g6: +5.620 (C=0.61, Me〇H) IR (KBr) : 1645, 1547, 1327, 1182, 1143 crrT1 NMR (DMS〇-d6, δ): 1.02 and 1·14 (6H, d, J=6.2Hz), 2.71 -4.53 (19H, m), 6·95-8·52 (7H, in) MASS: 569 (M+) (free) (15) (21〇-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎咐基)乙 基]-l-[3-甲胺基- 5-(三氟甲基)苄醯基]哌阱二鹽酸鹽 mp: 245.6-248.7°C [cx]g6·4: +21.44。 (C=0.26, MeOH) IR (KBr) : 1612, 1494, 1427, 1182, 1143, 1095 cm""1 NMR (DMS〇-d6/ δ): 1.15 (6H, d, J=6.0Hz)/ 2.68 (3H, s), 3.20-4.30 (19H, in), 6.14-7.47 (7H, m) MASS: 553 (M+) (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)_140_ (請先閱讀背面之注意事項再填寫本頁) tT--------- 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 13 9 五、發明說明() (16) (2R)-2-(4-氯苄基)- 1-[3-二甲胺基-5 -(三氟甲基) 苄釀基]-4-[2-(順-2,6-二甲嗎啉基)乙基]哌畊二鹽 酸鹽 mp: 148.2-153.3°C [a]g6·6: +19.82° (C=0.36, MeOH) IR (KBr) : 1645, 1464, 1425, 1182, 1138 cirT1 NMR (DMS〇-d6, δ): 1.15 (6H, d, J=6.0Hz), 2·94 (6H, s), 3.40-4.20 (19H, m) , 6.20-7.38 (7H, m) MASS: 567 (M+) (free) (17) (2賢)-2-(4-氯节基)-4-[2-(順-2,6-二甲嗎啉基)乙 基]甲硫基-5-(三氟甲基)苄_基]哌阱二鹽酸鹽 mp: 138.4-142.5°C [a]g6·6: +7.55° (C=0.26, Μ穿〇H) IR (KBr) : 1643, 1417, 1330, 1176, 1128, 1099 cirT1 NMR (DMS〇-d6> δ) : 1.02 and 1.15 (6H, d, J=6*2Hz) , 2.54 (3H, s),., 2.71-3.99 (19H, m) , 6.69-7.91 (7H, m) MASS: 570 (M+) (free) (18) (2!〇-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎啉基)乙 基]-l-[3-甲磺醯基_5-(三氟甲基)苄醯基]哌阱二鹽 酸鹽 nip: 138.4-142.5°C [α]§6·7: +7.55° (C=0,26, MeOH) IR (KBr): 1645, 1462, 1423, 1328, 1303, 1182, 1144 crrT1 NMR (DMS〇-d6, δ): 1·16 (6H, d, J=6.1Hz), 2.55-4.05 (19H, in), 3·38 (3H, s), 6.98-8.32 (7H, m〉 MASS: 602 (M+) (free) -141- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) -----I-----------I--訂 --------- (請先閱讀背面之注音W事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ , 140 五、發明說明f ) (19) (28)-2-(4-氯节基)-4-[2_(顒-2,6-二甲嗎咐基)乙 基]-l-[3-二甲胺硝醯基-5-(三氟甲基)苄釀基]哌阱 二鹽酸鹽 rap: 209.6-213.7°C [a]g6·5: +4·44° (C=0.31, Me〇H) IR (KBr) : 1645, 1461, 1423, 1344Γ 1173, 1146, 1103 cirT1 NMR (DMSO-dg, δ): 1.17 (6H, d, J=6.0Hz), 2.66 (6H, s), 3.00-4.46 (19H, m), 7.03-8.00 (7H, m) MASS: 631 (M+) (free) (20) (21?卜2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎啉基)乙 基]-l-[3-(l-(吡咯基)-5-(三氟甲基)苄醜基]_阱二 鹽酸鹽
mp: 152.7-157.9°C
[a]g6·2: +5.96。 (C=0.55, Me〇H) IR (KBr): 1345, 1496, 1178, 1130 cm"1 NMR (DMS〇-d6, δ): 1·15 (6H, d, J=5.9Hz), 2.70-4.20 (19H, m), 6.34 (2H, s) f 6.96-7.91 (9H, ra) MASS: 589 (M+) (free) (21) (21〇-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎_基)乙 基]-1-[ 3-(4-吡咯基)-5-(三氟甲基)苄_基]哌阱二 鹽酸鹽 rnp: 287.7-289.1°C [a]g6·9: -3.00° (C=0.36, MeOH) IR (KBr): 1641, 1635, 1427, 4270, 1178, 1130 crtT1 NMR (DMS〇-d6/ δ): 1.08 (6H, d, J=6.0Hz), 2.73-5.15 (19H, m) , 6.94-8.97 (11H, ra) MASS: 601 (M+) (free) 一 142- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ---------------------訂-------I (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7 141 五、發明說明() (22) (2R)-2 -(4-氯苄基)-1-[3-氯-5 -(三氟甲基)苄醯基] -4-[2-(順_2,6-二甲嗎啉基)乙基]哌畊二鹽酸鹽 mp: 136.4-141.0°C [α]§6·8: +1.06° (C=0.45, MeOH) IR (KBr) : 1644, 1417, 1326, 1178, 1135, 1095 crrT1 NMR (DMSO-dg, δ): 1.02 and 1.15 (6H, d, J=6.1Hz), 2.60-4.12 (19H, m), 6.93-7.96 (7H, m) MASS: 560 (M+H)+ (free) (23) (21〇-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎啉基)乙 基]-1-[3-氟-5 _(三氟甲基)苄醯基]«阱二鹽酸鹽
ip : 80 . 1 -82 . 5 1C
[α]§7·0: +3.54。 (C=〇.30, Me〇H) IR (KBr) : 1645, 1427, 1344, 1178, 1136, 1091 crrT1 NMR (DMS0-d6, δ): 1.16 (6H, d, J=6.1Hz), 2.60-4.53 (19H, m) , 6.78-7.78 (7H, m) MASS: 542 (M+) (free) (24) (21〇-2-(4-氯苄基)-4-[2-(順-2,6-二甲嗎啉基)乙 基]-l-[3-甲基-5-(三氟甲基)苄醯基]哌阱二鹽酸鹽 mp: 82.3-88,2°C 、 [a]g6·5: +4.05° (C=0.315, MeOH) IR (KBr) : 1643, 1635, 1425,、1174, 1128 cm"1 NMR (DMSO-dg, δ): 1.15 (6H, d, J=6.1Hz), 2.32-4.10 (22H, m), 6.68-7·57 (7H, m) MASS: 539 (M+H)+ (free) (25) (2R)-2-U-氯苄基)-1-(3,5-二氯苄釀基)-4-[2-(順-2,6-二甲嗎啉基)乙基]哌阱二鹽酸鹽 -143- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂---------^9— (請先閲讀背面之注音?事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(142) mp: 140,1-143.8°C [α]§5·7: +3.25° (C=0.55, HeOH) IR (KBr): 1643, 1452, 1446, 1409, 1330, 1277, 1092, 1036 cnT1 NMR (DMSO-d6, δ): 1.15 (6H,-d, J=6*2Hz) , 2.72-4.15 (19H, m) , 6.56-7.64 (7H, ra) MASS: 524 (M+) (free) (26) (2R)-2-(4-氯苄基)- l-[3-硝基-5-(三氟甲基)苄驢 基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]_阱 三鹽酸鹽 mp: 221-2280C 、 [a]g7*2: -11.50° (C=0.30, MeOH) .工R (KBr) : 3430, 3400, 1640A 1550, 1470, 1420 crrT1 NMR (DMSO-dg, δ): 2.6-5.2 (19H, m), 6.8-8.8 (10H, m) MASS (APCI): 588 (M+H}+ (free) (27) (2R)-2-(4-氯苄基)-1-[3-甲胺基-5-(三氟甲基)苄 醯基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌 阱三鹽酸鹽 mp :· 199-245°C 、' [0^7++2.31/(00.26^60^ IR (KBr): 3430, 3400, 1630, 1510, 1460, 1430 cirT1 NMR (DMS〇-d6, δ): 2·69 (3H, s), 2·8-5·3 (19H, m), 6.41 (1H, s), 6.83 (1H, s), β.9-7.5 (5H, m), 7.71 (1H, dd, J=5, 8Hz), 8·11 (1H, d, J=8Hz), 8·70 (1H, d, J=5Hz) MASS (APCI) : 572 (M+H)+ (free) -144- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------————訂 i——. (請先閱讀背面之注意事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 14 3 五、發明說明() (28) (2R)-2-(4-氯节基)-1-[3-甲硫基-5-(三氟甲基)节 釀基]-4-[2-(5·6,7·8-四氫-1,6-暸啶-6-基)乙基]哌 阱三鹽酸鹽
mp: 182-1950C
[σ·]§6·8: -9·58。(C=0.24, Me〇H) IR (KBr) : 3430, 3400, 1640, 1460, 1420 crcT1 NMR (DMSO-dg, δ): 2.55 (3HA s), 2,6-5.2 (19H, m), β.6-8.7 (10H, m) MASS (APCI): 589 (M+H)+ (free) (29) (2R)-2-(4-氯苄基)-1 - [3-甲磺醯基-5 -(三氟甲基) 苄醮基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基] 哌阱三鹽酸鹽
rap: 198 - 2130C
[a]§6·8: -13.71° (C=0.28, MeOH) IR (KBr” 3430, 3400, 1640, 1460, 1420 crcT1 NMR (DMSO-dg, δ): 2.6-5.2 (19H, m), 3.39 (3H, s), 6·9~~8·2 (8H, m)’ 8.33 (1H, s〉,8·67 (1H,d' J=5Hz〉 MASS: 621 (M+H)+ (free) (30) (2R )-2-(4-氯苄基)-l-[3-二甲胺磺醮基-5-(三氟 甲基)苄醯基]-4 - [2-(5,6,7,8-四氫-1,6-嘹啶-6-基) 乙基]賴畊三鹽酸鹽
ιαρ: 209 - 2260C
[a]g6·8: -8.38° (C=0.24, MeOH) IR (KBr) : 3740, 1680, 1640, 1520, 1460 cirT1 NMR (DMSO-dg, δ): 2,67 (6H, s), 2.8-5.2 (19H, m), 6.9-8.7 (l〇H, m) MASS: 650 (M+H)+ (free) -1 4 5 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------------------—訂--------- (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 __B7_ 144 五、發明說明() (31) (2R)-2-(4-氯苄基)-1-[3-(1-吡咯基)-5-(三氟甲 基)节醯基]-4-[2-(5,6,7,8 -四氫-1,6 -瞭喃-6-基)乙 基]_畊三鹽酸鹽
iap: 184-191°C
[a]g6·7: -12··130 (C=0.40, Me〇H) IR (KBr) : 3400, 1640, 1500, 1430 crtT1 NMR (DMS〇-d6, δ): 2.8-5.3 (19H, m), β·2-8·7 (14H, m) MASS: 608 (M+H)+ (free) (32) (2R) - 2 -(4-氯苄基)-l-[3-(4-_ 啶基)- 5-(三氟甲 基)苄醯基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙 基]哌畊三鹽酸鹽
rap: 206-2170C
[a]g5*8: -20.08° (C=0.27, MeOH) IR (KBr) : 3430, 3400, 1640, 1510, 143g cirT1 NMR (DMSO-d6, δ): 2.7-6.2 (19H, m), 6.8-8.1 (8H, m), 8.10 (1H, d, J=8,5Hz), 8.41 (2H, d, J=6.5Hz), 8.70 (1H, d, J=4.4Hz), 9.04 (2H, d, J=6.5Hz) MASS (API-ES): 620 (M+H)+ (free) (33) (2R)-2-(4-氯苄基)-l-[3-氯-5 -(三氟甲基)苄醯基] -4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌阱三 鹽酸鹽 mp: 130.6-135.7°C [a]^6*6: -12.12° (C=0.60, MeOH) IR (KBr): 1643, 1635, 1417, 1326, 1321, 1178, 1135 cnT1 NMR (DMSO-d6, δ): 2.79-4.78 (19H, m), 7·02-8·66 (10H, m) MASS: 577 (M + ) (free) 一 146- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ----------------------訂--------- (請先閱讀背面之注咅?事項再填寫本頁) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 14 5 五、發明說明() (34) (2R)-2-(4-氯苄基)-1-[3-氟-5-(三氟甲基)苄醜基] -4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌阱三 鹽酸鹽 rap: 127.3-130.9°C [a]g6*4: -10.20° (C=0.51, MeOH) IR (KBr): 1643, 1635, 1629, 1425, 1178, 1135 cnT1 NMR (DMSO~d6, δ): 2.80-4.60 (19H, m), 6·80-8·63、 (10H, m) MASS: 561 (M+) (free) (35) (2R )-2 -(4-氯苄基)-1-[3-甲基-5-(三氟甲基)苄釀 基]-4-[2-(5,6,7,8-四氮-1,6-暸啶-6-基)乙基]哌阱 三鹽酸鹽 mp: 102.5-110.4°C [a]g6·8: -13,35° (C=0.310, MeOH) IR (KBr) : 1643, 1635, 1423, 1419, 1173, 1128 crcT1 NMR (DMSO-dg, δ): 2 · 35 (2H, m) , 2 · 51-4 · 49 (20H, ra), 7·03-8·69 (1、0H, na) MASS: 557 (M+) (free) (36) (2R)-2-(4-氯苄基)-l-[3-二甲胺基-5-(三氟甲基) 苄醯基]-4-[2-(5 ,6,7,8-四氫-1,6-暸啶-6-基)乙基] 哌畊三鹽酸鹽
mp: 209-214°C
[α]^7·1: +1.51。(C=0'.27, MeOH) IR (KBr> : 3430, 3400, 1640/ 1500, 1460, 1420 cnT1 NMR (DMSO-dg, δ): 2.8-5.3 (19H, m), 2.95 (6H, s), 6.1- 7·5 (7H, m〉, 7·65 (1H, ddA J=5, 8Hz〉, 8·05 (1H, d, J=8Hz), 8.67 (1H, d, J=5Hz) MASS: 586 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-147 - ------:----I ---------訂 --------- (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 146 五、發明說明() (37)(2R)-2-(3-第三丁二苯砂燒氧基-4-甲f基)-i-[3_ (2,5-二甲吡咯-1-基磺釀基)-5-(三氟甲基)苄醜基]一 4-[2 - [(2S)-2 -(甲氧甲基嗎啉基]乙基]哌阱 IR (KBr) : 1643 citT1 NMR (DMSO-dg, δ): 1.04 (9Η, s) , 2.30 (6H, br s), 2.30 (3H, br s), 1.91-4.60 (25H, m), 6.05 (2H, s), 6.60-7·98 (16H, ra) MASS (ESI+): 931.3 (M+H)+ 例17 仿例11之方法再依例3之方法可得如下化合物。 (1)1-[3, 5 -雙(三氟甲基)节釀基]-2-(3 -羥基-4-甲节基) -4-[ (E)-3-(3-吡啶基)-2-丙烯]-哌阱二鹽酸鹽
mp: 60-80°C IR (KBr〉: 1707, 1693, 1676, 1645, 1628, 1550, 1539, 1516, 1477, 1464, 1454, 1427, 1392, 1365, 1281, 1182, 1136, 1049 cm"1 NMR (DMS〇-d6, δ): 1.90-5,60 (16H, m), 6.10-9.10 (10H, m) . fif MASS (APCI): 564 (M+H)+ (free) ⑵l-[3,5-雙(三氟甲基)苄醸基]-2-(3-羥基-4-甲苄基) -4-[1-甲基-1H- %唑-4-基)甲基]-哌阱鹽酸鹽 IR (KBr): 1707, 1693, 1676, 1645, 1562, 1550, 1547, 1533, 1516, 1454, 1427, 1392, 1363, 1319, 1281, 1182, 1138, 1057 crrT1 NMR (DMSO-d6/ δ): 1.60-5.20 (17Η, m) , 5.90-8.30 (8Η, m) MASS (APCI): 541 (M+H)+ (free) (3) (2R )-1-[3,5-雙(三氟甲基)苄醯基]-2-(3-羥基-4-甲 苄基)-4-[(2-胺_唑-4-基)甲基]-哌胼二鹽酸鹽 -1 4 8 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------丨訂---------^A_wi (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 — —____ 147 五、發明說明()
mp: 205-215°C
[α]§7: -12.13° (C=0.40, MeOH) IR (KBr): 3500-3000, 2700-2300, 1639, 1428, 1280 crcT1 NMR (DMSO-dg, δ): 2.07 (3H, s), 2.60-5.20' (11H, m), 6.20-8.20(7H, m), 8.00-9.00 (2H, m) MASS (APCI): 559 (M+H)+ (free) ⑷(2R)-l-[3,5-雙(三氟甲基)苄醢基]-2 -(3-羥基-4-甲 ▼基)-4-[(5 -胺基-1,2,4-_二唑-3-基)-甲基]哌哄 二鹽酸鹽
mp: 177~182°C
[a]g7: -31.5。 (Ο=0·18, Me〇H〉 IR (KBr): 3500-3000, 2700-2300, 1644, 1278 αχΓ1 3SIMR (DMSO-dg, δ): 2·07 (3H, s) , 2.60-5.20 (11H, m), 6·20-8·20(8Η, m), 8.00-9.00 (2H, m) MASS (APCI): 560 (M+H)+ (free), 447 (5) (2R)-l-[3,5-雙(三氟甲基)苄醢基]- 2-(3-羥基-4-甲 苄基)-4-[[2-(二甲胺基)瞎唑-4-基卜甲基]哌阱二鹽 酸鹽
mp: 162-165°C
[a]g7: -17·6。 (C=0.5, Me〇H> IR (KBr): 3500-3000, 2700-2300, 1639, 1427, 1365, 1280 cm"1 NMR (DMS〇-d6, δ): 1.80-1.90 (6H, ra), 2.07 (3H s), 2.60-5.20 (11H, m), 4.50-5.80 (2H, m) , 5.90-8.20 (7H, m) * MASS (APCI): 587 (M+H)+ (free) -149- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ------r-------------訂 ---------- (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 __^_ 148 五、發明說明() (e) (2R)-1_[3,5-雙(三氟甲基)苄醢基]-2-(3-羥基-4-甲 苄基)-4- [[3-(甲胺基)-1,2,4-Β|二唑-5-基卜甲基] 、哌阱二鹽酸鹽 一
[a]g6: -23.1° (C=0-55, MeOH) h、l〉:〆屮…C IR (KBr): 3500-3150, 2700-2300, 1644, 1428, 1363, 1280 cnT1 NMR (DMSO-dg, δ): 2.07 (3Hf s), 2.66-5.20 (14H, in), 6.10-8.30 (7Hf m) MASS (APCI): 558 (M+H)+ (free) 例18 仿例1之方法再依例3之方法可得如下化合物。 1-[3,5-雙(三氟甲基)苄醯基]-4-[2-[(2S)-5,5-二甲 基-2-(甲氧甲基)嗎_基]乙基]-2-(3-羥基-4-甲苄基) 哌阱二鹽酸鹽
mp: 150-180eC IR 《KBr>: 1707, 1693, 1678, 1645, 1628, 1562, 1547, 1539, 1533, 1516, 1477, 1464,·1454, 1427, 1392, 1367, 1281, 1182, 1138 cnT1 NMR (DMS0-d6/ δ): 1.10-1.60 (6H, m), 2.08 (3H, s), 2.30-5.20 (23H, m), 6·10-8·30 (6H, m), 9·15 (1H, br s) MASS (APCI): 632 (M+H)+ (free) 例19 將(210-1-[3,5-雙(三氟甲基)苄醯基卜2-(3-羥基-4-甲苄基)-4-[4-[(2S)-2-(甲氧甲基)嗎啉基]-2-丁炔基] 哌畊(0.33克)之甲醇(10毫升)於Lindlar觸媒(63毫克) 氫化。濾除觸媒,將濾液減壓蒸除。由矽膠柱層析純化 -15 0"· 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------------------訂--------- (請先閲讀背面之注音?事項再填寫本頁) 509688 A7 B7_ 149 五、發明說明() (請先閱讀背面之注意事項再填寫本頁) (二氯甲烷/甲醇=9:1)。收集含目的化合物部份並減壓 蒸除可得(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(3-羥 基-4-甲苄基)- 4-[(Z)-4-[(2S) - 2-(甲氧甲基)嗎啉基]-2-丁烯基]哌畊(0.22克)之油。 IR (Neat): 1707, 1693, 1678, 1645, 1635, 1547, 1539, 1535, 1516, 1464, 1454, 1423, 1417, 1405, 1387 cm·1 NMR (CDC13/ δ): 0.60-5.20 (28Η, τη), 5.40-5.90 (2\\, m) f 6.10-8.10 (6Η, m) MASS (APCI): 630 (M+H)+ 例20 仿例19之方法可得如下化合物。 (2R)-l-[3,5-雙(三氟甲基)苄醢基]-2 - [3-(2-甲氧乙 氧基)甲氧基]-4-甲苄基)-4- [(Z)-3-(3-吡啶基)-2- 丙烯基]哌阱 IR (Neat): 1670, 1641, 1585, 1550, 1510, 1431, 1379, 1350, 1329, 1279, 1130, 1101, 1012 cirT1 NMR (CDC13, δ): 0.70-5.50 (23H, m), 5·70-6·10 (1H, it〇, 6.10-8.80 (11H, m) MASS (APCI): 652 (M+H)+ 例21 經濟部智慧財產局員工消費合作社印製 仿例8之方法可得如下化合物。 (1) (2R)-1-[3,5-雙(三氟甲基)苄醯基]- 4-[3-(3-毗啶基) 丙基-2-[4-(三氟甲基)苄基]哌阱二鹽酸鹽 -151- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7 15 0 五、發明說明()
mp: 64-74°C
[a]g7: +7.470 (C=0.5, MeOH) (請先閱讀背面之注音3事項再填寫本頁) IR (KBr) : 1645 cirT1 NMR (DMS〇-d6, δ): 2·10·2·40 (2H, m),2.80-5.40 (13H, m) , 7.19-7.69 (6H, m), 7.97-8.03 (1H, m) , 8.19-8.22 (1H, m), 8·42-8·58 (1H, m), 8·81 《1H, d, J=5.5Hz), 8.90-9.00 (1H, m) MASS (APCI): 604 (M+H)+ (free) (2) (2R)-l-[3-甲氧基-5 -(三氟甲基)苄醯基]-4-[3 - (3-吡啶基)丙基-2-[4-(三氟甲基)苄基]哌哄二鹽酸鹽
mp: 70-80°C
[a]g7: +19.49° (C=0.0065, MeOH) IR (KBr): 1643, 1466, 1423 cm-1 NMR (DMSO-dg, δ): 2.10-2.40 (2H, m) , 2.80-5.30 (13H, m>, 3·82 (3H, s), 6·41-7·70 (7H, m), 7·97 (1H, dd, J=5.5 and 8.0Hz)f 8,45 (lHf d, J=8.0Hz), 8.79 (lHf d, J=5.5Hz), 8.88 (lH^s) MASS (APCI): 566 (M+H)+ (free) (3) (2 R)-l-[ 3, 5-雙(三氟甲基)苄醯基]-2-(4-氟苄基)-4-[3-(3-吡啶基)丙基]賴阱二鹽酸鹽 經濟部智慧財產局員工消費合作社印製
mp: 110.2-117.5°C
[a]g8: +19.46° (C=0.34, MeOH) IR 《KBr): 1644, 1513, 1280, 1184, 1135 cnT1 NMR 《DMSO-d6, δ): 1·〇3 (2H, d, J=6.07Hz), 2·23 (2H, m), 2.86-5.05 (11H, m), 6.99-8.85 (11H, m) MASS: 554 《M+H)+ (free) ⑷(2R)-2 -(4-氟苄基)-l-[3-甲氧基-5-(三氟甲基)苄醯 基]-4-[3-(3-吡啶基)丙基]-哌阱二鹽酸鹽 -152» 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 15 1 五、發明說明()
mp: 111.5-118.3°C
[a]g7·3: +11.30 (C=0.26, MeOH) IR (KBr): 1643, 1511, 1465, 1421, 1049 citT1 NMR (DMSO-dg/ δ): 2.21 (1H, br) , 2·88-5·41 (18H, m), 6.56-8,86 .(11H, m) e 11.5 (1H, br) MASS: 516 (M+H)+ (free) (5) (2R)-1-[3-甲氧基-5-(三氟甲基)¥醯基]-2-(2-葉甲 基)4胃[3-(3-_啶基)丙基]_阱二鹽酸鹽 [a]J8·2: -9.96。 (C=0.24, MeOH) IR (KBr): 3400, 1640 cm"1 NMR (DMSO-dg, δ): 2·1-2·4 (2H, m), 2·7-5·3 (13H, m), 3.61 and 3.71 (3H, s), 6.5-8.9 (14H, m) MASS: 548 (M+H)+ (free) 例22 將含(2R)-1 - [3,5-雙(三氟甲基)苄醯基]-2-[3 - [(2-甲氧乙氧基)甲氧基]-4-甲苄基]-4-[(l-三苯甲基-1H -吡唑-4-基)甲基]哌阱(1.184克)之1,4-二鸣烷(118毫 升)加人1N鹽酸(71毫升),於40 1C下攪拌7小時。冷卻 後,M4N氫氧化納溶液調至PH7後加入NaCl。分離有機 曆,於硫酸鎂下乾燥,真空蒸除。由矽膠柱層析純化 (二氯甲烷-甲醇(30:1))可得(2!〇-1-[3,5-雙(三氟甲基) 苄釀基]-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]-4-[(1H-吡唑-4-基)-甲基]哌阱(575毫克)。 IR (Neat): 3250, 1645, 1280, 1130 cm^1 NMR (CDC13, δ): 1.95-5.22 (23Η, m)f 6.24-7.90 (8H, m) MASS (APCI): 615 (M+H)+ (free) -153- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) . ----訂--------- si (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 Ί S 2 五、發明說明() 例23 將含(210-1-[3,5-雙(三氟甲基)苄醵基]-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]-4-[(1Η-吡唑-4-基)-甲基]哌阱(254毫克),2 -溴乙醇(259毫克碳酸鉀 (228毫克)及溴化四丁銨(13毫克)之Η,Ν -二甲基甲釀胺 (2.5毫升)於lOOt:下攪拌2天。冷卻後,真空蒸除, 加入水及乙酸乙酯。分雛有機層,清洗K食鹽水,於硫 酸鎂下乾燥並真空蒸除。由鋁柱層析純化(二氯甲烷-甲 酵(100:1))可得(2R)-l-[3,5-雙(三氟甲基)-苄釀基]-2-[3-[(2-甲氧乙氧基)甲氧基]-4-甲苄基]-4-[[l-(2-羥 乙基)- 1H-吡唑-4-基)-甲基]哌阱(185毫克)。 IR (Neat): 3400, 1640, 1440, 1280, 1135 cnT1 NMR (CDC13. δ): 1.84-5,38 (27Η, m), 6.30-7.90 (8Η, m) MASS (APCI): 659 (M+H)+ (free) 例24 將含(2R)-l-3,5-雙(三氟甲基苄醯基)-2-(3-羥基-4-甲苄基)-4-[4-[(2S)-2-(甲氧甲基)嗎啉基]-2-丁炔基] 哌畊(0.05克)之乙酸乙_(5毫升)處理K4N鹽酸-乙酸 乙酯(1毫升)後減壓濃縮。碾製K二氯甲烷及二異丙醚 ,減壓蒸除有機溶劑可得(2R)-l-[3,5-雙(三氟甲基)苄 醢基]-2-(3-羥基-4-甲苄基)- 4-[4-[(2S)-2-(甲氧甲基) 嗎啉基]-2-丁炔基]脈畊二鹽酸鹽(0.05克)粉。
mp: 110-130°C
[a]J5·5: -7.89° (C=0.40, MeOH) IR 《KBr): 1687, 1645, 1516, 1454, 1429, 1362, 1327, 1281, 1184, 1138 cm"1 NMR (DMSO-dg, δ): 1.70-5.30 (28H, m) , 6.00-8.40 (6H, m) MASS (APCI): 628 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-154- I--------------------訂---------^^1 (請先閱讀背面之注意事項再填寫本頁) 509688 ▼ A7 _B7_ 1 ς ^ i、發明說明() 例25 仿例24之方法可得如下化合物。 (2R)-l-[3,5-雙(三氟甲基)苄醣基]-2-(3-羥基-4-甲 苄基)-心[(2)-4-[(25)-2-(甲氧甲基)嗎啉基]-2-丁烯基] 哌阱二鹽酸鹽
mp: 180-200eC
[α]§5·6: +0·49β (C=CL205, MeOH) IR (KBr) : 1693, 1687, 1645, 1531-, 1516, 1454, 1427, 1363, 1321, 1281, 1184, 1140, 1003 cnr*1 NMR (DMS0-d6, δ): 0.80-5.30 (30H, m)f 5.80-8.40 (6H, m) MASS (APCI): 630 (M+H)+ (free) 例26 於含2-[3-甲氧基-4-(三氟甲基)苄基]哌阱二鹽酸鹽 (109毫克),碘化鉀(109毫克)及Η,Η-二異丙基乙胺 (0.26毫升)之Ν,Ν-二甲基甲釀胺(4毫升)攪拌溶液,於 510及氮氣下加人(2R)-4-(2-氯乙基)-2-(甲氧甲基)嗎 啉鹽酸鹽(29毫克),並逐漸園溫室溫過夜。於51C下將 3,5-雙(三氟甲基)-苄醯氯(118毫克)加至上述攪拌溶 液,並於同溫下攪拌1小時。萃取K乙酸乙酯,將萃取 液清洗Μ水,於硫酸鎭下乾燥。由矽膠柱層析純化(二 氯甲烷/甲酵=60:1)可得產物,溶於乙酸乙_並處理Κ 4Ν鹽酸-乙酸乙瞻可得1-[3,5-雙(三氟甲基)苄醮基]-2-[3-甲氧基-4-(三氟甲基)苄基]-4-[2-[(2S)-2-(甲氧 甲基)-嗎啉基]乙基]哌畊二鹽酸鹽(22毫克)粉。 NMR (DMSO-dg, δ): 2.80-5.20 (28Η, m), 6.60-8.50 (8Η, m) MASS (APCI): 672 (M+H)+ (free) -155- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------^--------- <請先閲讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 15 4 五、發明說明() 例27 將(21?)-1_[3,5-雙(三氟甲基)苄醯基]-2-[3-[(2-甲 氧乙氧基)甲氧基]-4-甲苄基)-4-[(3-溴-1,2,4-B琴二唑 -5-基)甲基]哌阱(250毫克)溶於2莫耳氨水之四氫呋 喃(10毫升)。於室溫下1天,減壓蒸除。於乙酸乙酯及 食鹽水分層。收集有機層,清洗Μ食鹽水,於硫酸鎂下 乾燥並減壓濃縮。由矽膠柱層析純化(二氯甲烷/甲醇= 30:1)。收集含目的化合物部份並減壓蒸除,處理Μ 4Ν 鹽酸-乙酸乙酯可得(2R)-l-[3,5-雙(三氟甲基)苄醮基] -2-(3- 經基-4- 甲节基)-4-[(3- 胺基-1,2,4-吗二唑-5-基)甲基]哌阱二鹽酸鹽(40毫克)。
mp: 160-170°C
[a]g6: -20.1° (C=0.38, MeOH) IR《KBr): 3500-3150, 2700-2300,· 1635, 1428, 1280 cnT1 NMR 《DMSO-dg, δ): 2·07 (3H, s)T 2.60-5.20 (13H, 6·10-8·20 (7H, m), 8.60-9.40 (2H, m) MASS (APCI) : 544 例28 仿例27之方法可得如下化合物。 (2R)-1 - [3, 5-雙(三氟甲基)节釀基]-2-(3 -羥基-4-甲 苄基)-4-[(3-(二甲胺基)-1,2,4-鸣二唑-5-基)甲基]哌 畊二鹽酸鹽 -156- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------訂·----1--- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 15 5 五、發明說明f )
mp: 140-150eC
[a]g7: -20.14° (C=0.35, MeOH) IR (KBr): 3500-3000, 2700-2300, 1635, 1606, 1430 cm^1 NMR 《DMSO-d6, δ): 2·07 (3Hf s)f 2.92 (3Hr s) r 2·94 (3H, s), 2.60-5.20 (11H, m), 6.10-8.20 (7H, m) , 8.60-9.60 (2H, m) MASS (APCI) : 572 (M-fH)+ (free) 例29 將(2R)-l-[3,5-雙(三氟甲基)苄醮基]-2-(3-羥基- 4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]-乙基]哌 阱二鹽酸鹽(0.50克)於乙酸乙酯及飽和碳酸氩鈉溶液中 分層,分雛有機層,清洗K食鹽水,於硫酸鎂下乾燥, 真空蒸除可得(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 -(3 -羥基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]- 乙基]哌阱(0.437毫克)。於含此化合物之二氯甲烷中, 於冰浴冷郤及氮氣下依序加入4-(二甲胺基)吡啶(9毫 克)及三氟甲磺酐(0.22毫升)。攪拌1小時,加入飽和 碳酸氫納溶液,分離有機層並將水層萃取K二氯甲烷。 將結合有機曆萃取液清洗Μ食鹽水,於硫酸鎂及矽膠下 (1.1克)乾燥,真空蒸除可得(2R)-l-[3,5-雙(三氟甲 基)苄醯基]- 2-(4-甲基-3-三氟甲磺醯氧苄基)- 4-[2-[ (2S)-2-(甲氧甲基)嗎啉基]乙基]_阱(358毫克)之油。 IR (Neat) : 1645, 1425, 1280, 12.10, 1135 crtT1 NMR (CDCl3〇, δ): 1.90-5.14 (28Η, m), 6.60-8.20 (6H, m) MASS (APCI): 736 (M+H)+ 一 157- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) n ·ι···ι a· a···· a··· 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 15 6 五、發明說明() 例30 將(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(4-甲基-3-三氟甲磺酿氧苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基] 乙基]哌胼(0.10克),二苯醑亞胺(30.5毫克),碳酸鉋 (62毫克),乙酸鈀(3毫克),及2,2’-雙(二苯膦基)-1, 1’-聯#基(12.7毫克)之甲苯,於80C及氮氣下攪拌22 小時。冷卻後,加入水及乙酸乙_,分維有機層,清洗 Μ食鹽水,於硫酸納下乾燥,並真空蒸除。由矽膠柱層 析純化(HH-DM1020, Fuji Silysia Chemical Ltd·;己 烷:乙酸乙酿= 3:1)可得(2R)-1 - [3,5-雙(三氟甲基)苄 醯基]-2-[3-(二苯亞甲胺基)-4-甲节基]-4_[2 - [(2S) - 2-(甲氧甲基)嗎啉基]乙基]哌畊(75毫克)之油。 [a]g3·7: -63.51° (C=0-222, MeOH) IR (Neat): 2620, 1625, 1435 cm一1 NMR (CDCl3f δ): 1.86-4.84 (28H, m), -6.00-7.95 (16H, m) MASS (APCI): 767 (M+H)+ 例31 將(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-[3-(二苯亞 甲胺基)-4-甲苄基]-4-[2 - [(2S)-2-(甲氧甲基)嗎啉基] 乙基]哌畊(65毫克)之甲酵氫解(3大氣壓氫氣)KlOiKPd -C(6毫克,50X溼)於50¾下16小時。冷卻後,過濾並 將濾液真空蒸除。加入乙酸乙酿及水,分雛有機層,於 硫酸鎂下乾燥,並真空蒸除。由矽膠柱層析純化(《11-DM1020, Fuji Silysia Chemical Ltd·;己燒:乙酸乙 酯=1:1)可得(2R)-l-[3,5-雙(三氟甲基)苄_基]-2-(3- -158- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I------ I-------------訂------------- (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1 R 7 五、發明說明() 胺基-4-甲苄基)-4-[2 - [(2S)-2-(甲氧甲基)嗎啉基]乙 基]-哌阱(18毫克)。於含此化合物之甲醇處理Μ 4H鹽酸 -乙酸乙酯(0.05毫升),真空蒸除可得(2R)-l-[3,5-雙 (三氟甲基)苄醯基]-2-(3-胺基-4 -甲苄基)-4-[2-[(2S) -2-(甲氧甲基)嗎啉基]乙基]-哌阱三鹽酸鹽(20毫克)。
mp: 180-186°C
[a]g4·4: +9·41° (C=0.085, MeOH) IR (KBr>: 3435, 2600, 1645, 1514, 1454, 1429, 1365, 1282, 1182, 1105 citT1 NMR (D2〇/ δ): 2.20-5.35 (28H, m), 6,80-8.30 (6H, m) MASS (APCI): 604 (M+H)+ (free) 例32 將(2R)-1 - [3,5-雙(三氟甲基)苄醯基]-2-(3-胺基-4 -甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎咐基]乙基]哌阱 (0.10克),丁二釀亞胺(30毫克)及福馬林(28毫克)之乙 醇(0.5毫升)攪拌於100TC下24小時。冷卻後,真空蒸 除,此化合物可不經純化用於下一反應: (2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-[4-甲基-3-[[ (2,5-二氧毗咯啶基)甲基]胺基]苄基]-4-[2 - [(2S)-2- (甲氧甲基)嗎啉基]乙基]哌阱 IR {Meat): 1705, 1640, 1280, 1130 现-1 NMR (CDC13/ δ): 1.50-5.20 (34Η, m), 6.02-7.90 (6H, m) MASS (API-ES): 714 (M+) (free) 例33 將(2R)-l-[3,5-雙(三氟甲基)苄_基]-2-[4-甲基-3-[[(2,5-二氧毗咯啶基)甲基]胺基]苄基]_4_[2-[(25)-2- -159- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------丨訂---------^^1 (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 15 8 五、發明說明() (甲氧甲基)嗎啉基]乙基]哌阱(0.14克)之二甲亞 (0.42 毫升)加人硼氯化納(10毫克),攪拌於8010下15小時。 冷卻後,加入水及乙酸乙酯。分離有機層,清洗Μ食鹽 水,於硫酸納下乾燥並真空蒸除。由矽膠柱層析純化 (二氯甲烷/甲醇= 30:1〜10:1)可各得(2R)-l-[3,5-雙 (三氟甲基)苄醯基]-2-[4-甲基-3 -(甲胺基)苄基]-4-[2 -[(2S)-2-(甲氧甲基)嗎啉基]乙基]哌阱(37毫克)及 (2R) -1-[3,5-雙(三氟甲基)苄醯基]-2-[4 -甲基-3 - [[5 -羥基-2-氧Bfcfe咯啶基)甲基]胺基]苄基]-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]乙基]哌胼(45毫克)。各化合物可依 習用方法轉為其三鹽酸鹽。
(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 -[4-甲基-3-(甲胺基)苄基]-4 - [2-[(2S)-2-(甲氧甲基)嗎_基]乙基] 峨畊三鹽酸鹽 mp: 156-163°C
[a]g5·9: -1.79° (C=0.003, MeOH) IR (KBr): 3425, 2669, 2605, 2451, 1647, 1516, 1462, 1429, 1281, 1134, 1105 crrT1 NMR (D2〇, δ): 2.05-5.57 (31H, m), 6.74-8.25 (6H, m) MASS (APCI): 617 (Μ+Η)+ (free), 581
(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2 - [4-甲基-3-[[5 -羥基-2-氧吡咯啶基)甲基]胺基]苄基]-4-[2 - [(2S)-2 -(甲氧甲基)嗎啉基]乙基]哌胼哌阱三鹽酸鹽 mp: 163-176°C IR (KBr): 3400, 2586, 2443r 1647, 1454, 1427, 1369, 1281, 1174, 1134, 1103 citT1 NMR (D20, δ) : 1.70-6.50 (35H, ,m), 6.70-8.30 (6H, m) MASS (APCI): 716 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐)-MO- —----------------—訂—----丨 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 15 9 五、發明說明() 例34 仿例30之方法可得如下化合物。 (1) (21〇-1-[3,5-雙(三氟甲基)苄醸基]-2-(4-甲基-3-咐 咯啶苄基卜4 - [2 - [(2S) - 2-(甲氧甲基)嗎啉基]乙基] 哌畊三鹽酸鹽
mp: 160-165°C
[a]g4*6: +20.83° (C=0.108f MeOH) IR (KBr}: 3438, 2665, 2586, 2482, 1645, 1516, 1454, 1429, 1282, 1182, 1138,· 1105 cnT1 NMR (D2〇/ δ): 2.05-5.50 (36Hf m), 6.74-8·30 (6H, m) MASS (APCI): 657 (M+H)+ (free) ^ 588 (2) (2R )-1-[3,5-雙(三氟甲基)苄醯基]-2 -(4-甲基-3-嗎 啉苄基)-4-[2-[(2S)-2 -(甲氧甲基)嗎啉基]乙基]喊 阱三鹽酸鹽
mp: 150-170°C
[a】g4·7: -4·48° (00.067, MeOH) IR (KBr): 3437, 2667, 2576, 2457, 1645, 1514, 1454, 1429, 1282, 1182, 1136 cm,1 NMR (D20, δ): 2.15-5·50 (36H, n〇, 6:74-8·30 (6H, m) MASS (APCI): 673 (Μ+Η)+ (free), 588 例35 將(2R)-l-[3,5-雙(三氟甲基)-苄釀基]-2-(3-胺基-4-甲苄基)-4-[2-[(2S)-2-(甲氧甲基)嗎_基]乙基]哌 阱(132毫克)之二氯甲烷依序加入4-(二甲胺基)_啶 (2奄克)及三氟乙酐(0.05毫升),於室溫下攪拌過夜。 真空蒸除並加入乙酸乙酯及水。分雛有機層,清洗Μ食 -1 61 ~ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----Ί--------------訂-------- (請先閱讀背面之注音?事項再填寫本頁) 509688 Α7 Β7 160 五、發明說明() 鹽水,於硫酸鎂下乾燥,並真空蒸除。由矽膠柱層析純 化(二氯甲烷/甲醇=25:1)可得(2R)-1-[3,5-雙(三氟甲 基)苄醯基]-2 - [4-甲基-3-(三氟乙醯胺基)苄基]-4-[2-[(2S)-2-(甲氧甲基嗎啉基]乙基]哌阱(134毫克)。 MASS (APCI) : 699 (M + H) + 例36 將(2R)-1-[3,5-雙(三氟甲基)苄釀基]-2-[4-甲基-3-(三氟乙釀胺基)苄基]-4 - [2 - [(2S)-2 -(甲氧甲基)-嗎啉 基]乙基]_阱(131毫克)之四氫呋喃(2毫升)加入HaH (10毫克),攪拌20分。加入甲基碘(28毫克),於室溫攪 拌過夜。加入食鹽水,分雛有機層,於硫酸鎂下乾燥, 並真空蒸除。由HPLC純化可得(2R)-l-[3,5-雙(三氟甲 基)苄醯基]-2-[4-甲基-3 -(N-甲基-N-三氟乙醢胺基)苄 基]-4-[2-[(2S)-2-(甲氧甲基)-嗎啉基]乙基]哌阱(31 毫克)之油。此化合物可依習用方法轉為其二鹽酸鹽。 [a]g7·3: -10.94° (C=0.032, MeOH) IR (KBr): 3425, 1695, 1647, 1282, 1207, 1180, 1140, 1101 crtT1 . NMR (DMSO-dg, δ): 1·95-5·32 (31H, m), 6·75-8·34 ( 6H, m) MASS (APCI): 713 (M+H)+ (free) 例37 將(2R) -1-[3-(2,5-二甲毗咯-1-基磺醢基)-5-(三氟 甲基)苄醢基]-2-(3-羥基-4-甲苄基卜4-[2-[(25)-2-(甲氧甲基)-嗎啉基]乙基]-哌畊(160.6毫克)之6N鹽酸 (10毫升)攪拌於70¾下2小時。倒至飽和碳酸氫鈉溶液 -162- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -n RK· ϋ «ϋ ϋ n si. 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 —-… ____B7 _ 五、發明說明(161) (150毫升)並萃取以乙酸乙酯(50毫升X3)。將结合有 機層萃取液清洗以食鹽水,於硫酸鎂下乾燥•並減壓蒸 除可得油(163.4毫克)。將油溶於乙酸乙酯(ΐ·6毫升), 於室溫依序加入4Ν鹽酸-乙酸乙酷(0.17毫克)及己烷(50 毫升)。濾集粉並減壓乾燥可得(2R)-2-(3-羥基-4-甲苄 基)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]乙基]-l-[3-胺 磺醯基-5-(三氟甲基)苄醯基]-哌畊二鹽酸鹽(149.3毫 克)之粉。
mp: 166-206eC
[a]J5: -11.93° (C=0.25, MeOH) IR (KBr): 3431, 3402, 1641 cnT1 NMR (DMSO-d6/ δ): 2.08 (3H, s) , 2.60-5*20 (25H# m), 6.18-9.20 (6H, m) MASS (APCI): 615 (M+H)+ (free) 製備例56 將(3R)-1-苄基-3-(3-羥基-4_甲苄基阱(8 40毫克) 之1,4-二鸣烷(7·5毫升),水(5毫升)及1H鹽酸(2.8毫 升)於0t!下依次加入二碳酸二第三丁酯(740毫克)之1, 4-二鸣烷(2.5毫升)及2Ν NaOH(1.9毫升)。於〇它下攪 拌1小時,加入含二碳酸二第三丁瞧(123毫克)之1,4-二嘮烷,於〇υ下攪拌2小時。M1N鹽酸(0.99毫升)調 至ΡΗ7-8並Μ二氯甲烷萃取(Χ3)。將結合萃取液清洗Κ 食鹽水,於硫酸鎂下乾燥並減壓濃縮可得油(1.74克), 由矽膠柱層析鈍化(矽膠,50毫升•,乙酸乙酯/己烷=1:5 〜1:4)可得(2R)-4-苄基-第三丁氧羰基-2-(3-羥基-4- 一 163- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----------ΙΦΜ --------訂---------^9— (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 162 五、發明說明() 甲苄基)-哌畊(1·〇8克)之泡沫。 IR (Neat): 1664 cm^1 NMR (CDC13/ δ): 1.40 (9Η, s), 1.92 (1H, dd, J=3.8 11.4Hz), 2.15 (3H, s) , 2.05-2.20 (IK, m) , 2-64-3.10 (4H, m), 3·19 (1H, dt, J=3.5 and 12·6Ηζ), 3·25 (1H, d, J=12.8Hz)/ 3.59 (1H, d, J=12.8H2), 3.80-4.15 (2H, m) , 4.77 (1H, br s), 6.15 (lHf br ,s), 6.55 (1H, d, J=7.5Hz), 6·91 (1H, d, J=7.5Hz), 7·26-7·37 (5H, m) MASS (APCI): 397 (M4-H) + 製備例57 將含(2R)-1-第三丁氧羰基-2-(3-羥基-4-甲苄基)-喊胼 (7.73克)及4-二甲胺吡啶(620奄克)之二氯甲烷(90毫 升)於室溫下依次加入三乙胺(15.82毫克)及第三丁二苯 矽烷氯(26·24毫克)。攪拌回流27.5小時,加入水(200 毫升),萃取Μ二氯甲烷(1〇〇毫升,50毫升Χ2)。將結 合有機萃取液依次清洗Κ水及食鹽水,於硫酸鎂下乾燥 ,減壓蒸除可得粗製油。由矽膠柱層析純化(矽膠,500 毫升;二氯甲烷/甲酵=95:5)可得(2R)-1-第三丁氧羰基 - 2-(3-第三丁二苯矽烷氧基-4-甲苄基)哌阱(12.07克) 之固體。
mp: 64.5-65.50C IR (KBr) : 2962, 2933, 1693 crrT1 NMR (CDC13, δ): 1.07-1.09 (9H, m) , 1.26-1·50 (9H, m), 2.00-3.80 (9H, m), 2.36 (3H, s), 6.13-6.20 (1H, m), 6.67(lH,d,J=7.6Hz),7.03(lH,d,J=7.6Hz>,7.26-7.34 (6H, m), 7.65-7.73 (4H, m) MASS (APCI): 545 (M+H)+ 一 164- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 五、發明說明(163) 例58 (請先閲讀背面之注意事項再填寫本頁) 仿例1之方法使用Ν,Ν-二異丙基乙胺取代碳酸鉀為鹼 可得如下化合物。 ⑴(2R)-1-第三丁氧羰基-2-(3-第三丁二苯矽烷氧基-4 -甲苄基)-4-[2-((2S)-2-甲氧甲基嗎啉基)乙基]哌阱 IR (Neat) : 1695 cirT1 NMR (CDC13. δ): 1.10 (9Η, s) , 1.21 (9H, s), 1.60-3.00 (17H, m), 2·34 (3H, s), 3·37 (3H,,s), 3·37-4·00 (5H, m) , 6.23 (1Η, s) f 6.64 (1H, d# J-7.6HZ), 7.3R (1H, d, J=7.6Hz), 7·34-7·42 7.66-7.73 (4H, m) MASS (ESI): 702.5 (M+H)+ (2) (2R)-l-(第三丁 氧羰基)-2-(4-羰苄基)-4-[2-(順-2, 6-二甲嗎啉基)乙基]哌阱 IR (Neat): 1693, 1410, 1367, 1087, cm一1 NMR (CDC13/ δ): 1.16 (6Η, d, J=6.3Hz), 1.38 (9H, s), 1.76 (1H, t, J=11.0Hz), 2.03 C2H, m), 2.51 (4H, m), 2.60-3.20 (8H, m), 3.50-4.15 (4H, m), 7.12-7.27 (4Hf m) MASS: 452 (M+) (3) (2R)-l-(第三丁 氧羰基)-2-(4-氯苄基)-4-[2-(5·6,7 ,8-四氫-1,6-暸啶-6-基)乙基]-哌阱 經濟部智慧財產局員工消費合作社印製 fa]g7·2: +4.89° (C=0.32, MeOH) IR (Neat): 2970, 2930, 281'σ, 1690Γ 1580 cnrl NMR (CDC13, δ): 1.39 (9H, s) , 1.9-2.2 (2H, m) , 2.4-3.3 {13H, m}, 3·67 (2H, s), 3·8-,·3 (2H, m), 7·07 (1H, dd, J=4.7 and 7·6Ηζ>, 7.13 (2H, d, J=8.4Hz), 7·22 (2H, d, J=8.4Hz)/ 7.33 (1H, .d, J=7.6Hz), 8.40 (1H, d, J=4.7Hz) MASS 《APCI): 471 (M+H)+ -165- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 16 4 五、發明說明() 製備例59 將含(2ϋ)-1-第三丁氧羰基_2-(3-第三丁二苯矽烷氧 基-4-甲苄基)-4 - [2 - [(2S)-2-甲氧甲基嗎啉基]乙基]哌 畊(13.43克)之二氯甲烷(67.0毫升)於〇υ下加入三氟乙 酸(67.0毫升)。攪拌於室溫30分,濃縮並滴加入飽和碳 酸氫鈉溶液。攪拌於室溫下30分,萃取Μ二氯甲烷(1〇〇 毫升XI, 50毫升Χ2)。將結合有機層於硫酸鎂下乾燥 並減壓蒸除可得(2R)-2-(3-第三丁二苯矽烷氧基-4-甲 苄基)-4-[2-[(2S)-2-甲氧甲基嗎啉基)乙基]哌胼(11.63 克)之棕色油。 IR (Neat): 1676, 1614, 1579 cm"1 NMR (CDC13, δ): 1·10 (9H, s), 1.·60-2·80 (17H, m), 2·36 (3Η, s), 3.37 (3Η, s) , 3.37-3.41 (2H, m) , 3.60-3.95 (3H, m>, 6·22 (1H, d, J=l-4Hz), 6·60 (1H, dd, J=1.4 and 7.6Hz), 7.06 (1H, d, J=7.6Hz), 7.31-7.42 (6Hf m), 7.68-7.73 (4H, m> MASS (APCI): 602 (M+H)+ 製備例60 將含(2R)-2-(3-第三丁二苯矽烷氧基-4-甲苄基)-4 -[2- [(2S)-2-甲氧甲基嗎啉基)乙基]哌畊(9·38克)之乙 酸乙酯(40毫升)於01下加入4Ν鹽酸-乙酸乙酷(11.7毫 升),並滴加入己烷(200毫升)。攪拌於室溫下2小時 ,冷卻至01C。濾集沈澱,清洗Μ己烷,並減壓乾燥可 得(2R) - 2-(3-第三丁二苯矽烷氧基-4-甲苄基)-4-[2-[ (2S)-2-(甲氧甲基)嗎啉基]乙基]哌阱三鹽酸鹽(10.75 -166- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----J----—--------訂·-------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 1 β 5 五、發明說明() 克)之粉。
mp: 173-185°C IR (KBr): 3398, 2935, 164”, 1510 cm’1 NMR (DMSO-dg, δ): 1.07 (9H.f s) , 2· 31 (3H, s) , 1.80-4,30 (25H, m)f 6.15 (1H, br s) f 6.70 (1H, d, J=7.7Hz)# 7.17 (1H, d, J=7.7Hz), 7.42-7.50 (6H, m), 7.65-7.70 (4H, m> NMR (D2〇, δ): 1·03 (9H, s), 2·27 (3H, s), 2.90-4.20 (22H, ία), 3·39 (3H, s), 6·32 (1H, s), 6·80-6·87 (1H, m), 7·19 《1Η, d, J=7.8Hz), 7·37-7·76 (10Η, m) MASS (APCI) : 602 (MfH)4· (free) 製備例61 將N,0-二甲羥胺鹽酸鹽(5.37克)加至3-甲氧基-4_(三 氟甲基)苄酸(11·0克),1-羥苯并三唑(6.76克),1-(3 -二甲胺丙基)- 3-乙基碳化二亞醯胺鹽酸鹽(9.59克)及Η, Ν -二異丙基乙胺(9.6毫升)之二氯甲烷(200毫升),攪 拌於室溫下18小時。加入飽和碳酸氩鈉溶液並分雛有機 層,於硫酸鎂下乾燥,並減壓乾燥。由矽膠柱層析純化 (25»;乙酸乙酯於己烷)可得3-甲氧基-Η-甲氧基-Η-甲基 -4-(三氟甲基)-苄釀胺(12.0克)之無色油。 NMR (CDC13, δ): 3·38 (3Η, s), 3·56 (3Η, s), 3·94 (3Η, s), 7.28 (2Η, m), 7.60 (1Η, df J=8.3Hz) MASS (APCI): 264 (M+H)+ 製備例62 於含3-甲氧基-N-甲氧基-N-甲基-4-(三氟甲基)-苄醯 胺(2.63克)之無水四氫呋喃(26毫升)攪拌溶液中,於 -167- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -----1——-------—訂—------ (請先閱讀背面之注咅?事項再填寫本頁) 509688 Α7 Β7 五、發明說明() -40 t!及氮氣下加入鋁氪化鋰(380毫克)。於SC攪拌1 小時,加入2Η NaOH。由Celite漶除不溶物,清洗Κ乙 酸乙酯。結合濾液及洗液並減壓乾燥可得粗製3 -甲氧基 -4-(三氟甲基)苄醛之無色油。於含粗製3-甲氧基-4-(三氟甲基)苄醛及1,4-二乙藤哌阱-2,5-二_ (1·98克) 之Η,Ν-二甲基甲醯胺(10毫升}及第三丁酵(1〇毫升)攪拌 溶液,於5*0下加入第三丁氧化鉀(1·1 2克)。攪拌於室 溫18小時。加人水(30奄升)及乙酸乙酯(1〇〇毫升),分 雛有機層,並將水層萃取Κ乙酸乙酯。將結合萃取液清 洗Μ水,於硫酸鎂下乾燥,並減壓蒸除。由矽膠柱層析 純化(50¾乙酸乙酯於己烷)可得卜乙釀基-3-[[3-甲氧 基-4-(三氟甲基)苯基]亞甲基]哌阱-2,5-二麵(2.11克) 之粉。 NMR (DMSO-dg, δ): 3.33 (3Η, s) , 3.90 (3Η, s) f 4.37 (2Hf s), 6·98 (1H, s), 7·26 (1H, d, J=8.1Hz), 7·38 (1H, s), 7.63 (1H, d, J=8.1Hz), 10.55 (1H, s) MASS (APCI): 343 (M+H)+ 製備例63 於含1-乙醯基-3-[[3 -甲氧基-4-(三氟甲基)苯基]亞 甲基]哌畊-2,5-二_(1.8克)之四氫呋喃(50毫升)於 10!KPd-C(50X溼,180毫克)及大氣壓下氫化5小時。濾 除觸媒,加入肼單水合物(395毫克)。攪拌於室溫1.5 小時並減壓濃縮。碾製K異丙醚(12毫升)並濾集沈澱, 清洗Μ異丙醚可得3-[3-甲氧基-4-(三氟甲基)苄基]哌 畊-2,5-二酬(1.29克)之粉。 -168- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) <請先閲讀背面之注意事項再填寫本頁) ---------訂--------. 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(167) NMR (DMSO-dg, δ): 2.94-3,19 (3Η, m> , 3.51 (1H, 3.84 (3H, s), 4.15 <1H, m), 6.90 (1H, d, J=7.9Hz)f 7.08 (1H, s), 7·52 (1H, d, J=7.9Hz), 7·99 (1H, m), 8·20 (1H, m) MASS (APCI): 303 (M+H)+ 製備例64 於含3-[3-甲氧基-4-(三氟甲基)苄基]哌阱-2,5-二麵 (1.2克)之四氫呋喃(10 0毫升)攒拌溶液中,於氮氣及 室溫下,由針筒加入硼烷-四氫呋喃複合物(1莫耳溶液 於四氫呋喃,39.7毫升),並加熱回流18小時。冷卻後, 過_並鑀慢加入12¾溴化氫-乙酸(16毫升)。加入異丙 _ (300毫升),攪拌1小時於51。濾集沈澱,減壓乾 燥可得2-[3-甲氧基-4-(三氟甲基)苄基]哌阱二氫溴酸 鹽(1.73毫克)之粉。 NMR (DMSO-d6, δ): 2·70_3·90 (9Hf m), 3·92 (3H, s), 6.50 (1H, m), 7.03 (1H, d, J=7,9Hz), 7.25 (1H, s)f 7.62 (1H, d, J=7.9Hz), 8·10 (1H, br s), 9·07 (2H, br s) MASS (APCI): 275 (M+H)+ (free) 製備例65 * 仿製備例56之方法可得如下化合物。 (2R)-4-苄基-1-(第三丁氧羰基)-2-(4-氯苄基)哌阱
mp: 139-140°C
[α]§6·8: -2.96° (C=0.27, MeOH) IR (KBr): 3740, 2970, 2810, 170D, 1650 cnT1 -169 一 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------— --------訂--------- (請先閱讀背面之注咅?事項再填寫本頁) 509688 A7 _B7_ 五、發明說明(168) NMR {CDC13, δ): 1·38 (9H, s), 1·9-2·2 (2H, m), 2·58 (1H, d, J=11.5Hz), 2.7-3,3 (4H, m) , 3.32 (1H, df J=12.9Hz), 3.56 (1H, d, J=12.9Hz), 3.7-4.3 (2H, m), 6.93 (2H, d, J=8.2Hz), 7.12 (2H, d, J=8.2Hz), 7.33 (5H, s) MASS (APCI): 401 (M+H)+ 製備例66 仿製備例59之方法可得如下化合物。 (1) (2R)-2 -(4-氯苄基)-4-[2-(順-2,6_二甲嗎啉基)乙基] 哌畊三鹽酸鹽 IR (KBr): 16今5, 1454, 1425, 1120, 1086 citT1 NMR (DMSO-dg, δ): 1.11 (6Η, d, J=6.2Hz)( 2.59-4.60 (19H, m), 7.34 (2H, d, J=8.5Hz), 7.44 (2H, d, J=8.5Hz), 9·47-10·0 (1H, br), 9·50 (0·5Η, bir), 10.5 (0.5H, br) MASS: 352 (M+) (2) (2R)-2-(4-氯苄基)-4-[2-(5,6,7,8-四氫-1,6-暸啶--6-基)乙基]_阱四鹽酸鹽 [a]g7·2: +13.10° (C=0,35, MeOH) IR (KBr): 3400, 1640, 1630, 1550, 1520 cm·1 NMR (DMSCHd6, δ): 2·8-6·2 (16H, 4·53 (2H, s), 7·34 經濟部智慧財產局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) (2H, d, J=8Hz), 7.43 (2H, d,十8Hz), 7.80 (1H, dd, J=5 and 8Hz), 8·23 (1H, d, J=8Hz), 8·75 (1H, d, J=5Hz), 9.7-10,0 (1H, br), 10,1-10.3 (1H, br) MASS (APCI): 371 (M+H)+ 製備例67 於含3-氯磺釀基-5-(三氟甲基)苄酸(0·4克),於0¾ 下加入28¾氨水(5.0毫升)。攪拌於0C後置於室溫過 -170- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_
IRQ 五、發明說明() 夜。減壓濃縮乾燥,加入IN鹽酸(5毫升),攪拌於ου 下30分。濾集粉並減壓乾燥得3-胺磺醯基-5-(三氟甲基) 苄酸(299.4毫克)之淡黃色粉。 mp: 244-246°C IR (KBr> : 1713 cirT1 NMR (DMSO-dg, δ): 7.73 (2H, s) e 8.34 (1H, s), 8·37 (1H, s), 8·62 (1H, s) MASS (ESI-): 268.1 (M-H) 製備例68 於含3-胺磺醯基-5-(三氟甲基)苄酸(200毫克)及2, 5-己二酮(0.26毫升)之甲苯(1毫升)中加入對甲苯磺酸 單水合物(28毫克),攪拌回流MDean-Stark Trap24小 時。加入2,5-己二_ (0.26毫升)及對甲苯磺酸單水合物 (30毫克 攪拌於同溫下24小時。蒸除並由矽膠柱層析 純化(矽膠,50毫升,甲醇:二氯甲烷=5:95〜20 : 80)可 得3_[ (2,5-二甲吡咯-1-基)-磺_基]-5-(三氟甲基)苄酸 (280毫克)之粗製固體。將固體溶於1H Ha0H(10毫升) 及水(20毫升),M1N鹽酸調至pHI〜2(20毫升)。濾集粉 並減壓乾燥可得純物(191.1毫克)。 mp: 150-153°C IR (KBr): 1701 cm一1 NMR (DMSO-dg, δ): 2.33 (6H, s), 6.07 (2H, s), 8·13 (1H, s), 8·23 (1H, s), 8·46 (1H, s) MASS (APCI): 348 (M+H广 製備例69 將含3-氯磺醯基-5-三氟甲基苄酸(0.5克)及吡咯啶 -171- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
509688 A7 B7_ 17 0 五、發明說明() (0.72毫升)於二氯甲烷(5毫升)攪拌於室溫遴夜。蒸乾 後加入水(50毫升),K1N鹽酸調至pHI.O。濾集沈澱, (請先閱讀背面之注意事項再填寫本頁) 減壓乾燥於45t!可得3-(吡咯啶磺醜基)-5-(三氟甲基) 苄酸(0.514克)之粉。 mp: 198-199eC IR (KBr) : 1697 cnT1 NMR《DMSO-d6, δ): 1.64-1.77.(4H, m), 3·18-3·29 (4H, m), 8·28 (1H, s), .8.45 (1H, js), 8·46 (1H, s) MASS 《APCI): 324 (M+H)+ ^ 製備例70 仿製備例69之方法可得如下化合物。 (1) 3 -(嗎咐磺醯基)-5-(三氟甲基)苄酸 mp: 210-213eC IR (KBr) : 1707 cirT1 NMR (DMSO-dg, δ): 2.96-3.01 (4H, in) , 3.62-3.67 (4H, m), 8·22 (1H, s), 8·41 (1H, s),』.48 (1H, s) MASS (ESI-): 338.1 (M-H) (2) 3-甲胺磺醯基-5-(三氟甲基)苄酸 mp: 194-197°C — - IR (KBr): 1705 cm-1 經濟部智慧財產局員工消費合作社印製 NMR (DMSO-d6, δ): 2.46 (3H, s) , 7.84-7.94 (1H, m), 8.28 (1H, s), 8.41 (1H, s), 8.55 (1H, s) NMR (CD3〇D, δ>: 2·57 (3H, s), 8·29 (1H, s), 8·48 (1H, s>, 8·65 (1H, s) MASS (ESI-): 282 (M-H) ’ (3) 3-二甲胺磺釀基-5-(三氟甲基)苄酸 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 171 五、發明說明() mp: 145-155°C IR (KBr): 1705 cm"1 NMR (DMS〇-d6, δ): 2·70 (6H, s), 8.24 (1H, s), 8.42 (1H, s), 8.46 (1H, s〉 MASS (APCI): 298 (M+H)+ 製備例71
將含3-胺基-5-(三氟甲基)苄酸(2.0克)及2,5-二甲 氧四氫呋喃(1.52毫升)之乙酸(10毫升)及1,4-二鸣烷 (10毫升)攪拌於1001C下2小時。冷卻至室溫,濃縮並 由矽膠柱層析純化(矽膠,50毫升,甲酵:二氯甲烷=10 :90)可得粗製固體。將固體再結晶自乙酸乙酿(5.0毫升) 及己烷(200毫升)可得3-(吡咯-1-基)-5-(三氟甲基)-苄酸(1 . 72克)之粉。 mp: 191-192.5°C IR (KBr): 1705, 1614, 1496 cnT1 NMR (CDC13, δ): 6·43 (2H, s), 7·19 (2H, s), 7·87 (1H, s) , 8.22 (1H, s) ,. 8.31 (1H, s) MASS (ESI-): 254 (M-H), 509.1 (2M-1) 製備例72 於含3-碘-5-(三氟甲基)苄酸(2·32克)及三乙胺(1.13 毫升)之二氯甲烷(20毫升)中,於- 30¾及10分內滴加入 含氯甲酸乙酯(1.4毫升)之二氯甲烷(2.0毫升),攪拌 於-30t!下1小時。於-301C及5分内滴加人2-胺基_2-甲基-1-丙醇,攪拌於-30t)下3.0分再於室溫下1小時。 於0CM氯化銨溶液中止反應,並萃取Μ二氯甲烷(Χ2) 。將結合有機層依次清洗Μ飽和碳酸氫納溶液,1Ν鹽酸 -173- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注咅?事項再填寫本頁) -I I I I I I I i — ΙΙΙΙΙΙ — 經濟部智慧財產局員工消費合作社印制衣 509688 A7 B7_ 17 2 五、發明說明() 及食鹽水,於硫酸鎂下乾燥,蒸乾並由矽膠柱層析純化 (矽膠,乙酸乙酯·•己烷=20: 80)可得N-(2-羥基-1,1-二 甲基乙基)-3-碘-5_(三氟甲基)苄醯胺(2.10克)之油。 IR (Neat): 3400, 1640, 1550 cm"1 NMR (CDC13, δ) : 1·44 (6Η, s) , 3·69 ’(2H, d, J=5·9Hz), 4.02 (1H, t, J=5.9Hz), 7.93 (1H, d, J=0.6Hz), 8.05 (1H, d, J=0.6Hz), 8·22 (1H/ s> NMR (DMSO-dg, δ): 3.33 (6H, s) , 3.53 (2H, d, J=5.7Hz), 4·81 (1H, t, J=5.7Hz), 8·12 (1H, s), 8·22 (1H, s), 8.45 (1H, s) ^ MASS (ESI+): 410-1 (M+Na)+ 製備例73 於含H-(2-羥基-1,1-二甲基乙基)-3-碘- 5-(三氟甲基) 苄釀胺(2.11克)中加入磺醯氯(1·29毫升),攪拌於室溫 下4小時。減壓濃縮,Μ飽和碳酸氫鈉溶液中止反應, 並萃取Κ乙酸乙酯(Χ2)。將結合有機層於硫酸鎂下乾 燥,減壓乾燥,並由矽膠柱層析純化(矽膠,乙酸乙酯 :己烷=2.5:97.5)可得2-[3-碘-5-(三氟甲基)-苯基]-4,
4-二甲基-4,5-二羥鸣唑(1·66克)之固體。 mp: 73-74.5°C IR (KBr): 2968, 1645, 1566 cm"1 NMR (CDC13, δ): 1.39 (6H, s), 4.14 (2H, s), 8.03 (1H, d, J=0.7Hz), 8.16 (1H, d, J=0.7Hz), 8.48 (1H, s) MASS (APCI): 370 (M+H)+ 製備例74 於含2-[3-碘-5-(三氟甲基)-苯基]-4,4-二甲基-4,5- -174- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) « — — III. 509688 A7 B7_ 17^ 五、發明說明() 二羥鸣唑(2.11克)及硼酸三異丙酯(1.26克)之四氫呋喃 (21毫升)中,於-70¾下滴加入丁鋰(1.6莫耳溶液於己 烷)。攪拌4小時,Μ 2N鹽酸溶液中止反應並萃取Μ乙 酸乙酯。將結合有機層清洗Μ食鹽水,於硫酸鎂下乾燥 ,並真空蒸除可得3-(4,4-二甲基-4,5-二羥鸣唑-2-基) -5-(三氟甲基)苯硼酸(1.65克)之黃油。此油因不穩定 而可不經純化立即用於下個反應。 製備例75 於含3 -(4,4-二甲基-4,5-二羥鸣唑-2-基)-5-(三氟甲 基)苯硼酸(0.58克)及4-溴吡啶鹽酸鹽(0·39克)之碳酸 鈉溶液(2莫耳溶液,6毫升)及1,2-二甲氧乙烷(4毫 升)中,於氮氣下加入四叉(三苯膦基)鈀(0.116克)。攪 拌於80 °C下12小時,Μ水中止反應並萃取Μ乙酸乙酯 (Χ2)。將結合有機層於硫酸鎂下乾燥,蒸除,並由矽 膠柱層析純化(矽膠,乙酸乙酯:己烷=1:3-2 :1-1:2)可 得4- [3-(4,4-二甲基-4, 5-二羥吗唑-2 -基)-5-(三氟甲 基)苯基]吡啶(0.61克)之漿液。 IR (KBr): 2972, 1651, 1597, 1446 cnT1 經濟部智慧財產局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) NMR (CDC13, δ): 1.42 (6Η, s) , 4.14 (2Η, s) , 7.57 (2Η, d, J=6.2Hz), 7.96 (1H, s), 8·28 (1H, s), 8·40 (1H, s), 8.72 (2H, d, J=6.2Hz) MASS (ESI+): 321,1 (M+H)+ 製備例76 將含4-[3-(4,4 -二甲基-4,5-二羥鸣唑-2-基)-5-(三 氟甲基)苯基]吡啶(0.60克)及6N鹽酸(6毫升)攪拌於 -175 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 17 4 五、發明說明() (請先閱讀背面之注意事項再填寫本頁)
9〇υ下5小時。冷卻至室溫後濃縮。加入少量水,濾集 結晶並減壓乾燥可得5-(4-吡啶基)-3-(三氟甲基)苄酸 鹽酸鹽(0.33克)之粉。同樣地,由母液可得第二結晶 (0· 1克卜 mp: - 230°C IR《KBr> : 2534, 1703, 1641, 1608, 1514 cm*"1 NMR (DMSO-dg, δ): 8.36 (1H, s),.8.50 (2H, d, J=6,7Hz), 8·60 (1H, s), 8·69 (1H, s), 9,01 (2H, d, J=6.7Hz) MASS (ESI+): 268.2 (M+H)+ 製備例77 仿製備例11之方法可得如下化合物。 2-苄胺基-2-甲基-1-丙醇 NMR (CDC13/ δ): 1.14 (6Hf s) , 3.3*4 (2H, s) , 3.67 (2Hf s), 7.20-7.34 (5Hf m) mSS (APCI): 180 (M+H)+ . 製備例78 仿製備例12之方法可得如下化合物。 2 -甲基-[2-[N -节基-N-[(2S)-2 -羥基-3-甲氧丙基]胺 基]-1-丙醇 經濟部智慧財產局員工消費合作社印製 IR (Neat): 3400, 2973, 2881,^1643, 1454 cm^1 NMR (CDC13/ δ): 1.03 (3H, s)f 1.13 (3H, s), 2.49 (1H, dd, J=3.5 and 14·0Ηζ>, 2·79 (1H, dd, J=9.2 and 14.0Hz), 3.28 (3H, s), 2.92-3.32 (3H; m) , 3.38-3.48 (1H, in), 3·48-3·61 (2H, m)" 4·02 (1H, d, J=15.3Hz), 7·17_7·41 (5H, m) MASS (APCI): 268 (M+H)+ -176- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1 7 P; 五、發明說明() 製備例79 仿製備例13之方法可得如下化合物。 ⑴(2S)-1-[N-苄基氯-1,1-二甲基乙基)胺基]-3 -甲氧基-2-丙酵 IR (Neat): 2933, 1645, 1456 cnT1 NMR (CDCI3/ δ): 1.08-1.53 (6Η, m), 2,46-4.10 (9Η, m), 3.34 (3Η, s), 7.23-7.40 (5Η, m) MASS (APCI) : 286 (M+H)4* - (2) (1R,4S )-3,3-二甲基-5 -(2-氯乙基)-2 - B| -5 - B丫雙環 [2·2·1]庚烷鹽酸鹽 IR (KBr): 2945, 2603, 1514, 1462 cm"1 NMR (DMSO-dg, δ): 1.16 (3H, s) , 1..45 (3H, s) , 2.20-2.40 (2H, m), 3.21 (lHf d, J=11.9Hz)v 3.40-3.80 (3H, m), 3.90-4.15 (2H, m), 4.31 (1H, s)f 4.56 (1H, s) MASS (APCI): 190 (M+H)+ (free) 製備例80 仿製備例14之方法可得如下化合物。 (2S)-4-苄基- 5,5-二甲基-2-(甲氧甲基)嗎啉 .-V.. NMR (CDC13, δ): 1·10 (3H, s), 1·12 (3H, s), 2·21 (1H, dd, J=10.5 and 11·7Ηζ), 2·37 (1Η, dd, J=3.0 and 11.7Hz), 3.00 (1H, d, J=13.8Hz), 3.32 (3H, s), 3.24-3.56 (4H, m), 3.61-3.71 (1H, m), 4.02 (1H, d, J=13.8Hz)f 7.20-7.36 (5H, m) MASS (APCI): 250 (M+H)+ 製備例81 仿製備例15之方法可得如下化合物。 (1) (2S)-5,5-二甲基-2-(甲氧甲基)嗎咐鹽酸鹽 -177- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(176) IR (Neat) : 3398, 2947, 1458, mcnT1 NMR (CDC13, δ): 1·26 (3H, s), 1·33 (3H, s), 2.90-3.00 (2Η, m), 3·27 (3Η, s), 3·35-3·50 (2Η, m), 3·49-3·64 (2Η, m), 3·82-3·94 (1Η, m) MASS (APCI): 1.60 (Μ+Η)+ (free) ⑵UR,4S)-3,3-二甲基-2-鸣-5-吖雙環[2·2·1]庚烷鹽 酸鹽
mp: 237-238eC IR (KBr): 2895, 2727, 1587, 1464^1^1 NMR (DMSO-dg, δ): 1.11 (3H, s) , 1.31 (3H, s) , 1.92 (1H, d, J=11.3Hz), 2.28 (1H, d, J=11.3Hz), 3.00-3.15 (2H, m), 4.08 (1H, s), 4.53 (lHf s) MASS (APCI): 128 (M+H>+ (free) 製備例82 仿製備例7之方法可得如下化合物。 (1) (2S)-5,5-二甲基-4-(2-羥乙基)-2-(甲氧甲基嗎啉 IR (KBr) : 3433, 2970, 2875, 1458,, 1365 crtT1 NMR (CDC13, δ): 0·98 (3H, s), 1·06 (3H, s), 2·12 (1H, ddd, J=2.2, 3·2 and 12·9Ηζ), 2·31 (1Η, dd, J=10.8 and 11.8Hz), 2·63 (1Η, dd, J=2.9 and 11·8Ηζ), 2·96 (1H, ddd, J=5.3, 10.7 and 12·9Ηζ), 3·39 (3H, s), 3·33-3·60 (6H, m), 3.60-3·80 (1H, m) MASS (APCI): 204 (M+H)+ ⑵(lR,4S)-3,3-二甲基-5-(2-羥乙基)- 2-唁-5-吖雙環 [2·2. 1]庚烷 -178- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閲讀背面之注意事項再填寫本頁) --------訂---------應 509688 A7 B7_ 17 7 五、發明說明() IR (KBr): 3433, 2978, 1460 cm"1 (請先閱讀背面之注意事項再填寫本頁) NMR (CDC13, δ): 1·13 (3H, s),‘1.34 (3H, s), 1·63 (1H, dd, J=1.7 and 10·2Ηζ), 1.99 (1Η, ddd, J=l.l, 1·1 and 10·2Ηζ), 2.32 (1H, dd, J=1.7 and 10.4Hz), 2·52 (1H, ddd, J=U, 5.4 and 12.3Hz) , 2/85《1H, ddd, J=4.8, 6.8 and 12,3Hz), 2.98 (1H, br-s), 3.00 (1H, d, J=10.4Hz)f 3.40-3.75 (2Hf m), 4·38 (1H, br s) * \ MASS (APCI): 172 (M+H)+ ③4,4_二氟-1-(2-羥乙基)哌啶 NMR (CDC13# δ): 1,85-2,05 *(5Hf m) , 2.55-2.65 (6H, m), 3.62 (2H, t, J=5.3Hz) MASS (APCI): 166 (M+H)+ 製備例83 將溴化甲鎂(0.93莫耳溶液於四氫呋喃,120毫升)於 乾冰丙_浴冷卻及氮氣下加至含N-苄基-反-4-羥基-L-脯胺酸甲酯(5.0克)之四氫呋喃(50毫升),攪拌30分。 加入飽和氯化銨溶液後分雛有機層,清洗Μ食鹽水,於 硫酸納下乾燥,並真空蒸除可得(2S,4R )-1-苄基-2-(1-羥基-1-甲基乙基)-4-羥吡咯啶(5.0克)之油。 IR (Neat): 3400, 1455, 1370, 1120-cnT1 剛R (CDC13_D20,’5): 1·15 口1,. s), 1·30 (3H, s), 經濟部智慧財產局員工消費合作社印制衣 1.80-2.02 (2H, m), 2.52-2.66 (1H, m), 3,02 (1H, ddf J=11.9 and 3.8Hz), 3.15 (1H, d, J=8.0Hz)f 3.92 (1H, d, J=13.6Hz), 4.17 (1H, d, J=13.6Hz), 4.32-4.45 (1H, m), 7,15-7.44 (5H, m) MASS (APCI): 236 (M+H)+ -179- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 ___Β7___
ι 7 X 五、發明說明() 製備例84 於含三乙胺(4.32毫升)及(25,4!〇-卜苄基-2-(1-羥基 -1-甲基乙基)-4-羥吡咯嗦(4.87克)之二氯甲烷(50毫升) ,於0t!下加入甲磺酿氯(2.4毫升)。於室溫下攪拌4 小時,加入水中止反應並萃取Μ乙酸乙_(X2)。將結 合有機曆清洗K食鹽水,於硫酸鎂下乾燥,減壓蒸除, 並由矽膠柱層析純化(矽膠,500毫升,甲酵••二氯甲烷 = 4:96)可得(2S,4R)-1-苄基-2 -(1-羥基-1-甲基乙基)-4-(甲磺_氧基)吡咯啶(3·34克)之淡黃色固體。 IR (Neat): 3431, 3402, 1647, 1458 cm"1 NMR (CDCl3r δ): 1.15 (3Η, s), 1.32 (3H, s)f 2.04-2.35 (2H, m), 2.93-3.21 (3H, m), 3.02 (3Hf s), 3.89 (1H, d, J=13.'9Hz), 4·13 (1H, d, J=13.9Hz), 5.14 (1H, br s), 7.23-7.35 (5H, m) MASS (APCI): 314 (M+H)+ 製備例85 於含(2S,4R)-1-苄基-2-(1-羥基-1-甲基乙基)-4-(甲 磺醯氧基)吡咯啶(3.65克)之Ν,Ν-二甲基甲釀胺(36毫升) ,於Ot:下加人NaH(1.12g, 60¾礦物油)。攪拌於室溫下 2.5小時後靜置過夜。Μ甲醇(20毫升)中止反應,攪拌 30分後蒸除。加入水(300毫升)並萃取Μ乙酸乙酿(1〇〇 毫升X 3)。將結合有機層依次清洗Κ水及食鹽水。將有 機曆於硫酸鎂下乾燥,蒸除並由矽膠柱層析純化(矽膠, 125毫升,乙酸乙酿:己烷=5 : 95-20:80)可得(1R,4S)-2 -节基二甲基-鸣 *~5-雙環[2·2·1] -庚燒(2·32 -180- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -------訂-----I II I ^ AWI . 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_
1 7 Q 五、發明說明() 克)之無色油。 IR (Neat): 2978, 1676, 1647^^1 NMR (CDC13, δ): 1.08 (3Η, s) , 1.40 (3Hf s) f 1.73 (lHr dd, J=1.9 and 10.1Hz), 1·92 (1H, ddd, J=l.l, 1·1 and 10.1Hz), 2.30 (1H, dd, J=1 ;6 and 10.5Hz), 2.92 (1H, br s), 2·98 (1H, d, J=10.5Hz>, 3·62 (1H, d, J=13.6Hz), 3.77 (1H, d, J=13.6Hz), 4.36 (1H, br s) f 7.19-7.42 (5H, m) MASS (APCI): 218 (M+H)+ 製備例86 仿例1之方法可得如下化合物。 (2S,5S)-4-(4-氯-2-丁炔基)-2-甲氧甲基-5-甲嗎啉 IR (Neat): 2877, 1454, 1381, 1327 cm"1 NMR (CDC13, 、δ): 1.20 (3Η, d, J=6.3Hz), 1.94-2.14 (2H, m), 2.69-2.79 (2H, m), 3,35 (2Hf t, J=2.0Hz)/ 3.38 (3H, s), 3·38-3·51 (2H, m) ,,3.68-3.81 (2H, m), 4.17 (2H, t, J=2.0Hz) MASS (APCI): 232 (M+H)+ 製備例87 於含3,4-二氫-2卜吡啶井[3,2-1>]-1,4-嘮阱(0.4克) 之Η,Ν-二甲基甲隨胺(5毫升)中分批加入HaH(0.24g, 60¾礦物油)。數分後,滴加人含2-氯甲基-1,3-二噚茂 烷(0.43克)之Η,Ν-二甲基甲醮胺(2毫升)。攪拌2小時 後倒至水及乙酸乙酯。分離有機層,清洗Κ水2次,於 硫酸鎂下乾燥,並減壓蒸除。由矽膠柱層析純化(乙酸 乙酯:己烷=1:1)可得3,4-二氫-4-[(1,3-二鸣S烷-2-基) -1 8 1 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂-------- 509688 A7 B7 18 0 五、發明說明() -甲基]-2卜吡啶井[3,2-1>]-1,4-嘮胼(0.28克)之油。 NMR (CDCl3r δ): 3,30-4.40 (10Η, m)r 5,10 (1H, t, J=4.4Hz), 6.49 (lHf dd, J=4.9 and 7.6Hz)f 6.91 (1H, dd, J=1.5 and 7.6Hz), 7.73 (1H, dd, J=1.5 and 4.9Hz) MASS (APC I) : 223 (M + H) + 製備例88 於含3,4-二氫-4-[(l,3 -二B琴茂烧-2 -基)-甲基]- 2H-吡啶井[3,2-b]-l,4-嗒阱(0.13克)之丙_(10毫升),於 存在對甲苯磺酸(2.24克)下加熱回流3天。減壓濃縮後 倒至飽和碳酸氫納溶液。將水層萃取K乙酸乙_3次, 將結合有機層於硫酸鎂下乾燥後減壓濃縮。由矽膠柱層 析純化(甲醇:二氯甲烷=1:10)。收集含目的化合物部份 並減壓蒸除可得2-[3,4-二氫-2 H-吡啶并[3,2-b]-1,4 -鳄阱-4-基]乙醛(0·09克)之油。 NMR (CDC13/ δ): 3.56 (2Η, t, J=4,.5Hz)f 4.00-4.40 (4H, m), 6.57 (1H, dd, J=5.5 and 8Hz), 6.97 (1H, dd, J=1.4 and 8.0Hz), 7.69 (1H, del, J=1.4 and 5.5Hz), 9.73 (1H, s) MASS (APCI): 179 (M+H)+ _ 製備例89 於含4,5·6,7-四氬瞎吩并[3,2-c]吡啶(0·86克),2 -溴乙醇(0.66克),碳酸鉀(2·58克)及KU3.10克)之Η,Η-二甲基甲釀胺(20毫升)攪拌於70¾下2小時。冷卻後, 加入乙酸乙酯及水。分雛有機曆,清洗Μ水2次,於硫 酸鎂下乾燥並減壓蒸除。由矽膠柱層析純化(甲酵:二氯 甲烷=1:10)。收集含目的化合物部份並減壓蒸除可得5- -182- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂---------% 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7____ 五、發明說明(181) (2-羥乙基)-4,5,6,7-四氫瞎吩并[3,2-c]吡啶(0.53克) 之油。 IR (Neat): 1664, 1456, 1441, 1406, 1360, 1327, 1111, 1065, 1043 cm"1 NMR (DMSO-d6/ δ) : 2.60-3.10 (6H, m) , 3.50-3.90 (4H, m), 6.74 (1H, d, J=5.1Hz)/ 7.10 <1H, d, J=5.1Hz) MASS (APCI): 184 (M+H)+ 製備例90 於含5-(2-羥乙基)-4,5,6,7-四氩_吩并[3,2-c]吡啶 (0· 49克)之二氯甲烷(20毫升)滴加人磺釀氯(0.39毫升) 。攪拌於40 10下1· 5小時。減壓蒸除,碾製Μ二異丙醚 。漶集粉,清洗Μ二異丙醚後減壓乾燥可得5-(2 -氛乙 基)-4,5,6,7-四氫瞎吩并[3,2-c]毗啶鹽酸鹽(〇·44克)。
mp: 205-215°C IR (KBr}: 2667, 2576, 2544, 2467, 2397, 1693, 1645, 1547, 1539, 1516, 1452, 1437, 1184, 1155, 1086, 1066 cin-1 NMR (DMSO-d6, δ): 2·80-4·80 (10H, n〇 厂6:91 (1H, d, J=5.2Hz), 7.49 (1H, d, J=5.2Hz) MASS (ESI): 202.2 (M+H)+ (free) 製備例91 仿製備例90之方法可得如下化合物。
⑴1-(2-氯乙基)-4,4-二氟哌阱鹽酸鹽 mp: 158-159eC IR (KBr" 2700-2300, 1477, 1388 cm一1 NMR (DMSO-d6/ δ): 2·20-2·60 (4H, m), 3·00 (4H, m) , 3 · 55 (2H, t, J=7.0Hz), 4.07 (2H, t,, J=7.0Hz) 一 183- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 __B7__ 1 〇 ο 五、發明說明() (2) (2S) -4 -(2-氯乙基)_5,5-二甲基-2-(甲氧甲基)-嗎啉 鹽酸鹽 IR(KBr): 1562, 1558, 1547, 1539, 1516, 1498, 1464, 1456, 1198, 1180, 1126, 1105, 1041 citT1 NMR (DMSO-dg, δ): 1.41 (3H, s), 1.54 (3H, s), 2.60-4.70 (14H, m) MASS (APCI) : 222 (M+H)4* (free) 製備例92 仿製備例7之方法再仿製備例90之方法可得如下化合 物0 (1) (3S,5S)-4-(2-氯乙基)-3,5-二甲嗎淋鹽酸鹽 mp: 190-195eC (decomp·) IR (KBr): 1516, 1454, 1398, 13,71, 1342, 1250, 1205, 1153, 1132, 1103, 1974, 1024 cm·1 NMR (DMSO-dg/ δ): 0.90-1.50 (6Hf m) , 3.00-4.50 (10Hf m) MASS (APCI): 178 (M+H)+ (free} ⑵順-4-(2-氯乙基)-3,5-二甲嗎啉鹽酸鹽 mp: 70-80°C (decomp·} IR (KBr): 2559, 2478, 2407, ,1477, 1466, 1454, 1429, 1390, 1146, 1120,,1074, 1030 cirT1 NMR (DMSO-dg, δ): 1,27 ( 6H, J=6 · 1Ηζ> , 3 · 20-4 · 40 (10H, m) , 11·58 (1H, br s) MASS (APCI): 178 (M+H)+ (free) ③(2R)-4-(2 -氯乙基)-2-(甲氧甲基)嗎啉鹽酸鹽 P : 150-155 ¾ (分解) -184- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ---I---^訂---11---- 輾 509688 A7 B7_ 1 ο ο 五、發明說明() [a]g7·5: -9.69° (C=0.485, MeOH) IR (KBr): 2673, 2590, 2476, 1516, 1477, 1454, 1400, 1201, 1132, 1107, 1084 cm,1 NMR (DMSO-d6, δ): 2·80-3·20 (2H, m),3.28 (3H, s), 3.30-4.40 (11H, m) MASS (APCI): 194 (M+H)+ (free) 製備例93 將含(2S)-2-(甲氧甲基)嗎啉鹽酸鹽(0.5克),1-溴 -3-氯丙烷(1·47毫升)及碳酸鉀(2.06克)之Ν,Η-二甲基 甲醯胺(6毫升)攪拌於室溫下1小時。加入乙酸乙_及 水,分雛有機層,清洗Μ水2次,於硫酸鎂下乾燥並減 壓蒸除。由矽膠柱層析純化(乙酸乙酯)。收集含目的化 合物部份並減壓蒸除。將油處理Μ 4Ν鹽酸-乙酸乙酿可 得(2S)-4-(3 -氯丙基)-2-(甲氧甲基)嗎啉鹽酸鹽(0.44 克)。 mp: 165-170°C (decomp.)二 IR (KBr): 1547, 1539, 1516, 1454, 1192, 1142, 1111, 1092, 1066 cnT1 NMR (DMSO-dg, δ): 2.10-2.40 (2H, m) , 2.70-4.20 (16H, m)f 11.53 (1H, br s) MASS (APCI): 208 (M+H)+ (free) 製備例94 仿製備例93之方法可得如下化合物。 (1) (2S)-4-[(E)-4-氯-2-丁炔基-2-(甲氧甲基)_嗎啉鹽 酸鹽 -185- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂----------線屬 經濟部智慧財產局員工消費合作社印製 509688 A7 B7 18 4 五、發明說明() IR (Neat): 1722, 1450, 1400, 1360, 1286, 1255, 1201, 1136, 1090, 1030 cm—1 (請先閱讀背面之注意事項再填寫本頁) NMR (DMSO-dgf δ): 2·60-3·60 (10H, m), 3·60-4·20 (4H, m), 4·28 (2H, d, J=5.9Hz), 5.80-6.30 (2H, m), 11·87 (1H, br s) MASS (APCI): 220 (M+H)+ (free) (2) (2S)-4-[4-氯-2-丁炔]-2-(甲氧甲基)-嗎啉鹽酸鹽 mp: 70-75oC (decomp·) IR (KBr): 1516, 1464, 1454, 1427, 1398, 1273, 1194, 1136, 1086, 1032,cnT1 NMR (DMSO-d6/ δ): 2.60-4.80 (16H,. m) MASS (APCI): 218 (M+H)+ (free) 製備例95 仿製備例27之方法可得如下化合物。 乙醮胺基-2-(4-节氧基-3-甲氧节基)丙二酸二乙酯
mp: 105-106eC IR (KBr): 3224, J977, 17§2, 1635, 1519, 1301, 1236 cnT1 NMR (CDC13, δ): 1·29 (6H, t,,J=7.2Hz), 2·02 (3H, s), 3.58 (2H, s), 3.82 (3H, s)f 4.12-4.32 (4H, m), 5.11 (2H, s), 6.48 (1H, dd, J=2,0 and 8.1Hz), 6·55 (1H, 經濟部智慧財產局員工消費合作社印製 d, J=2.0Hz), 6.56 (1H, s) , 6.76 (1H, d, J=8.1Hz), / 7.29-7.40 (5H, m) / MASS (APCI): 444 (M+H)+, 402, 354 製備例96 仿製備例28之方法可得如下化合物。 (D,L)-H-乙醸基-4-苄氧基-3-甲氧基-DL-笨丙胺酸 -1 8 6 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A7
509688 五、發明說明(185)
mp: 125.0-130.0°C IR (KBr): 3316, 3200-2500, 1714, 1652, 1544 cnT1 NMR (DMSO-dg, δ): 1.7 9 (3H, s) , 2.76 {IE, del, J=9.6 and 13.7Hz), 2·96 (1H, ddf J=4.8 and 13.7Hz), 3.74 (3H, s), 4.35-4.37 (1H, m) , 5,02 (2H, s.) , 6.71 (1H, dd, J=1.8 and 8.2Hz), 6.86 (1H, d, J=1.8Hz), 6.92 (1H, d, J=8.2Hz), 7.31-7.45 (5H, m), 8·15 (1H, d, J=8.0Hz)r 12.63 (lHf br s) MASS (APCI): 344 (M+H)+, 302 製備例97 (D)-H-乙釀基-4-节氧基-3-甲氧基-D-苯丙胺酸
【a]g6: -14·3β (C=0.5, DMF) mp: 148.0-149.0°C IR (KBr): 3324, 3200-2700, 1741, 1616, 1550, 1513, 1398 cm"1 NMR (DMS0_d6, δ): 1.79 (3H, s) , 2.76 (1H, dd, J=9,2 and 13.9Hz)# 2.97 (1H, dd, J=4.8.and 13.9Hz), 3.74 (3Hf s), 4.31-4,42 (1H, m), 5.02 (2H, s) f 6.71 (1H, dd, J=1.8 and 8.2Hz), 6.86 (1H, d, J=1.8Hz), 6.92 (1H, d, J=8.2Hz), 7.28-7.45 (5H, m), 8.14 (1H, d, J=8.2Hz}, 12.85 (1H, br s) MASS (APCI): 344 (M+H)+, 3J2 製備例98 仿製備例17之方法可得如下化合物。
4-羥基-3-甲氧基-D-苯丙胺酸鹽酸鹽 mp: 188-200eC IR (KBr): 3500-3150, 2700-2300, 1739, 1589, 1488 enT1 NMR (D20, δ): 3.13 (1H, dd, J=7.6 and 14.6Hz), 3.28 (1H, dd, J=5.8 and 14·6Ηζ), 3.85 (3H, s) , 4.28 (1H, dd, J=5.8 and 7.6Hz), 6.77-6..95 (3Hf m) MASS (APCI) : 212 (M+H)4*, (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-187 - I--I----I I I I I I ^ ·111111! (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 五、發明說明(186) 製備例99 將二碳酸二第三丁酯(2.55克)加至含4-羥基-3-甲氧 基-D-苯丙胺酸鹽酸鹽(2.2克)及三乙胺(2.9毫升)之 丙嗣(25毫升)及水(25毫升)。攪拌於室溫下5小時後, 稀釋K水並萃取Μ乙酸乙酯。分雛有機層,於硫酸鎂下 乾燥並減壓蒸除可得Η-第三丁氧羰基-4-羥基-3-甲氧基 -D-苯丙胺酸(2·6克)之油。 NMR (CDC13,'5): 1·42 (9Η, s), 2.82-3ς20 (2Η, m), 3·83 (3Η, s) , 4,20-5.50 (2H, m) , 6.56-6.68 (2H, m), 6.83 (1H, d, J=8.5Hz), 7.23 (1H, s) MASS 《APCI): 212 (M+H-Boc)+, 195 製備例100 將苄基溴(2.34毫升,19.8毫升)加至含第三丁氧羰 基-4-羥基-3-甲氧基苯丙胺酸(3.44克)及Ν,Η-二異 丙基乙胺(3·85毫升)之Ν,Η-二甲基甲釀胺(20毫升)。攪 拌於室溫下6小時後,稀釋Κ水並萃取Κ乙酸乙酿。分 雛有機層,於硫酸鎂下乾燥並減壓蒸除。由矽膠柱層析 純化(己烷·•乙酸乙酯=4:1)可得(2R)-2-(第三丁氧羰胺 基)-3-(4-羥基-3-甲氧苯基)丙酸苄酯(2·98克)之無色 粉。 IR (KBr): 3438^ 3378, 2700-2300, 1725? 1683, 1521/ 1488 cm-1 NHR (CDC13, δ>: 1·41 (9H, s>, 3·03 《2H,山 J=5.8Hz}, 3·76 《3H, s), 4·45-4-55 (1H, m), 4·95-5·05 (1H, m>, 5.09 (1H# d, J=12.5Hz)# 5.18 (1H# d, J=12.5Hz), 5.53 (lHf s), 6.56-6.68 (2H, m) , 6·76 (lHf df J=8.0Hz), 7.25-7.36 (5H, m) HASS (APCI" 302 (M+H-Boc) + __188—_ 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注意事項再填寫本頁) -1®^ 訂 - - - ------· 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明() 製備例101 將4H鹽酸於1,4-二鸣烷(9毫升)加至含(2R)-2-(第三 丁氧羰胺基)-3-(4-羥基-3-甲氧苯基)丙酸苄酯(2.90克) 之二氯甲烷(29毫升)冰水溶液。攪拌於同溫下2小時後 減壓濃縮可得(2R)-2-胺基-3-( 4-羥基-3-甲氧苯基)丙 酸苄酿鹽酸鹽(2.8克)之油。 NMR (DMSO-dg, δ): 3.00-3,10 (2Η,,m), 3·70 (3Η, s), 4·31 (1Η, t, J=6.2Hz), 5·18 (2H,,s), 6·54 (1Η, dd, J=1.7 and 8.0Hz), 6,68 (lHr df J=8..0Hz)f 6·81 (1H, d, J=1.7Hz), 7·29-7·39 (5H, m), ·8·57 (3H, br s), 8·97 (1H, s> MASS (APCI): 301 (M+H)+ (free) 製備例102 仿製備例19之方法可得如下化合物。 (2R)-2-[N-(氯乙醯基)胺基]-3-(4-羥基-3-甲氧苯基) 丙酸苄_ 製備例103 仿製備例20前半段之方法可得如下化合物。 (21〇-2-[11-[(苄胺基)乙釀基]胺基]-3-(4-羥基-3-甲氧 苯基)丙酸苄酯 製備例104 仿製備例20第二部份之方法可得如下化合物。 (3R)-1-苄基-3-(4-羥基-3-甲氧苯基)哌畊-2,5-二酮 -189- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I-------------------訂-------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 1 Ο Ο 五、發明說明()
[a]g6: -5.2° (C=0.5, DMF) mp: 225.0-226.0°C (請先閱讀背面之注意事項再填寫本頁) IR (KBr): 3335, 1677, 1515, 1463, 1276, 1185 cnT1 NMR (DMSO-d6/ δ): 2.73 (1H, d, . J=17·2Hz), 2·78 (1H, dd, J=4.6 and 13.6Hz), 3.04 (1H, dd, J=4.6 and 13.6Hz), 3·42 (1H,山 J=17.2Hz), 3·66 (3H, s), 4·28 (1H, m), 4.27 (1H, d, J=14.6Hz), 4.47 (1H, d, J=14.6Hz)r 6.43 (1H, ddr J=1.8 and 8.0Hz),.6.54 (1H, d, J=8.0Hz), 6.67 (1H, d, J=1.8Hz), 7,05-7.31 (SHm), 8.31 (1H, br s), 8.84 (1H, s) MASS (APCI): 341 (M+H)+ 製備例105 經濟部智慧財產局員工消費合作社印製 將鋁氫化鋰(614毫克)於室溫下加至含(3R)-1-苄基-3-(4-羥基-3-甲氧苯基)哌阱-2,5-二_ (1.1克)之四氫 呋喃(40毫升)。攪拌回流5小時,於氮氣下處理Μ 2N HaOH(5毫升)。稀釋Κ水U0毫升),於冰冷卻下滴加入 3,5-雙(三氟甲基)苄釀氯(1·6毫升)。攪拌30分,萃取 Μ乙酸乙酯。分雛有機層,於硫酸鎂下乾燥並減壓蒸除 。由矽膠柱層析純化(己烷:乙酸乙酯=4:1),可得目的 (2R )-4-苄基-1 - [3,5-雙(三氟甲基)苄醯基]-2-(4-羥基 -3-甲氧苄基)哌阱及其3,5-雙(三氟甲基)苄酸鹽,其可 由處理KIN NaOH及甲醇轉為其目的化合物。 NMR (CDC13/ δ): 2.20-4.55 (14Η, m), 6.20-7.90 (12Η, m) MASS (APCI): 553 (M+H)+ 製備例106 於30分內及低於ίου之下,將三氟甲磺酸酐(5.25毫 一 190- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A7 ^^____B7______ 五、發明說明(189) 升)滴加至含(2R)-4-苄基- l-[3,5-雙(三氟甲基)苄醯基] 〜2-(4-羥基-3-甲氧苄基)哌阱(14.3克)及4-(二甲胺基) 吡啶(0.47克)及2,6 -處替啶(3.6毫升)之二氯甲烷(150 奄升)冰水溶液。搅拌於同溫下2小時,倒至水中。Μ 稀釋鹽酸調至ρΗ7 ,分雛有機層,於硫酸鎂下乾燥並減 艇蒸除。由矽膠柱曆析鈍化(甲苯:乙酸乙酯=100:1-5:1) 可得目的三氟甲磺酸酐4-[[(2R)-l-[3,5-雙(三氟甲基) 节醜基]-4-苄基]W阱-2-基]甲基]-2 -甲氧苯酯油。 製備例107 將C0於室溫下Μ吹泡引入至含三氟甲磺酸酐4 - [[(2R) _1-[3,5-雙(三氟甲基)苄酿基]-4-苄基]哌哄-2-基]甲 基卜2-甲氧苯酯(15.0克),乙酸鈀(150毫克),1,3-雙 (二苯鱗基)丙烷(275毫克)及三乙胺(4 .28毫升)之甲醇 (30毫升)及Η,Ν-二甲基甲醢胺(75毫升)1小時。回溫至 70¾,於C0下攪拌3小時。瀘經Celite,清洗Μ乙酸乙 _。結合濾液及洗液並減壓蒸除。溶於乙酸乙_並依次 清洗Μ水及食鹽水,於硫酸鎂下乾燥,並減壓蒸除。由 矽膠柱曆析純化(甲苯-己烷)。收集含目的化合物部份 並減壓蒸除可得漿液,將其處理Μ 4Ν鹽酸_乙酸乙酯可 得4-[[(21〇-1_[3,5-雙(三氟甲基)节醯基]-4-:1?哌阱-
2-基]甲基]-2-甲氧苄酸甲酿鹽酸鹽(7.71克)之粉。 mp: 100-102eC IR (KBr): 3335, 1720, 1648, 1614, 1459, 1427, 1185 citT1 NMR (DMSO-dg, δ): 2·95-5·20 (11H, m) , 3.41 (3H, s) , 3.75 (3H, s), 6.40擊8·25 (11H, m),, 11·50-11·80 (1H, m) MASS {API-ES): 617 (M+Na, free)' 595 (M+H, free)+ -191- 本紙張尺度適用中國國家標準(CNS)A4規格(21G x 297公釐) — ---- (請先閱讀背面之注意事項再填寫本頁) -a -I i·— ϋ I 一 1__1 ϋ 1 -I- n 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1 Q 〇 五、發明說明() 製備例108 仿製備例22之方法可得如下化合物。 4-[[(2R)-1-[3,5-雙(三氟甲基)苄醢基]-4-苄哌阱-2- 基]甲基]-2-羥苄酸甲酯 IR (Neat): 1677, 1643, 1438,.1280 crrT1 NMR (CDC13/ δ): 2.00-5.10 (HHf m) , 3.93 (3H, s) f 6·20-7.90 (11H, m) , 10.71. (1H, br s) MASS (API-ES): 603 (M+Na)+, 581 (M+H)+ 製備例109 將第三丁二甲矽烷基氯(2.34克)於室溫下加至含4-[[ (2R)-1-[3,5-雙(三氟甲基)苄醯基]哌畊-2-基]甲基]-2-羥苄酸甲酷(2.56克),4-(二甲胺基)吡啶(126毫克) 及三乙胺(2.51毫升)之二氯甲烷(50毫升)。攪拌於室溫 下15小時,再加入三乙胺(2.51毫升)及第三丁二甲矽烷 基氯(2.34克),攪拌1天。加入水(200毫升)並萃取Μ 二氯甲烷。將有機層依次清洗Μ水及食鹽水,於硫酸鎂 下乾燥,並減壓蒸除可得粗製油。由矽膠柱層析純化 (二氯甲烷及甲醇)可得4-[[(2R)-1_[3,5-雙(三氟甲基) 苄醯基]_畊-2-基]甲基]-2-(第三丁二甲矽烷氧基)苄 酸甲酯(1 · 72克)。 IR (Neat}: 2955, 1727, 1639, 1436, 1280 ατΓ1 NMR (CDC13/ δ): 0.10-0-30 (6Η, m), 1.00 (9Hf s), 2.80-5.10 (9H, m), 3.85 (3H, s), 6.30-7.90 (6H, m) MASS (APCI): 605 (M+H)+, 573, 491 製備例110 於含(2R)-2-第三丁氧羰胺基-3-(4-甲氧苯基)丙酸 -192- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
509688 A7 B7 1 Q 1 五、發明說明() (5.14克)之二氯甲烷(50奄升)中,於冰浴冷卻下加入三 乙胺(8·49毫升),Ν-苄基甘胺酸苄酯鹽酸鹽(5.08克), 及2 -氯-1-甲吡錠碘(4.89克)。搅拌於室溫下90分,減 壓濃縮,於攪拌下加入乙酸乙酯(50毫升)及水(50毫升) ,Μ稀釋鹽酸調至ΡΗ1 。分雛有機層,清洗Κ食鹽水, 於硫酸鎂下乾燥,並減膣濃縮。由矽膠柱層析純化(矽 膠,100g;甲苯:乙酸乙_=10:1)。收集含目的化合物 部份並減壓蒸除可得N-苄基(苄氧羰甲基)-(2R)-2-(第三丁氧羰胺基)-3-(4-甲氧苯基)丙醯胺(8·57克)之漿液。 [a]g4·0: +6.60。 (C=0.50, MeOH) IR (Neat): 3300, 1740, 1700, 1650, 1240 cm"1 NMR (DMSO-dg, δ): 1.27 and 1-31 (9Hf s, s), 2.76 (2H, m), 3.69 and 3.70 (3H, s, s), 3.95-4.90 (5H, m), 5.13 《2H, m), 6·70-7·36 (15H, n〇 MASS (APCI): 533 (M+H)+ 製備例111 將4H鹽酸於1,4-二鸣烷(48毫升)於冰浴冷卻下滴加至 含N-苄基-NM苄氧羰甲基)-(2R)-2-(第三丁氧羰胺基)-3 -(4-甲氧苯基)丙藤胺(8·48克)之二氯甲烷(48毫升)。 於同溫下攪拌2小時後減壓濃縮。加至重碳酸鈉溶液 (50毫升)及二氯甲烷(50毫升),分雛有機層•清洗Μ 食鹽水,於硫酸鎂下乾燥,再減壓蒸除可得(3R)-1-苄 基-3-(4-甲氧苄基)哌阱-2,5-二_ (3.65克)之粉。 一193- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
-0 n «I n n· n 11 ϋ 一 I m ϋ _1 BB_i ϋ ·Μ·1 1··· I 經濟部智慧財產局員工消費合作社印製 ^^688
五、發明說明(192) talg7·9: -38^.60 (C=Q.50, MeOH) IR (Nujol) : 3250, 1680, 1640, 1,245 cm-1 (請先閱讀背面之注意事項再填寫本頁) NMR 《DMSO-d6, δ): 2·60 (1H, d, J=17Hz), 2·80 《1H, dd, J=4.7 and 14Hz), 3·09 (1H, dd, J=3.8 arid 14Hz), 3.46 (1H, d, J=17Hz), 3·67 (3H, s), 4·11 (1H, d, J=14Hz), 4·22 (1H, br), 4·65 (1H, d, J=14Hz), 6:63 (2H, d, 6.93 (2H, d, J=8.7Hz), 7.10-7.40 (5H, m), 8·30 (1H, br) MASS (APCI): 325 (M+H)+ 製備例112 於氮氣下,於含鋁氫化鋰(0.85克)之四氩呋喃(65毫 升)中,於冰浴冷卻下分批加人(3R)-1-苄基-3-(4-甲氧 苄基)哌阱-2,5-二_(3.65克)。回流攪拌1小時。冷卻 後,依次加人水(0·85毫升),15S!Ha0H(0.85毫升),及 水(2.5毫升)Μ中止反應,搅拌於室溫30分。濾除不溶 物,將漶液加至乙酸乙_(50毫升)及食鹽水(70毫升)。 分雛有機層,於硫酸鎂下乾燥,並減壓濃縮可得(2R) - 2-(4-甲氧苄基)-4-苄哌胼(3.51克)之漿液。 IR (Neat): 3250, 1240 cm-1 NMR (DMS0-d6, δ): 1·60-2·00 (4Η, m) , 2·40-2·90 (5Η, m), 3·30-3·50 (2Η, m), 3·70,(3Η, 6·81 (2Η, d, 經濟部智慧財產局員工消費合作社印製 J=8.6Hz), 7·07 (2Η, d, J=8.6Hz), 7·15-7·40 (6Η, m) MASS (APCI): 297 (M+H)+ 製備例113 於含3·5-雙(三氟甲基)苄酸(3·04克)及吡啶(0.030毫 升)之四氫呋喃(9毫升),於5分內滴加入草醜氯(1·80 克),加熱至5510並攪拌1小時。冷卻後,於低於5ti及 30分內及於氮氣下滴加至含(2R)-2-(4-甲氧苄基)-4-苄 -194- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 五、發明說明() 哌阱(3·47克)及三乙胺(3·55克)之二氯甲烷(35毫升)。 攪拌於室溫1小時並減壓濃縮。於攪拌下加入乙酸乙酯 (請先閱讀背面之注意事項再填寫本頁) (40毫升)及水(20毫升)。分雛有機層,清洗Μ食鹽水, 並於硫酸鎂下乾燥。蒸除溶劑後由矽膠柱層析鈍化(矽 膠70g;甲苯:乙酸乙酯=5:1)。收集含目的化合物部份 並減壓蒸除可得(2R)-l-[3,5-雙(三氟甲基)苄醜基]-2- (4-甲氧苄基)-4-苄哌畊(5·03克)之漿液。 ta]^8·0: -21.4° (C=0.50, MeOH) IR (Neat): 1740, 1640, 1270 cm—1 NMR (DMSO-d6/ δ): 1.70-2.40 (3H, m) f 2.60-3.80 (11H, m), 6.60-7.60 (10H, m), 7.65-8.55 (2H, m) MASS (APCI): 537 (M+H)+ 製備例114 於含(2R)-1 - [3,5-雙(三氟甲基)节釀基]-2-(4-甲氧 苄基)-4-苄哌阱(4·90克)之乙酵(50毫升),於氮氣下加 入水(5毫升),甲酸銨(1.44克),及10iKPd-C(50!K溼, 0.49克)。加熱至601C並攪拌2小時。滤除不溶物,將 濾液減壓濃縮。加入乙酸乙_ (40毫升)及水(40毫升), 經濟部智慧財產局員工消費合作社印製 分雛有機層,清洗K食鹽水,並於硫酸鎂下乾燥。蒸除 溶劑後由矽膠柱曆析純化(70g;乙酸乙酯:甲醇=10:1) 。收集含目的化合物部份並減壓蒸除可得(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(4-甲氧苄基)哌畊(3·18克)之 漿液。 [α]^8·1: -32.6° (C=0.50, MeOH) IR (Neat): 3300, 1630, 1280 cm^1 NMR (DMSO-dg, δ): 2.40-3.55 (9H, m), 3.72 (3H, s), 6.70-8.45 (7H, m) MASS (APCI): 447 (M+H)+ _-195-_ 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 8
經濟部智慧財產局員工消費合作社印制衣 五、發明說明(194) 製備例115 仿製備例56之方法可得如下化合物。 (1) (2R)-4-苄基-1-(第三丁氧羰基)-2-[4-(三氟甲基)苄 基]哌阱 _ (CDC13, δ>: 1·36 (9H, s), 1·98 (1H, dd, J=11.5 and 3.7Hz), 2.10 (1H, td, J=12,0 and 3.4Hz), 2·58 (1H, d, J=11.5Hz), 2.83-3.13 (3Hf m), 3.20 (1H, td, J=12.8 and 3·4Ηζ), 3,26 (1H, d, J=12.8Hz)f 3,58 (1H, d# J=12.8Hz), 3.80-4.30 (2^f m) f 7.12 (2H, df J=7.7Hz), 7.26-7.42 (7H, m) MASS (APCI): 435 (M+H)+ (2) (2R )-4-苄基-2 -(4-氯-3-甲氧苄基)-1-(第三丁氧羰 基)哌畊 IR (Neat): 1516, 1458, 1400, 1327,·1275, 1217, 1169 cm·1 NMR (CDC13, δ) : 1·39 (9H, s) , 1·95,2·13(2Η,ιη),2·60-3.24 (5H, m), 3.32-3.57 (2Uf m), 3.79 (3H, s), 3.90㈣4.14 (2H, m), 6.52-7.35 (8H, m) MASS (APCI); 415 (M+H)+ (3) (2R)-4-苄基-1-(第三丁氧羰基)-2-[4-氯-3-(第三丁 二甲矽烷氧基)苄基]哌阱 IR(Neat): 1695,1480,1415,1250,1170cm-1
构(35,45)-1-(第三丁氧羰基)毗咯啶-3,4-二醇 mp: 156-158eC IR 《KBr): 3398, 3334, 1662, 1431, 1174, 1122, 1082, 985 ατΓ1 NMR (DMSO-dg, δ): 1.42 (9H, s)/ 3.10 (2H, br d, J=11.3Hz)/ 3.25-3.44 (2H,,m), 3.86 (2H, br s) f 5.05 (2H, d, J=3,2Hz) MASS (ES+): 429·3 (2M+Na)+, 226·2 (M+Na)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) (請先閱讀背面之注咅?事項再填寫本頁)
509688 A7 B7_ 1 Q ς 五、發明說明() 製備例116 仿製備例37之方法可得如下化合物。 (D4-[[(2R)-l-[3,5-雙(三氟甲基)苄醜基]哌胼-2-甲基] -2-經苄酸甲酯 IR (Neat): 3083, 1677, 1639, 1438, 1280 cnT1 (2) (2R)-1 -[3,5-雙(三氟甲基)苄醯基]-2-[3 -(第三丁二 甲矽烷氧基)-4-氯苄基]哌阱
mp: 95-97°C IR {KBr): 1954, 1628, 1481, 1437 cm-1 NMR (CDC13^5): 0.17 (3H, s) , 0.20 (3H, s) , 1.01 (9H, s), 2·50義5·10 (9H, 6·30-7··70 (5H, m), 7·87 (1H, s) MASS (APCI): 581 (M+H卜 (3) (2R)-2-[3-(第三丁二甲矽燒氧基)- 4 -氯节基]-l-[3 - 氯-5-(三氟甲基)苄醯基]哌阱 IR (Neat): 2954, 2933, 1635, 1483, 1419 cnT1 NMR 《CDC13, δ): 0.18 (3Η, s), 0.21 (3Η, s), 1.02 (9Η, s), 2.50-5.20 (9Η, m), 6·20τ7·70 (6Η, m) MASS (APCI): 547 (M+H)+ ⑷(2R) - 1-(第三丁氧羰基)- 2-[4-氯-3 -(第三丁二甲矽 烷氧基)苄基]哌畊 經濟部智慧財產局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) NMR (DMSO^dgr δ) : 0.99 (9Η, s) f 1.24 (9H/ s) , 2.15 (6H, s), 2.20-4-10 (9H, m), 6.78-7.33 (3H, m) MASS (APCI): 441 (M+H)+ 製備例117 仿製備例24之方法可得如下化合物。 ⑴(2R) -1-(第三丁氧羰基)-2-[4-(三氟甲基苄基]哌阱 -197- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) J^688
經濟部智慧財產局員工消費合作社印製 五、發明說明(196)
mp: 61-62°C IR (KBr): 2981, 2952, 1682, 1417, 1330 cm-1 NMR (CDC13, δ>: 1·33 (9H, s), 2.67-4.40 (9H, m), 7·35 (2H, d, J=8.0Hz), 7·54 (2H, d, J=8.0Hz) MASS (ESI): 345.3 (M+H)+, 289.2 (M-Bu)+ (2) (210-2-(4-氯-3-甲氧苄基)-1-(第三丁氧羰基)毈畊 IR (Neat): 1689, 1515, 1414, 1273, 1165, 1115 cnT1 NMR (CDC13/ δ): 1.38 (9H, s), 2.70-3,14 (8H, m), 3.87 (3H, s), 3.88-4.18 (2Hf m) , 6.74-7,26 (3H, m) MASS (APCI); 225 (M-Boc+l)4*, 269 (M-tBu+l) + (3) (2R)-l-[3-(二甲胺磺醜基)-5-(三氟甲基)-苄酿基]_ 2-[4-(三氟甲基)苄基]哌阱 IR (KBr): 2956, 1639, 1462, 1423, 1329 citT1 NMR (CDC13/ δ): 2.60-5.20 (9H, m), 2.72 (6H, s), 7.00-7.60 (5H, m), 7.67 (1H, s\f 8.00 (1H, s) MASS (APCI): 524 (Μ+Η)+ (4) (2R)-l-[3-(甲胺磺釀基-5_(三氟甲基)苄醮基]-2-[4 Μ三氟甲基)苄基]哌阱鹽酸鹽
mp: 94.5-101°C IR (KBr): 3433, 1645 cm"1 NMR (DMSO-d6/ δ): 2.80-5.30 (12H, m), 7·00-8·31 (7H, m) MASS (APCI): 495 (M+H)+ (free) (5) (2R)-2-(3-第三丁二甲矽烷氧基-4-甲苄基)-l-[3-甲 氧基-5-(三氟甲基)苄釀基]__ IR (KBr): 2956, 2935, 1641, 1606 cm-1 NMR (CDC13, δ): 0·14, 0·17 (6H, s), 0·99 (9H, s), 2.15 (3Η, s), 2·50-5·20 (9Η, m), 3·81 (3Η, s), 6.75-7.13 (6Η, m) MASS (APCI): 523 (M+H)+ -1 9 8 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) —------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 1 q 7 五、發明說明() 製備例118 仿例1之方法但使用Ν,Ν-二異丙基乙胺取代碳酸鉀之 鹼可得如下化合物。 ⑴(2R)-l-(第三丁 氧羰基)-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]- 2-[4-(三氟甲基)-苄基]哌阱 IR (KBr): 2974, 2935, 2814, 1693 cm*1 NMR (CDC13/ δ) : 1.35 (9Η, s), 2.04-2.17 (2Η, m), 2.50-4.30 (17Η, m), 7·07 (1Η, dd, J=4.8 and 7·6Ηζ), 7·27-7·34 (3H, m), 7·50 (2士 d, J=8.0Hz), 8·40 (1H, d, J=4.8Hz) MASS (APCI): 505 (M+H)+ (2) (2R)-l-(第三丁氧羰基)-4 - [2-(順-2,6 -二甲嗎啉基) 乙基]-2-U -(三氟甲基)苄基]-哌阱 IR (Neat): 2974, 1693, 1680 cm’1 NMR (CDC13, δ): 1·19, 1·20 (6H,山 J=6.2Hz), 1·32 (9H, s), 2.02-2.21 (4Η, m) , 2.71-3.31 (11H, m), 3.90-4.50 (4H, m), 7.34 (2H, d, J=7.9Hz), 7.54 (2H, d, J=7.9Hz) MASS (APCI) : 486 (M+H) + (3) (21〇-1-(第三丁氧羰基)-4-[2-[(25)-2-(甲氧甲基) 嗎啉基]乙基]-2-[4-(三氟甲基)-苄基]哌畊 IR (Neat): 3438, 2816, 1691 cnfl NMR (CDCl3f δ): 1.33 (9Η, s) , Ζ.02-4.30 (22Η, m), 3.37 (3Hf s), 7.35 (2Η, d, J=8.0Hz), 7.54 (2H, d, J=8.0Hz) MASS (APCI): 502 (M+H)+ (4) (2R)-2-(4-氟-3-甲氧苄基)-1-(第三丁氧羰基)-4-[2 -(順-2,6-二甲嗎啉基)乙基]_畊 -199- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 _B7_ 1 q « 五、發明說明() IR (Neat): 1515, 1458, 1414, 1367, 1323, 1115, 1086 cm"1 NMR (CDC13, δ): 1·14 (6H, d, J=1.2Hz), 1·40 (9H, s), 1-70-2.10 (4H, m), 2.36-3.20 (12H, m), 3.61-4.18 3.88 (3H, s>, 6.7 4-7.02 (3H, m> MASS (APCI): 466 (M+H)+ (5) (2R)-2-(4-顛-3-甲氧苄基)-1-(第三丁氧羰基)-4-[2 -[(2S)-2-(甲氧甲基)嗎啉基)-乙基]哌畊 IR (Neat): 1516, 1456, 1414, 1273, 1165, 1111, 1036 cnT1 NMR (CDCl3r δ): 1.40 (9H, s) f 1.90-4.25 (22H, m), 3.38 (3H, s), 3·87 (3H, s), 6·69-7·27 (3H, m) MASS: 482 (M+H)+ (6) (2R)-2-(4-氟-3-甲氧苄基)-1-(第三丁氧羰基)-4 - [2 -(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]哌阱 NMR (DMSO-dg/ δ): 1.40 (9Η, s), 1.99-2.15 (2H, m), 2.51-3.18 (14H, m), 3.67-4.18 (3H, m), 3.86 (3H, s), 6,73-8.40 (6H, m) MASS: 485 (M+H)+ ⑺(2R)-l-(第三丁氧羰基)-2-(4-氯-3-羥苄基)-4-[2-[ (2S)-2 -(甲氧甲基)嗎啉基]-乙基]哌畊 製備例11 9 仿製備例41之方法可得如下化合物。 ⑴(2R)-4-苄基-1-[3 -(二甲胺磺_基)-5-(三氟甲基)苄 釀基]_2-[4-(三氟甲基)苄基]哌畊 IR (Neat): 1645, 1456, 1419, 1319 cm—1 NMR (CDC13, δ): 2.00-2.40 (2Η, m) f 2.70-5.10 (9H, m), 2·73 (6H, s), 6·90-7·60 (10H, m), 7·73 (1H, s), 8.01 (1H, s) MASS (APCI): 614 (M+H)+ 一200- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) --------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_
1 Q Q 五、發明說明() ⑵(2R)-4-苄基- l-[3-甲胺磺釀基-5-(三氟甲基)苄驢基] -2-[4-(三氟甲基)苄基]喊阱 (請先閱讀背面之注意事項再填寫本頁) NMR (CDC13, δ): 2.00-2.40 (2Η, .m) f 2.70-3.71 (8H, m), 3.06 (3H, s) f 4.50-5.10 (1H, m) , 6.80-7.60 (10H, m), 7.86 (1H, s>, 8.19 (1H, s) MASS (APCI): 585 (M+H)+ ’ (3) (2R )-1-[3,5-雙(三氟甲基)苄醯基]-4-苄基-2-[3-( 第三丁二甲矽烷氧基)-4-氯苄基]哌阱 IR (Neat): 2935, 2860, 2812, 1645, 1483, 1423 citT1 NMR (CDCl3f δ): 0.10-0.30 (6Hf br)f 1.00 (9H, s), 1.80- '5.10 (11H, m), 6.20-8.00 (10H, m), 7.87 (1H, s) MASS (APCI): 671 (M+H) + ⑷(2R)-4-苄基-2 - [3-(第三丁二甲矽烷氧基)-4-氯苄基] -1-[3-氯-5-(三氟甲基)苄醯基]哌阱 IR (Neat): 2935, 1641, 1483, 1417 cm-1 NMR (CDC13/ δ): 0.10-0.30 (6Η, br), 1·01 (9Η, s), 1.80- 5.00 (11Η, m), 6.20-7.70 (10Η, m), 7.59 (1H, s) MASS (APCI): 637 (M+H)+ ® (2R)-4-苄基-2 - [3-(第三丁二甲砂烷氧基)-4-氯苄基] -1-[3-甲氧基-5-(三氟甲基)苄_基]-_胼 IR (KBr): 1643, 1464, 1421, 1267 cm·1 經濟部智慧財產局員工消費合作社印制衣 NMR (CDCI3/ δ): 0.09 (6Hf|br s)f 0.98 (9H, s), 2.04-2.21 (2H, m), 2.14 (3E, s), 2.60-5.10 (12Hf m)f 6.24-7.36 (11H, m) HASS (APCI): 613 (M + H) + 製備例120 仿製備例59之方法可得如下化合物。 (1) (21〇-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]-2-[4-(三氟甲基)苄基]哌阱 -201- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(2()<>) NMR (DMS〇-d6/ δ): 3·03-4·00 (19Η, m), 7·57 (2Η, d, J=8.1Hz), 7·75 (2H, d, J=8.1Hz), 7·85 (1H, dd, J=7.7 and 5·6Ηζ), 8·29 (1H, d, J=7.7Hz), 8·78 (1H, d, J=5.6Hz)
MASS (APCI): 405 (M+H)+ (free) ©(21〇-4-[2-(順-2,6-二甲氧甲嗎啉基)乙基]-2-[4-(三氟甲基)苄基]毈胼三鹽酸鹽 mp: >250°C IR (KBr): 2563, 2426, 1456, 1327 cm-1 NMR (CDC13, δ): 1.11 (6H, d, J=6.2Hz)f 2.59-4.50 (19H, m), 7.56 (2H, d, J=8·1Hz), , 7.75 (2H, d, J=8.1Hz) MASS (APCI): 386 (M+H)+ (free) (3) (2R)-4-[2 - [(2S)-2-(甲氧甲基)嗎啉基]乙基]-2 - [4-(三氟甲基)苄基]哌阱三鹽酸鹽
mp: 80-95°C IR (KBr): 1695, 1516 cnT1 NMR (DMSO-dg, δ): 2.80-4.60 . (25H, m), 7.56 (2H, df J=8.1Hz), 7·75 (2H, d, J=8.1Hz) MASS (APCI): 402 (M+H)+ (free) (4) (2R) - 2-(4-氟-3-甲氧苄基)- 4-[2-(順-2,6-二甲氧甲 嗎咐基)乙基]哌畊三鹽酸鹽 IR (KBr}: 1610, 1517, 1452, 1425, 1367, 1326, 1274 cnT1 NMR (DMSO-dg, δ): 1.11 (6H, d, J=6.0Hz), 2.49-4.40 (21H, m), 3·86 (3H, s), 6·87·7·24 (3H, m), 9.55-10.06 (2H, m) MASS: 366 (M+H)+ (free) (5) (2R)-2-(4-氟-3-甲氧苄基)-4-[2-[(2S)-2-(甲氧甲 基)嗎啉基]乙基]哌畊三鹽酸鹽 -202- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) - 訂--------- 509688 經濟部智慧財產局員工消費合作社印製 Α7 Β7 O A 1 1、發明說明() IR 《KBr}: 3465, 3435, 3400, 1615, 1515, 1455, 1270, 1235 cm,1 NMR (DMSO-dg, δ): 2.65-4.20 (22H> m)f 3.27 (3Hf s), 3.86 (3H, s) f 6.82-7.23 (3Hf m) MASS (APCI): 382 (M+H)+ (f^ee) ® (2R)-2-(4-氟-3-甲氧苄基卜4-[2 -(5,6,7,8-四氫-1, 6-嚓啶-6-基)乙基]哌畊四鹽酸鹽 IR (KBr): 1515, 1464, 1269, U53, 1095 cnT1 NMR (CDC13/ δ): 2.60-4,50 (22H, m) , 3.84 (3H, s) f 6·85_10·0 (8H, m) MASS: 385 (M+H)+ (free) ⑺(2R>-2-(4-氯-3-羥苄基)- 4 - [2-[(2S)-2-(甲氧甲基) 嗎啉基]乙基]哌阱三鹽酸鹽 IR (KBr): 1645广1450, 1425, 1370r 1236, 1140 cnT1 NMR {DMSO-d6, δ): 2·64繼4·50 t22H, m), 3·27 (3H, s), 6.71-7.32 (3H, s) MASS (APCI): 384 (M+H)+ (free)
(8) (3S,4S)-3,4-二甲氧吡咯啶鹽酸鹽 mp: 168°C IR 《KBr}: 3464, 2900-2350,,1198, 1109, 1065, 1024 cnT1 NMR (DMS0-d6, δ): 3·05_3·35 (4H, m), 3·31 (6H, s), 4.00 (2H, d, J=3.5Hz), 9.67,(2H, br s) MASS (APCI): 132 (M+H)+ (free) 製備例121 將2-溴乙醇(310毫克)加至含(2R>-l-[3,5-雙(三氟 甲基)苄醜基]-2-[4-(三氟甲基)-苄基]哌阱(1克)之乙 睛(10奄升)。攪拌於70¾下19小時。過漶,將濾紙上殘 渣清洗Μ二氯甲烷2次。將濉液及結合洗液減壓濃縮。 -203- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ---------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7 202 五、發明說明() 由矽膠柱曆析純化(甲醇於二氯甲燒為2¾再可得 (2R)-1 - [3, 5-雙(三氟甲基)苄醯基]一4_ (2-羥乙基)-2-[4-(三氟甲基)苄基]哌哄(927毫克)之不定形粉。 IR (Neat): 3462, 3435, 2949, 2817, 1637, 1439 ατΓ1 NMR (CDC13, δ): 2·1-5·2 (14Η, m), 6·9-8·0 (7Η, m> MASS (APCI): 529 (M+H)+ 製備例122 仿製備例121之方法可得如下化合物。 (2R)-1 - [3,5-雙(三氟甲基)苄醯基]-2-(4-氟-3-甲氧苄 基)-4-(2-羥乙基)瞰阱 IR (Neat): 2945, 2817, 1639, 1518, 1442 cm^1 NMR (CDC13, δ): 2·20-5·10 (13H, in), 4·52 (3H, s>, 6.30-7.89 (6H, m) MASS (APCI): 509 (M+H)+ 製備例1 2 3 仿製備例9之方法可得如下化合物。 (1) (2R) -1-[3,5-雙(三氟甲基)苄醯基]- 4-(2-氯乙基)一 2- [4-(三氟甲基)苄基]哌阱鹽酸鹽 IR (KBr): 3437, 3429, 2561, 1649, 1427 cnT1 NMR (DMSO-d6, δ): 2.20-5.40 (13H, m), 7.10-8.30 (7Hf m) MASS (APCI): 547 (M+H)+ (free) (2) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-4 -(2-氯乙基)一 2-
(4-氟-3-甲氧苄基]-哌畊鹽酸鹽 mp: 75-79°C IR (KBr): 1647, 1518, 1427' cirT1 NMR (DMSO-dg, δ): 2.75-5.20 (13H, m), 4.49 (3H, s) f 6.50-8.23 (6Hf m) MASS (APCI): 527 (M+H)+ (free) -204- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注音?事項再填寫本頁) 訂---------.· 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 B7____ 五、發明說明() 製備例124 仿製備例57之方法可得如下化合物。 (2R)-4-苄基-2 - [3-(第三丁二甲矽烷氧基)- 4-甲苄基] 哌阱 IR (Neat): 2952, 2933, 2856, 1504 cm""1 NMR (DMSO-dg, δ): 0.21 (6H, s), 1.02 (9H, s), 1.66-2.00 (2H, m), 2.13 (3H, s), 2.49-2.85 (*4H, m) f 3.37-3.41 (5H, m), 6.63 (1H, s) , 6.69 (1H, d, J=7.6Hz), 7.05 (1H, d, J^7.6Hz), X.25-7.40 (Sft^ m) MASS (ESI+): 411.4 (M+H)+ 製備例125 將含(2S,4R)-1-苄基-4-羥基-2-(羥甲基)毗咯啶(1.49 克)之Ν,Ν-二甲基甲醯胺(10毫升),於室溫下滴加至含 NaH(60i<:油中,689奄克)之Ν,Ν -二甲基甲醯胺(5毫升) 。於同溫攪拌1小時。滴加入含甲基碘(2 .55克)之Ν,Ν-二甲基甲醯胺(3毫升)。攪拌於室溫下2小時,倒至冰 水並萃取Κ乙酸乙酯2次。將結合有機層傅次清洗Μ飽 和碳酸氫納溶液,5¾硫代硫酸鈉溶液,及飽和氯化納溶 液,於硫酸鎂下乾燥,並減壓濃縮。由矽膠柱曆析純化 (甲醇於二氯甲烷為1¾再為2¾)可得(2S,4R)-1-苄基-4-甲氧基-2 -(羥甲基)吡咯啶(1.07克)之油。 IR (Neat): 2877, 2817, 1452 cm"1 NMR (CDC13/ .δ) : 1.79-2.02 (2Η, m)-, 2.26. (1H, dd, J=9.9 and 5·6Ηζ), 2.88-3.01 (1H, p), 3·19-3·49 (4H, m), 3.25 (3H, s), 3.35 (3H, s) , 3,86 (lHf m) , 4.10 (1H, d, J=13.1Hz), 7.20-7.33 (5H,. m) MASS (APCI): 236 (M+H)+ -205- 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) (請先閱讀背面之注意事項再填寫本頁) 訂·--------. 509688 A7 B7 _ 五、發明說明(2(>4) 製備例126 仿製備例15之方法可得如下化合物。 (請先閱讀背面之注意事項再填寫本頁) (1) (2S,4R)-4-甲氧基-2-(甲氧甲基)吡咯啶 IR (Neat) : 3342, 2881, 1668, 1444 .cm"1 NMR (CDCl3r δ)Τ 1.55 (1Η, m), 1.93 (1H, dd, J=13.6 and 7.1Hz), 2.88-3.09 (2H, m) , 3.24-3.52 (3H, m), 3.29 (3H, s), 3.36 (3H, s), 3.89 (1H, m) MASS (APCI): 146 (M+H)+ ©(35,41〇-吡咯啶-3,4-二醇鹽酸鹽
mp: 69-73°C IR (KBr): 3400, 1622, 1442, 1238,,1109, 1030, 989 cm"1 NMR (DMS〇-dg-D2〇/ δ): 3.05 (2H, d, J=12.1Hz)f 3.28 (2H, dd, J=12.1 and 3·2Ηζ), 4·10 (2H, d, J=3.2Hz) MASS 《APCI): 104 (M+H)+ (free) (3)順-2, 6-二甲氧甲喊阱鹽酸鹽
mp: 200-202eC IR (KBr): 3402, 2941, 2821, 2735, 1645, 1516广1456 cm 1 NMR (DMSO-dg, δ): 1,30-1.90 (6H, m)f 3.10-3,40 (2H, m), 3.30 (6H, s), 3.54 (4H, d, J=5.3Hz) MASS (APCI): 1-74 (M+H)+ (free) ⑷順-3, 5-二甲氧甲哌畊鹽酸鹽 經濟部智慧財產局員工消費合作社印製
mp: 220-222eC IR (KBr): 2939, 2806, 2783, 1460, 1392 cnT1 NMR 《DMSO-d6, δ): 0·99 (1H, q, J=12.4Hz), 1.69 《1H, m), 1.90-2.25 (2H, m), 2.50 (2H, t, J=12.3Hz)/ 3.10-3.40 (6H, m), 3·23 (6H, s) MASS (APCI): 174 (M+H)+ (free) (5)順-2, 6-二甲氧甲嗎啉鹽酸鹽 -206- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7
? 0 R 五、發明說明() IR (Neat): 2935, 2819, 1595, 1513, 1456 cm’1 NMR (CDC13/ δ): 2.13 (2Η, t, J=12.0H^)f 3.18 (2H, d, J=12.0Hz), 3.35 (6H, s), 3.35-3.46 (4H, m), 3.92-4.05 (2H, m) MASS (APCI): 176 (M+H)+ (free) (6) 2,2-二甲氧甲嗎咐鹽酸鹽 IR (Neat): 2935, 2522, 1594, 1454 cm·1 NMR (CDC13, δ): 2.92-3.00 (4H, rt〇., 3·29 (6H, s), 3.46 (2H, d, J=10.2Hz), 3.51 (2H, d, J=10.2Hz), 3.81- 3.86 (2H, m) ' MASS (APCI): 176 (M+H)+ (free)
⑺8-Bf -3-吖雙環[3·2· 1]-辛烷鹽酸鹽 mp: 205-207.5°C IR 《KBr>: 2920, 2792, 1591, 1442 cm·1 NMR (DMSO-dg, δ): 1.85-2,18 (4H, itv) f 2.97-3.08 (4Hf m), 4·39-4·40 (2H, m) MASS (APCI): 114 (M+H)+ (free) 製備例127 仿製備例89之方法可得如下化合物。 (1) (2S,4R)-l-(2-羥乙基)-4-甲氧基-2-(甲氧甲基)吡咯啶 IR (Neat): 3400, 2881, 1660, 1458, 1379 em^1 NMR (CDC13, δ): 1.77 (1H, m), 2·00 (1H, pa), 2·45 (1H, dd, J=10.4, 4.5Hz), 2.62 (1H, dt, J=12,7, 3.7Hz), 2.95-3.11 (2H, m), 3.29-3.45 (3H, m)、, 3.30 (3H, s), 3·36 (3H, s>, 3·50-3·70 (2H, m), 3·90 (1H, m) MASS (APCI): 190 (M+H)+ ⑵2,2-二甲基-4-(2-羥乙基)嗎啉 -207 — 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------------—------訂—i— (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7___ 五、發明說明(2(>6) IR (Neat): 2972, 2941, 1458, 1387 cm^1 NMR (CDC13, δ): 1·26 (6H, s), 2·3! (2H, s), 2.45-2·54 (4Η, m), 3.63 (2Η, t, J=5.1Hz), 3.77 (2H, t, J=5.1Hz) ' MASS (APCI): 160 (M+H)+ (3)(33,43)-1-(2-溴乙基)-3,4-二甲氧吡咯啶鹽酸鹽 製備例128 仿製備例90之方法可得如下化合物。 (1) (2S,4R)-l-(2-氯乙基>-4-甲氧基-2-(甲氧甲基)吡咯 啶鹽酸鹽 IR (Neat): 3400, 2939, 1645, 1450 cm·1 NMR (DMSO-dg, δ) : 1.80 (1H, π〇, 2.23 (1H, m), 3.26 (3H, s}, 3·32 (3H, s), 3.20-4.20 (10H, m) MASS (APCI): 208 (M+H)+ (free) (2) 2,2-二甲基-4-(2-氯乙基)嗎啉鹽酸鹽
mp: 180-185°C IR (KBr): 2978, 2677, 2630, 2584, 1456 cnT1 NMR (DMSO-dg, δ): 1.18 (3H, s), 1.44. (3H, s), 2.80-3.10 (2H, ia), 3·30-3·91 (6H, m), 4·10 (2H, t, J=6.9Hz) MASS (APCI): 178 (M+H)+ (free) 、 @(35,45)-1-(2-氯乙基)-3,4-二甲氧吡咯啶鹽酸鹽 IR (Neat}: 3400, 2,563, 2440, 1637, 146Ό, 1113 cnT1 NMR (DMSO-dg, δ): 3.20-3.86 (6H, m)r 3,32 (6Hf s), 3.92-4.16 (4H, m), 11.44 (1H, s) MASS (APCI); 194 (M+H)+ (free) 製備例1 2 9 將含3-二甲胺基-1H-吡咯并[3,2-b]吡啶(1.53克)及 六亞甲四胺(1.22克)之丙酸(6.68克,66¾)滴加至含於 -208- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
-h I— I a^i ϋ· ϋ· ^^1 —i I J^688 A7
五、發明說明(2〇7) (請先閱讀背面之注意事項再填寫本頁) 六亞甲四胺(2·44克)之相同溶劑(8.92克)之回流溶液。 此加入係於1小時間完成,並回流3.5小時Μ上。減壓 禳縮並加入水ί30毫升),乙酸乙酯(25毫升),及四氫呋 喃(20毫升)。分離有機層,於硫酸鎂下乾燥,並減壓濃 縮。由矽膠柱層析純化(12g;二氯甲烷:甲酵=15;1)。 收集含目的化合物部份並減壓蒸除可得3-甲醯基-1 Η-吡 咯并[3,2-b]吡啶(0·45克)之粉。 hid: 230 t!(分解) IR (KBr): 2744, 1658, 1466, 1408, *1142, 1113, 111 cm^1 NMR (DMSO-dg, δ) : 7 ·27 (1H, dd, · 6 and 8 · 3Hz) , 7 · 92 (lHf d, J=8.3Hz)r 8.44 (1H, s), 8.50 (1H, d, J=4.6Hz), 10.19 (1H, s) , 12.38 (1H, s) MASS (APC I) : 147 (M + H) + 製備例130 仿製備例125之方法可得如下化合物。 (1) (35,4$)-1-(第三丁氧羰基卜3,4-二甲氧吡咯啶 IR (Neat): 1690, 1410, 1365, 1165, 1100 cm"1 NMR (CDC13, δ): 1·45 (9H, s), 3·37 (6H,· s), 3·30-3·56 (4Η, m), 3·72-3·85 (2Η, m) MASS (APCI): 132 (M-Boc+H)+ (2) 順-2,6-二甲氧甲基-1 -苄毈畊 經濟部智慧財產局員工消費合作社印製 IR (Neat): 2924, 2883, 1489, 1450 cnT1 NMR (CDC13, δ): 1·30-1·85 (6H, m), 2.68-2·78 (2H, m), 3.13 (6Η, s), 3.18 (2H# dd, J=9.6, 6.2Hz), 3.35 (2H, dd, J=9.6, 4.4Hz), 3.84 (2Hf s) , 7.17-7.42 (5H, m) MASS (APCI): 264 (M+H)+ ~ 2 0 9 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(2G8) (3)順-3,5-二甲氧甲基-1 -苄哌哄 IR (Neat): 2920, 2829, 1454, 1389 cm"1 NMR (CDC13/ δ): 0.68 (1H, q, J=12.2Hz), 1-61 (2Hf tf J=ll.lHz)/ 1.78 (1H, m), 1.85-2.20 (2H, m), 2.90-3.05 (2H, m), 3.19 (4H, d, J=6.2Hz), 3.29 (6H, s) f 3.52 (2H, s), 7.20-7.32 (5H, m) MASS (APCI): 264 (M+H)+ 製備例131 將含(S)_甲基甘胺酸醚(10克)及苄胺(3·62克)之甲醇 (50毫升)攪拌於5512小時。加入(S)-甲基甘胺酸醚(1 克),攪拌於551C下2小時後減壓蒸除。加入甲苯後減 壓蒸除得(2S)-1-[N-苄基-N-[(2S)-2-羥基-3-甲氧丙基] 胺基]-3-甲氧丙-2-醇(8.84克)之淡黃色油。 IR (Neat): 3430, 3402, 2889, 1454 ατΓ1 NMR (CDC13/ δ): 2.52-2.70 (4Η, m) , 3.,34.(6H, s) , 3.26-3.44 (4H, m), 3.61 (1H, d, J=13,7Hz), 3.81-3.92 (2H# m), 3.84 (1H, d, J=13.7Hz), 7.20-7.33 (5H, m) MASS (APCI): 284 (M+H)+ 製備例132 將含三苯膦(10.2克),叠氮二羧酸二乙酯(6.12毫升) ,及(2S)-1-[N-苄基-N - [(2S)-2-羥基-3-甲氧丙基]胺 基]-3-甲氧丙-2-醇(7.34克)之四氫呋喃(70毫升)攪拌 於0它下5小時。依次加入三苯膦(2.04克)及叠氮二羧 酸二乙酯(1.2毫升),攪拌ου下3小時。倒至水並萃 取Μ二氯甲烷(Χ3)。將結合有機層清洗Μ食鹽水,於 硫酸鈉下乾燥並蒸除。加入異丙醚(50奄升)並攪拌於室 -210- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(2<>9) 溫下30分。濾除沈澱,將溶液蒸除並由矽膠柱層析鈍化 (1st:矽膠,800毫升,乙酸乙酯:異丙醚=2:8-3:7) (2nd:矽膠,300毫升,乙酸乙酯:異丙醚=3:97-10.9) 可得4-苄基-順-2,6-二甲氧甲嗎啉(2.65克)之油。 IR (Neat): 2883, 1514, 1458, 1099 cm^1 NMR (CDC13, δ): 1.93 (2Η, t, J=11.0Hz), 2·77 (2H, d, J=lle〇Hz), 3.34 (6Hf s) , 3.36-3-50 (4H, m) f 3.51 (2H, s), 3.75-3.87 (2H, m), 7.25-7.32 (5H, m) MASS (APCI): 266 (M+H)+ 製備例133 於含N-苄乙酵胺(302克)之水(8.92毫升)及甲苯(1510 毫升)及雙(2-甲氧乙)醚(151毫升)中,於30分内滴加 入硫酸(128毫升),攪拌回流6小時。冷卻至室溫,加 入甲酵(300毫升),並攪拌1小時。濾集沈漉,清洗K 甲酵(300毫升X4),並乾燥可得硫酸2-(N-苄胺基)乙 酯(352.6克)之白色粉。 MASS (APCI) ·· 232 (M + H) + 元素分析C9 H13Ni 〇4 S: 計算值 C:46.74!K, H:5.67»!, 11:6.06¾ 實測值 C:46.42X, Η:5·63!Κ, 11:5.93¾ 製備例134 於含硫酸2-(N-苄胺基)乙酷(28克)之水(36.3毫升), 及40¾ NaOH溶液(12.1毫升),於室溫及30分內加入2,2 -雙(甲氧甲基丙環(16.0克)。攪拌於室溫下87小時, 於20分內滴加入40!KHa0H溶液(73毫升)。攪拌於室溫下 -211- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -P衣 訂---------% 509688 A7 _B7_ 2 10 五、發明說明()
1小時再於40¾下20小時,萃取Μ乙酸乙酯(100毫升X 3)。將有機曆萃取Μ1Ν鹽酸(Χ6)。將結合有機層中和 (請先閱讀背面之注意事項再填寫本頁) MNaOH,加人NaCl,並萃取以乙酸乙酯(100毫升Χ3)。 將結合有機層清洗K食鹽水,於硫酸鎂下乾燥,並減壓 蒸除可得4-苄基-2,2-二甲氧甲嗎啉(31.79克)之桔油。 IR (Neat): 2922, 2877, 2812, 1454 cm"1 NMR (CDC13/ δ): 2.38-2.44 (4Η, m), 3.27-3.45 (4H, m), 3.37. (6H, s), 3·65 (2H, d, J=9..6Hz), 3·77-3·84 (2H, m), 7.20-7.34 (5H, m) MASS(APCI): 266(M + H” 製備例135 將含2,5-雙(羥甲基)四氫呋喃雙(對甲苯磺酸鹽)(10 克)及苄胺(9·7克)攪拌於701C下24小時。加入NaOH溶 液(1.85克)之甲酵(30毫升),攪拌於室溫下30分後過_ 。將濂液減壓蒸除,加入二氯甲烷後過濾。將濾液減壓 蒸除,由矽膠柱層析純化(矽膠,25 0毫升,乙酸乙酯: 己烷=1:4)可得3-苄基-8-噚-3-吖雙環[3.2.1]-辛烷 (4 · 0 5克)之油。 IR (Neat): 2951, 2800, 1452 cnT1 經濟部智慧財產局員工消費合作社印製 NMR (CDCI3/ δ): 1.78-2.07 (4Η, m) , 2.33 (2Η, dd, J=ll.l and 1.8Hz), 2.54 (2H, br d, J=ll.lHz), 3.45 (2H, s), 4·25-4·28 (2H, m), 7·18-7·3.4 (5H, m) MASS (APCI): 204 (M+H)+ 例38 ⑴(2R) - l-[3,5-雙(三氟甲基)苄醯基]-4-[2-(2,2-二甲 嗎咐基)乙基]-2-[4-(三氟甲基)苄基]哌哄二鹽酸鹽 -212- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7 9 1 1 五、發明說明()
[a]g6: +11.00° (C=0.25f MeOH) mp: 215-231°C (請先閱讀背面之注意事項再填寫本頁) IR (KBr): 3438, 1645, 1329, 1281 cnT1 NMR (DMSO-dg, δ): 1*25, 1·33 (6Hf s), 2.60-5.30 (19H, m), 7.21-8.19 (7H, m) MASS (APCI): 626 (M+H)+ (free) (2) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-4-[2-[(2S,5S)- 2-甲氧甲基-5-甲嗎啉基]乙基]-2-[4-(三氟甲基)苄基] 哌阱二鹽酸鹽 [a]g6: +12.33° (C=0.25, MeOH)
mp: 142-182°C IR (KBr): 1647, 1281 cm-1 NMR (DMSO-dg, δ): 1.16 (3H, d, J=6.2Hz), 2.70-5.30 (24H, ia) , 7.21-8.19 (7H,、m) MASS (APCI): 656 (M+H>+ (free) (3) (21〇-1-[3,5-雙(三氟甲基)苄釀基]-4-[2-(順-2,6-二甲氧甲嗎啉基)乙基]-2-( 4-(三氟甲基)苄基)哌阱 二鹽酸鹽
[a]g4: +9.00。 (C=0.25, MeOH) mp: 130-138°C IR (KBr): 3437, 1647, 1427, 1329, 1282 cnT1 經濟部智慧財產局員工消費合作社印製 NMR (DMSO-dg, δ): 2.80-5.30 (29H, m), 7.21-8.18 (7H, m) MASS (APCI): 686 (M+H)+ (free) ⑷(2R)-l-[3,5-雙(三氟甲基)苄醯基]-4 - [2-(2,2-二甲氧 甲嗎啉基]乙基]-2-[ 4-(三氟甲基)苄基]哌阱二鹽酸鹽 [a]§6: +5.270 (C=0.25, MeOH)
mp: 123-149°C IR (KBr): 3435, 1647 cm·1 NMR (DMSO-dg, δ): 2,70-5.30 (29H, m) , 7.21-8.19 (7Hf m) MASS (APCI): 686 (M+H)+ (free) -213- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 212 五、發明說明() (5) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-4-[2-(8-_-3-吖雙環[3.2.1]-辛烷-3-基)乙基]- 2-[4 -(三氟甲基) 苄基]哌阱二鹽酸鹽
ta]g5: +11.67° (C=0,25r MeOH) mp: 232-250°C IR (KBr): 3438, 1645, 1281 cm-1 NMR (DMS〇-d6, δ) : 1·91-2·27 (4H, m), 2·80-5·40 (19H, m), 7.21-8.19 (7H, m) MASS 《APCI}: 624 (M+H)+'(free) (6) (2R) -1-[3,5-雙(三氟甲基)苄醯基]-4-[2-(2,2-二甲 嗎啉基)乙基]-2-(4-氟-3-甲氧苄基)哌阱二鹽酸鹽
[a]g6: +9.73° (C=0.25, MeOH) mp: 152-162°C IR (KBr): 3438, 1645, 1516, 1282 cnT1 NMR 《DMSCHd6, δ): 1·30 (6H, br s), 2·60-5·30 (22H, m), 6.40-8.20 (6Hf m) MASS (APCI): 606 (M+H)+ (free) ⑺(2R)-l-[3,5-雙(三氟甲基)苄醯基]-4-[2-[(2S,5S)-2-甲氧甲基-5-甲嗎啉基]乙基]-2-(4-氟-3-甲氧苄基) 哌阱二鹽酸鹽
[a]g4: +12.33° (C=0.25, MeOH) mp: 140-164eC IR (KBr): 3437, 1645, 1282 cirT1 NMR (DMSO-d6, δ): 1·16 (3H, d, J=6.1Hz), 2·70-5·30 (27H, m), 6.50-8.20 (6H, m) MASS (APCI): 636 (M+H)+ (free) 一 214- 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) ------I--------------丨訂---------線 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明() ⑻(2R) -1-[3,5-雙(三氟甲基)苄醜基]-4-[2-(順-2,6-二甲氧甲嗎啉基)乙基]-2-(4-氟-3-甲氧苄基)哌畊二 鹽酸鹽
ta]g6: 4-10.60° (C=0-25, MeOH) mp: 148-156°C IR (KBr): 1645, 1516, 1281 cm"1 NMR (DMSO-dg, δ): 2.60-5.20 (32H^ m)f 6.40-8.20 (6H, m) MASS 《APCI): 666 (M+H>+ 《frde) (9)(21〇-1-[3,5-雙(三氟甲基)苄醢基]-4-[2-(2,2-二甲
氧甲嗎_基)乙基]-2 -(4-氟-3-甲氧苄基)哌阱二鹽酸鹽 [a]g3: +6.60° (C=0-25, MeOH) mp: 132-150°C IR (KBr) : 3437, 1645, 1516, 1282 cm"*1 NMR (DMSO-d6, δ): 2·60-5·30 (32H, m), 6.45-8.20 (6H, m> MASS (APC I) : 666 (M + H) + ⑽(2R )-1 -[3,5-雙(三氟甲基)苄釀基]-4_[2-(8-鴨-3- 吖雙環[3·2·1]-辛烷-3-基)乙基]-2-(4-氟-3-甲氧苄 基)哌阱二鹽酸鹽
[a]g3: +13·20° (C=0.25, MeOH) mp: 163-178eC IR (KBr): 3431, 1645, 1518, 1427, 1282 cm'1 NMR {DMSCHdg, δ): 1.91 -2.30 (4.H, m), 2·70-5·30 (22H, m), 6.45-8.25 (6Hf m) MASS (APCI): 604 (M+H)+ (free) 例39 仿例1之方法但使用二異丙基乙胺取代碳酸鉀之 鹼可得如下化合物。 -215- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) II---II---丨—β^--------訂--------線# (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7 _ 五、發明說明(214) d)4-[[(2R)-l-[3,5-雙(三氟甲基)苄醯基]- 4-[2-[(2S) - 2-(甲氧甲基)嗎啉基]乙基]哌阱-2-基]-甲基]-2- (請先閱讀背面之注意事項再填寫本頁) (第三丁二甲矽烷氧基)苄酸甲_ IR (Neat): 1677, 1643, 1438, 1280 cirT1 NMR (CDCl3r δ): 0.10-0.3(Γ'Γ6Η, mj / 0:;99 (9H, s), 2.00-5.10 (22H, m) r 3.38 (3H,„ s) , 3.87 (3H, s), 6.30-7.90 (6H, m) MASS (APCI): 784 (M+Na)+, 763 (M+H)+ ©(2!〇-1-[3,5-雙(三氟甲基)苄醮基]-2-(4-甲氧苄基> -4-[2-[(2S)-2-(甲氧甲基)嗎咐基]-乙基]哌畊二鹽 酸鹽
[a]g5: -5.16° (C=0.32f MeOH) mp: 146-149°C IR (KBr): 1645, 1282, 1182, 1136 cm·1 NMR (DMSO-d6, δ) : 2.60-5.20 (29H, m), 6.75-6.90 (4Hf m), 7.29-8.21 (3H, m) MASS (APCI): 604 (M+H)+ (free) ③(2R)-2-[3-(第三丁二甲矽烷氧基)-4-甲苄基]- l-[3 - 甲氧基-5 -(三氟甲基)苄釀基]-4-[2-(5,6,7,8-四氫- 1 , 6-暸啶-6-基)乙基]哌阱 經濟部智慧財產局員工消費合作社印製 IR (Neat): 2935, 1641, 1464, 1421 cm"1 NMR (CDC13/ δ): 0.13 (6Η, br s), 0.99 (9H, s) , 2.15 (3H, s), 2·10-5.10 (19H, m), 3.81 (3H, s)r 6.20-7,10 (7H, m), 7·32 (1H, d, J=6.7Hz), 8·40 (1H, d, j= 3 · 8 H z) MASS (APCI): 683 (M+H)+ -216- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_
9 1 R 五、發明說明() ⑷(2R)-2-[3-(第三丁二甲矽烷氧基)-4-甲苄基]- 4-U-(3,3-二甲嗎啉基)-2-丁炔基]-1-[3-甲氧基-5 -(三氟 甲基)苄醜基]哌阱 IR (Neat): 2952, 1645, 1510 cm’1 NMR (CDC13/ δ): 0.14 (6Hf br s), 0.99 (9H, s), 1.05 (6H, s), 2.15 (3H, s), 2.20-5·20 (19H, m), 3·81 (3H, s), 6.20-7.58 (6Hr m) MASS (APCI): 688 (M+H)+ (5) (2R)-l-[3-(二甲胺磺釀基)-5-(三氟甲基)苄醯基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基)乙基]-2-[4_ (三氟甲基)苄基]雜阱三鹽酸鹽 [a]g6: +1.33° (C=0.25, MeOH)
mp: 190-194°C IR (KBr) : 3398, 1647 citT1 NMR (DMSO-dg, δ): 2.66 (6H, s) , 2.80-5.30 (19Hf m), 6·90-8·71 (10H, m)' MASS (APCI): 684 (M+H)+ (free) (6) (2R)-l-[3-甲磺醯基-5 -(三氟甲基)苄醯基]-2-[4 - (三氟甲基)苄基]-4-[2 -(5,6,7,8-四氫-1,6-暸啶-6- 基)乙基]-哌阱三鹽酸鹽
[ot】g6: -2.33。(C=0.25, MeOH) mp: 192-197eC IR (KBr): 3433, 3400, 1647 cm-1 NMR (DMSO-dg, δ): 2.70-5.30 (22H, m) , 7.05-8.68 (10H, m) MASS (APCI): 655 (M^H)^ (free) ⑺(2R)-l-[3,5-雙(三氟甲基)苄醯基]-4-[2-[(2R)-2- (甲氧甲基)嗎啉基乙基]-2-[4-(三氟甲基)苄基]-哌 阱二鹽酸鹽 -217- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I--------------------訂 ---------線^^" (請先閱讀背面之注意事項再填寫本頁)
五、發明說明(216)
[a]g6·5: +5·18。 (C=0.28, MeOH) mp: 188-194°C (請先閱讀背面之注意事項再填寫本頁) IR {KBr): 3438, 1645, 1516, 1464, 1456 cnT1 NMR (DMSCHd6, δ): 2·50-5·30 (22H:, m), 3·27 (3H, s), 7.10-8.30 (7Hf m)- MASS (API-ES positive): 642 (M+H)+ (free) (8) (2R)-l-[3,5-雙(三氟甲基)苄醜基卜4-[2-[(2S,4R)-4-甲氧基-2-(甲氧甲基)吡咯啶基]乙基]-2-[ 4-(三氟 甲基)苄基]哌畊二鹽酸鹽
[a]g6·7: -17.43° (C=0.23f MeOH) mp: 56.59°C IR (KBr): 3438, 1647, 1427 cm—1 ’ NMR (DMSO-dg, δ): 1.70-5,40 (21Hr m}, 3.29 (3Hf s)f 3.35 43H, s}, 7.10-7.80 (6H, m), 8.19 (1H, br s> MASS (APCI): 656 (M+H)+ 《free〉 (9) (2R)-l-[3,5-雙(三氟甲基)苄醯基]-4-[2-[(3S,4S)-3,4-二甲氧吡咯啶基]乙基]-2-[ 4-(三氟甲基)-苄基] 哌阱二鹽酸鹽
[α】^3·1: +5.94° (C=0.202, Me〇H) mp: 203-208°C 經濟部智慧財產局員工消費合作社印製 IR (KBr): 3437, 2565, 2440, 1647,· 1429, 1331, 1282, 1178, 1128, 1066 cm"1 NMR (DMSO-dg, δ): 2·76-5·32 (25H, m), 7·10-8·26 (7H, m} MASS (APCI): 642 (M-fH)+ (free) ⑽(2R)-l-[3,5-雙(三氟甲基)苄醢基]-2 -(4-氟-3-甲氧 苄基)-4-[2-[(2S,4R)-4-甲氧基-2-(甲氧甲基)吡咯 啶基]乙基]哌阱二鹽酸鹽 -218- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 經濟部智慧財產局員工消費合作社印製 A7 B7 9 17 五、發明說明()
[a]g6·6: -12.27° (C-0.30, MeOH) mp: 128-134°C IR (KBr>: 3437, 3400, 1645, 1516 cnT1 NMR (DMSO-d6/ δ): 1.70-5.30 (21H, m), 3.29 (3H, s), 3.35 (3H, s), 3.57 (3H, s), 6.40-8.30 (6H, m) MASS (APCI) : 636 (M-fH)+ (free) (11) (2R)-l-[3,5-雙(三氟甲基)苄醸基]-2-(4-氟-3-甲 氧苄基)-4 - [2-[(2!〇-2-(甲氧甲基)嗎琳基]-乙基]_ 阱二鹽酸鹽
[a]g6·8: +6·240 (C=0.33, MeOH) rap: 139-148eC IR {KBr): 3438, 1644, 1516, ·1464, 1427 cnT1 NMR (DMSO-dg, δ): 2.60-5.30 (25H, m), 3,27 (3Hf s)r 6.40-8.30 (6H, m) MASS (APCI): 622 (M+H)+ (free) (12) (2R) - l-[3,5-雙(三氟甲基〉苄醢基]-4-[2 - [(3S,4S) - 3,4-二甲氧吡咯啶基]乙基]-2-U-氟-3-甲氧芣基) 哌阱二鹽酸鹽
[a]J3·5: +8.05°* (C=0.205, MeOH) mp: 112-120oC IR (KBr): 3431, 2561, 2436, 1645, 1516, 1464, 1427, 1282, 1182, 1134, 1034 cnT1 NMR (DMSO-d6/ δ): 2.65-5.24 (28H, m), 6.44-8.30 (6H, m) MASS (APCI): 622 (M+H)+ (free) (13) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-2_(4-氯-3-羥 苄基)- 4-[2 - [(2R)-2 -(甲氧甲基)嗎啉基]-乙基]哌阱 二鹽酸鹽 -219- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注咅?事項再填寫本頁) --------訂---------線赢 509688 A7 B7_ 五、發明說明(218)
[a]g6·5: -11.28° (C=0.27; MeOH) mp: 204-2140C (請先閱讀背面之注意事項再填寫本頁) IR (KBr): 1645, 1539, 1516 cm—1 NMR (DMSO-dg, δ): 2·50一5·20 (22H, m>, 3,27 (3H, s), 6·30-8·30 (6H, m), 9.90-10·30 (1H, br) MASS (API-ES positive) : 624 (M+H)+ (free) (14) (2R)-1 -[3,5-雙(三氟甲基)苄醯基]-2-(4-氯-3-羥 苄基)- 4-[2-[(2S,4R) - 4-甲氧基-2-(甲氧甲基)吡咯 啶基]乙基]_阱二鹽酸鹽
[a]g6·4: -25.54° (C=0.33, MeOH) mp: 95-105eC IR (KBr): 3400, 1645, 1516, 1429 cm"1 NMR (DMSO-dg, δ): 1.70-5.30 (21H, m), 3.28 (3H, s), 3.35 (3H/ s)/ 6.20*~8.30 (6H/ in) / 10,07 — 11.26 (lHf br) MASS (APCI}: 638 (M+H)+ (free), (15) (21〇-1-[3,5-雙(三氟甲基)苄醢基]-2-(4-氯-3-羥 苄基)-4 - [2-[(3S,4S)-3,4-二甲氧_咯啶基]-乙基] 哌阱二鹽酸鹽 [a]g3·8: -6·490 (C=0.23, MeOH) mp: 150-155°C . -,, IR (KBr): 3398, 2600, 2436, 1645, 1429, 1281, 1180, 經濟部智慧財產局員工消費合作社印製 1136, 1107, 1047 CM'1 NMR (DMSO-dg, δ): 2·55-5·15 (25H, m), 6·24-8·30 (6H, m) MASS {APCI): 624 (M+H)+ (free) (16) (2R)-2-[3 -(第三丁二甲矽烷氧基)-4-氯苄基]-1 -[3-氯-5-(三氟甲基)苄醯基]-4 - [2-(順-2,6-二甲基 嗎啉基]乙基]哌畊 -220 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 509688 A7 B7_ 五、發明說明(219) IR (Neat): 2935, 1641, 1417 cnT1 (請先閱讀背面之注意事項再填寫本頁) NMR (CDC13/ δ): 0.18 (6Η, br s), 1.02 (9H, s), 1.16 (6H, d, J=6.3Hz), 1.76 (2H, t, J=10.7Hz), 2.00-5.10 (17H, m), 6.30-7.50 (5H, m), 7.61 (1H, s) MASS (APC I) : 688 (M + H” (17)(2R)-2-[3-(第三丁二甲矽烷氧基)-4-氯苄基]-1 -[3-氯-5 -(三氟甲基)苄藤基]-4-[2 -(5,6,7,8-四氫-1 , 6-暸啶-6-基)乙基]哌阱 IR (KBr): 2954, 2935, 1643, 1419 cnT1 NMR (DMSO-d6, δ): 0·00-0·07 (6H, br>, 0·83 (9H, s>, 1.70-5.00 (19Η, m), 6.20-8.10 (8E, m), 8.18 (1H, d, J=4.7Hz) MASS (API-ES positive): 707 (M+H)+ 例40 將(2R)-4-(2-氯乙基)-1-[3,5-雙(三氟甲基)苄釀基] - 2-[4-(三氟甲基)苄基]哌阱鹽酸鹽與(2S) - 2-(羥甲基) 吡咯啶,依例1之方法但使用Ν,Ν-二異丙基乙胺取代碳 酸鉀之鹼可得如下化合物。 經濟部智慧財產局員工消費合作社印製 (21〇-1-[3,5-雙(三氟甲基)苄醸基]-4-[2-[(25)-2-(羥甲基)吡咯啶基]乙基]-2-[4-(三氟甲基)-苄基]哌阱 鹽酸鹽 [oc]g4·0: +6·430 (C=0.28, Me〇H) mp: 221-224°C ' IR (KBr): 1643, 1516, 1427 cm’1 NMR (DMSO-dg, δ): 1.65-2.30 (4H, m), 2.60-5.40 (19H, m), 7.10-8.30 (7H, m) ' MASS (APCI) : 612 (M-f-H)+ (free) -221~ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(22<>) 例41 仿例40之方法可得如下化合物。 (1) (210-1-[3,5-雙(三氟甲基)苄醯基]-4 - [2-(順-2,6 -二羥甲哌啶基)乙基]-2-[4-(三氟甲基)-苄基]哌阱二 鹽酸鹽
[a]g4·2: +10.36° (C=0.14, MeOH) mp: 164-1670C IR (KBr): 3396, 3369, 1645, 1516, 1427 cm一1 NMR (DMSO-dg, δ): 1.30-2.10 (6H, m) , 2.40-5.60 (21H, m), 7.00-8.30 (7H, m) MASS (APCI) : 656 (M-fH)+ (free) ②(2R) -1-[3,5-雙(三氟甲基)苄醯基]-4-[2-(順- 2,6- 二甲氧甲哌啶基)乙基]-2-[4-(三氟甲基)苄基]峨阱 二鹽酸鹽 [a]各3·1: +5.120 (C=0.21/ Me〇H)
mp: 147-151°C IR (KBr): 1645, 1516, 1454, 1427 cm"1 NMR (DMS〇-d6, δ): 1.40-2.00 (6Hf m), 2.80-5.30 (25H, m), 7.10- 8.40 (7H, m) MASS (APCI): 684 (M+H)+ (free) (3) (2R)-l-[3,5-雙(三氟甲基)苄醢基]-4-[2-(順-3,5-二甲氧甲哌喃基)乙基]-2-[4-(三氟甲基)-苄基]«阱 二鹽酸鹽
[a]g3·4: +8,28° (C=0.32, MeOH) mp: 157-160°C IR (KBr): 3438, 1647, 1464, 1427 cirT1 NMR《DMS〇-d6, δ) ·· 1·05 (1H, q( J=12.4Hz) , 1·70 (1H, m), 2.10- 5.40 (23H, m), 3·24 (6H, s), 7.10-8.30 (7H, m) MASS (APCI): 684 (M+H)+ (free) -222 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) --------------------訂 --------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 __B7_ 五、發明說明(221) ⑷(2R)-l-[3,5-雙(三氟甲基)苄醸基]-4-[2-[(3S,4S) -3,4-二羥吡咯啶基]乙基]-2 - [4-(三氟甲基)-苄基]毈 阱二鹽酸鹽 [a]g3·9: +7.37。 (C=0.29, MeOH)
mp: 154-159°C IR (KBr): 3398, 3369, 1645, 1427 crtT1 NMR (DMSO-dg, δ): 2,20-5.40 (21Hf m), 7,1-8.3 (7H, m) MASS (APC I) : 614 (M + H) + (5) (2R)-1 - [3,5-雙(三氟甲基)苄釀基]-2 - U-氟-3-甲氧 苄基)-4-[2-[(2S)-2-(羥甲基)吡咯啶基]-乙基]哌胼 二鹽酸鹽
[alg4·1: +4.76° (C=0.25, MeOH) mp: 198-201eC IR (KBr): 1645, 1516, 1464, 1425 citT1 NMR (DMSO-dg, δ): 1.60-5.40 (23H, m), 3·59 (3H, s)’ 6.40- 8.30 (6H, m) MASS (APCI): 592 (M+H)+ (free) (6) (2R)-l-[3,5-雙(三氟甲基)苄醯基]_4-[2-(順- 2,6-二羥甲哌啶基)乙基]-2-(4-氟-3-甲氧苄基]哌阱二鹽 酸鹽
[a]g4·3: +11.33° (C=0-27f MeOH) mp: 159-161eC IR (KBr): 3367, 1645, 1516, 1464, 1427 citT1 NMR (DMSO-dg# δ): 1.40-2,00 (6Hf m), 2.60-5.30 (24H, m), 6.40- 8.30 (6H, m) MASS 《APCI): 636 (M+H)+ (free) ⑺(2R )-1-[3, 5-雙(三氟甲基)苄釀基]-4-[2-(順-3*5- -223- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------—------—訂—---- (請先閲讀背面之注意事項再填寫本頁) 509688 A7 B7 五、發明說明(222) 二甲氧甲哌啶基)乙基]- 2-(4-氟-3-甲氧苄基]哌阱二 鹽酸鹽
[a]g3·7: +9.45° (C=0.28, MeOH) mp: 150-156°C IR 《KBr): 3438, 2939, 1645, 1518, 1464, 1427 cnT1 NMR (DMSO-dg, δ): 1.05 (1H, qf J=12.3Hz)f 1.70 (1H, m)f 2.10-5.30 (26H, m), 3.24 (6H, s), 6.40-8.30 (6Hf m) MASS (APCI): 664 (M+H)+ (free) 例42 仿例13之方法可得如下化合物。 (1) (2R)-2-(3-羥基-4-甲苄基)-1 - [3-甲氧基-5-(三氟甲 基)节醯基]-4-[2-(5,6,7,8 -四氫-1·6 -瞭嗤-6-基)乙 基]哌阱三鹽酸鹽
[a]J7: -17.11° (C=0.15, MeOH) mp: 192-208°C IR (KBr): 1643, 1628, 1464 cm"1 NMR (DMSO-dg, δ): 2.06 (3H, s) , 2.60-5.10 (22H, m), 6.20-7.30 (6H, m), 7.62-7.69 (1H, m) , 8.05 (1H, d, J=7.8Hz), 8.67 (1H, d, J=4.0Hz) MASS (APCI): 569 (M+H)+ (free) (2) (2R)-4 - [4-(3,3-二甲基嗎啉基)-2-丁 炔基]-2-(3-羥 -4-甲苄基)-1-[3-甲氧基-5-(三氟甲基)苄醢基]_阱 二鹽酸鹽
[a]g7: +13.87° (C=0.25, MeOH) mp: 181-188°C IR {KBr): 1645, 1464, 1425 cm-1 NMR (DMSO-dg, δ): 1.25-1.32 (6H, m), 2.07 (3H, s), 2.70-5.20 (22H, m) f 6.20-7.29 (6H, m) MASS (APCI): 574 (M+H)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐)-224- (請先閱讀背面之注咅?事項再填寫本頁) 訂--------— 經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 509688 A7 ________ B7 五、發明說明(223) (3) (2R) - 2-(4-氯-3-經节基)-1 - [3 -氯-5 -(三氟甲基)节 醯基]-4-[2-(順-2 ,6 -二甲基嗎啉基)乙基]哌阱二鹽 酸鹽
[α]§6·5: -12.04° (C=0.25f MeOH) mp: 196-199eC IR (KBr): 3398, 1643, 1514, 1456, 1425 citT1 NMR (DMSO-d6# δ): 1.15 (6H, d, J=6.1Hz), 2.60-5.20 (19H, m)/ 6.30-8.10 (6Hf m) , 10.08 (1H, br s) MASS (APCI): 574 (M+H)+ (free) (4) (2 R)-2-(4-氯-3-羥苄基)-1 - [3_氯-5-(三氟甲基)苄 醯基]-4-[2-(5,6·7,8-四氫-1,6-暸啶-6-基)乙基]哌 阱三鹽酸鹽
[α]^6·5: -20·57° (C=0.28, MeOH) mp: 200-204eC IR (KBr): 3430, 3400, 1645, 1514, 1464, 1425 cm-1 NMR (DMS〇-dg/ δ): 2.60-5.20 (19H, .in) , 6 · 30-8 · 10 (8H, m), 8.63 (1H, d, J=4.6Hz), 10.09 (1H, br) MASS (APCI): 593 (M+H)+ (free) 例43 仿例41之方法可得如下化合物。 (1) (2R)-2_(4-氯苄基)-4-[2-(2S)-2-(甲氧甲基)-嗎啉 基]乙基]-l-[3-(4-吡啶基)-5-(三氟甲基)-苄醸基] 哌阱三鹽酸鹽 [a]§7: +1.5° (C=0.5, MeOH) IR (KBr): 1645, 1510, 1460, 1425, 1270, 1240, 1175, 1135 cm·1 NMR (DMSO-dg, δ): 2.62-5.15 (22H, m) , 3.28 (3H, s) f 6·16-9·01 (11H, m) MASS (APCI): 617 (M)+ (free) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)-225- -------------------訂---------^^^1 (請先閲讀背面之注音?事項再填寫本頁) 川 9688 A7
五、發明說明(224 ) 經濟部智慧財產局員工消費合作社印製 (2) (2R)-2-(4-氯苄基)- 4-[2-(2S)-2-(甲氧甲基)嗎啉基] 乙基]甲基-5 -(三氟甲基卜苄醯基]哌哄二鹽酸鹽 [a]g7: +10·9。 (d=0.5, MeOH) mp: 148-151°C , IR 《KBr): 1645, 1510, 1465, 1425, 1270, 1230 cnT1 NMR (DMSO-d6/ δ): 2.33 (3H, s), 3.28 (3H, s) , 2.66-5.24 (22H, m), 6.16-7.70 (7H, m) MASS (APCI): 554 (M)+ (free) ③(2R)-2-(4 -氯苄基)-1 - [3-環戊磺醯基-5-(三氟甲基) 苄醯基]-4-[2 -(2S)-2-(甲氧甲基)嗎啉基]乙基]哌阱 二鹽酸鹽 [a]g7: +12·1β 《C=0.5, DMF)
mp: >230°C IR (KBr): 1650, 1465, 1425, 1335, 1305, 1235, 1135 citT1 NMR (DMS〇-d6/ δ): 1.45-1.93 (9H, m), 2.80-5,20 (22H, m), 3·27 (3H, s), 6.14-8.30 (7H,.m) MASS (APCI): 672 (M)+ (free) (4) (2R)-2-(4-氯苄基)-4-[2-(2S) - 2-(甲氧甲基)-嗎啉 基]乙基]-l-[3-甲硫基-5 -(三氟甲基)苄醢基]峨阱三 鹽酸鹽
[α]^7: +13·3β (C=0.5, MeOH) mp: 140-146°C IR (KBr" 1625, 1415, 1320, 1270, 1225, 1175 cnT1 NMR (DMSO-d6, δ): 2.54 (3H, s), 2·66-5·20 <22H, n〇, 3·27 (3H, s), 6·66-7·64 (7H, m> MASS (APCI): 586 (M)+ (free) (5) (2ϋ)-2 -(4-氯苄基)-l-[3-氯-5 -(三氟甲基)苄釀基]- 一 226- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(225 ) 4-[2-(2S)-2-(甲氧甲基)嗎啉基]乙基]哌阱二鹽酸鹽
[α]^7: +7·0· (C=0.5, MeOH) mp: 148-1530C
IR (KBr): 1645, 1460, 1420, 1315, 1270, 1230, 1175 cnT NMR (DMSO-dgr δ): 2.66-5,20 (22H, m), 3.28 (3H, s), 6.02-8.00 J7H, m) , .... MASS (APCI): 574 (M)+ (free) (6) (2R) - 2-(4-氯节基)-l-[3 -氟-5-(三氟甲基)节釀基]-4-[2-(2S)-2-(甲氧甲基)嗎啉基]乙基]哌哄二鹽酸鹽
[oc]g7: +10.0。(C=0.5, MeOH) mp: 199-204°C IR (KBr): 1645, 1425, 1235, 1175, 1135 cm^1 NMR (DMSO-dg, δ): 2.70-5.16 (22H, m), 3.28 (3H, s), 6.16-7.90 (7H, m) MASS (APCI): 558 (M)+ (free) ⑺(2R)-1 - [3 -甲硫基-5-(三氟甲基)苄醯基]-2-[4-(三 氟甲基)苄基]-4-[2-(2S)- 2-(甲氧甲基)嗎咐基]乙基] 哌阱二鹽酸鹽 [a]g2: +21.93° (C=0.25r MeOH)
mp: 153-170eC IR (KBr): 3433, 1645 cm·1 NMR (DMSO-dg, δ): 2.54 (3H, s) , 2.70-5.30 (25Hf m), 6·50-7·80 (7H, m) MASS (APCI) : 620 (M+H)4- (free) ⑻(2R卜卜[3-氯-5-(三氟甲基)苄釀基]-2-[ 4-(三氟甲 基)苄基]-4-[2 -(2S)-2-(甲氧甲基)-嗎咐基]乙基]哌 畊二鹽酸鹽 -227- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) I---------------1----訂·-------- (請先閱讀背面之注咅?事項再填寫本頁) 509688 A7 __B7_ 五、發明說明(226 ) [a]g2: +29.60° (C=0.21, MeOH)
mp: 168-173°C (請先閱讀背面之注意事項再填寫本頁) IR (KBr) : 3433, 1647 citT1 NMR (DMSO-dg, δ): 2.80-5,30 (25Hr m), 6.87-8.00 (7H, m) MASS (APCI): 608 (M+H)+ (free) ⑼(2R)-1-[3-氟-5-(三氟甲基)苄釀基]-4-[2-(2S)-2-(甲氧甲基)-嗎啉基]乙基]-2-[4 -(三氟甲基)苄基]哌 阱二鹽酸鹽 [a]p^: +17.47° f€=0.25^ MeOH) 〜 mp: 173-176eC … IR (KBr): 1647 cm—1 NMR (DMSO-dg, δ): 2.80-5.30 (25H, m), 6.70-7,90 (7H, m) MASS (APCI): 592 (Μ+Η)+ (free) ⑽(2R)-4-[2-[(2S)-2-(甲氧甲基)嗎啉基]乙基]-1 -ΜΗ-吡 啶基)_5-( 三氟 甲基)苄 醯基]-2-[4-( 三氟 甲基) 苄基]哌阱三鹽酸鹽 [a]g6: +13.60。 (C=0.25, MeOH)
mp: 81-91°C IR (KBr): 3435, 1643 cm"1 NMR (DMSO-dg, δ): 2,80-5.30 (25H, m), 6.88-8,98 (11H, m) MASS(APCI)·· 651(M + H)+ (free) 經濟部智慧財產局員工消費合作社印製 (11)(21〇-4-[2-(順-2,6-二甲嗎啉基)乙基]-1-[3-甲硫 基-5 -(三氟甲基)苄醯基]-2-[4-(三氟甲基)苄基]哌 畊二鹽酸鹽 [a]g7: +19.00° (C=0.25, MeOH)
mp: 154_156eC IR (KBr): 3435, 1647 citT1 NMR (DMSO-dg, δ): 1.15 (6H, d, J=6.1Hz), 2.54 (3H, s), 2.60-5.30 (19H, m), 6.50-7.70 (7H, m) MASS (APCI): 604 (M+H)+ (free) 擊228讎 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) 509688 A7 B7__ 五、發明說明(227 ) (請先閱讀背面之注咅W事項再填寫本頁) (12) (2R)-4-[2-(順-2,6-二甲嗎啉基)乙基]-1-[3-甲磺 _基-5-(三氟甲基)苄醮基]-2-[4-(三氟甲基)苄基] 哌阱二鹽酸鹽 [a]g5: +12.60° (0=0.25, MeOH) mp: 188-1950C IR (KBr): 1647 cm"1 NMR {DMSO-d6, δ): 1·15 (6H, d, J=6.1Hz), 2·60·5·30 (22H, m)f 7.00-8.32 (7Hf m) MASS (APCI): 636 (M+H)+ (free) (13) (2R)-4-[2-(順-2,6-二甲嗎啉基)乙基]-l-[3-(4-吡啶基)-5-(三氟甲基)苄隨基]-2-[4-(三氟甲基)苄 基]哌阱三鹽酸鹽
[a]g6: +8.40。 (C=0.25, MeOH) mp: 135-145eC IR (KBr): 3433, 3402, 1641 cm"1 NMR (DMS〇-dgf δ): 1,15 (6H, df J=6.2Hz), 2.60-5,30 (19H, m>, 6.80-9.02 (11H, m) MASS (APCI): 635 (M+H)+ (free) (14) (2R)-l-[3-甲硫基-5-(三氟甲基)苄酺{基]-4-[2 -(5 ,6,7,8-四氫-1,6-_啶-6-基)乙基]-2-[4-(三氟甲基) 苄基]哌阱二鹽酸鹽 經濟部智慧財產局員工消費合作社印製 [a]g7: +1#53° (0=0.25, MeOH)
mp: 190-210eC IR (KBr): 3431, 1643 cm"1 NMR (DMSO-d6, δ): 2·54 (3H, s), 2·80-5·30 (19H, m), 6.50-8.71 (10Hf m) HASS (APCI>: 623 (M.H)+ (freo) -229- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(228 ) (15) (2R)- 1-[3_(4-吡啶基)-5-(三氟甲基)苄醯基]-4- [2-(5,6,7,8-四氫-1,6-瞭膝-6-基)乙基]-2-[4-(三 氟甲基)苄基]哌阱二鹽酸鹽 [a]g6: -5.73° (C=0.25, MeOH)
mp: 205-218oC IR (KBr) : 3400, 1641 cnT1 NMR (DMSO-d6, δ>: 2·60-5·30 (19H, m), 6.85-9.02 (14H, m) MASS (APCI): 654 (M+H)+ (free) (16) (21〇-2-(4-氟-3-甲氧节基)-4-[2-(順-2,6-二甲嗎 啉基)乙基]-l-[3-甲硫基-5-(三氟甲基)苄醯基]哌阱 二鹽酸鹽
[a]g7*3: +23.47° (C=0.36, MeOH) mp: 62.5-82.4°C IR (KBr): 1645, 1518, 1421, 1176, 1126 cm"1 NMR (DMSO-dg, δ): 1·15 (6ΗΓά/ J=671Hz), 2.60-4.20 (27Hf m), 6.50-7.56 (6H, m) MASS: 584 (M+H)+ (free) (17) (2R)- 2-(4-氟-3-甲氧苄基)-4-[2-(順-2,6-二甲嗎 啉基)乙基]-1-[3 -(4 -吡啶基)-5-(三氟甲基)苄醯基] 哌阱三鹽酸鹽
[a]g7·4: +14*30° (C=0-37, MeOH) mp: 137.6-142.5°C IR (KBr): 1641, 1515, 1425, 1270, 1176, 1145, 1132 cnT1 NMR (DMSO-dg/ δ): 1.14 (6H, d, J=6.0Hz), 2.60-4.20 (25H, m), 6.52-8.90 (10H, m) MASS (APCI): 615 (M+H)+ (free) (18) (2R) - 2-(4-氟-3-甲氧苄基)- l-[3_甲硫基-5-(三氟 -230- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------—-----------訂- ----1---- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(229 ) 甲基)苄醢基]-4-[2-(5,6,7,8-四氫-1,6-暸啶-6-基) 乙基]哌阱三鹽酸鹽
[α]§7·4·· -3·510 (C=CK39, Me〇H) mp: 143.3-147.5°C IR 《KBr): 1645, 1516, 1417, 1173, 1126 cnT1 NMR (DMSO-dg, δ): 3.80-5.20 (28H, m), 6.53-8.68 (9H, m) MASS (APCI): 603 (M+H)+ (free) (19) (2R)-2-(4-氟-3-甲氧苄基)- l-[3 -(4-吡啶基)-5 - (三氟甲基)苄釀基]- 4-[2-(5,6,7·8-四氫-1,6 -暸啶- 6-基)乙基]哌阱四鹽酸鹽 [α]§7·9: -9·07ο (C=0.46, Me〇H)
mp: 236·8-248.5°C IR (KBr): 1641, 1635, 1516, 1423, 1273, 1130 cm-1 NMR (DMSO-dg, δ): 2,65-5.10 (26H, m)., 6.51-9.00 (13H, m) MASS: 634. (M+H)+ (free) (20) (2R)-2-(4-氟-3-甲氧节基)-4-[2-[(2S)-2-(甲氧 甲基)嗎啉基]乙基]-l-[3-(4-吡啶基)-5 -(三氟甲基) 苄醯基]哌阱三鹽酸鹽 [a】g8: +32·5β (C=0.5, Me〇H) IR (KBr) : 1645, 1515, 1425, 1270, 1235 ^1 NMR (DMS〇-d6/ δ): 2.66-5.24 (25H, m), 3·27 (3H, s), 6.45-8.93 (10H, m) MASS (APCI): 631 (M+H)+ (free) (21) (2R)-1 - [3-氯-5-(三氟甲基)苄醴基]-2-(4-氟-3-甲氧苄基)- 4-[2 - [(2S)-2-(甲氧甲基)嗎啉基]乙基] _阱二鹽酸鹽 -231- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------—---1----訂 --------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(23Q)
[α]^8: +25.4° (C=0.5, MeOH) mp: 139-142eC IR (KBr) : 1645, 1515, 1460, 1420, 1315, 1270, 1230 cirT1 NMR (DMSO~d6, δ): 2.72-5.21 (22H, m), 3.29 (3H, s), 3.44 (3H, s), 6.17-8.00 (6H, in) MASS (APC I) : 588 (H) + (free) (22) (21〇-2-(4-氟-3-甲氧苄基)-4-[2-[(25)-2-(甲氧 甲基)嗎啉基]乙基]-l-[3-甲硫基-5-(三氟甲基)苄釀 基]哌阱二鹽酸鹽
[a]J8: +28.1° (C=0.5, MeOH) nip: 132-135eC IR (KBr): 1645, 1515, 1460, 1420, 1315, 1270, 1230, 1130 cm·1 NMR (DMSO_d6, δ): 2.54 (3H, s>, 2.73-5.27 (22H, m), 3·28 (3H, s), 3·41 (3H, s), 6·15-7·83 (6H, m> MASS (APCI): 600 (M+H)+ (free) (23) (2R)-2-(4-氟-3-甲氧苄基)-1-[3-氟-5-(三氟甲基) 苄醯基]-4 - [2-[(2S)-2-(甲氧甲基)嗎啉基]乙基]哌 阱二鹽酸鹽 [a】g7: +21.4。 (C=0.5, MeOH) IR (KBr): 1640, 1515, 1465, 1425, 1345, 1275, 1230, 1135 cm*"1 NMR (DMS〇-d6, δ): 2·76-5·20 (22H, in), 3·29 (3H, s), 3.42 (3H, s), 6.16-7.86 (6H, m) MASS (APCI): 572 (M+H)+ (free) 例44 仿製備例21後半段之方法可得如下化合物。 -232- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --------------------訂--------- (請先閱讀背面之注意事項再填寫本頁) 509688 A7 B7_ 五、發明說明(231) (請先閱讀背面之注咅?事項再填寫本頁) (1) (2R)-2-(4 -氯-3-經节基)-1 - [3 -氯-5-(三氟甲基)节 醮基]-4_[2-[(2S) - 2-(甲氧甲基)嗎啉基]乙基]哌阱 二鹽酸鹽 [a]g8: +6.1° (0=0.5, MeOH) IR (KBr): 1645, 1510, 1425, 1235, 1175 cm"1 NMR (DMSO-dg, δ) : 2,55-5.10 (22H, m> , 3·27 (3H, s), 6.31-8.03 (6H, m), 10.07 (1H, br s) MASS (APCI): 590 (M)+ (free) (2) (2R)-2-(4-氯-3-羥苄基)-4-[2-[(2S)-2-(甲氧甲基) 嗎啭基]乙基]-l-[3-甲硫基-5-(三氟甲基)苄醯基]哌 胼二鹽酸鹽
[a]g8: +15.0° (C=0.5, MeOH) mp: 169-174°C IR 《KBr): 3475, 3420, 1640, 1425, 1320, 1270, 1230, 1135 cm*1 NMR (DMSO-d6, δ>: 2·54 (3H, s), 2.56-5.10 (22H, m), 3·27 (3H, s)f 6·29-7·69 (6H, m), 10.10 (1H, br s) MASS (APCI): 602 (M)+ (free) (3) (2R)-2-(4-氯-3-羥苄基)-1 -[3-氟-5-(三氟甲基)苄 醯基]-4-[2-[(2S)-2 -(甲氧甲基)-嗎啉基]乙基]哌阱 二鹽酸鹽 經濟部智慧財產局員工消費合作社印製
[a】g7: +7·6β (C=0.5, MeOH) mp: 176-178eC IR (KBr): 1645, 1510, 1460, 1425,,1235, 1175 cm一1 NMR (DMSO-d6, δ) : 2·52-4.98 (22H, m), 3.28 (3H, s), 6.34-7.77 (7H, m) MASS (APCI): 574 (M)+ (free) -233- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(232) 例45 仿例11之方法可得如下化合物。 (1) (2IO-1-[3,5-雙(三氟甲基)苄醯基]-2-(4-氯-3-羥苄 基)4-[(1Η-吡咯并[3,2-b]吡啶-3-基)-甲基]哌阱二 鹽酸鹽 [a]g5·0: +5·42β (C=0.60, MeOH) mp: 208-211°C . IR (KBr): 1647, 1281, 1180, 1138 citT1 NMR (DMSO-d6/ δ): 2.60-5..10 (HH, m) , 6.26-7.20 (3H, m), 7.43-7.82 (3H, m), 8.18-8.72 (4H, m) , 10.08 (1H, br}, 13·11 (1H, s) MASS (APCI): 597 (M+H)+ (free) ⑵(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(4-氯-3-羥苄 基)4 - [(1H-吡咯并[2,3-b]吡陡-3-基甲基]哌阱二 鹽酸鹽 [a】g4·9: -0·9。。 {C=0.50, MeQH) mp: 197-200oC · IR (KBr): 1647, 1281, 1180, 1136 cm"1 NMR (DMSO-dg, δ): 2.60-5.20 (11H, m) , 6·24-7·40 (4H, , 7.45 (1H, s>, 7·76 (1H, s), 7·95-8·55 (4H, m), 11·60 (1H, br), 12.45 (1H, s) MASS (APCI) : .597 (M+H)4- (free) 例46 將碘甲鎂於乙醚1莫耳溶液(3.15毫升)加至含4-[[(2R) - l-[3,5-雙(三氟甲基)苄釀基]-4-[2-[(2S) - 2-(甲氧甲 基)-嗎啉基]乙基]哌阱-2-基]-甲基]- 2-(第三丁二甲矽 -234- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------————訂-—----- (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 509688 A7 B7_ 五、發明說明(233) 烷氧基)苄酸甲酯(0.8克)之甲苯(8毫升)。攪拌於45 t! 下4小時,加入飽和氯化銨溶液K中止反應,再萃取Μ 乙酸乙_。分離有機層,依次清洗水及食鹽水,於硫酸 鎂下乾燥,減壓蒸除可得粗製油。由矽膠柱層析純化 (二氯甲烷:甲醇= 40:1)可得(2R)-1-[3,5-雙(三氟甲基) 苄醯基]- 2-[3-(第三丁二甲矽烷氧基)- 4-(1-羥基-1-甲 基乙基)苄基卜4-[2 - [(2S)-2-(甲氧甲基)嗎啉基]乙基] 哌阱(0· 333克)。 IR (Neat): 1643, 1438, 1280 cm"1 NMR (CDC13/ δ): 0.10-0.50 (6Η, m)f 1.03 (9Hf s), 1.58 (6H, s), 2.00-5.10 (22H, m)> 3.38 (3Hf s), 6.30-7.90 (6H, m) ? MASS (API-ES): 784 (M+Na)+, 763 (M+H)+ 例47 將甲磺醯氯(0.115毫升)加入含(2R)-l-[3,5-雙(三氟 甲基)苄醯基]_2-[3-(第三丁二甲矽烷氧基)-4-(1-羥基 -1-甲基乙基)苄基]-4-[2-[(2S)-2M甲氧甲基)嗎啉基] 乙基]It阱(0·76克)及三乙胺(0·35毫升)之二氯甲烷(9 毫升)冰水溶液。攪拌於同溫下2小時,清洗Μ水。分 雛有機層,清洗Κ食鹽水,於硫酸鎂下乾燥並減壓蒸除 可得甲磺釀化及未甲磺釀化混合物。將其不經純化溶於 甲酵,於室溫及3大氣壓下氫化K 20¾氫氣化鈀-碳 (0.1克)5小時。漶經矽藻土後清洗Μ甲醇。結合濾液 及洗液並減壓蒸除。將所得之漿液溶於四氫呋喃(6.5毫 升),於低於10C下加入氟化四丁銨(1奠耳四氫呋喃溶 -2 3 5 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ----------—--------訂-------- (請先閱讀背面之注咅?事項再填寫本頁) 509688 A7 B7_ 五、發明說明(234) 液,0.1毫升)。於室溫攪拌後減壓蒸除,再由矽膠柱 層析純化(二氯甲烷:甲醇=40:1)可得油。將所得油處理 K4N鹽酸-乙酸乙酯可得(2R)-l-[3,5-雙(三氟甲基)苄 醯基]-2-[3-羥基-4-(1-甲基乙基)苄基]-4-[2-[(2S) -2-(甲氧甲基)嗎啉基]乙基]哌畊二鹽酸鹽(150毫克)之 粉。
[a]g6: -1.250 (00.2, MeOH> mp: 218-2280C IR (KBr) : 3500-3150, 2700-2300,, 1644, 1498, 1461, 1282, 1174 cm*1 NMR (DMSO-dg, δ): 1.00-1.30 (6H m), 2.60-5.10 (26H, m), 6.20-8.20 (6H, m), 9.22 (1H/ br s) MASS (APCI): 632 (M+H)+ (free) --------------------訂---------- (請先閱讀背面之注音3事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -236- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Claims (1)
- 六、申請專利範圍 專利案 第88 1 2 1 878號「哌畊衍生物 (91年8月2日修正) 六、申請專利範圍: 1 · 一種如下式化合物或其鹽式中 Y爲C i _ 6伸烷基; R1爲苯基’其經由1或2個相同或不同取代基取代, 選自鹵素,烷基,0^_6烷氧基,單(或二或 三)鹵CV 6烷基,硝基,胺基,0卜6烷胺基, —^ Ci-6纟兀fl女基,院硫基,Ci—6垸礦釀基, 環C3_ 6烷磺醯基,胺磺醯基,C^_ 6烷胺磺醯基, 二_ 6烷胺磺醯基,吡咯啶磺醯基,嗎啉磺醯 基,吡咯磺醯基,吡啶磺醯基,吡咯基及吡啶基; R2爲苯基,其經由羥基及一取代基取代,選自Ch 6 烷基,單(或二或三)鹵(^_6烷基,單(或二或三) 鹵cv 6烷磺醯氧基,鹵素,cv 6伸烷二氧基, 6烷氧基,6烷氧羰基,C卜6烷氧(^_ 6烷 氧烷氧基,二苯Ci—6烷矽烷氧基,三C^ 6烷矽烷氧基,、羥Ci_6烷基,氰基,胺基,[單 (或二或三)鹵Ci—6烷羰基]胺基,C^6烷胺基, 509688 六、申請專利範圍 N-di烷基)-[單(或二或三)鹵Ci-6烷羰基]胺 基,吡咯啶基及嗎啉基,其可取代以Ch 6烷氧 C i _ 6烷基或C i _ 6烷基; R3爲氫,且 R4爲3-(3-吡啶基)丙基 3 - ( 3 -吡啶基)丙炔基; (2,6 -二甲嗎啉基)C i _ 6烷基; (3,3-二甲嗎啉基)C2_ 6炔基; (順-3,5-二甲嗎啉基)6烷基; ((3S,5S)-3,5·二甲嗎啉基)Ci— 6 烷基; (2 -甲氧甲嗎啉基)C i _ 6烷基; (3 -甲氧甲嗎啉基)C i _ 6烷基; (2 -甲氧甲基-5-甲嗎啉基)Ci—6烷基; (2-甲氧甲基-5, 5-二甲嗎啉基)Ci—6烷基;或 (2-甲氧甲嗎啉基)C2_ 6烯基, 及其鹽類。 2 .如申請專利範圍第1項之化合物,其中 Y爲(:卜4伸烷基; R1爲雙[單(或二或三)鹵Ci—4烷基]苯基; R2爲苯基,其經由羥基及一取代基取代,選自C i _ 4 院基,單(或二或三)鹵Ci—4烷基,鹵素及Cn 院氧基 ; R3爲氫,且 R4爲3 - ( 3-吡啶基)丙基 509688 六 申請專利範圍 3 - ( 3 -吡啶基)丙炔基; (2,6-二甲嗎啉基)(:1_4烷基; (2-甲氧甲嗎啉基)I _4烷基; (3-甲氧甲嗎啉基)Ci_4烷基;或 (2-甲氧甲基-5-甲嗎啉基)Ci 4烷基。 3 .如申請專利範圍第2項之化合物或其製藥容許鹽, 其係選自如下⑴1-[3, 5-雙(三氟甲基)苄醯基]-2-(3-羥基甲苄 基)-4-[2-[(3R)-3-(甲氧甲基)嗎啉基]乙基]哌畊, ⑵1 - [ 3,5 -雙(三氟甲基)苄醯基]-4 - [ 2 -(順-2,6 -二 甲嗎啉基)乙基]-2 - ( 3 -羥基-4 -甲苄基)哌畊, ③1-[3, 5 -雙(三氟甲基)苄醯基]-2-(3 -羥基-4-甲 ;基)-4-[2-(2S,5S)-2-甲氧甲基-5·甲嗎啉基]乙 基]哌畊, ⑷1-[3, 5 -雙(三氟甲基)苄醯基]-2-(3 -羥基甲 苄基)-4 - [ 3 - ( 3 -吡啶基)-2 -丙炔基]哌哄,(5) 1-[3,5 -雙(三氟甲基)苄醯基]-4-[2-[(2Sh (甲氧甲基)嗎啉基]乙基]-2-(3-羥基-4•甲韦基)_ 哌畊, (6) (21〇-1-[3,5-雙(三氟甲基)苄醯基]-叭[;24(2^. 2-(甲氧甲基)嗎啉基]乙基]-2-(3 -羥基-4_甲韦 基)-哌畊, ⑺1-[3,5 -雙(二氟甲基)1^醯基]-羥基_4_甲 苄基)-4 - [ 3 - ( 3 -吡啶基)-丙基]哌哄,509688 六、申請專利範圍 ⑻(2R)-l-[3,5-雙(三氟甲基)苄醯基]-2-(4-氯- 3-羥苄基)-4- [2 - [ (2S) - 2·(甲氧甲基)嗎啉基]乙 基卜哌畊; 或其製藥可接受鹽類。 4 . 一種製備如申請專利範圍第1項之化合物或其鹽之 方法,其含 ⑴將下式(Π )化合物或其鹽 Y-R2 (II) V 式中R^R^R3及Y定義各如申請專利範圍第1項 所示, 與式(M )化合物或其鹽 w, - r4 ( m 式中R4定義如申請專利範圍第1項所示且Wi爲離 去基, 反應可得式(I )化合物或其鹽 Y-R2式中R、R2,R3,R4及Y定義各如申請專利範圍第1 項所示,或509688 六、申請專利範圍 ⑵將下式(I a )化合物或其鹽 Y - R2(la) 式中R、R2,R3及Y定義各如上 R5爲3-吡啶基,且 Z1爲C 2 _ 6伸炔基, 進行還原可得式(I b )化合物或其鹽 Y-R2 (lb) V 式中RWj3,Y及R5定義各如上,且 X1爲6伸烷基。 5 · —種用於防治速激肽仲介病之醫藥組成物,其係包含 如申請專利範圍第1項之化合物或其製藥容許鹽爲 活性成份混合以製藥容許載體。 6 ·如申i靑專利範圍第1項之化合物,其可作爲速激月太 拮抗劑。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP7706A AUPP770698A0 (en) | 1998-12-14 | 1998-12-14 | Piperazine derivatives |
AUPQ3568A AUPQ356899A0 (en) | 1999-10-21 | 1999-10-21 | Piperazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
TW509688B true TW509688B (en) | 2002-11-11 |
Family
ID=25645943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088121878A TW509688B (en) | 1998-12-14 | 1999-12-14 | Piperazine derivatives |
Country Status (20)
Country | Link |
---|---|
US (2) | US7166598B2 (zh) |
EP (1) | EP1140924B1 (zh) |
JP (2) | JP3454427B2 (zh) |
KR (1) | KR20010086104A (zh) |
CN (1) | CN1152877C (zh) |
AR (1) | AR021662A1 (zh) |
AT (1) | ATE321042T1 (zh) |
AU (2) | AU768652B2 (zh) |
BR (1) | BR9917047A (zh) |
CA (1) | CA2354875A1 (zh) |
CZ (1) | CZ20012130A3 (zh) |
DE (1) | DE69930543T2 (zh) |
ES (1) | ES2257089T3 (zh) |
HK (1) | HK1043998B (zh) |
HU (1) | HUP0203651A2 (zh) |
IL (1) | IL143577A0 (zh) |
PT (1) | PT1140924E (zh) |
TR (1) | TR200101649T2 (zh) |
TW (1) | TW509688B (zh) |
WO (1) | WO2000035915A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU768652B2 (en) * | 1998-12-14 | 2003-12-18 | Astellas Pharma Inc. | Piperazine derivatives |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
TW591025B (en) * | 2000-06-13 | 2004-06-11 | Fujisawa Pharmaceutical Co | Production of the piperazine derivative |
IT1317049B1 (it) * | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. |
US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
UA77515C2 (en) * | 2002-04-04 | 2006-12-15 | Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity | |
US7776535B2 (en) | 2006-02-06 | 2010-08-17 | Franklin And Marshall College | Site-specific incorporation of fluorinated amino acids into proteins |
CN102812014B (zh) | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途 |
KR102074089B1 (ko) | 2009-12-04 | 2020-02-05 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
EP2653464B1 (en) | 2012-04-20 | 2017-09-27 | Rohm and Haas Company | Benzylamine hydrophobe |
US20160304479A1 (en) * | 2013-12-19 | 2016-10-20 | Archer Daniels Midland Company | Sulfonates of furan-2,5-dimethanol and (tetrahydrofuran-2,5-diyl)dimethanol and derivatives thereof |
EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
MA45795A (fr) | 2016-07-29 | 2019-06-05 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
KR102605854B1 (ko) | 2017-02-16 | 2023-11-23 | 선오비온 파마슈티컬스 인코포레이티드 | 조현병의 치료방법 |
EP3661929B1 (en) | 2017-08-02 | 2021-07-14 | Sunovion Pharmaceuticals Inc. | Isochroman compounds and uses thereof |
MX2020008537A (es) | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Sales, formas cristalinas y metodos de produccion de las mismas. |
US20220041562A1 (en) * | 2018-11-02 | 2022-02-10 | Texas Tech University System | Novel selective kappa opioid receptor antagonists and methods related thereto for treatment of addiction and neuropathic pain |
US11136304B2 (en) | 2019-03-14 | 2021-10-05 | Sunovion Pharmaceuticals Inc. | Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
WO2021087268A1 (en) * | 2019-10-30 | 2021-05-06 | Texas Tech University System | Novel selective kappa opioid receptor antagonists and methods related thereto for treatment of addiction and neuropathic pain |
CN115734785A (zh) | 2020-04-14 | 2023-03-03 | 桑诺维恩药品公司 | (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
US5541054B1 (en) * | 1995-04-20 | 1998-11-17 | Imation Corp | Spectral sensitizing dyes for photothermographic elements |
BR9610277A (pt) * | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
CA2240835A1 (en) * | 1995-12-18 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
AU743723B2 (en) * | 1997-06-17 | 2002-01-31 | Astellas Pharma Inc. | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
AU768652B2 (en) * | 1998-12-14 | 2003-12-18 | Astellas Pharma Inc. | Piperazine derivatives |
-
1999
- 1999-12-10 AU AU16837/00A patent/AU768652B2/en not_active Ceased
- 1999-12-10 CZ CZ20012130A patent/CZ20012130A3/cs unknown
- 1999-12-10 CA CA002354875A patent/CA2354875A1/en not_active Abandoned
- 1999-12-10 PT PT99959751T patent/PT1140924E/pt unknown
- 1999-12-10 BR BR9917047-7A patent/BR9917047A/pt not_active Application Discontinuation
- 1999-12-10 KR KR1020017007333A patent/KR20010086104A/ko active IP Right Grant
- 1999-12-10 DE DE69930543T patent/DE69930543T2/de not_active Expired - Fee Related
- 1999-12-10 AT AT99959751T patent/ATE321042T1/de not_active IP Right Cessation
- 1999-12-10 JP JP2000588175A patent/JP3454427B2/ja not_active Expired - Fee Related
- 1999-12-10 ES ES99959751T patent/ES2257089T3/es not_active Expired - Lifetime
- 1999-12-10 EP EP99959751A patent/EP1140924B1/en not_active Expired - Lifetime
- 1999-12-10 WO PCT/JP1999/006943 patent/WO2000035915A1/en not_active Application Discontinuation
- 1999-12-10 HU HU0203651A patent/HUP0203651A2/hu unknown
- 1999-12-10 IL IL14357799A patent/IL143577A0/xx unknown
- 1999-12-10 CN CNB998161322A patent/CN1152877C/zh not_active Expired - Fee Related
- 1999-12-10 TR TR2001/01649T patent/TR200101649T2/xx unknown
- 1999-12-14 TW TW088121878A patent/TW509688B/zh not_active IP Right Cessation
- 1999-12-14 AR ARP990106361A patent/AR021662A1/es unknown
-
2002
- 2002-07-30 HK HK02105609.0A patent/HK1043998B/zh not_active IP Right Cessation
-
2003
- 2003-01-31 JP JP2003023481A patent/JP2003238563A/ja not_active Withdrawn
-
2004
- 2004-03-16 AU AU2004201111A patent/AU2004201111A1/en not_active Abandoned
- 2004-10-20 US US10/968,473 patent/US7166598B2/en not_active Expired - Fee Related
-
2006
- 2006-11-21 US US11/562,149 patent/US20070123532A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU768652B2 (en) | 2003-12-18 |
BR9917047A (pt) | 2002-07-30 |
TR200101649T2 (tr) | 2001-10-22 |
HK1043998A1 (en) | 2002-10-04 |
DE69930543D1 (de) | 2006-05-11 |
HUP0203651A2 (en) | 2003-02-28 |
EP1140924A1 (en) | 2001-10-10 |
AR021662A1 (es) | 2002-07-31 |
CA2354875A1 (en) | 2000-06-22 |
KR20010086104A (ko) | 2001-09-07 |
AU1683700A (en) | 2000-07-03 |
CZ20012130A3 (cs) | 2001-10-17 |
CN1152877C (zh) | 2004-06-09 |
WO2000035915A1 (en) | 2000-06-22 |
US7166598B2 (en) | 2007-01-23 |
JP2002532499A (ja) | 2002-10-02 |
DE69930543T2 (de) | 2006-11-09 |
EP1140924B1 (en) | 2006-03-22 |
US20060014948A1 (en) | 2006-01-19 |
ATE321042T1 (de) | 2006-04-15 |
IL143577A0 (en) | 2002-04-21 |
PT1140924E (pt) | 2006-08-31 |
AU2004201111A1 (en) | 2004-04-22 |
HK1043998B (zh) | 2005-03-18 |
ES2257089T3 (es) | 2006-07-16 |
JP3454427B2 (ja) | 2003-10-06 |
CN1334812A (zh) | 2002-02-06 |
JP2003238563A (ja) | 2003-08-27 |
US20070123532A1 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW509688B (en) | Piperazine derivatives | |
CN105209464B (zh) | P2x7调节剂 | |
US9440957B2 (en) | Compounds and compositions for modulating EGFR Activity | |
US9815842B2 (en) | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | |
US10947252B2 (en) | Inhibitors of KEAP1-Nrf2 protein-protein interaction | |
CN103717599B (zh) | 吲唑 | |
CN101102773B (zh) | 治疗青光眼和其他rho激酶-介导疾病的氨基吡嗪类似物 | |
US20220313698A1 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
TW201529574A (zh) | 磺醯胺衍生物及其醫藥用途 | |
CN118076593A (zh) | 3CLpro蛋白酶抑制剂 | |
KR20240042620A (ko) | 시아노피리딘 및 시아노피리미딘 bcl6 분해제 | |
US20230167131A1 (en) | Heterocyclic pad4 inhibitors | |
US20240158370A1 (en) | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | |
US20240158414A1 (en) | Bi-aryl dihydroorotate dehydrogenase inhibitors | |
US11951094B2 (en) | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | |
RU2258068C2 (ru) | Производные пиперазина, способ их получения, фармацевтическая композиция и способ ингибирования рвоты | |
CN116390917A (zh) | Mrgx2拮抗剂 | |
TW198721B (zh) | ||
CN116239597A (zh) | 一种嘧啶并吡咯类衍生物及其药用组合物和应用 | |
MXPA01006018A (es) | Derivados de piperazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |